<html lang="en"><head><!-- Shady DOM styles for custom-style --><!-- Shady DOM styles for dom-template --><!-- Shady DOM styles for dom-repeat --><!-- Shady DOM styles for array-selector --><!-- Shady DOM styles for dom-if --><!-- Shady DOM styles for state-modifier --><style scope="state-modifier">a[inherit].state-modifier {
  color: inherit;
}</style><!-- Shady DOM styles for browser-ui --><!-- Shady DOM styles for outlined-text-field --><style scope="outlined-text-field">outlined-text-field {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: column;
}

outlined-text-field span.outlined-text-field {
  display: flex;
  flex-direction: row;
  align-items: center;
}

outlined-text-field input.outlined-text-field {
  height: 40px;
  padding: 0 33px 0 16px;
  
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  flex-grow: 1;
}

outlined-text-field[orig] input.outlined-text-field {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-text-field[dense] input.outlined-text-field {
  height: 32px;
}

outlined-text-field[uppercase] input.outlined-text-field {
  text-transform: uppercase;
}

outlined-text-field:not([wizard-focused]):hover input.outlined-text-field {
  border-color: #737375;
  color: #414447;
}

outlined-text-field:not([wizard-focused]):focus-within input.outlined-text-field,outlined-text-field[wizard-focused] input.outlined-text-field {
  border-color: #3574e0;
  caret-color: #80a5f1;
}

outlined-text-field[wizard-focused] input.outlined-text-field {
  border-width: 2px;
}

outlined-text-field input.outlined-text-field::placeholder {
  color: #65686c;
}

outlined-text-field[uppercase] input.outlined-text-field::placeholder {
  text-transform: none;
}</style><!-- Shady DOM styles for mat-keyword-editor --><!-- Shady DOM styles for mat-chips-input --><!-- Shady DOM styles for mat-input-chip --><!-- Shady DOM styles for pat-dialog --><style scope="pat-dialog">pat-dialog {
  background: white;
  position: absolute;
  border-radius: 8px;
  
  box-shadow: 0 24px 38px 3px rgb(0 0 0 / 14%),
              0 9px 46px 8px rgb(0 0 0 / 12%),
              0 11px 15px -7px rgb(0 0 0 / 20%);
  z-index: 1;
  display: flex;
  flex-direction: column;
}

pat-dialog:not([open]) {
  display: none;
}</style><!-- Shady DOM styles for mat-tabs --><!-- Shady DOM styles for filter-chip --><style scope="filter-chip">filter-chip {
  align-items: center;
  background-color: #fff;
  border-color: #dadce0;
  border-radius: 8px;
  border-style: solid;
  border-width: 1px;
  color: #606368;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 32px;
  letter-spacing: 0.2px;
  padding: 0 16px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

filter-chip[disabled] {
  background-color: #e8e8e8;
  border-color: #e8e8e8;
  color: #a9abad;
  cursor: auto;
}

filter-chip svg.filter-chip {
  visibility: collapse;
  font-size: 18px;
  width: 0;
  height: 18px;
}

filter-chip[selected] svg.filter-chip {
  visibility: visible;
  margin: 0 8px;
  width: 18px;
}

filter-chip[selected] svg.filter-chip path.filter-chip {
  fill: #4577d1;
}

filter-chip:not([disabled]):hover {
  background-color: #f7f8f8;
  border-color: #d7d9dc;
  color: #454649;
}

filter-chip:not([disabled]):hover:active {
  background-color: #eff0f0;
  border-color: #d2d5d8;
  color: #222326;
}

filter-chip:not([disabled]):focus {
  background-color: #e7e8e8;
  border-color: #232528;
  color: #202124;
}

filter-chip:not([disabled])[selected] {
  background-color: #e9f0fd;
  border-color: #e9f0fd;
  color: #4577d1;
  padding-left: 0;
}

filter-chip:not([disabled]):focus[selected] {
  background-color: #d5e1fb;
  border-color: #d5e1fb;
  color: #2550a0;
}

filter-chip:not([disabled]):hover[selected] {
  box-shadow: rgba(0, 0, 0, 0.2) 0px 3px 1px -2px,
    rgba(0, 0, 0, 0.14) 0px 2px 2px 0px, rgba(0, 0, 0, 0.12) 0px 1px 5px 0px;
}

filter-chip:not([disabled]):hover:active[selected] {
  background-color: #abc8f2;
  border-color: #abc8f2;
  color: #2a54a3;
}</style><!-- Shady DOM styles for figure-callout --><!-- Shady DOM styles for mat-button --><style scope="mat-button-0">.mat-button-0 {
  ;
  align-items: center;
  border-radius: 4px;
  color: hsl(217 4% 39%); 
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: 0.2px;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

.mat-button-0[filled] {
  background-color: hsl(217 73% 54%); 
  color: white;
}

.mat-button-0[filled]:hover {
  background-color: hsl(217 60% 47%);
}

.mat-button-0[filled]:focus {
  background-color: hsl(217 59% 44%);
}

.mat-button-0[filled]:active {
  background-color: hsl(217 59% 45%);
}

.mat-button-0[filled][disabled] {
  background-color: hsl(217 2% 90%); 
  color: hsl(217 1% 65%);
}</style><!-- Shady DOM styles for search-term-wizard --><style scope="search-term-wizard">search-term-wizard:not([open]) {
  display: none;
}

search-term-wizard .header.search-term-wizard {
  border-bottom: 1px solid #e5e5e5;
  padding: 24px;
  padding-bottom: 0;
}

search-term-wizard .title.search-term-wizard {
  color: #3c4043;
  font-family: Google Sans,Roboto,Arial,sans-serif;
  font-size: 22px;
  user-select: none;
  margin: 0 48px;
}

search-term-wizard #panels.search-term-wizard > *.search-term-wizard:not([selected]) {
  display: none;
}</style><!-- Shady DOM styles for outlined-textarea --><style scope="outlined-textarea">outlined-textarea {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: row;
  
  position: relative;
}

outlined-textarea span.outlined-textarea {
  display: flex;
  flex-direction: column;
  flex-grow: 1;
  justify-content: center;
}

outlined-textarea span.right-button-container.outlined-textarea {
  position: absolute;
  right: 0;
  height: 100%;
}

outlined-textarea textarea.outlined-textarea {
  padding: 16px 16px 0 16px;
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  resize: none;
}

outlined-textarea[dense] textarea.outlined-textarea {
  padding: 8px;
}

outlined-textarea[has-icon] textarea.outlined-textarea {
  padding-right: 38px;
}

outlined-textarea[orig] textarea.outlined-textarea {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-textarea:not([rows]) textarea.outlined-textarea {
  height: 40px;
}

outlined-textarea textarea.resizable.outlined-textarea {
  resize: vertical;
}

outlined-textarea textarea.outlined-textarea:focus,outlined-textarea[wizard-focused] textarea.outlined-textarea,outlined-textarea textarea.outlined-textarea:focus:hover {
  border-color: #3574e0 !important;
  
  outline: none !important;
}

outlined-textarea textarea.outlined-textarea:hover {
  border-color: #202124;
  color: #414447;
}

outlined-textarea.hasValue textarea.outlined-textarea {
  border-color: #888d91;
  color: #45474a;
}

outlined-textarea #helperText.outlined-textarea {
  color: #6a6c71;
  font-size: 12px;
  letter-spacing: 0.3px;
  margin-left: 17px;
  margin-top: 6px;
  user-select: none;
}

outlined-textarea:not([helper-text]) #helperText.outlined-textarea {
  display: none;
}

outlined-textarea[error] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
  color: #3d4043;
}

outlined-textarea textarea.outlined-textarea::placeholder {
  font-size: 14px;
  font-weight: 400;
}

outlined-textarea:not([error]):not([disabled]) textarea.outlined-textarea::placeholder {
  color: #6a6c71;
}

outlined-textarea[error] textarea.outlined-textarea::placeholder {
  color: #c84132;
}

outlined-textarea[error] #helperText.outlined-textarea {
  color: #cd5648;
}

outlined-textarea[error] textarea.outlined-textarea:focus {
  border-color: #c84031;
  border-width: 2px;
  outline: none !important;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover {
  border-color: #97231b;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover::placeholder,outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover + #helperText.outlined-textarea {
  color: #a94945;
}

outlined-textarea[disabled] textarea.outlined-textarea {
  border-color: #e9e9e9;
  color: #b5b6b8;
}

outlined-textarea[disabled] #helperText.outlined-textarea {
  color: #c4c6c7;
}

outlined-textarea[error][disabled] {
  opacity: 50%;
}

outlined-textarea[error][disabled] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
}

outlined-textarea[error][disabled] #helperText.outlined-textarea,outlined-textarea[error][disabled] textarea.outlined-textarea {
  color: #a94945;
}

outlined-textarea[error][disabled] textarea.outlined-textarea::placeholder {
  color: #c84132;
}</style><!-- Shady DOM styles for chemistry-search-term-wizard --><style scope="chemistry-search-term-wizard">chemistry-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

chemistry-search-term-wizard .suggestions.chemistry-search-term-wizard {
  margin-top: 4px;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard svg.chemistry-search-term-wizard {
  margin-right: 24px;
}

chemistry-search-term-wizard path.chemistry-search-term-wizard {
  fill: #5f6368;
}

chemistry-search-term-wizard .help.chemistry-search-term-wizard {
  margin-left: 12px;
  margin-right: 0;
  cursor: pointer;
}

chemistry-search-term-wizard outlined-text-field.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard mat-button.chemistry-search-term-wizard {
  margin-left: 48px;
}

chemistry-search-term-wizard filter-chip.chemistry-search-term-wizard {
  margin-right: 4px;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard outlined-text-field[batchMode].chemistry-search-term-wizard {
  display: none;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard:not([batchMode]) {
  display: none;
}</style><!-- Shady DOM styles for text-search-term-wizard --><style scope="text-search-term-wizard">text-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

text-search-term-wizard > span.text-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

text-search-term-wizard > span.text-search-term-wizard svg.text-search-term-wizard {
  margin-right: 24px;
}

text-search-term-wizard path.text-search-term-wizard {
  fill: #5f6368;
}

text-search-term-wizard outlined-text-field.text-search-term-wizard {
  flex-grow: 1;
}

text-search-term-wizard mat-button.text-search-term-wizard {
  margin-left: 48px;
}

text-search-term-wizard filter-chip.text-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for classification-wizard --><style scope="classification-wizard">classification-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

classification-wizard > span.classification-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

classification-wizard .suggestions.classification-wizard {
  margin-top: 4px;
}

classification-wizard > span.classification-wizard svg.classification-wizard {
  margin-right: 24px;
}

classification-wizard path.classification-wizard {
  fill: #5f6368;
}

classification-wizard outlined-text-field.classification-wizard {
  flex-grow: 1;
}

classification-wizard mat-button.classification-wizard {
  margin-left: 48px;
}

classification-wizard filter-chip.classification-wizard {
  margin-right: 4px;
}

classification-wizard .no-matches.classification-wizard {
  margin-left: 64px;
}

classification-wizard .table-container.classification-wizard {
  max-height: 300px;
  overflow: scroll;
  margin-top: 8px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar {
  -webkit-appearance: none;
  width: 10px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar-thumb {
  border-radius: 5px;
  background-color: #5f636880;
  -webkit-box-shadow: 0 0 1px rgba(255,255,255,.5);
}

classification-wizard table.classification-wizard {
  margin-left: 51px;
  max-width: 575px;
}

classification-wizard tr.classification-wizard {
  margin-top: 4px;
}

classification-wizard tr.classification-wizard suggestive-chip.classification-wizard {
  margin-right: 8px;
}

classification-wizard #spinner.classification-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}</style><!-- Shady DOM styles for suggestive-chip --><!-- Shady DOM styles for mat-checkbox --><!-- Shady DOM styles for measure-search-term-wizard --><style scope="measure-search-term-wizard">measure-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

measure-search-term-wizard > span.measure-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

measure-search-term-wizard .suggestions.measure-search-term-wizard {
  margin-top: 4px;
}

measure-search-term-wizard > span.measure-search-term-wizard svg.measure-search-term-wizard {
  margin-right: 24px;
}

measure-search-term-wizard path.measure-search-term-wizard {
  fill: #5f6368;
}

measure-search-term-wizard outlined-text-field.measure-search-term-wizard {
  flex-grow: 1;
}

measure-search-term-wizard mat-button.measure-search-term-wizard {
  margin-left: 48px;
}

measure-search-term-wizard filter-chip.measure-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for numerical-search-term-wizard --><style scope="numerical-search-term-wizard">numerical-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

numerical-search-term-wizard .suggestions.numerical-search-term-wizard {
  margin-top: 4px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard svg.numerical-search-term-wizard {
  margin-right: 24px;
}

numerical-search-term-wizard path.numerical-search-term-wizard {
  fill: #5f6368;
}

numerical-search-term-wizard outlined-text-field.numerical-search-term-wizard,numerical-search-term-wizard outlined-textarea.numerical-search-term-wizard {
  flex-grow: 1;
}

numerical-search-term-wizard mat-button.numerical-search-term-wizard {
  margin-left: 48px;
}

numerical-search-term-wizard filter-chip.numerical-search-term-wizard {
  margin-right: 4px;
}

numerical-search-term-wizard #spinner.numerical-search-term-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}

numerical-search-term-wizard #suggestions.numerical-search-term-wizard {
  margin-left: 58px;
  display: flex;
  flex-direction: column;
  align-items: flex-start;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard mat-checkbox.numerical-search-term-wizard {
  margin-right: 8px;
}</style><!-- Shady DOM styles for text-button --><style scope="text-button">text-button {
  align-items: center;
  border-radius: 4px;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: .25px;
  margin: 6px 0;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
  line-height: 36px;
  text-decoration: none;
  text-transform: none;
  color: #5f6368;
}

text-button:hover {
  background-color: #f8f9fa;
}

text-button:active {
  background-color: #d5e2fa;
}

text-button[selected] {
  background-color: #e8f0fe;
  color: #1967d2;
}

text-button[selected]:active {
  background-color: #d2e3fc;
}</style><!-- Shady DOM styles for mat-spinner --><!-- Shady DOM styles for requery-tile --><style scope="requery-tile">requery-tile {
  display: flex;
  justify-content: space-between;
  align-items: center;
  box-sizing: border-box;
  min-height: 40px;
  padding: 8px 12px 8px 8px;
  gap: 8px;

  border-radius: 16px;
  background: #f7f8f9;
  color: #1f1f1f;
}

requery-tile:hover {
  background: #d7d8d9;
}

requery-tile > [slot="image"] {
  flex-shrink: 0;

  border-radius: 8px;

  background: #fff;
}

.label.requery-tile {
  flex-grow: 999;

  font: 16px/20px "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
}

.search-icon.requery-tile {
  flex-shrink: 0;

  width: 24px;
  height: 24px;
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/search/default/24px.svg');
}</style><!-- Shady DOM styles for s-more-inline --><style scope="s-more-inline">s-more-inline {
  display: block;
  margin-top: 24px;
  padding: 16px;
  padding-top: 0;
  position: relative;

  line-height: 18px;
  text-overflow: ellipsis;
  white-space: nowrap;
  cursor: pointer;
}

hr.s-more-inline {
  background-color: #dadce0;
  margin-top: 18px;
  position: absolute;
  border: 0;
  height: 1px;
  left: 0;
  width: 100%;
}

.button.s-more-inline {
  display: flex;
  align-items: center;
  justify-content: center;

  position: relative; 
  margin: 0 auto;

  font: 400 14px Roboto, arial, sans-serif;
  height: 36px;
  width: 300px;
  border-radius: 18px;
  background-color: #f1f3f4;
}

.button.s-more-inline:hover {
  background-color: #d8d7dc;
}

.button.s-more-inline > [slot] {
  padding-right: 8px;
}

.expand.s-more-inline {
  display: inline-block;
  width: 20px;
  height: 20px;
}

.expand.less.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_less/default/20px.svg');
}

.expand.more.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_more/default/20px.svg');
}</style><!-- Shady DOM styles for workspace-ui-search --><!-- Shady DOM styles for keyword-wizard --><style scope="keyword-wizard">keyword-wizard {
  display: inline-block;
}

iron-icon.keyword-wizard {
  height: 20px;
    width: 20px;
    color: #999;
    cursor: pointer;
}

iron-icon[active].keyword-wizard {
  color: #4285f4 !important;
}

iron-icon.keyword-wizard:hover {
  color: #ccc;
}

#wizardIcon.keyword-wizard {
  padding-left: 1px;
    height: 16px;
    width: 16px;
    margin: 4px 1px 1px 1px;
}

#wizard.keyword-wizard {
  padding: 0;
    left: 0;
    top: 37px;
    position: absolute;
    background-color: white;
    z-index: 2;
    overflow: hidden;
}

.wizard-header.keyword-wizard {
  display: block;
    width: 100%;
    color: #737373;
    text-transform: uppercase;
    font-size: 13px;
    margin: 16px 0 6px 12px;
}

.filter-chips.keyword-wizard {
  margin-left: 20px;
}

.chip.keyword-wizard {
  background-color: #ebebeb;
    color: #6a6a6a;
    display: inline-block;
    font-size: 13px;
    font-family: inherit;
    border-radius: 12px;
    padding: 6px 12px;
}

.chip.keyword-wizard:hover {
  cursor: pointer;
}

.chip[selected].keyword-wizard {
  background-color: #4285f4;
    color: white;
}

.input-label.keyword-wizard {
  display: inline-block;
    font-size: 13px;
    font-family: inherit;
}

.keyword-input.keyword-wizard {
  display: inline-block;
    border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    padding: 3px;
}

.keyword-input.keyword-wizard::placeholder {
  font-style: italic;
}

.keyword-input.keyword-wizard:hover,.keyword-input.keyword-wizard:focus {
  border-color: #4284f4;
    border-width: 1px;
    outline: none;
}

.cpc-field.keyword-wizard {
  display: inline-block;
    margin: 6px 0 0 24px;
}

#checkboxCPC.keyword-wizard:hover {
  cursor: pointer;
}

.checkbox-label.keyword-wizard {
  font-size: 13px;
    font-style: italic;
    color: #737373;
}

.chemistry-field.keyword-wizard {
  display: block;
}

#inputChem.input-batch.keyword-wizard {
  height: 150px;
    border: 1px solid #dfe1e5;
    padding: 6px;
}

#inputChem.keyword-wizard {
  resize: none;
    height: 15px;
    vertical-align: text-top;
    font-size: 13px;
    font-family: inherit;
    padding: 2px;
}

.chem-type-label.keyword-wizard {
  display: inline;
    font-size: 13px;
    margin-left: 12px;
    margin-right: 4px;
}

#chemType.keyword-wizard {
  border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    margin: 6px;
    padding: 2px;
    outline: none;
    font-family: inherit;
    font-size: 13px;
}

.import.keyword-wizard {
  font-size: 13px;
    font-family: inherit;
}

.import-text.keyword-wizard {
  vertical-align: middle;
    display: inline-block;
}

.import-button.keyword-wizard {
  margin: 6px 0 0 24px;
}

.import-button.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.import-button.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard {
  float: right;
    padding: 12px;
}

.wizard-buttons.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    margin: 2px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
}

@media screen and (max-width: 700px) {
#wizard.keyword-wizard {
  width: 275px;
}

.chip.keyword-wizard {
  margin: 4px 2px;
}

.keyword-input.keyword-wizard {
  width: 82%;
      margin: 4px 12px 12px 24px;
}

.search-within.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 225px;
      margin: 12px 0 6px 0;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  margin-top: 6px;
}

#inputChem.keyword-wizard {
  width: 82%;
      padding: 2px;
      margin: 8px 12px 12px 24px;
}

#inputChem.input-batch.keyword-wizard {
  width: 220px;
      padding: 4px;
}

#chemType.keyword-wizard {
  width: 150px;
}

.import-text.keyword-wizard {
  margin: 6px 12px 6px 24px;
      width: 220px;
}

iron-icon.help-header.keyword-wizard {
  display: none;
}

}

@media screen and (min-width: 700px) {
#wizard.keyword-wizard {
  width: 540px;
}

.chip.keyword-wizard {
  margin: 0 2px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 240px;
      margin: 12px 16px 6px 6px;
}

.cpc-inputs.keyword-wizard {
  display: inline;
}

.find-patents.keyword-wizard .keyword-input.keyword-wizard {
  width: 53%;
      margin: 4px 10px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard::placeholder,#inputAnd.keyword-wizard::placeholder,#inputExact.keyword-wizard::placeholder,#inputOr.keyword-wizard::placeholder,#inputMinus.keyword-wizard::placeholder {
  color: white;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  width: 35%;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  width: 42%;
      margin: 6px 4px;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

#inputChem.keyword-wizard {
  width: 290px;
      margin: 2px 12px 2px 6px;
}

#inputChem.input-batch.keyword-wizard {
  width: 280px;
      padding: 6px;
}

.import-text.keyword-wizard {
  margin: 6px 12px;
      width: 415px;
}

#chemType.keyword-wizard {
  width: 105px;
}

iron-icon.keyword-wizard:hover.help-header {
  cursor: default;
}

iron-icon.help-header.keyword-wizard {
  height: 16px;
      padding: 0 2px 2px 2px;
      color: #a3a3a3;
}

.help.keyword-wizard p.keyword-wizard {
  margin: 0 0 8px 0
}

.help.keyword-wizard .q.keyword-wizard {
  font-family: monospace;
      color: #0b8043;
      white-space: nowrap;
}

.help.keyword-wizard {
  z-index: 4;
      position: absolute;
      right: 10px;
      padding: 12px;
      border-radius: 2px;
      border: 1px solid #e0e0e0;
      box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.2), 0 6px 10px 0 rgba(0, 0, 0, 0.3);
      background: white;
      font-size: 13px;
      line-height: 20px;
      width: 450px;
      max-height: 400px;
      overflow: auto;
}

#withinHelp.keyword-wizard {
  top: 75px;
}

#chemHelp.keyword-wizard {
  top: 0;
}

#searchBooleanHelp.keyword-wizard {
  top: 140px;
}

}</style><!-- Shady DOM styles for bottom-bar --><style scope="bottom-bar">.fixed.bottom-bar {
  display: block;
  position: fixed;
  height: 46px;
  bottom: 0;
}

.fixed[medium].bottom-bar {
  height: 280px;
}

.fixed[large].bottom-bar {
  height: 480px;
}

.shadow.bottom-bar {
  background: white;
  padding: 16px;
  border-radius: 8px 8px 0px 0px;
  box-shadow: 0px 8px 10px 1px rgba(0,0,0,.14), 0px 3px 14px 2px rgba(0,0,0,.12), 0px 5px 5px -3px rgba(0,0,0,.2);
}

.oneline.bottom-bar {
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  cursor: pointer;
}

.button.bottom-bar {
  cursor: pointer;
}

.buttonAlign.bottom-bar {
  margin-top: -4px;
}

.header.bottom-bar {
  height: 30px;
  font-family: 'Google Sans';
  font-size: 18px;
  padding-bottom: 8px;
}

.list.bottom-bar {
  overflow-y: auto;
  line-height: 20px;
}

.definition.bottom-bar {
  padding: 0px 0px 4px 0px;
  cursor: pointer;
}

[medium].bottom-bar .content.bottom-bar {
  height: 230px;
}

[large].bottom-bar .content.bottom-bar {
  height: 430px;
}

[medium].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 200px;
}

[large].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 400px;
}

[hidden].bottom-bar {
  display: none;
}

.label.bottom-bar {
  font-family: 'Google Sans';
  font-size: 12px;
  line-height: 16px;
  font-weight: 400;
  padding: 6px 0px 4px 0px;
  color: #1f1f1f;
}

[pad].bottom-bar {
  margin-left: 16px;
}

.layout.vertical.bottom-bar {
  display: flex;
  flex-direction: column;
}

.layout.horizontal.bottom-bar {
  display: flex;
  flex-direction: row;
}

.flex.bottom-bar {
  flex: 1;
  flex-basis: 0.000000001px;
}

.layout.start.bottom-bar {
  align-items: flex-start;
}

.layout.center.bottom-bar {
  align-items: center;
}

.layout.end.bottom-bar {
  align-items: flex-end;
}

.flex-2.bottom-bar {
  flex: 2;
}

.flex-3.bottom-bar {
  flex: 3;
}

.flex-4.bottom-bar {
  flex: 4;
}

.flex-5.bottom-bar {
  flex: 5;
}

.flex-6.bottom-bar {
  flex: 6;
}

.flex-7.bottom-bar {
  flex: 7;
}

.flex-8.bottom-bar {
  flex: 8;
}

.flex-9.bottom-bar {
  flex: 9;
}

.flex-10.bottom-bar {
  flex: 10;
}

.flex-11.bottom-bar {
  flex: 11;
}

.flex-12.bottom-bar {
  flex: 12;
}</style><!-- Shady DOM styles for landscape-link --><!-- Shady DOM styles for landscape-summary-box --><!-- Shady DOM styles for search-state --><!-- Shady DOM styles for iron-overlay-backdrop --><!-- Shady DOM styles for opaque-animation --><!-- Shady DOM styles for iron-dropdown --><style scope="iron-dropdown">iron-dropdown {
  position: fixed;
}

#contentWrapper.iron-dropdown  > * {
  overflow: auto;
}

#contentWrapper.animating.iron-dropdown  > * {
  overflow: hidden;
}</style><!-- Shady DOM styles for iron-meta --><!-- Shady DOM styles for iron-icon --><style scope="iron-icon-0">.iron-icon-0 {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;-ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;-ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
        position: relative;

        vertical-align: middle;

        fill: currentcolor;
        stroke: none;

        width: 24px;
        height: 24px;;
}

.iron-icon-0[hidden] {
  display: none;
}</style><!-- Shady DOM styles for iron-iconset-svg --><!-- Shady DOM styles for iron-list --><!-- Shady DOM styles for paper-icon-item --><!-- Shady DOM styles for paper-item-body --><!-- Shady DOM styles for paper-item --><!-- Shady DOM styles for dropdown-menu --><style scope="dropdown-menu">dropdown-menu {
  display: inline-block;
        line-height: 24px;
}

.label.dropdown-menu {
  cursor: pointer;
        color: #666;
        align-items: center;
        margin-right: 8px;
        display: inline-block;
        padding: 2px 0;
}

#selected.dropdown-menu {
  color: #212121;
}

.label[open].dropdown-menu {
  border-color: #e0e0e0;
}

iron-dropdown.dropdown-menu {
  margin-top: 26px;
}

iron-icon.dropdown-menu {
  height: 15px;
        width: 15px;
}

#menu.dropdown-menu {
  max-height: 300px;
        padding: 8px 0;
        background: white;
        display: block;
        border-radius: 2px;
        box-shadow: 0 0 2px rgba(0,0,0,0.12), 0 2px 2px rgba(0,0,0,0.24);
}

.item.dropdown-menu {
  cursor: pointer;
        color: rgba(0,0,0,.87);
        font-size: 13px;
        line-height: 18px;
        padding: 6px 18px;
}

.item.dropdown-menu:hover {
  background-color: #e0e0e0;
}

.item[selected].dropdown-menu {
  background-color: #e0e0e0;
}

[multi].dropdown-menu .item.dropdown-menu {
  padding: 6px 18px 6px 34px;
}

[multi].dropdown-menu .item[selected].dropdown-menu {
  background-image: url('https://www.gstatic.com/images/icons/material/system/2x/done_grey600_24dp.png');
        background-position: 8px center;
        background-size: 16px;
        background-repeat: no-repeat;
}</style><!-- Shady DOM styles for chips-input --><!-- Shady DOM styles for input-chip --><!-- Shady DOM styles for keyword-editor --><!-- Shady DOM styles for paper-ripple --><!-- Shady DOM styles for paper-button --><!-- Shady DOM styles for date-editor --><!-- Shady DOM styles for metadata-editor --><!-- Shady DOM styles for restrict-editor --><!-- Shady DOM styles for overlay-tooltip --><style scope="overlay-tooltip">overlay-tooltip {
  display: none;
        color: #fff;
        background-color: #000;
        padding: 10px 12px;
        border-radius: 3px;
        font-size: 13px;
        font-weight: normal;
        line-height: normal;
        position: fixed;
        z-index: 100;
}

#arrow.overlay-tooltip {
  width: 0;
        height: 0;
        border-style: solid;
        border-width: 0 6px 8px 6px;
        border-color: transparent transparent #000 transparent;
        position: absolute;
        top: -8px;
        left: calc(50% - 6px);
}</style><!-- Shady DOM styles for query-renderer --><!-- Shady DOM styles for result-nav --><style scope="result-nav">result-nav {
  display: block;
        white-space: nowrap;
        padding: 0 30px;
        line-height: 30px;
        height: 30px;
        margin-top: 17px;
        font-weight: 500;
        font-size: 15px;
}

state-modifier.result-nav {
  color: #333;
}

state-modifier[disabled].result-nav {
  pointer-events: none;
        color: #ccc;
}</style><!-- Shady DOM styles for raw-html --><!-- Shady DOM styles for paper-material --><style scope="paper-material-0">.paper-material-0 {
  display: block;
        position: relative;
}

.paper-material-0[elevation="1"] {
  box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.14),
                    0 1px 5px 0 rgba(0, 0, 0, 0.12),
                    0 3px 1px -2px rgba(0, 0, 0, 0.2);
}

.paper-material-0[elevation="2"] {
  box-shadow: 0 4px 5px 0 rgba(0, 0, 0, 0.14),
                    0 1px 10px 0 rgba(0, 0, 0, 0.12),
                    0 2px 4px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="3"] {
  box-shadow: 0 6px 10px 0 rgba(0, 0, 0, 0.14),
                    0 1px 18px 0 rgba(0, 0, 0, 0.12),
                    0 3px 5px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="4"] {
  box-shadow: 0 8px 10px 1px rgba(0, 0, 0, 0.14),
                    0 3px 14px 2px rgba(0, 0, 0, 0.12),
                    0 5px 5px -3px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="5"] {
  box-shadow: 0 16px 24px 2px rgba(0, 0, 0, 0.14),
                    0  6px 30px 5px rgba(0, 0, 0, 0.12),
                    0  8px 10px -5px rgba(0, 0, 0, 0.4);
}

.paper-material-0[animated] {
  transition: box-shadow 0.28s cubic-bezier(0.4, 0, 0.2, 1);
}

.paper-material-0 {
  ;
}</style><!-- Shady DOM styles for search-box --><style scope="search-box">.layout.horizontal.search-box,.layout.vertical.search-box {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-box {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-box {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-box {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-box {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-box {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-box,.layout.center-center.search-box {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-box,.layout.center-center.search-box {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-box {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-box {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-box {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.inputbox.search-box {
  border: 1px solid #ccc;
        padding: 0 12px;
        background: white;
}

.inputbox[focused].search-box {
  border: 1px solid #4285f4 !important;
}

.inputbox.search-box:hover {
  border: 1px solid #999;
}

#searchInput.search-box {
  font-family: inherit;
        font-size: 16px;
        padding: 8px 0;
        outline: none;
        border-right: none;
        width: 100%;
        margin-right: 0;
        border: 0;
}

#searchButton.search-box {
  cursor: pointer;
        background-color: #4285f4;
        border: none;
        color: #fff;
        vertical-align: top;
        width: 70px;
        height: 37px;
        outline: none;
}

.suggest-bg.search-box {
  display: inline-block;
        min-width: 0;
        white-space: nowrap;
}

#suggestMenu.search-box {
  position: absolute;
        margin-top: 38px;
        width: 100%;
        background: white;
        z-index: 1;
}

#suggestMenu.search-box .row.search-box {
  font-size: 13px;
        line-height: 28px;
        white-space: nowrap;
        overflow: hidden;
        text-overflow: ellipsis;
        padding: 4px 2px;
        cursor: pointer;
}

.row[selected].search-box {
  background: rgba(0, 0, 0, 0.05);
}

.suggest-icon.search-box {
  height: 20px;
        width: 20px;
        padding: 0 12px 0 6px;
        transition: transform .15s linear;
        transform: scale(1);
}

.suggest-icon[hide].search-box {
  transform: scale(0);
}

#corpora.search-box {
  padding: 6px 0;
        user-select: none;
}

#corpora.search-box iron-icon.search-box {
  height: 20px;
        width: 20px;
        color: #ccc;
        cursor: pointer;
}

#corpora.search-box iron-icon[active].search-box {
  color: #4285f4 !important;
}

#corpora.search-box iron-icon.search-box:hover {
  color: #999;
}</style><!-- Shady DOM styles for iron-media-query --><!-- Shady DOM styles for paper-header-panel --><!-- Shady DOM styles for iron-a11y-announcer --><style scope="iron-a11y-announcer">iron-a11y-announcer {
  display: inline-block;
        position: fixed;
        clip: rect(0px,0px,0px,0px);
}</style><!-- Shady DOM styles for iron-autogrow-textarea --><!-- Shady DOM styles for iron-input --><!-- Shady DOM styles for paper-input-char-counter --><!-- Shady DOM styles for paper-input-container --><!-- Shady DOM styles for paper-input-error --><!-- Shady DOM styles for paper-input --><!-- Shady DOM styles for paper-textarea --><!-- Shady DOM styles for paper-toast --><style scope="paper-toast-0">.paper-toast-0 {
  display: block;
        position: fixed;
        background-color: #323232;
        color: #f1f1f1;
        min-height: 48px;
        min-width: 288px;
        padding: 16px 24px;
        box-sizing: border-box;
        box-shadow: 0 2px 5px 0 rgba(0, 0, 0, 0.26);
        border-radius: 2px;
        margin: 12px;
        font-size: 14px;
        cursor: default;
        -webkit-transition: -webkit-transform 0.3s, opacity 0.3s;
        transition: transform 0.3s, opacity 0.3s;
        opacity: 0;
        -webkit-transform: translateY(100px);
        transform: translateY(100px);font-family: 'Roboto', 'Noto', sans-serif;
        -webkit-font-smoothing: antialiased;
}

.paper-toast-0.capsule {
  border-radius: 24px;
}

.paper-toast-0.fit-bottom {
  width: 100%;
        min-width: 0;
        border-radius: 0;
        margin: 0;
}

.paper-toast-0.paper-toast-open {
  opacity: 1;
        -webkit-transform: translateY(0px);
        transform: translateY(0px);
}</style><!-- Shady DOM styles for paper-toolbar --><!-- Shady DOM styles for search-footer --><style scope="search-footer">#footer.search-footer {
  font-size: 13px;
        margin-top: 10px;
        background: #fafafa;
        padding: 20px 10px;
        align-items: center;
        border-top: 1px solid #ebebeb;
}

#footer.search-footer .links.search-footer > *.search-footer {
  display: inline-block;
        margin: 0 12px;
}

.layout.horizontal.search-footer,.layout.vertical.search-footer {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-footer {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-footer {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-footer {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-footer {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-footer {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-footer {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-footer {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-footer {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-footer {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-footer {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-footer {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-footer {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-footer {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-footer {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-footer {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-footer {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-footer {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-footer {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-footer {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-footer {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-footer {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-footer {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-footer {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-footer {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-footer {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-header --><style scope="search-header">search-header {
  display: block;
}

.lockup-logo.search-header,.lockup-text.search-header {
  display: inline-block;
}

.lockup-logo.search-header {
  width: 74px;
        height: 24px;
        background-image: url('https://www.gstatic.com/images/branding/googlelogo/1x/googlelogo_color_74x24dp.png');
        background-size: 74px 24px;
}

.lockup-text.search-header {
  font-family: "Product Sans", Arial, Helvetica, sans-serif;

        
        font-size: 22.1px;

        
        text-rendering: optimizeLegibility;

        
        position: relative;
        top: -6px;
        left: -5px;

        
        -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
}

.lockup-brand.search-header {
  opacity: 0.54;
}

@media (-webkit-min-device-pixel-ratio: 1.5), (min-resolution: 144dpi) {
.lockup-logo.search-header {
  background-image: url('https://www.gstatic.com/images/branding/googlelogo/2x/googlelogo_color_74x24dp.png');
}

.lockup-text.search-header {
  font-size: 21.3px;
          left: -7px;
}

}

header.search-header {
  background-color: #fafafa;
        border-bottom: 1px solid #ebebeb;
        color: #333;
        height: 60px;
        width: 100%;
        z-index: 1;
        display: block;
}

[latestStyle].search-header header.search-header {
  background-color: transparent;
}

.headerpad.search-header {
  margin-left: 16px;
}

[wide].search-header .headerpad.search-header {
  margin-left: 32px;
}

.leftheader.search-header {
  width: 322px;
}

header.search-header h1.search-header {
  display: none;
}

header.search-header h1.search-header state-modifier.search-header {
  color: #777;
        text-decoration: none;
        display: inline-block;
}

[wide].search-header header.search-header h1.search-header {
  box-sizing: border-box;
        margin: 0;
        padding: 20px 0 10px;
        font-size: 20px;
        font-weight: 400;
        white-space: nowrap;
        display: block;
}

search-box.search-header {
  height: 37px;
        padding: 0 16px;
        width: 900px;
        align-self: center;
}

.layout.horizontal.search-header,.layout.vertical.search-header {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-header {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-header {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-header {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-header {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-header {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-header {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-header {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-header {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-header {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-header {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-header {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-header {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-header {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-header {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-header {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-header {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-header {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-header {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-header {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-header {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-header {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-header {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-header {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-header {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-header {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-ui --><style scope="search-ui-0">.search-ui-0 paper-button.search-ui {
  display: inline-block;
        text-align: center;
        font-family: inherit;
}

.search-ui-0 .layout.horizontal.search-ui,.search-ui-0 .layout.vertical.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.search-ui-0 .layout.inline.search-ui {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.search-ui-0 .layout.horizontal.search-ui {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.search-ui-0 .layout.vertical.search-ui {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.search-ui-0 .layout.wrap.search-ui {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.search-ui-0 .layout.no-wrap.search-ui {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .flex.search-ui {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.search-ui-0 .flex-auto.search-ui {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.search-ui-0 .flex-none.search-ui {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.search-ui-0 .layout.start.search-ui {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.end.search-ui {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.search-ui-0 .layout.baseline.search-ui {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.search-ui-0 .layout.start-justified.search-ui {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .layout.end-justified.search-ui {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.search-ui-0 .layout.around-justified.search-ui {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.search-ui-0 .layout.justified.search-ui {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.search-ui-0 .self-start.search-ui {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.search-ui-0 .self-center.search-ui {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.search-ui-0 .self-end.search-ui {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.search-ui-0 .self-stretch.search-ui {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.search-ui-0 .self-baseline.search-ui {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.search-ui-0 .layout.start-aligned.search-ui {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.search-ui-0 .layout.end-aligned.search-ui {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.search-ui-0 .layout.center-aligned.search-ui {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.search-ui-0 .layout.between-aligned.search-ui {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.search-ui-0 .layout.around-aligned.search-ui {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.search-ui-0 {
  display: block;
        min-width: 350px;
        height: 100%;
}

.search-ui-0 #content.search-ui {
  height: 100%;
}

.search-ui-0 #leftBarOverflow.search-ui {
  padding-right: 16px;
}

.search-ui-0 [wide].search-ui #leftBarOverflow.search-ui {
  overflow: auto;
}

.search-ui-0 #leftBar.search-ui {
  box-sizing: border-box;
        color: #666;
        font-size: 13px;
        padding: 16px 0 16px 16px;
        border-bottom: 1px solid #e5e5e5;
}

.search-ui-0 [wide].search-ui #leftBar.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;

        -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
        position: relative;
        width: 350px;
        margin-bottom: 0;
        padding-bottom: 0;
        border-bottom: none;
}

@media print {
.search-ui-0 #leftBar.search-ui {
  display: none !important;
}

}

.search-ui-0 #leftBar.search-ui h3.search-ui {
  text-transform: uppercase;
        font-size: 13px;
        font-weight: normal;
        margin-top: 6px;
        margin-bottom: 6px;
        cursor: default;
        display: inline-block;
        color: #a3a3a3;
}

.search-ui-0 #closeButton.search-ui {
  position: absolute;
        right: 0;
}

.search-ui-0 #searchTermsHeader.search-ui {
  position: relative;
}

.search-ui-0 #searchTermsQ.search-ui iron-icon.search-ui {
  height: 16px;
        padding: 0 2px 2px 2px;
        color: #a3a3a3;
}

.search-ui-0 #searchTermsHeader.search-ui:hover iron-icon.search-ui {
  color: #4285f4;
}

.search-ui-0 #closeLeftBar.search-ui {
  height: 16px;
        width: 16px;
        padding: 0 0 8px 0;
        cursor: pointer;
}

.search-ui-0 #compactQuery.search-ui iron-icon.search-ui {
  height: 20px;
}

.search-ui-0 #backToResultsButton.search-ui {
  color: #fff;
        background: #4285f4;
        margin-top: 20px;
        text-align: center;
}

.search-ui-0 #main.search-ui {
  display: block;
        min-height: calc(100vh - 127px);
}

@media print {
.search-ui-0 [wide].search-ui main.search-ui {
  margin-left: 0;
}

}</style><!-- Shady DOM styles for import-list --><!-- Shady DOM styles for iron-request --><!-- Shady DOM styles for iron-ajax --><!-- Shady DOM styles for paper-dialog --><!-- Shady DOM styles for coverage-stats --><!-- Shady DOM styles for iron-image --><!-- Shady DOM styles for iron-selector --><!-- Shady DOM styles for paper-card --><!-- Shady DOM styles for paper-checkbox --><!-- Shady DOM styles for landing-page --><!-- Shady DOM styles for remote-fetch --><!-- Shady DOM styles for paper-spinner --><style scope="paper-spinner-0">.paper-spinner-0 {
  display: inline-block;
        position: relative;
        width: 28px;
        height: 28px;
}

.paper-spinner-0 #spinnerContainer.paper-spinner {
  width: 100%;
        height: 100%;

        
        direction: ltr;
}

.paper-spinner-0 #spinnerContainer.active.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite;
        animation: container-rotate-paper-spinner-0 1568ms linear infinite;
}

@-webkit-keyframes container-rotate-paper-spinner-0 {
to {
  -webkit-transform: rotate(360deg)
}

}

@keyframes container-rotate-paper-spinner-0 {
to {
  transform: rotate(360deg)
}

}

.paper-spinner-0 .spinner-layer.paper-spinner {
  position: absolute;
        width: 100%;
        height: 100%;
        opacity: 0;
        white-space: nowrap;
        color: #4285f4;
}

.paper-spinner-0 .layer-1.paper-spinner {
  color: #4285f4;
}

.paper-spinner-0 .layer-2.paper-spinner {
  color: #db4437;
}

.paper-spinner-0 .layer-3.paper-spinner {
  color: #f4b400;
}

.paper-spinner-0 .layer-4.paper-spinner {
  color: #0f9d58;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0;
        -webkit-animation-duration: 5332ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-name: fill-unfill-rotate-paper-spinner-0;
        animation-duration: 5332ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
        opacity: 1;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-1.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-2.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-3.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-4.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
}

@-webkit-keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  -webkit-transform: rotate(135deg)
}

25% {
  -webkit-transform: rotate(270deg)
}

37.5% {
  -webkit-transform: rotate(405deg)
}

50% {
  -webkit-transform: rotate(540deg)
}

62.5% {
  -webkit-transform: rotate(675deg)
}

75% {
  -webkit-transform: rotate(810deg)
}

87.5% {
  -webkit-transform: rotate(945deg)
}

to {
  -webkit-transform: rotate(1080deg)
}

}

@keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  transform: rotate(135deg)
}

25% {
  transform: rotate(270deg)
}

37.5% {
  transform: rotate(405deg)
}

50% {
  transform: rotate(540deg)
}

62.5% {
  transform: rotate(675deg)
}

75% {
  transform: rotate(810deg)
}

87.5% {
  transform: rotate(945deg)
}

to {
  transform: rotate(1080deg)
}

}

@-webkit-keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@-webkit-keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

.paper-spinner-0 .circle-clipper.paper-spinner {
  display: inline-block;
        position: relative;
        width: 50%;
        height: 100%;
        overflow: hidden;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after {
  left: 45%;
        width: 10%;
        border-top-style: solid;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after,.paper-spinner-0 .circle-clipper.paper-spinner::after {
  content: '';
        box-sizing: border-box;
        position: absolute;
        top: 0;
        border-width: 3px;
        border-radius: 50%;
}

.paper-spinner-0 .circle-clipper.paper-spinner::after {
  bottom: 0;
        width: 200%;
        border-style: solid;
        border-bottom-color: transparent !important;
}

.paper-spinner-0 .circle-clipper.left.paper-spinner::after {
  left: 0;
        border-right-color: transparent !important;
        -webkit-transform: rotate(129deg);
        transform: rotate(129deg);
}

.paper-spinner-0 .circle-clipper.right.paper-spinner::after {
  left: -100%;
        border-left-color: transparent !important;
        -webkit-transform: rotate(-129deg);
        transform: rotate(-129deg);
}

.paper-spinner-0 .active.paper-spinner .gap-patch.paper-spinner::after,.paper-spinner-0 .active.paper-spinner .circle-clipper.paper-spinner::after {
  -webkit-animation-duration: 1333ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-duration: 1333ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.left.paper-spinner::after {
  -webkit-animation-name: left-spin-paper-spinner-0;
        animation-name: left-spin-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.right.paper-spinner::after {
  -webkit-animation-name: right-spin-paper-spinner-0;
        animation-name: right-spin-paper-spinner-0;
}

@-webkit-keyframes left-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(130deg)
}

50% {
  -webkit-transform: rotate(-5deg)
}

to {
  -webkit-transform: rotate(130deg)
}

}

@keyframes left-spin-paper-spinner-0 {
0% {
  transform: rotate(130deg)
}

50% {
  transform: rotate(-5deg)
}

to {
  transform: rotate(130deg)
}

}

@-webkit-keyframes right-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(-130deg)
}

50% {
  -webkit-transform: rotate(5deg)
}

to {
  -webkit-transform: rotate(-130deg)
}

}

@keyframes right-spin-paper-spinner-0 {
0% {
  transform: rotate(-130deg)
}

50% {
  transform: rotate(5deg)
}

to {
  transform: rotate(-130deg)
}

}

.paper-spinner-0 #spinnerContainer.cooldown.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
        animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
}

@-webkit-keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}</style><!-- Shady DOM styles for paper-spinner-lite --><!-- Shady DOM styles for concept-card --><!-- Shady DOM styles for concept-mention --><style scope="concept-mention">.block.concept-mention {
  display: block;
}

[hidden].concept-mention {
  display: none !important;
}

.invisible.concept-mention {
  visibility: hidden !important;
}

.relative.concept-mention {
  position: relative;
}

.fit.concept-mention {
  position: absolute;
        top: 0;
        right: 0;
        bottom: 0;
        left: 0;
}

body.fullbleed.concept-mention {
  margin: 0;
        height: 100vh;
}

.scroll.concept-mention {
  -webkit-overflow-scrolling: touch;
        overflow: auto;
}

.fixed-bottom.concept-mention,.fixed-left.concept-mention,.fixed-right.concept-mention,.fixed-top.concept-mention {
  position: fixed;
}

.fixed-top.concept-mention {
  top: 0;
        left: 0;
        right: 0;
}

.fixed-right.concept-mention {
  top: 0;
        right: 0;
        bottom: 0;
}

.fixed-bottom.concept-mention {
  right: 0;
        bottom: 0;
        left: 0;
}

.fixed-left.concept-mention {
  top: 0;
        bottom: 0;
        left: 0;
}

#target.concept-mention:hover {
  background-color: #e8f0fe;
}

#target[noicon].concept-mention {
  padding: 1px;
}

#target.concept-mention:hover[noicon] {
  border: 1px solid #e8f0fe;
        padding: 0;
}

#target.concept-mention {
  display: inline-block;
}

.inline-icon.concept-mention {
  cursor: pointer;
        height: 12px;
        width: 12px;
        padding-left: 4px;
        color: #5e6368;
}

concept-card.concept-mention {
  z-index: 1;
        position: absolute;
}</style><!-- Shady DOM styles for fterm-concept-card --><!-- Shady DOM styles for fterm-concept-mention --><!-- Shady DOM styles for paper-fab --><!-- Shady DOM styles for paper-icon-button --><!-- Shady DOM styles for paper-icon-button-light --><!-- Shady DOM styles for classification-tree --><style scope="classification-tree">.layout.horizontal.classification-tree,.layout.vertical.classification-tree {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.classification-tree {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.classification-tree {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.classification-tree {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.classification-tree {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.classification-tree {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.classification-tree {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.classification-tree {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.classification-tree {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

classification-tree {
  display: block;
        line-height: 20px;
}

.wrap.classification-tree {
  padding: 6px 12px;
}

.wrap.classification-tree:hover {
  background: #fafafa;
}

.description.classification-tree {
  padding-left: 4px;
}

iron-icon.classification-tree {
  color: #eaeaea;
}

.code[first].classification-tree {
  font-weight: 500;
}

.code[additional].classification-tree {
  font-style: italic;
}</style><!-- Shady DOM styles for classification-viewer --><style scope="classification-viewer">.table.classification-viewer {
  border: 1px solid #eaeaea;
        display: block;
}

.more.classification-viewer {
  padding: 6px 12px;
        cursor: pointer;
        font-style: italic;
        color: #aaa;
}

.more.classification-viewer:hover {
  background: #fafafa;
}

.chip.classification-viewer {
  display: inline-block;
        padding: 4px 6px;
        border-radius: 2px;
}

.chip[additional].classification-viewer {
  font-style: italic;
}</style><!-- Shady DOM styles for image-carousel --><!-- Shady DOM styles for image-viewer --><!-- Shady DOM styles for patent-result --><style scope="patent-result">#wrapper.patent-result {
  padding: 20px;
        max-width: 1050px;
        outline: 0;
}

.scroll-target.patent-result:before {
  display: block;
        content: '';
        visibility: hidden;
}

h1.patent-result {
  font-weight: 500;
        font-size: 20px;
        margin: 0 0 20px 0;
}

h3.patent-result {
  font-size: 15px;
        font-weight: 500;
        margin: 28px 0 18px 0;
}

dl.patent-result {
  line-height: 1.5;
        font-size: 0;
}

dt.patent-result,dd.patent-result {
  display: inline;
        font-size: 13px;
        margin: 0;
}

dt.patent-result {
  font-weight: 500;
        color: #000;
}

dt.patent-result::after {
  content: ': ';
}

dd.patent-result {
  color: #aaa;
}

dd.patent-result ~ dd.patent-result::before {
  content: ', ';
}

dt.patent-result + dd.patent-result::before {
  content: '';
}

dd.patent-result ~ dt.patent-result::before {
  display: block;
        content: '';
        margin-top: 8px;
}

dd.patent-result core-icon.patent-result {
  width: 14px;
        height: 14px;
        vertical-align: top;
        color: inherit;
}

.table.patent-result {
  display: table;
        border-collapse: collapse;
        border-spacing: 0;
        border: 1px solid #eaeaea;
        width: 100%;
        box-sizing: border-box;
}

.tr.patent-result {
  display: table-row;
        border-bottom: 1px solid #eaeaea;
}

.th.patent-result,.td.patent-result {
  display: table-cell;
        padding: 10px 12px;
}

.thead.patent-result {
  display: table-header-group;
}

.tbody.patent-result {
  display: table-row-group;
}

.th.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.td.patent-result {
  vertical-align: top;
}

.td.patent-result > p.patent-result {
  margin-top: 0;
}

.nowrap.patent-result {
  white-space: nowrap;
}

.knowledge-card.patent-result {
  border: 1px solid #e5e5e5;
        border-radius: 2px;
}

.knowledge-card.patent-result > header.patent-result {
  -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
        background: #4285f4;
        color: #fff;
        padding: 20px 12px;
}

.knowledge-card.patent-result > header.patent-result state-modifier.patent-result,.knowledge-card.patent-result > header.patent-result a.patent-result {
  color: inherit;
        margin: 0 12px 0 0;
        display: inline-block;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result,.knowledge-card.patent-result > header.patent-result .tagline.patent-result {
  margin: 0;
        font-weight: normal;
        padding-top: 4px;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result {
  font-size: 20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result {
  background: #3367d6;
        padding: 10px 12px;
        margin: 20px -12px -20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result core-icon.patent-result {
  margin-right: 12px;
        width: 24px;
        height: 24px;
}

.knowledge-card.patent-result dl.patent-result {
  padding: 16px 12px;
}

.knowledge-card.patent-result hr.patent-result {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 0;
}

.main-link.patent-result {
  margin: 14px;
        font-weight: 500;
}

.footer.patent-result h3.patent-result state-modifier.patent-result,.footer.patent-result h3.patent-result a.patent-result {
  float: right;
        font-weight: 400;
        font-size: 13px;
        line-height: 24px;
}

.footer.patent-result dl.patent-result {
  margin-left: 30px;
}

.footer.patent-result > ul.patent-result > li.patent-result {
  margin-bottom: 8px;
}

h3.patent-result .righthead.patent-result {
  color: #aaa;
        font-weight: 400;
        font-size: 13px;
        cursor: help;
}

.tooltip-hint.patent-result {
  border-bottom: 1px dotted #ccc;
}

[marginRight].patent-result {
  margin-right: 60px;
}

.flex-width.patent-result {
  min-width: 0;
        word-break: break-word;
}

.responsive-table.patent-result {
  width: 100%;
        overflow-x: auto;
        overflow-y: hidden;
}

.layout.horizontal.patent-result,.layout.vertical.patent-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.flex.patent-result,.flex-1.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-2.patent-result {
  -ms-flex: 2;
        -webkit-flex: 2;
        flex: 2;
}

.flex-3.patent-result {
  -ms-flex: 3;
        -webkit-flex: 3;
        flex: 3;
}

.flex-4.patent-result {
  -ms-flex: 4;
        -webkit-flex: 4;
        flex: 4;
}

.flex-5.patent-result {
  -ms-flex: 5;
        -webkit-flex: 5;
        flex: 5;
}

.flex-6.patent-result {
  -ms-flex: 6;
        -webkit-flex: 6;
        flex: 6;
}

.flex-7.patent-result {
  -ms-flex: 7;
        -webkit-flex: 7;
        flex: 7;
}

.flex-8.patent-result {
  -ms-flex: 8;
        -webkit-flex: 8;
        flex: 8;
}

.flex-9.patent-result {
  -ms-flex: 9;
        -webkit-flex: 9;
        flex: 9;
}

.flex-10.patent-result {
  -ms-flex: 10;
        -webkit-flex: 10;
        flex: 10;
}

.flex-11.patent-result {
  -ms-flex: 11;
        -webkit-flex: 11;
        flex: 11;
}

.flex-12.patent-result {
  -ms-flex: 12;
        -webkit-flex: 12;
        flex: 12;
}

@media print {
#text.patent-result {
  flex-direction: column-reverse !important;
}

}

patent-result-ref-list.patent-result {
  width: 100%;
}

patent-result-ref-list.patent-result + patent-result-ref-list.patent-result {
  margin-left: 10px;
}

[narrow].patent-result {
  flex-direction: column-reverse !important;
}

.famheader.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.collapse.patent-result {
  color: #616161;
        font-size: 13px;
        cursor: pointer;
}

#imageDrag.patent-result {
  position: fixed;
        cursor: col-resize;
}

#imageDrag.patent-result div.patent-result {
  width: 4px;
        height: 100%;
        margin: 0 4px;
        background: #eee;
}

#imageDrag.patent-result:hover {
  background: #eee;
}

#imageDrag.patent-result:hover div.patent-result {
  background: #ccc;
}

.imageWrapper.patent-result {
  position: fixed;
        top: 60px;
        background: white;
        margin-left: 12px;
}

#notices.patent-result {
  padding: 20px;
}

#figures.patent-result {
  background: #efefef;
}

.headerButton.patent-result {
  color: #3c80f6;
        cursor: pointer;
        display: inline-block;
        padding: 0 14px;
        line-height: 27px;
}

.headerButton.patent-result iron-icon.patent-result {
  width: 16px;
        height: 16px;
}

.tr.conceptDomain.patent-result {
  display: table-row;
}

.responsive-grid.patent-result {
  display: grid;
        gap: 8px;
        grid-template-columns: none;
}</style><!-- Shady DOM styles for family-viewer --><!-- Shady DOM styles for app-row --><!-- Shady DOM styles for application-timeline --><style scope="application-timeline">.layout.horizontal.application-timeline,.layout.vertical.application-timeline {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.application-timeline {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.application-timeline {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.application-timeline {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.application-timeline {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.application-timeline {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.application-timeline {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.application-timeline {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.application-timeline {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.wrap.application-timeline {
  padding: 16px 12px;
}

.event.application-timeline {
  padding: 3px 0;
}

[date].application-timeline {
  color: #5f6368;
        font-size: 13px;
        padding: 3px 0;
        width: 70px;
        line-height: 16px;
}

[critical].application-timeline [date].application-timeline {
  color: #202124;
        font-weight: 500;
        line-height: 18px;
}

.line.application-timeline {
  margin: 9px 6px;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
}

.dot.application-timeline {
  margin: 3px 0;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
        display: inline-block;
}

[critical].application-timeline .line.application-timeline {
  background: #4285f4;
}

[current].application-timeline .line.application-timeline {
  background: #81c995;
}

[current][critical].application-timeline .line.application-timeline {
  background: #81c995;
}

.title.application-timeline {
  font-size: 13px;
        padding: 3px 0;
        line-height: 16px;
}

.title-text.application-timeline {
  color: #5f6368;
}

.description-item.application-timeline {
  font-size: 12px;
        padding: 6px 0;
        max-width: 300px;
}

#legal.application-timeline {
  height: 14px;
        width: 14px;
        padding: 0 3px 1px 3px;
        vertical-align: text-bottom;
}

#icon.application-timeline {
  height: 12px;
        width: 12px;
        padding: 0 3px 3px 3px;
        vertical-align: text-bottom;
}

.unknown.application-timeline {
  font-style: italic;
}

.not_active.application-timeline {
  text-decoration: line-through;
}

.active.application-timeline {
  font-weight: 500;
}

#cc[this].application-timeline {
  color: #202124 !important;
        text-decoration: underline;
}

#cc[this].not_active.application-timeline {
  text-decoration: line-through underline;
}

hr.application-timeline {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 10px 0 16px 0;
}

.header.application-timeline {
  font-size: 13px;
        line-height: 20px;
        font-weight: 500;
        color: #202124;
        padding-bottom: 8px;
}

.block.application-timeline {
  padding: 0 6px 0 0;
}

.year.application-timeline {
  color: #5f6368;
        font-size: 13px;
        font-weight: 500;
        padding: 3px 1px;
        width: 70px;
}

.expand.application-timeline {
  cursor: pointer;
        padding: 6px 0 3px 0;
}</style><!-- Shady DOM styles for patent-text --><style scope="patent-text">.layout.horizontal.patent-text,.layout.vertical.patent-text {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-text {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-text {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-text {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-text {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-text {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-text {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-text {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-text {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-text {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-text {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-text {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-text {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-text {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-text {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-text {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-text {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-text {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-text {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-text {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-text {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-text {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-text {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-text {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-text {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-text {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

patent-text {
  display: block;
}

#text.patent-text {
  line-height: 20px;
        min-width: 0;
}

#margin.patent-text {
  width: 16px;
}

#createHighlight.patent-text {
  position: relative;
        width: 16px;
        height: 16px;
        cursor: pointer;
}

.notranslate.patent-text > .google-src-text.patent-text {
  display: none;
}

.notranslate.patent-text:hover,mark.patent-text {
  background-color: #fbfcae;
}

.description-paragraph.patent-text {
  margin-block-start: 1em;
        margin-block-end: 1em;
}

.claim-text.patent-text {
  margin: 14px 0 0 20px;
}

.claim-dependent.patent-text {
  margin-left: 40px;
        color: #888;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim-text.patent-text {
  height: 0;
        width: 0;
        visibility: hidden;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim.patent-text:after {
  content: ""
}

.patent-full-image.patent-text {
  max-width: 100%;
        height: auto;
}

.small-patent-image.patent-text {
  display: inline;
}

ul.patent-text {
  padding: 0 0 0 50px;
}

li.patent-text {
  list-style-type: none;
        position: relative;
}

ol.claims.patent-text li.patent-text {
  list-style-type: decimal;
        font-weight: bold;
}

ol.claims.patent-text li.patent-text > *.patent-text {
  font-weight: normal;
}

li.patent-text > para-num.patent-text {
  position: absolute;
        left: -45px;
        color: #888;
}

mark.patent-text {
  background: #fff59d;
}

mark.searchText.patent-text {
  background: #80deea;
}

.searchTextHeader.patent-text {
  font-weight: 500;
}

pre.patent-text {
  white-space: pre-wrap;
}

heading.patent-text {
  display: block;
        font-weight: 500;
        font-size: 13px;
}

#comment.patent-text {
  width: 16px;
        height: 16px;
}

[has-search][no-results].patent-text {
  display: none;
}

.highlight.patent-text {
  background-color: #fef7e0;
}</style><!-- Shady DOM styles for para-num --><!-- Shady DOM styles for result-container --><style scope="result-container">paper-spinner.result-container {
  position: absolute;
        
        top: calc(50%  + 56px - 16px);
        left: calc(50% + 175px - 16px);
}</style><!-- Shady DOM styles for scholar-result --><!-- Shady DOM styles for search-result --><style scope="search-result">.layout.horizontal.search-result,.layout.vertical.search-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

search-result {
  display: block;
        font-size: 13px;
}

#mainContainer.search-result {
  min-height: calc(100vh - 127px);
        color: #333;
}

#compactQuery.search-result {
  padding: 18px 20px 10px 20px;
        cursor: pointer;
}

#compactQuery.search-result > span.search-result {
  padding: 0 14px 0 0;
}

#compactQuery.search-result iron-icon.search-result {
  padding-right: 6px;
        height: 16px;
        width: 16px;
}</style><!-- Shady DOM styles for webdoc-result --><!-- Shady DOM styles for iron-pages --><!-- Shady DOM styles for paper-tab --><!-- Shady DOM styles for paper-tabs --><!-- Shady DOM styles for debug-info --><!-- Shady DOM styles for search-paging --><!-- Shady DOM styles for search-result-item --><!-- Shady DOM styles for search-result-image --><!-- Shady DOM styles for search-result-entities --><!-- Shady DOM styles for search-result-measures --><!-- Shady DOM styles for search-results --><!-- Shady DOM styles for summary-box --><!-- Shady DOM styles for timeline-page --><!-- Shady DOM styles for iron-localstorage --><!-- Shady DOM styles for search-app --><style scope="search-app">search-app {
  display: block;
        height: 100%;
}

#toast.search-app {
  min-height: 64px;
        min-width: 742px;
}</style><style>body {transition: opacity ease-in 0.2s; } 
body[unresolved] {opacity: 0; display: block; overflow: hidden; position: relative; } 
</style>
    <title>NO333921B1 - 
  Human monoclonal antibody to a costimulatory signal transfer molecule, AILIM, DNA encoding all or part of the antibody, vector comprising the DNA, cell producing the antibody, genetically recombined non-human host transformed with the vector and pharmaceutical preparation comprising the antibody, and use thereof
 
      - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/NO333921B1/en">
    
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="
  Human monoclonal antibody to a costimulatory signal transfer molecule, AILIM, DNA encoding all or part of the antibody, vector comprising the DNA, cell producing the antibody, genetically recombined non-human host transformed with the vector and pharmaceutical preparation comprising the antibody, and use thereof
 
     ">
    <meta name="DC.date" content="2002-01-17" scheme="dateSubmitted">
    <meta name="DC.description" content="">
    <meta name="citation_patent_application_number" content="NO:20020263A">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/55/12/54/11c471d15ff965/NO333921B1.pdf">
    <meta name="citation_patent_publication_number" content="NO:333921:B1">
    <meta name="DC.date" content="2013-10-21">
    <meta name="DC.contributor" content="Katsunari Tezuka" scheme="inventor">
    <meta name="DC.contributor" content="Takashi Tsuji" scheme="inventor">
    <meta name="DC.contributor" content="Nobuaki Hori" scheme="inventor">
    <meta name="DC.contributor" content="Japan Tobacco Inc" scheme="assignee">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      body { transition: none; }
    </style>

    <script src="https://apis.google.com/_/scs/abc-static/_/js/k=gapi.lb.en.IKZeRvoAYNY.O/m=client/rt=j/sv=1/d=1/ed=1/am=AAAQ/rs=AHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw/cb=gapi.loaded_0?le=scs" async=""></script><script>
      window.version = 'patent-search.search_20240531_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <style>[hidden]:not([style-scope]):not(.style-scope) {
  display: none !important;
}

</style><style></style><style></style><style></style><style></style><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,300,300italic,400italic,500,500italic,700,700italic"><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto+Mono:400,700"><style></style><style></style><style>
  html, body {
    min-width: 100%;
    width: 100%;
    min-height: 100%;
    height: 100%;
  }

  body {
    background-color: #fff;
    font-family: 'Roboto', sans-serif;
    color: #333;
    margin: 0;
    padding: 0;
    /*
     * Turn off https://github.com/WICG/ScrollAnchoring/blob/master/explainer.md
     * https://memegen.googleplex.com/5230756293246976
     */
    overflow-anchor: none;
  }

  body h1, body h2, body h3 {
    -webkit-font-smoothing: antialiased;
    -moz-osx-font-smoothing: grayscale;
  }

  body a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  body a:visited {
    color: #3c80f6;
  }

  body a[open-result]:visited {
    color: #7e57c2;
  }

  /* For Firefox */
  a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  a:visited {
    color: #3c80f6;
  }

  a[open-result]:visited {
    color: #7e57c2;
  }

  ::selection , body ::selection {
    background-color: #c6dafc;
    color: #333;
  }
</style><link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.html">
  <style>[hidden] { display: none !important; }</style><script type="text/javascript" charset="UTF-8" src="https://apis.google.com/js/client.js" gapi_processed="true"></script></head>
  <body>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.js"></script><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span>
    <search-app>
    
    <remote-fetch class="style-scope search-app"></remote-fetch>
    <search-state class="style-scope search-app"></search-state>
    <browser-ui class="style-scope search-app"></browser-ui>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    
      <search-result id="result" class="style-scope search-app">
    
    
    <search-ui mode="result" class="style-scope search-result x-scope search-ui-0">
    
    
    
    <div id="content" class="style-scope search-ui" wide="">
      <search-header show-search="" class="style-scope search-ui">
    
    
    <div class="style-scope search-header" wide="">
      <header class="style-scope search-header">
        <div class="layout horizontal headerpad style-scope search-header">
          <div class="layout horizontal leftheader style-scope search-header">
            <h1 class="style-scope search-header">
              <state-modifier inherit="" act="{&quot;type&quot;: &quot;HOME&quot;}" class="style-scope search-header"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                <div class="lockup style-scope search-header">
                  <span class="lockup-logo style-scope search-header"></span>
                  <span class="lockup-text style-scope search-header">
                    <span class="lockup-brand style-scope search-header">&nbsp;Patents</span>
                  </span>
                </div>
              </a></state-modifier>
            </h1>
          </div>
          
            <search-box class="style-scope search-header">
    
    <div class="layout horizontal style-scope search-box" style="position: relative;">
      <div class="inputbox flex layout horizontal style-scope search-box">
        <div class="suggest-bg flex style-scope search-box">
          <input name="q" id="searchInput" data-proto="SEARCH_INPUT" autocomplete="off" class="style-scope search-box">
        </div>
        <div id="corpora" class="style-scope search-box">
          <iron-icon icon="icons:lightbulb-outline" id="patentIcon" class="style-scope search-box x-scope iron-icon-0" active=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M9 21c0 .55.45 1 1 1h4c.55 0 1-.45 1-1v-1H9v1zm3-19C8.14 2 5 5.14 5 9c0 2.38 1.19 4.47 3 5.74V17c0 .55.45 1 1 1h6c.55 0 1-.45 1-1v-2.26c1.81-1.27 3-3.36 3-5.74 0-3.86-3.14-7-7-7zm2.85 11.1l-.85.6V16h-4v-2.3l-.85-.6C7.8 12.16 7 10.63 7 9c0-2.76 2.24-5 5-5s5 2.24 5 5c0 1.63-.8 3.16-2.15 4.1z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#patentIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include patents
    </div>
  </overlay-tooltip>
          <iron-icon icon="social:school" id="nplIcon" class="style-scope search-box x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M5 13.18v4L12 21l7-3.82v-4L12 17l-7-3.82zM12 3L1 9l11 6 9-4.91V17h2V9L12 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#nplIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include non-patent literature
    </div>
  </overlay-tooltip>
          <keyword-wizard id="wizardIcon" class="style-scope search-box">


<div id="wizardContainer" class="style-scope keyword-wizard">
  <iron-icon icon="image:tune" id="wizardIcon" class="style-scope keyword-wizard x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M3 17v2h6v-2H3zM3 5v2h10V5H3zm10 16v-2h8v-2h-8v-2h-2v6h2zM7 9v2H3v2h4v2h2V9H7zm14 4v-2H11v2h10zm-6-4h2V7h4V5h-4V3h-2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
  <paper-material elevation="2" id="wizard" class="style-scope keyword-wizard x-scope paper-material-0" hidden="">
    
    

    
    
    <div class="search-within style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Search within
        <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="within"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="withinHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search within the title, abstract, claims, or full patent document</b>: You can
          restrict your search to a specific field using field names.</p>
        <p class="style-scope keyword-wizard">Use <span class="q style-scope keyword-wizard">TI=</span> to search in the title, <span class="q style-scope keyword-wizard">AB=</span> for the
          abstract, <span class="q style-scope keyword-wizard">CL=</span> for the claims, or <span class="q style-scope keyword-wizard">TAC=</span> for
          all three. For example, <span class="q style-scope keyword-wizard">TI=(safety belt)</span>.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search by Cooperative Patent Classifications (CPCs)</b>: These are commonly used to
          represent ideas in place of keywords, and can also be entered in a search term box. If
          you're searching for<span class="q style-scope keyword-wizard">seat belts</span>, you could also search for
          <span class="q style-scope keyword-wizard">B60R22/00</span> to retrieve documents that mention safety belts or body
          harnesses. <span class="q style-scope keyword-wizard">CPC=B60R22</span> will match documents with exactly this CPC,
          <span class="q style-scope keyword-wizard">CPC=B60R22/low</span> matches documents with this CPC or a child
          classification of this CPC.
        </p>
          <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="filter-chips style-scope keyword-wizard">
        <span class="chip style-scope keyword-wizard" id="title" selected="">Title</span>
        <span class="chip style-scope keyword-wizard" id="abstract" selected="">Abstract</span>
        <span class="chip style-scope keyword-wizard" id="claims" selected="">Claims</span>
        <span class="chip style-scope keyword-wizard" id="fullDoc" selected="">Full Document</span>
      </div>
      
      <div class="cpc-field style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputCPC" class="style-scope keyword-wizard">or CPC</label></span>
        <div class="cpc-inputs style-scope keyword-wizard">
          <input class="keyword-input style-scope keyword-wizard" id="inputCPC" placeholder="Or search with CPC">
          <input type="checkbox" id="childCPC" checked="" class="style-scope keyword-wizard">
          <label class="checkbox-label style-scope keyword-wizard" for="childCPC">
            Include child classifications
          </label>
        </div>
      </div>
    </div>
    
    <div class="find-patents style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Find patents
        <iron-icon class="help-header style-scope keyword-wizard x-scope iron-icon-0" icon="icons:help-outline" id="searchBoolean"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="searchBooleanHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Keywords and boolean syntax (USPTO or EPO format)</b>:
          <span class="q style-scope keyword-wizard">seat belt</span> searches these two words, or their plurals and close
          synonyms. <span class="q style-scope keyword-wizard">"seat belt"</span> searches this exact phrase, in order.
          <span class="q style-scope keyword-wizard">-seat -belt</span> searches for documents not containing either word.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">For searches using boolean logic</b>, the default operator is
          <span class="q style-scope keyword-wizard">AND</span> with left associativity. <i class="style-scope keyword-wizard">Note:</i> this means
          <span class="q style-scope keyword-wizard">safety OR seat belt</span> is searched as <span class="q style-scope keyword-wizard">(safety OR seat)
          AND belt</span>. Each word automatically includes plurals and close synonyms. Adjacent
          words that are implicitly ANDed together, such as <span class="q style-scope keyword-wizard">(safety belt)</span>,
          are treated as a phrase when generating synonyms.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputAnd" class="style-scope keyword-wizard">with ALL of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputAnd" placeholder="with ALL of the words">
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputExact" class="style-scope keyword-wizard">with the EXACT PHRASE</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputExact" placeholder="with the EXACT PHRASE"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputOr" class="style-scope keyword-wizard">with AT LEAST ONE of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputOr" placeholder="with AT LEAST ONE of the words"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputMinus" class="style-scope keyword-wizard">WITHOUT the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputMinus" placeholder="WITHOUT the words"></div>
    </div>
    <div class="search-by style-scope keyword-wizard">
      <div class="wizard-header style-scope keyword-wizard">
          Search by
          <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="chem"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </div>
      
      <div class="help style-scope keyword-wizard" id="chemHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Chemistry searches</b> match terms (trade names, IUPAC names, etc.
          extracted from the entire document, and processed from .MOL files.)
        </p>
        <p class="style-scope keyword-wizard">Substructure (use <span class="q style-scope keyword-wizard">SSS=</span>) and similarity (use
          <span class="q style-scope keyword-wizard">~</span>) searches are limited to one per search at the top-level
          <span class="q style-scope keyword-wizard">AND</span> condition. Exact searches can be used multiple times throughout
          the search query.
        </p>
        <p class="style-scope keyword-wizard">Searching by SMILES or InChi key requires no special syntax. To search by SMARTS, use
          <span class="q style-scope keyword-wizard">SMARTS=</span>.
        </p>
        <p class="style-scope keyword-wizard">To search for multiple molecules, select "Batch" in the "Type" menu. Enter multiple
          molecules separated by whitespace or by comma.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      
      <div class="chemistry-field style-scope keyword-wizard">
          <span class="input-label style-scope keyword-wizard"><label for="inputChem" class="style-scope keyword-wizard">Chemistry</label></span>
          <span class="chem-type-label style-scope keyword-wizard"><label for="chemType" hidden="" class="style-scope keyword-wizard">Type</label></span>
          <select id="chemType" class="style-scope keyword-wizard">
            <option value="identical" class="style-scope keyword-wizard">Identical</option>
            <option value="substructure" class="style-scope keyword-wizard">Substructure</option>
            <option value="smarts" class="style-scope keyword-wizard">SMARTS</option>
            <option value="similarity" class="style-scope keyword-wizard">Similarity</option>
            <option value="batch" class="style-scope keyword-wizard">Batch</option>
          </select>
          <textarea class="keyword-input style-scope keyword-wizard" id="inputChem" placeholder="Trade name, SMILES, InChiKey"></textarea>
      </div>
      <div class="import style-scope keyword-wizard">
        <div class="wizard-header style-scope keyword-wizard">
          Patent numbers
        </div>
        <span class="import-button style-scope keyword-wizard">
          <a href="https://patents.google.com/import" class="style-scope keyword-wizard"><button class="style-scope keyword-wizard">Import</button></a>
        </span>
        <p class="import-text style-scope keyword-wizard">
          Search specific patents by importing a CSV or list of patent publication or application numbers.
        </p>
      </div>
    </div>
    
    <div class="wizard-buttons style-scope keyword-wizard">
      <button type="reset" class="style-scope keyword-wizard">Close</button>
      <button type="button" autofocus="" class="style-scope keyword-wizard">Add</button>
    </div>
  
  </paper-material>
</div>
</keyword-wizard>
          <overlay-tooltip positioning-target="#wizardIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Display advanced search options
    </div>
  </overlay-tooltip>
        </div>
      </div>
      <paper-material id="suggestMenu" class="style-scope search-box x-scope paper-material-0" elevation="1" hidden="">
    
    

    
        <template is="dom-repeat" class="style-scope search-box"></template>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Sorry, we couldn't find this patent number.
        </div>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> 
        </div>
      
  </paper-material>
      <button id="searchButton" class="style-scope search-box"><iron-icon class="style-scope search-box x-scope iron-icon-0" icon="search"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></button>
    </div>
  </search-box>
          <template is="dom-if" class="style-scope search-header"></template>
          <div class="flex style-scope search-header"></div>
          
            <div id="header-container" class="style-scope search-header">
              <result-nav class="style-scope search-header">
    
    <div class="style-scope result-nav" hidden="">
      <state-modifier id="current" act="{&quot;type&quot;: &quot;BACK_TO_RESULTS&quot;}" inherit="" class="style-scope result-nav"><a id="link" href="#" class="style-scope state-modifier" inherit=""><span class="style-scope result-nav"></span> of
      <template is="dom-if" class="style-scope result-nav"></template>
      0<template is="dom-if" class="style-scope result-nav"></template></a></state-modifier>
      <state-modifier id="prevResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-left" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.41 7.41L14 6l-6 6 6 6 1.41-1.41L10.83 12z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier><state-modifier id="nextResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-right" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M10 6L8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier>
      <overlay-tooltip positioning-target="#prevResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Previous result
    </div>
  </overlay-tooltip>
      <overlay-tooltip positioning-target="#nextResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Next result
    </div>
  </overlay-tooltip>
    </div>
  </result-nav>
            </div>
          <template is="dom-if" class="style-scope search-header"></template>
        </div>
      </header>
    </div>
  </search-header>

      <div class="layout horizontal style-scope search-ui">
        <template is="dom-if" class="style-scope search-ui"></template>

        <div id="main" class="style-scope search-ui">
          <search-term-wizard class="style-scope search-ui"><pat-dialog open="" class="style-scope search-term-wizard">
  <span class="header style-scope search-term-wizard">
    <span class="title style-scope search-term-wizard">Search tools</span>
    <span id="language" class="style-scope search-term-wizard">
      <text-button id="textButton" selected="" class="style-scope search-term-wizard">Text
</text-button>
      <text-button id="classificationButton" class="style-scope search-term-wizard">Classification
</text-button>
      <text-button id="chemistryButton" class="style-scope search-term-wizard">Chemistry
</text-button>
      <text-button id="measureButton" class="style-scope search-term-wizard">Measure
</text-button>
      <text-button id="numbersButton" class="style-scope search-term-wizard">Numbers
</text-button>
    </span>
  </span>
  <span id="panels" class="style-scope search-term-wizard">
    <text-search-term-wizard id="textPanel" class="style-scope search-term-wizard" selected=""><span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Type a concept you want to search for here" class="style-scope text-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Type a concept you want to search for here">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="title" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Title</filter-chip>
  <filter-chip id="abstract" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Abstract</filter-chip>
  <filter-chip id="claims" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="all" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
All</filter-chip>
  <filter-chip id="any" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Any</filter-chip>
  <filter-chip id="exact" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="not" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Not</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope text-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope text-search-term-wizard">Add AND condition</span></mat-button></span></text-search-term-wizard>
    <classification-wizard id="classificationPanel" class="style-scope search-term-wizard"><span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope classification-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Enter a CPC here" uppercase="" class="style-scope classification-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Enter a CPC here">
  
</span>
</outlined-text-field>
</span>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope classification-wizard"></path>
  </svg>
  <filter-chip id="notExact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These CPCs and their children
  </filter-chip>
  <filter-chip selected="" id="exact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These exact CPCs
  </filter-chip>
</span>
<span class="style-scope classification-wizard">
  <mat-button id="button" filled="" class="style-scope classification-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope classification-wizard">Add AND condition</span></mat-button>
</span></classification-wizard>
    <chemistry-search-term-wizard id="chemistryPanel" class="style-scope search-term-wizard"><span class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Trade name, SMILES, InChI Key" class="style-scope chemistry-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Trade name, SMILES, InChI Key">
  
</span>
</outlined-text-field>
  <outlined-textarea id="textArea" placeholder="Enter multiple SMILES or InChI Keys, one per line" rows="4" class="style-scope chemistry-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple SMILES or InChI Keys, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
  <a href="https://support.google.com/faqs/answer/7049475#zippy=%2Csearching-by-chemistry" target="_blank" class="style-scope chemistry-search-term-wizard">
    <svg class="help style-scope chemistry-search-term-wizard" xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49">
      <path d="M11.95 18q.525 0 .888-.363.362-.362.362-.887t-.362-.887q-.363-.363-.888-.363t-.888.363q-.362.362-.362.887t.362.887q.363.363.888.363Zm-.9-3.85h1.85q0-.825.188-1.3.187-.475 1.062-1.3.65-.65 1.025-1.238.375-.587.375-1.412 0-1.4-1.025-2.15T12.1 6q-1.425 0-2.312.75-.888.75-1.238 1.8l1.65.65q.125-.45.563-.975Q11.2 7.7 12.1 7.7q.8 0 1.2.437.4.438.4.963 0 .5-.3.937-.3.438-.75.813-1.1.975-1.35 1.475-.25.5-.25 1.825ZM12 22q-2.075 0-3.9-.788-1.825-.787-3.175-2.137-1.35-1.35-2.137-3.175Q2 14.075 2 12t.788-3.9q.787-1.825 2.137-3.175 1.35-1.35 3.175-2.138Q9.925 2 12 2t3.9.787q1.825.788 3.175 2.138 1.35 1.35 2.137 3.175Q22 9.925 22 12t-.788 3.9q-.787 1.825-2.137 3.175-1.35 1.35-3.175 2.137Q14.075 22 12 22Zm0-2q3.35 0 5.675-2.325Q20 15.35 20 12q0-3.35-2.325-5.675Q15.35 4 12 4 8.65 4 6.325 6.325 4 8.65 4 12q0 3.35 2.325 5.675Q8.65 20 12 20Zm0-8Z" class="style-scope chemistry-search-term-wizard"></path>
    </svg>
  </a>
</span>
<span id="chemQuantifiers" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M5 21.2q-1.4 0-2-1.25-.6-1.25.3-2.325l5.5-6.7V5.15h-.825q-.475 0-.8-.338Q6.85 4.475 6.85 4q0-.475.325-.813.325-.337.8-.337h8.05q.475 0 .8.337.325.338.325.813 0 .475-.325.812-.325.338-.8.338H15.2v5.775l5.5 6.7q.9 1.075.3 2.325-.6 1.25-2 1.25Zm2.15-3.275h9.7l-3.275-3.85h-3.15Zm-2 1h13.7l-5.925-7.2V5.15h-1.85v6.575Zm6.85-6.9Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="exact" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="exactBatch" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact Batch</filter-chip>
  <filter-chip id="similar" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Similar</filter-chip>
  <filter-chip id="substructure" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure</filter-chip>
  <filter-chip id="smarts" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure (SMARTS)</filter-chip>
</span>
<span id="location" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="claims" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims only</filter-chip>
</span>
<span class="style-scope chemistry-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope chemistry-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope chemistry-search-term-wizard">Add AND condition</span></mat-button>
</span>
</chemistry-search-term-wizard>
    <measure-search-term-wizard id="measurePanel" class="style-scope search-term-wizard"><span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M4.1 18.15q-.95 0-1.612-.663-.663-.662-.663-1.612v-7.75q0-.95.663-1.613Q3.15 5.85 4.1 5.85h15.8q.95 0 1.613.662.662.663.662 1.613v7.75q0 .95-.662 1.612-.663.663-1.613.663Zm0-2.275h15.8v-7.75H17V12h-2V8.125h-2V12h-2V8.125H9V12H7V8.125H4.1v7.75ZM7 12h2Zm4 0h2Zm4 0h2Zm-3 0Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="measureExpression" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M3.875 20.15V8.85h4.25v11.3Zm6 0V3.85h4.25v16.3Zm6 0v-7.3h4.25v7.3Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="context" placeholder="activity, wavelength, embossing depth, absorption" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="activity, wavelength, embossing depth, absorption">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope measure-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope measure-search-term-wizard">Add AND condition</span></mat-button>
</span>
</measure-search-term-wizard>
    <numerical-search-term-wizard id="numericalPanel" class="style-scope search-term-wizard"><span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-textarea id="batch" placeholder="Enter multiple Patent Application and Publication Numbers, one per line" rows="4" class="style-scope numerical-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple Patent Application and Publication Numbers, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
</span>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="m10.825 23.45-1.6-1.625L10.9 20.15H8q-.35.9-1.162 1.488-.813.587-1.838.587-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.025.588-1.837Q2.95 16.35 3.85 16V8q-.9-.35-1.487-1.163Q1.775 6.025 1.775 5q0-1.35.938-2.288Q3.65 1.775 5 1.775q1.025 0 1.838.587Q7.65 2.95 8 3.85h2.9L9.225 2.175l1.6-1.625L15.275 5l-4.45 4.45-1.6-1.625L10.9 6.15H8q-.25.65-.725 1.125T6.15 8v8q.65.25 1.125.725T8 17.85h2.9l-1.675-1.675 1.6-1.625 4.45 4.45ZM19 22.225q-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.05.588-1.863.587-.812 1.487-1.137V8q-.9-.325-1.487-1.137-.588-.813-.588-1.863 0-1.35.938-2.288.937-.937 2.287-.937 1.35 0 2.288.937.937.938.937 2.288 0 1.05-.587 1.863Q21.05 7.675 20.15 8v8q.9.35 1.488 1.163.587.812.587 1.837 0 1.35-.937 2.288-.938.937-2.288.937ZM5 19.95q.4 0 .675-.275T5.95 19q0-.4-.275-.675T5 18.05q-.4 0-.675.275T4.05 19q0 .4.275.675T5 19.95Zm14 0q.4 0 .675-.275T19.95 19q0-.4-.275-.675T19 18.05q-.4 0-.675.275T18.05 19q0 .4.275.675t.675.275Zm-14-14q.4 0 .675-.275T5.95 5q0-.4-.275-.675T5 4.05q-.4 0-.675.275T4.05 5q0 .4.275.675T5 5.95Zm14 0q.4 0 .675-.275T19.95 5q0-.4-.275-.675T19 4.05q-.4 0-.675.275T18.05 5q0 .4.275.675T19 5.95ZM5 19Zm14 0ZM5 5Zm14 0Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <filter-chip id="applicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Application Numbers</filter-chip>
  <filter-chip id="publicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Publication Numbers</filter-chip>
  <filter-chip id="either" selected="" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Either</filter-chip>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M12 22.2q-2.1 0-3.962-.8-1.863-.8-3.25-2.175Q3.4 17.85 2.6 15.988 1.8 14.125 1.8 12t.8-3.988q.8-1.862 2.188-3.237Q6.175 3.4 8.038 2.6 9.9 1.8 12 1.8q2.125 0 3.988.8 1.862.8 3.237 2.175Q20.6 6.15 21.4 8.012q.8 1.863.8 3.988t-.8 3.988q-.8 1.862-2.175 3.237Q17.85 20.6 15.988 21.4q-1.863.8-3.988.8Zm-1-2.325v-1.95q-.8 0-1.387-.575-.588-.575-.588-1.4v-.975L4.275 10.2q-.075.45-.137.9-.063.45-.063.9 0 3 1.975 5.25T11 19.875Zm6.85-2.525q.5-.55.888-1.175.387-.625.65-1.313.262-.687.4-1.412.137-.725.137-1.45 0-2.425-1.338-4.438-1.337-2.012-3.612-2.887v.375q0 .825-.587 1.4-.588.575-1.388.575h-2v2q0 .4-.287.687-.288.288-.688.288h-2v2h5.95q.425 0 .713.287.287.288.287.688v2.975h1q.65 0 1.163.387.512.388.712 1.013Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryFilter" placeholder="Restrict search to these countries" class="style-scope numerical-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Restrict search to these countries">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M2.85 18.225V15.95h6.3v2.275Zm0-5.075v-2.3h12.3v2.3Zm0-5.1V5.775h18.3V8.05Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryOrder" placeholder="Prefer results from these countries in this order" class="style-scope numerical-search-term-wizard" value="US, EP, WO, JP, CN"><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Prefer results from these countries in this order">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope numerical-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope numerical-search-term-wizard">Add AND condition</span></mat-button>
</span>
</numerical-search-term-wizard>
  </span>

</pat-dialog>
</search-term-wizard>
          
      <div content="" class="style-scope search-result">
        <div id="mainContainer" class="vertical layout style-scope search-result">
          <template is="dom-if" class="style-scope search-result"></template>
          <result-container class="style-scope search-result">
    

    <paper-spinner class="style-scope result-container x-scope paper-spinner-0" aria-hidden="true" hidden=""><div id="spinnerContainer" class="  style-scope paper-spinner"><div class="spinner-layer layer-1 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-2 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-3 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-4 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div></div></paper-spinner>
    
      <patent-result class="style-scope result-container">
    
    
    <div class="layout horizontal style-scope patent-result">
      <div style="width: 1200px; height: auto; overflow: auto;" class="style-scope patent-result">
        <div id="wrapper" tabindex="0" class="style-scope patent-result">
          <result-tags class="style-scope patent-result"></result-tags>
          <h1 id="title" class="scroll-target style-scope patent-result">
            
  Human monoclonal antibody to a costimulatory signal transfer molecule, AILIM, DNA encoding all or part of the antibody, vector comprising the DNA, cell producing the antibody, genetically recombined non-human host transformed with the vector and pharmaceutical preparation comprising the antibody, and use thereof
 
     </h1>
          <div class="horizontal layout style-scope patent-result">
            
            <div class="flex-3 style-scope patent-result" style="margin-top:-20px;overflow:hidden;" marginright="">
              <section id="abstract" class="style-scope patent-result" hidden="">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Abstract</div>
                  <div class="righthead style-scope patent-result" hidden="">translated from </div>
                </h3>
                <patent-text name="abstract" class="style-scope patent-result">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"></section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <section id="classifications" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Classifications</div>
                  <div id="machineClassifiedWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">machine-classified</div>
                  <div id="machineClassifiedCPCWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">cpc-machine-classified</div>
                  <div id="machineClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-machine-classified</div>
                  <div class="style-scope patent-result" hidden="">&nbsp;</div>
                  <div id="familyClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-family-classified</div>
                </h3>
                <overlay-tooltip positioning-target="#machineClassifiedWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedCPCWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The CPC classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#familyClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned based on a patent family member containing these classification codes.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <classification-viewer class="style-scope patent-result">
    
    <div class="table style-scope classification-viewer">
      
        <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/00"><a id="link" href="#" class="style-scope state-modifier">C07K16/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" first="true" data-cpc="C07K16/18"><a id="link" href="#" class="style-scope state-modifier">C07K16/18</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
      <template is="dom-repeat" class="style-scope classification-viewer"></template>
      
      <div class="style-scope classification-viewer">
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P13/00"><a id="link" href="#" class="style-scope state-modifier">A61P13/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the urinary system</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P13/12"><a id="link" href="#" class="style-scope state-modifier">A61P13/12</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the urinary system of the kidneys</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P17/00"><a id="link" href="#" class="style-scope state-modifier">A61P17/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for dermatological disorders</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P17/06"><a id="link" href="#" class="style-scope state-modifier">A61P17/06</a></state-modifier>
                  <span class="description style-scope classification-tree">Antipsoriatics</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P19/00"><a id="link" href="#" class="style-scope state-modifier">A61P19/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for skeletal disorders</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P19/02"><a id="link" href="#" class="style-scope state-modifier">A61P19/02</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P29/00"><a id="link" href="#" class="style-scope state-modifier">A61P29/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P3/00"><a id="link" href="#" class="style-scope state-modifier">A61P3/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the metabolism</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P3/08"><a id="link" href="#" class="style-scope state-modifier">A61P3/08</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the metabolism for glucose homeostasis</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P3/10"><a id="link" href="#" class="style-scope state-modifier">A61P3/10</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P37/00"><a id="link" href="#" class="style-scope state-modifier">A61P37/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for immunological or allergic disorders</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P37/02"><a id="link" href="#" class="style-scope state-modifier">A61P37/02</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunomodulators</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P37/00"><a id="link" href="#" class="style-scope state-modifier">A61P37/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for immunological or allergic disorders</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P37/02"><a id="link" href="#" class="style-scope state-modifier">A61P37/02</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunomodulators</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P37/06"><a id="link" href="#" class="style-scope state-modifier">A61P37/06</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunosuppressants, e.g. drugs for graft rejection</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P37/00"><a id="link" href="#" class="style-scope state-modifier">A61P37/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for immunological or allergic disorders</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P37/08"><a id="link" href="#" class="style-scope state-modifier">A61P37/08</a></state-modifier>
                  <span class="description style-scope classification-tree">Antiallergic agents</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P43/00"><a id="link" href="#" class="style-scope state-modifier">A61P43/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/00"><a id="link" href="#" class="style-scope state-modifier">C07K16/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/18"><a id="link" href="#" class="style-scope state-modifier">C07K16/18</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/28"><a id="link" href="#" class="style-scope state-modifier">C07K16/28</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/00"><a id="link" href="#" class="style-scope state-modifier">C07K16/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/18"><a id="link" href="#" class="style-scope state-modifier">C07K16/18</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/28"><a id="link" href="#" class="style-scope state-modifier">C07K16/28</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/2803"><a id="link" href="#" class="style-scope state-modifier">C07K16/2803</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/2818"><a id="link" href="#" class="style-scope state-modifier">C07K16/2818</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A01"><a id="link" href="#" class="style-scope state-modifier">A01</a></state-modifier>
                  <span class="description style-scope classification-tree">AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A01K"><a id="link" href="#" class="style-scope state-modifier">A01K</a></state-modifier>
                  <span class="description style-scope classification-tree">ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A01K2217/00"><a id="link" href="#" class="style-scope state-modifier">A01K2217/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Genetically modified animals</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="A01K2217/05"><a id="link" href="#" class="style-scope state-modifier">A01K2217/05</a></state-modifier>
                  <span class="description style-scope classification-tree">Animals comprising random inserted nucleic acids (transgenic)</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K39/00"><a id="link" href="#" class="style-scope state-modifier">A61K39/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing antigens or antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="A61K2039/505"><a id="link" href="#" class="style-scope state-modifier">A61K2039/505</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing antigens or antibodies comprising antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/00"><a id="link" href="#" class="style-scope state-modifier">C07K2317/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/20"><a id="link" href="#" class="style-scope state-modifier">C07K2317/20</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features characterized by taxonomic origin</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="C07K2317/21"><a id="link" href="#" class="style-scope state-modifier">C07K2317/21</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/00"><a id="link" href="#" class="style-scope state-modifier">C07K2317/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/50"><a id="link" href="#" class="style-scope state-modifier">C07K2317/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features characterized by immunoglobulin fragments</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="C07K2317/56"><a id="link" href="#" class="style-scope state-modifier">C07K2317/56</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/00"><a id="link" href="#" class="style-scope state-modifier">C07K2317/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/70"><a id="link" href="#" class="style-scope state-modifier">C07K2317/70</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="C07K2317/73"><a id="link" href="#" class="style-scope state-modifier">C07K2317/73</a></state-modifier>
                  <span class="description style-scope classification-tree">Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/00"><a id="link" href="#" class="style-scope state-modifier">C07K2317/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/70"><a id="link" href="#" class="style-scope state-modifier">C07K2317/70</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/73"><a id="link" href="#" class="style-scope state-modifier">C07K2317/73</a></state-modifier>
                  <span class="description style-scope classification-tree">Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="C07K2317/732"><a id="link" href="#" class="style-scope state-modifier">C07K2317/732</a></state-modifier>
                  <span class="description style-scope classification-tree">Antibody-dependent cellular cytotoxicity [ADCC]</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/00"><a id="link" href="#" class="style-scope state-modifier">C07K2317/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/70"><a id="link" href="#" class="style-scope state-modifier">C07K2317/70</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="C07K2317/76"><a id="link" href="#" class="style-scope state-modifier">C07K2317/76</a></state-modifier>
                  <span class="description style-scope classification-tree">Antagonist effect on antigen, e.g. neutralization or inhibition of binding</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/00"><a id="link" href="#" class="style-scope state-modifier">C07K2317/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2317/90"><a id="link" href="#" class="style-scope state-modifier">C07K2317/90</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="C07K2317/92"><a id="link" href="#" class="style-scope state-modifier">C07K2317/92</a></state-modifier>
                  <span class="description style-scope classification-tree">Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="C07K2319/00"><a id="link" href="#" class="style-scope state-modifier">C07K2319/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Fusion polypeptide</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K2319/00"><a id="link" href="#" class="style-scope state-modifier">C07K2319/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Fusion polypeptide</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="C07K2319/30"><a id="link" href="#" class="style-scope state-modifier">C07K2319/30</a></state-modifier>
                  <span class="description style-scope classification-tree">Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        <template is="dom-repeat" class="style-scope classification-viewer"></template>
        <div class="more style-scope classification-viewer" style="" hidden="">View 21 more classifications</div>
        <div class="more style-scope classification-viewer">Hide more classifications</div>
      </div>
      <template is="dom-if" class="style-scope classification-viewer"></template>
    </div>
  </classification-viewer>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              
                <section class="style-scope patent-result">
                  <h3 class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Landscapes</div>
                  </h3>
                  <div class="responsive-grid style-scope patent-result">
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Health &amp; Medical Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Health &amp; Medical Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Chemical &amp; Material Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Chemical &amp; Material Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    <template is="dom-repeat" class="style-scope patent-result"></template>
                  </div>
                  <s-more-inline class="style-scope patent-result"><hr aria-hidden="true" class="style-scope s-more-inline">

<div class="button style-scope s-more-inline">
  <span slot="expand_text" class="style-scope patent-result">Show more</span>
  <span class="expand more style-scope s-more-inline"></span>
</div>
<div class="button style-scope s-more-inline" hidden="">
  <span slot="collapse_text" class="style-scope patent-result">Show less</span>
  <span class="expand less style-scope s-more-inline"></span>
</div>
</s-more-inline>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
            <div class="flex-2 style-scope patent-result">
              <section class="knowledge-card style-scope patent-result">
                <header class="style-scope patent-result">
                  <h2 id="pubnum" class="style-scope patent-result">NO333921B1</h2>
                  <p class="tagline style-scope patent-result">Norway</p>
                  <overlay-tooltip positioning-target="#pubnum" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                    <div style="max-width: 300px;" class="style-scope patent-result">Granted patent</div>
                  
    </div>
  </overlay-tooltip>

                  <div class="knowledge-card-action-bar style-scope patent-result">
                    <a target="_blank" class="style-scope patent-result" href="https://patentimages.storage.googleapis.com/55/12/54/11c471d15ff965/NO333921B1.pdf"><iron-icon icon="description" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download PDF</a>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_FIND_PRIOR_ART&quot;, &quot;keywords&quot;: $keywords, &quot;before&quot;: &quot;$before&quot;}" class="style-scope patent-result" data-keywords="[&quot;human&quot;,&quot;antibody&quot;,&quot;ailim&quot;,&quot;cells&quot;,&quot;dna&quot;]" data-before="20000518"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="find-in-page" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 19.59V8l-6-6H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c.45 0 .85-.15 1.19-.4l-4.43-4.43c-.8.52-1.74.83-2.76.83-2.76 0-5-2.24-5-5s2.24-5 5-5 5 2.24 5 5c0 1.02-.31 1.96-.83 2.75L20 19.59zM9 13c0 1.66 1.34 3 3 3s3-1.34 3-3-1.34-3-3-3-3 1.34-3 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Find Prior Art
                    </a></state-modifier>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_SIMILAR_DOCUMENTS&quot;, &quot;id&quot;: &quot;$id&quot;}" class="style-scope patent-result" data-id="patent/NO333921B1"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="editor:functions" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M18 4H6v2l6.5 6L6 18v2h12v-3h-7l5-5-5-5h7z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Similar
                    </a></state-modifier>
                  </div>
                </header>

                <dl class="important-people style-scope patent-result">
                  
                    <dt class="style-scope patent-result">Other languages</dt>
                    <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/NO333921B1/no"><a id="link" href="#" class="style-scope state-modifier">Norwegian</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                  
                  <dt class="style-scope patent-result">Inventor</dt>
                  <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Katsunari Tezuka"><a id="link" href="#" class="style-scope state-modifier">Katsunari Tezuka</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Takashi Tsuji"><a id="link" href="#" class="style-scope state-modifier">Takashi Tsuji</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Nobuaki Hori"><a id="link" href="#" class="style-scope state-modifier">Nobuaki Hori</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>

                  <template is="dom-if" class="style-scope patent-result"></template>
                </dl>

                <hr class="style-scope patent-result">

                <application-timeline class="style-scope patent-result">
    
    
    <div class="wrap style-scope application-timeline">
      <div class="header style-scope application-timeline">Worldwide applications</div>
      <div class="event style-scope application-timeline">
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2001</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP3597140B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">JP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: JP2001099508A</div>
                <div class="style-scope application-timeline">Filing date: 2001-03-30</div>
                <div class="style-scope application-timeline">Legal status: Expired - Fee Related</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA2635963C/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">CA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CA2635963A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-07</div>
                <div class="style-scope application-timeline">Legal status: Expired - Fee Related</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA2722134A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">CA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CA2722134A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-07</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA2344086C/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">CA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CA002344086A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-07</div>
                <div class="style-scope application-timeline">Legal status: Expired - Lifetime</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/AU773625B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">AU</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: AU43881/01A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-14</div>
                <div class="style-scope application-timeline">Legal status: Ceased</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/SG135917A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">SG</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: SG200300836-4A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-15</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/AU5674701A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">AU</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: AU56747/01A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-15</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CZ302902B6/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">CZ</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CZ20020054A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-15</div>
                <div class="style-scope application-timeline">Legal status: IP Right Cessation</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/WO2001087981A2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">WO</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PCT/JP2001/004035</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-15</div>
                <div class="style-scope application-timeline">Legal status: Application Filing</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/NZ533324A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">NZ</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: NZ533324A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-15</div>
                <div class="style-scope application-timeline">Legal status: IP Right Cessation</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/NZ516411A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">NZ</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: NZ516411A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-15</div>
                <div class="style-scope application-timeline">Legal status: IP Right Cessation</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/TR200202736T1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">TR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: TR2002/02736T</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-15</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CN100482688C/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">CN</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CNB018020496A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-15</div>
                <div class="style-scope application-timeline">Legal status: Expired - Fee Related</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/HU230770B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">HU</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: HU0202532A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-15</div>
                <div class="style-scope application-timeline">Legal status: IP Right Cessation</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/BRPI0106646B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">BR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: BRPI0106646-3A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-15</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/SK287862B6/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">SK</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: SK241-2002A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-15</div>
                <div class="style-scope application-timeline">Legal status: IP Right Cessation</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/KR100609442B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">KR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: KR1020027000709A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-15</div>
                <div class="style-scope application-timeline">Legal status: IP Right Grant</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/KR20050008858A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">KR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: KR10-2004-7021273A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-15</div>
                <div class="style-scope application-timeline">Legal status: Application Discontinuation</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/TR200202735T1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">TR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: TR2002/02735T</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-15</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/TR200200781T1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">TR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: TR2002/00781T</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-15</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/SG153626A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">SG</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: SG200305582-9A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-15</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/IL147448A0/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">IL</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: IL14744801A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-15</div>
                <div class="style-scope application-timeline">Legal status: IP Right Grant</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/BR0106646A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">BR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: BR0106646-3A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-15</div>
                <div class="style-scope application-timeline">Legal status: IP Right Cessation</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/SG165161A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">SG</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: SG200608176-4A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-15</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/TWI304811B/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">TW</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: TW090111577A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-15</div>
                <div class="style-scope application-timeline">Legal status: IP Right Cessation</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/TWI316546B/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">TW</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: TW097103433A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-15</div>
                <div class="style-scope application-timeline">Legal status: IP Right Cessation</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/MXPA02000687A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">MX</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: MXPA02000687A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-15</div>
                <div class="style-scope application-timeline">Legal status: IP Right Grant</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/SG187990A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">SG</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: SG2011014305A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-15</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/MY137640A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">MY</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: MYPI20012286A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-16</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US6803039B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US09/859,053</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-16</div>
                <div class="style-scope application-timeline">Legal status: Expired - Lifetime</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/PE20011337A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">PE</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PE2001000441A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-17</div>
                <div class="style-scope application-timeline">Legal status: Application Discontinuation</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/AR028927A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">AR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: ARP010102353A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-17</div>
                <div class="style-scope application-timeline">Legal status: IP Right Grant</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ATE473243T1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">AT</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: AT01111930T</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-18</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/DE60142500D1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">DE</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: DE60142500T</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-18</div>
                <div class="style-scope application-timeline">Legal status: Expired - Lifetime</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP1158004B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP01111930A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-18</div>
                <div class="style-scope application-timeline">Legal status: Expired - Lifetime</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP2295467A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP10182520A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-18</div>
                <div class="style-scope application-timeline">Legal status: Withdrawn</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ES2347758T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">ES</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: ES01111930T</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-18</div>
                <div class="style-scope application-timeline">Legal status: Expired - Lifetime</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP2216343A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP10158665A</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-18</div>
                <div class="style-scope application-timeline">Legal status: Withdrawn</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/PT1158004E/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">PT</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PT01111930T</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-18</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/DK1158004T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">DK</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: DK01111930.2T</div>
                <div class="style-scope application-timeline">Filing date: 2001-05-18</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2002</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/IL147448A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">IL</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: IL147448A</div>
                <div class="style-scope application-timeline">Filing date: 2002-01-03</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/NO333921B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline" this="">NO</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: NO20020263A</div>
                <div class="style-scope application-timeline">Filing date: 2002-01-17</div>
                <div class="style-scope application-timeline">Legal status: IP Right Cessation</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/HK1043371B/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">HK</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: HK02103924.3A</div>
                <div class="style-scope application-timeline">Filing date: 2002-05-27</div>
                <div class="style-scope application-timeline">Legal status: IP Right Cessation</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2003</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US7166283B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US10/625,105</div>
                <div class="style-scope application-timeline">Filing date: 2003-07-22</div>
                <div class="style-scope application-timeline">Legal status: Expired - Fee Related</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2004</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/AU2004201697A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">AU</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: AU2004201697A</div>
                <div class="style-scope application-timeline">Filing date: 2004-04-22</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2006</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/AR058366A2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">AR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: ARP060105572A</div>
                <div class="style-scope application-timeline">Filing date: 2006-12-15</div>
                <div class="style-scope application-timeline">Legal status: Application Discontinuation</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2007</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US7988965B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US11/752,659</div>
                <div class="style-scope application-timeline">Filing date: 2007-05-23</div>
                <div class="style-scope application-timeline">Legal status: Expired - Fee Related</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2010</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/IL207060A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">IL</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: IL207060A</div>
                <div class="style-scope application-timeline">Filing date: 2010-07-18</div>
                <div class="style-scope application-timeline">Legal status: IP Right Grant</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CY1110816T1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">CY</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CY20101100880T</div>
                <div class="style-scope application-timeline">Filing date: 2010-10-04</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2011</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US20120039874A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US13/166,288</div>
                <div class="style-scope application-timeline">Filing date: 2011-06-22</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        <template is="dom-repeat" class="style-scope application-timeline"></template>
      </div>
      <hr class="style-scope application-timeline">
      <div class="header style-scope application-timeline">Application NO20020263A events <iron-icon id="legal" icon="icons:help-outline" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        <overlay-tooltip positioning-target="#legal" direction="right" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
          <div style="max-width: 300px;" class="style-scope application-timeline">
            A timeline of key events for this patent application, including priority claims, publications, legal status, reassignments, and litigation.<br class="style-scope application-timeline"><br class="style-scope application-timeline">
            Google has not performed a legal analysis and makes no representation as to the accuracy or completeness of the events listed.
          </div>
        
    </div>
  </overlay-tooltip>
      </div>
      <div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="filed style-scope application-timeline">2002-01-17</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_ASSIGNEE&quot;, &quot;assignee&quot;: &quot;$assignee&quot;}" class="style-scope application-timeline" data-assignee="Japan Tobacco Inc"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Application filed by Japan Tobacco Inc</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2002-01-17</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/NO20020263D0/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of NO20020263D0</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2002-03-18</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/NO20020263L/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of NO20020263L</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2013-10-21</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/NO333921B1/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of NO333921B1</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><template is="dom-repeat" strip-whitespace="" class="style-scope application-timeline"></template>
      <template is="dom-if" class="style-scope application-timeline"></template>
    </div>
  </application-timeline>
                <hr class="style-scope patent-result">

                <dl class="links style-scope patent-result">
                  <dt class="style-scope patent-result">Info</dt>

                  
                  <dd class="style-scope patent-result"><a href="#patentCitations" class="style-scope patent-result">Patent citations (50)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#citedBy" class="style-scope patent-result">Cited by (87)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#legalEvents" class="style-scope patent-result">Legal events</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#similarDocuments" class="style-scope patent-result">Similar documents</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#relatedApplications" class="style-scope patent-result">Priority and Related Applications</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <dt class="style-scope patent-result">External links</dt>

                  <dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=NO&amp;NR=333921B1&amp;KC=B1&amp;FT=D">Espacenet</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://globaldossier.uspto.gov/#/result/publication/NO/333921/1">Global Dossier</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patents.stackexchange.com/questions/tagged/NO333921B1">Discuss</a></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                </dl>
              </section>
            </div>
          </div>

          <div id="text" class="horizontal layout style-scope patent-result">
            <div class="flex flex-width style-scope patent-result" marginright="">
              <section id="description" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Description</div>
                  <div class="righthead style-scope patent-result">translated from Norwegian</div>
                </h3>
                <patent-text name="description" id="descriptionText" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><description mxw-id="PDES337201539" lang="EN" load-source="google" class="style-scope patent-text">
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Teknisk omrde </span>Technical area</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Foreliggende oppfinnelse gjelder humane antistoffer som bindes til AILIM (aktiveringsinduserbart, lymfocyttimmunmodulerende molekyl, ogs betegnet ICOS (induserbar kostimulator)); humane, monoklonale antistoffer som bindes til AILIM eller en del av dette; DNA som koder for det humane, monoklonale antistoff eller en del derav, eller en del av dette DNA; celler (innbefattet genetisk rekombinante celler) som produserer det humane, monoklonale antistoff eller en del derav; humant, monoklonalt antistoff eller en del av dette produsert av de genetisk rekombinante cellene; farmasytisk preparat som omfatter det humane, monoklonale antistoff eller en del av dette; farmasytisk preparat som omfatter antistoff mot AILIM for behandling av forstyrrelser forbundet med forsinket allergi; fremgangsmte for identifisering, kvantifisering eller analyse av forbindelser som bindes til AILIM eller AILIM-ligand; og sett som anvendes for fremgangsmten. </span>The present invention relates to human antibodies that bind to AILIM (activation inducible, lymphocyte immunomodulating molecule, also referred to as ICOS (inducible costimulator)); human monoclonal antibodies that bind to AILIM or a portion thereof; DNA encoding the human monoclonal antibody or part thereof, or part of this DNA; cells (including genetically recombinant cells) that produce the human monoclonal antibody or part thereof; human monoclonal antibody or part thereof produced by the genetically recombinant cells; pharmaceutical preparation comprising the human monoclonal antibody or part thereof; pharmaceutical preparation comprising antibody against AILIM for the treatment of disorders associated with delayed allergy; methods for identifying, quantifying or analyzing compounds that bind to AILIM or AILIM ligand; and kits used for the method.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Teknikkens stand </span>State of the art</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En levende pattedyrkropp har immunresponssystemer som ekskluderer patogene mikroorganismer (virus, bakterier, parasitter osv.) eller fremmedlegemer (begge kalles "antigen" i det pflgende) som har invadert kroppen. Ett av systemene betegnes det naturlige immunresponssystem, og det andre det ervervede immunresponssystem. Det frste er en eksklusjonsmekanisme som omfatter fagocytose ved fagocytter (polymorfonuklere leukocytter, monocytter, makrofager osv.), angrep fra naturlige dreperceller (NK-celler) og uspesifikk gjen-kjennelse, f.eks. opsonering av antigen ved komplement. Det andre systemet, det ervervede immunresponssystem, er en eksklusjonsmekanisme ved lymfocytter (hovedsakelig T-celler og B-celler) som har ervervet spesifisitet overfor antigenet (nrmere bestemt aktiverte lymfocytter). B-celler som har ervervet antigenspesifisitet, angriper antigen som foreligger utenfor cellene ved produksjon av antistoffer som er spesifikke for antigenet. T-celler med ervervet antigenspesifisitet (nrmere bestemt aktiverte T-celler) oppdeles i T-hjelpeceller og cytotoksiske T-celler (cytotoksisk lymfocytt, CTL). T-hjelpecellene regulerer differensiering av B-celler og produksjon av antistoff, og delegger antigenet i samarbeid med fagocytter. CTL angriper virusinfiserte celler osv. alene (Experimental Medicine: SUPPLEMENT, "Bio Science Term Library, Immunity", Yodosha, s. 14-17 (1995)). </span>A living mammalian body has immune response systems that exclude pathogenic microorganisms (viruses, bacteria, parasites, etc.) or foreign bodies (both called "antigen" hereinafter) that have invaded the body. One of the systems is called the natural immune response system, and the other the acquired immune response system. The first is an exclusion mechanism that includes phagocytosis by phagocytes (polymorphonuclear leukocytes, monocytes, macrophages, etc.), attack by natural killer cells (NK cells) and non-specific recognition, e.g. opsonization of antigen by complement. The second system, the acquired immune response system, is an exclusion mechanism by lymphocytes (mainly T cells and B cells) that have acquired specificity towards the antigen (more specifically activated lymphocytes). B cells that have acquired antigen specificity attack antigen that exists outside the cells by producing antibodies that are specific for the antigen. T cells with acquired antigen specificity (more specifically activated T cells) are divided into T helper cells and cytotoxic T cells (cytotoxic lymphocyte, CTL). The T helper cells regulate the differentiation of B cells and the production of antibodies, and destroy the antigen in cooperation with phagocytes. CTLs attack virus-infected cells etc alone (Experimental Medicine: SUPPLEMENT, "Bio Science Term Library, Immunity", Yodosha, pp. 14-17 (1995)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Denne ervervelse av antigenspesifisitet ved T-celler (nrmere bestemt aktivering av T-celler) innledes ved at T-cellene gjenkjenner antigenet presentert p antigenpresenterende celler (APC), f.eks. makrofager, B-celler eller dendrittceller. Antigenpresenterende celler prosesserer de inkorporerte antigenene og presenterer disse prosesserte antigenene ved at de bindes til vevstypekomplekset (MHC). T-celler mottar primrsignalet for aktivering av cellene (eller ervervelse av spesifisitet) ved at de gjenkjenner de prosesserte antigenene som presenteres av antigenpresenterende celler via et kompleks mellom T-cellereseptoren (TcR) og CD3-antigen som foreligger p overflaten av cellemembranen (TcR/CD3-kompleks). </span>This acquisition of antigen specificity by T cells (more specifically activation of T cells) is initiated by the T cells recognizing the antigen presented on antigen presenting cells (APC), e.g. macrophages, B cells or dendritic cells. Antigen presenting cells process the incorporated antigens and present these processed antigens by binding to the tissue type complex (MHC). T cells receive the primary signal for cell activation (or acquisition of specificity) by recognizing the processed antigens presented by antigen-presenting cells via a complex between the T cell receptor (TcR) and CD3 antigen present on the surface of the cell membrane (TcR/ CD3 complex).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det TcR-/CD3-kompleksformidlede primrsignal alene kan imidlertid ikke i tilstrekkelig grad aktivere T-cellene og frer til ikke-responsivitet eller klonal anergi, slik at cellene ikke kan respondere p et senere mottatt stimulus. Autokrin stimulering med interleukin-2 (IL-2) er ndvendig for aktivering av T-cellene, for differensiering til antigenspesifikke T-cellekloner og for proliferasjon. Ved klonal anergi inaktiveres T-cellene grunnet manglende produksjon av IL-2 og lignende, og manglende celledeling. Nrmere bestemt krever aktivering av T-cellene, ledsaget av produksjon av cytokiner som IL-2, et sekundrsignal som flger det frste signal via TcR-/CD3-komplekset. Dette sekundrsignalet betegnes kostimulerende signal. </span>However, the TcR/CD3 complex-mediated primary signal alone cannot sufficiently activate the T cells and leads to non-responsiveness or clonal anergy, so that the cells cannot respond to a later received stimulus. Autocrine stimulation with interleukin-2 (IL-2) is necessary for activation of the T cells, for differentiation into antigen-specific T cell clones and for proliferation. In clonal anergy, the T cells are inactivated due to lack of production of IL-2 and the like, and lack of cell division. Specifically, activation of the T cells, accompanied by the production of cytokines such as IL-2, requires a secondary signal that follows the first signal via the TcR/CD3 complex. This secondary signal is called costimulatory signal.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">T-cellene mottar dette sekundrsignalet og overfrer det inn i cellene ved interaksjon (celleadhesjon) med molekyler forskjellige fra MHC p antigenpresenterende celler via molekyler som er forskjellige fra TcR-/CD3-komplekset p T-celleoverflaten. Dette sekundrsignalet gjr at celleanergi (klonal anergi) unngs og aktiverer cellene. </span>The T cells receive this secondary signal and transfer it into the cells by interaction (cell adhesion) with molecules other than MHC on antigen-presenting cells via molecules other than the TcR/CD3 complex on the T cell surface. This secondary signal means that cell anergy (clonal anergy) is avoided and activates the cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Selv om deler av mekanismen for sekundrsignaloverfringen mellom antigenpresenterende celler og lymfocytter, f.eks. T-celler, ikke er blitt fullstendig utredet, har underskelser hittil vist at en viktig faktor for sekundrsignaloverfringen er interaksjonen mellom CD28 (ogs betegnet Tp44-, T44- eller 9.3-antigen), som er et celleoverflatemolekyl som hovedsakelig uttrykkes p T-celler og brisselceller, og CD80 (ogs betegnet B7-1, B7, BB1 eller B7/BB1), som er et celleoverflatemolekyl som uttrykkes p antigenpresenterende celler (makrofager, monocytter, dendrittceller osv.), og med CD86 (ogs betegnet B7-2 eller B70), som ogs er et celleoverflatemolekyl p antigenpresenterende celler (nrmere bestemt celleadhesjon ved at disse molekylene sammenbindes). Det er videre blitt utledet eksperimentelt at interaksjonen mellom cytolytisk T-lymfocyttassosiert antigen-4 (CTLA-4), hvis ekspresjon antas  forsterkes avhengig av sekundrsignalet, og CD80 (B7-1) og CD86 (B7-2) (nrmere bestemt celleadhesjon ved binding mellom disse molekyler) ogs spiller en viktig rolle for regulering av T-celleaktiveringen via sekundrsignalet. Med andre ord omfatter reguleringen av T-celleaktivering ved overfring av sekundrsignalet minst interaksjon mellom CD28 og CD80/CD86, forsterket CTLA-4-ekspresjon, som antas  avhenge av interaksjonen, og interaksjonen mellom CTLA-4 og CD80/CD86. </span>Although parts of the mechanism for the secondary signal transmission between antigen-presenting cells and lymphocytes, e.g. T cells, have not been fully investigated, investigations have so far shown that an important factor for the secondary signal transmission is the interaction between CD28 (also called Tp44, T44 or 9.3 antigen), which is a cell surface molecule mainly expressed on T cells and brussels cells, and CD80 (also termed B7-1, B7, BB1 or B7/BB1), which is a cell surface molecule expressed on antigen-presenting cells (macrophages, monocytes, dendritic cells, etc.), and with CD86 (also termed B7-2 or B70 ), which is also a cell surface molecule on antigen-presenting cells (specifically cell adhesion by these molecules joining together). Furthermore, it has been deduced experimentally that the interaction between cytolytic T-lymphocyte-associated antigen-4 (CTLA-4), whose expression is thought to be enhanced depending on the secondary signal, and CD80 (B7-1) and CD86 (B7-2) (specifically cell adhesion by binding between these molecules) also plays an important role in regulating T-cell activation via the secondary signal. In other words, the regulation of T cell activation by transmission of the secondary signal includes at least interaction between CD28 and CD80/CD86, enhanced CTLA-4 expression, which is believed to depend on the interaction, and the interaction between CTLA-4 and CD80/CD86.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CD28 vites  vre et kostimulerende molekyl som overfrer sekundrsignalet (det kostimulerende signal) som er ndvendig for aktivering av T-celler og unngelse av anergi. Sekundrsignalet som overfres ved binding av dette molekyl til kostimulatormolekyler, CD80 (B7-1) og CD86 (B7-2) p antigenpresenterende celler (celleadhesjon via binding mellom disse molekyler), stabiliserer mRNA for cytokiner av Th 1-type og fremmer sledes T-cellenes produksjon av store mengder cytokiner av Thl-type, f.eks. IL-2, IFN-y og TNF-a. Ekspresjonen av CTLA-4 induseres av primrsignalet som overfres via TcR/CD3, og ekspresjonen fremmes ogs av sekundrsignalet som overfres ved binding mellom CD28 og CD80. Det har vist seg at CTLA-4 mottar disse signalene og bidrar til  inhibere T-cellefunksjonen, noe som str i motsetning til aktivering av T-celler via sekundrsignalet som overfres av CD28. </span>CD28 is known to be a costimulatory molecule that transmits the secondary signal (the costimulatory signal) necessary for activation of T cells and avoidance of anergy. The secondary signal transmitted by binding of this molecule to costimulator molecules, CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells (cell adhesion via binding between these molecules), stabilizes mRNA for Th 1-type cytokines and thus promotes T- the cells' production of large amounts of Th1-type cytokines, e.g. IL-2, IFN- and TNF-. The expression of CTLA-4 is induced by the primary signal transmitted via TcR/CD3, and the expression is also promoted by the secondary signal transmitted by binding between CD28 and CD80. It has been shown that CTLA-4 receives these signals and helps to inhibit T-cell function, which is in contrast to activation of T-cells via the secondary signal transmitted by CD28.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Humant CD28 og CTLA-4 er glykoproteiner av type I med molekylvekt p 44 kD henholdsvis 41-43 kD. Begge har et immunglobulinlignende domene og tilhrer immunglobulin-superfamilien, og begge fungerer som celleadhesjonsmolekyler og som signaloverfrings-molekyler. </span>Human CD28 and CTLA-4 are type I glycoproteins with a molecular weight of 44 kD and 41-43 kD, respectively. Both have an immunoglobulin-like domain and belong to the immunoglobulin superfamily, and both function as cell adhesion molecules and as signal transduction molecules.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Humant CD28 danner en homodimer med en disulfidbinding, mens CTLA-4 foreligger som en monomer. Genene for bde CD28 og CTLA-4 er lokalisert til "2q33" i det humane genom og "1C" i musegenomet, og bestr av fire (4) exoner. Humant CD28 og CTLA-4 bestr av 220 henholdsvis 223 aminosyrer, innbefattet ledersekvensene, og aminosyre-homologien mellom dem er 20-30 %. </span>Human CD28 forms a homodimer with a disulfide bond, while CTLA-4 exists as a monomer. The genes for both CD28 and CTLA-4 are located at "2q33" in the human genome and "1C" in the mouse genome, and consist of four (4) exons. Human CD28 and CTLA-4 consist of 220 and 223 amino acids respectively, including the leader sequences, and the amino acid homology between them is 20-30%.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ligandene for CD28 og CTLA-4 er CD80 (B7-1) og CD86 (B7-2) hos mennesker og mus. CTLA-4 har ca. 20 ganger hyere affinitet til begge ligander enn CD28. Det er blitt vist at aminosyresekvensstrukturene "MYPPPY (Met-Tyr-Pro-Pro-Pro-Tyr)", som er konservert hos forskjellige dyrearter, er viktige for binding av CD28 og CTLA-4 til CD80 (B7-1). Det er ogs blitt rapportert at nr CD28 er stimulert, assosieres PI3-kinase (fosfoinositid-3-kinase, PI3K) med den fosforylerte tyrosinresten i delsekvensen "YMNM (Tyr-Met-Asn-Met)" i CD28, og at CD28 spiller en viktig rolle i den intracellulre signaloverfring via denne "YxxM"-struktur. Det er videre blitt rapportert at CTLA-4 ogs har en sekvens representert ved "YxxM", nemlig "YVKM (Tyr-Val-Lys-Met)", i sitt cytoplasmatiske omrde, og at SYP etter stimulering assosieres med denne sekvens. </span>The ligands for CD28 and CTLA-4 are CD80 (B7-1) and CD86 (B7-2) in humans and mice. CTLA-4 has approx. 20 times higher affinity to both ligands than CD28. The amino acid sequence structures "MYPPPY (Met-Tyr-Pro-Pro-Pro-Tyr)", which are conserved in different animal species, have been shown to be important for binding of CD28 and CTLA-4 to CD80 (B7-1). It has also been reported that when CD28 is stimulated, PI3-kinase (phosphoinositide-3-kinase, PI3K) associates with the phosphorylated tyrosine residue in the "YMNM (Tyr-Met-Asn-Met)" subsequence of CD28, and that CD28 plays a important role in the intracellular signal transmission via this "YxxM" structure. It has further been reported that CTLA-4 also has a sequence represented by "YxxM", namely "YVKM (Tyr-Val-Lys-Met)", in its cytoplasmic region, and that after stimulation SYP associates with this sequence.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CD28 uttrykkes spesifikt i thymocytter og T-celler fra perifert blod, og CTLA-4 uttrykkes spesifikt i aktiverte T-celler (Cell Engineering: SUPPLEMENT, "Handbook of Adhesion Molecule", Shujunsha, s. 93-102 (1994); ibid., s. 120-136; Experimental Medicine: SUPPLEMENT, "Bio Science Term Library, Immunity", Yodosha, s. 94-98 (1995); Experimental Medicine: SUPPLEMENT, "Bio Science Term Library, Intracellular Signal Transduction", Yodosha, s. 58-59 (1997); Nihon Rinsho, vol. 55, nr. 6, s. 215-220 (1997)). </span>CD28 is specifically expressed in thymocytes and peripheral blood T cells, and CTLA-4 is specifically expressed in activated T cells (Cell Engineering: SUPPLEMENT, "Handbook of Adhesion Molecule", Shujunsha, pp. 93-102 (1994); ibid. , pp. 120-136; Experimental Medicine: SUPPLEMENT, "Bio Science Term Library, Immunity", Yodosha, pp. 94-98 (1995); Experimental Medicine: SUPPLEMENT, "Bio Science Term Library, Intracellular Signal Transduction", Yodosha, pp. 58-59 (1997); Nihon Rinsho, Vol. 55, No. 6, pp. 215-220 (1997)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I reguleringen av T-cellefunksjonen (aktivering og inhibering av T-cellenes funksjoner) er sledes betydningen av interaksjoner mellom flere molekyler, f.eks. kostimulerende molekyler (CD28, CD80 (B7-1), CD86 (B7-2) osv.) og CTLA-4, som samarbeider med disse blitt kjent, og dette har rettet oppmerksomheten mot sammenhengen mellom disse molekyler og sykdommer, og behandlingen av sykdommer ved  regulere disse molekylers funksjon. </span>In the regulation of T-cell function (activation and inhibition of T-cell functions) the importance of interactions between several molecules, e.g. costimulatory molecules (CD28, CD80 (B7-1), CD86 (B7-2) etc.) and CTLA-4, which cooperate with these have become known, and this has focused attention on the connection between these molecules and diseases, and the treatment of diseases by regulating the function of these molecules.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Som beskrevet ovenfor, selv om en levende kropp aktiverer sitt ervervede immunresponssystem mot antigener som er fremmedlegemer for kroppen (selvet), s har den ogs immunologisk toleranse slik at ingen immunrespons fremvises mot kroppens egne bestanddeler (autoantigener). Dersom den immunologiske toleranse nedbrytes av en eller annen grunn, opptrer immunrespons mot autoantigener, autoantigenreagerende T-celler induseres ved samme mekanismer som nevnt ovenfor, slik at en unormal immunitetstilstand oppstr, og resultatet er forskjellige autoimmune sykdommer. </span>As described above, even if a living body activates its acquired immune response system against antigens that are foreign to the body (self), it also has immunological tolerance so that no immune response is shown against the body's own components (autoantigens). If the immunological tolerance is broken down for one reason or another, an immune response against autoantigens occurs, autoantigen-reactive T cells are induced by the same mechanisms as mentioned above, so that an abnormal state of immunity occurs, and the result is various autoimmune diseases.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Med andre ord, ettersom ikke-stimulerte, antigenpresenterende celler (APC) i </span>In other words, as unstimulated antigen-presenting cells (APCs) i</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">normale vev ikke uttrykker kostimulerende molekyler nr kroppens immunsystem er normalt, er T-cellene i en ikke-responderende tilstand slik at immunologisk toleranse opprettholdes, selv om autoantigenreaktive T-celler som reagerer med autoantigen foreligger. Det er blitt foresltt at ved en unormal immunitetstilstand aktiveres flere autoantigenreaktive T-celler grunnet et unormalt overskudd og kontinuerlig ekspresjon av kostimulerende molekyler, slik at autoimmune sykdommer oppstr. </span>normal tissues do not express costimulatory molecules when the body's immune system is normal, the T cells are in a non-responsive state so that immunological tolerance is maintained, even though autoantigen-reactive T cells that react with autoantigen are present. It has been proposed that in an abnormal state of immunity, several autoantigen-reactive T cells are activated due to an abnormal excess and continuous expression of costimulatory molecules, so that autoimmune diseases occur.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ut fra slike synspunkter har det i senere tid vrt mange forsk p  behandle autoimmune sykdommer ved  modulere overfringen av kostimulerende signaler, f.eks. den ovenfor nevnte signaloverfring mellom CD28/CTLA-4 og CD80/CD86. </span>From such points of view, there have recently been many attempts to treat autoimmune diseases by modulating the transmission of costimulatory signals, e.g. the above-mentioned signal transduction between CD28/CTLA-4 and CD80/CD86.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatene fra slike forsk har enn ikke klargjort i detalj mekanismen for T-celleaktivering ved interaksjon mellom kostimulerende molekyler og de beslektede molekylene. Andre ukjente molekyler kan tenkes  inng i denne mekanismen. </span>The results of such experiments have not yet clarified in detail the mechanism of T-cell activation by interaction between costimulatory molecules and the cognate molecules. Other unknown molecules may be involved in this mechanism.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det er nylig blitt identifisert et nytt kostimulerende molekyl som ligner de ovenfor beskrevne "CD28" og "CTLA-4", og som antas  utfre overfringen av et sekundrsignalet (kostimulerende signal) som er avgjrende for aktivering av lymfocytter, f.eks. T-celler, og signalkoblet funksjonell regulering av aktiverte lymfocytter, f.eks. aktiverte T-celler. Dette molekylet er blitt betegnet AILIM (aktiveringsinduserbart, lymfocyttimmunmodulerende molekyl) (i menneske, mus og rotte: Int. Immunology, vol. 12, nr. 1, s. 51-55, 2000), ogs betegnet ICOS (induserbar kostimulator) (i mennesket: Nature, vol. 397, nr. 6716, s. 263-266, 1999). </span>A new costimulatory molecule similar to the above-described "CD28" and "CTLA-4" has recently been identified, which is believed to carry out the transmission of a secondary signal (costimulatory signal) essential for the activation of lymphocytes, e.g. T cells, and signal-coupled functional regulation of activated lymphocytes, e.g. activated T cells. This molecule has been termed AILIM (activation inducible lymphocyte immunomodulatory molecule) (in human, mouse and rat: Int. Immunology, vol. 12, no. 1, pp. 51-55, 2000), also termed ICOS (inducible costimulator) (in the human: Nature, vol. 397, no. 6716, pp. 263-266, 1999).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">P den annen side er svrt nylig blitt identifisert nye molekyler betegnet B7h, B7RP-1, GL50 eller LICOS, som er ligander (AILIM-ligander) som interagerer med det kostimulerende overfringsmolekyl AILIM (ICOC) (Nature, vol. 402, nr. 6763, s. 827-832, 1999; Nature Medicine, vol. 5, nr. 12, s. 1365-1369,1999; J. Immunology, vol. 164, s. 1653-1657, 2000; Curr. Biol., vol. 10, nr. 6, s. 333-336, 2000). </span>On the other hand, very recently new molecules designated B7h, B7RP-1, GL50 or LICOS have been identified, which are ligands (AILIM ligands) that interact with the costimulatory transfer molecule AILIM (ICOC) (Nature, vol. 402, no. 6763 , pp. 827-832, 1999; Nature Medicine, vol. 5, no. 12, pp. 1365-1369, 1999; J. Immunology, vol. 164, pp. 1653-1657, 2000; Curr. Biol., vol. 10, No. 6, pp. 333-336, 2000).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Identifiseringen av disse to typene av nye molekyler, nemlig AILIM (ICOS) og B7RP-1 (B7h, GL50, LICOS), som signaloverfringsveien for det kostimulerende signal som er ndvendig for den ovenfor beskrevne aktivering av lymfocytter, f.eks. T-celler, og for kontroll av aktiverte T-cellers funksjon, viste at det foreligger den nye, tredje reaksjonsveien ved interaksjonen mellom AILIM (ICOS) og B7RP-1 (B7h, GL50, LICOS), i tillegg til den kjente frste og andre signalvei, som er den allerede kjente overfringsvei mellom CD28 og CD80 (B7-1)/CD86 (B7-2), og mellom CTLA-4 og CD80 (B7-1)/CD86 (B7-2). </span>The identification of these two types of new molecules, namely AILIM (ICOS) and B7RP-1 (B7h, GL50, LICOS), as the signal transduction pathway for the costimulatory signal necessary for the above-described activation of lymphocytes, e.g. T cells, and to control the function of activated T cells, showed that there is a new, third reaction pathway in the interaction between AILIM (ICOS) and B7RP-1 (B7h, GL50, LICOS), in addition to the known first and second signaling pathway, which is the already known transmission pathway between CD28 and CD80 (B7-1)/CD86 (B7-2), and between CTLA-4 and CD80 (B7-1)/CD86 (B7-2).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Underskelser av disse nye molekylenes biologiske funksjoner, kontroll av lymfocytters, f.eks. T-cellers, funksjon via denne tredje kostimulerende signaloverfring via disse molekylene og sammenhengen mellom den nye signaloverfring og sykdommer er p gang (J. Immunol, 166( 1), s. 1,2001; J. ImmunoL, 165( 9), s. 5035,2000; Biochem. Biophys. Res. Commun., 275(1), s. 335, 2000; Immunity, 13( 1), s. 95, 2000; J. Exp. Med., 192( 1), s. 53, 2000; Eur. J.Immunol., 30(4), s. 1040, 2000; WO 01/15732). EP-A 0984023 beskriver mus-anti-AILIM antistoffer som inhiberer agglutinering av lymfocytiske celler og brukbarheten av nevnte antistoffer for behandling av autoimmune sykdommer og allergiske sykdommer. </span>Investigations of these new molecules' biological functions, control of lymphocytes, e.g. T-cells function via this third costimulatory signal transmission via these molecules and the connection between the new signal transmission and diseases is ongoing (J. Immunol, 166(1), p. 1, 2001; J. ImmunoL, 165( 9), p . 5035,2000; Biochem. Biophys. Res. Commun., 275(1), p. 335, 2000; Immunity, 13( 1), p. 95, 2000; J. Exp. Med., 192( 1), p. 53, 2000; Eur. J. Immunol., 30(4), p. 1040, 2000; WO 01/15732). EP-A 0984023 describes mouse anti-AILIM antibodies which inhibit the agglutination of lymphocytic cells and the utility of said antibodies for the treatment of autoimmune diseases and allergic diseases.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FASEB J., vol. 14, april 20, 2000, A 1169 beskriver at muse-induserbare kostimulerende (ICAS) molekyluttrykk er kt med CD28 kostimulering og regulerer utvikling av Th2-celler. </span>FASEB J., vol. 14, April 20, 2000, A 1169 discloses that mouse inducible costimulatory (ICAS) molecule expression is increased by CD28 costimulation and regulates development of Th2 cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Beskrivelse av oppfinnelsen </span>Description of the invention</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nrmere bestemt er et forml med den foreliggende oppfinnelse  avslre biologiske funksjoner til det nye molekyl AILIM, som i likhet med "CD28" og "CTLA-4" betraktes som et molekyl som overfrer sekundrsignalet (det kostimulerende signal) som er ndvendig for aktivering av lymfocytter, f.eks. T-celler, og som kontrollerer funksjonen av aktiverte lymfocytter, f.eks. aktiverte T-celler, ved  arbeide med signalet, og  vise sammen-henger mellom ekspresjonen av AILIM og sykdommer, og  tilveiebringe en fremgangsmte og et farmasytisk middel som inhiberer utviklingen av de forskjellige sykdommene som avhenger av ekspresjonsmnsteret for AILIM eller som behandler sykdommene ved  kontrollere de biologiske funksjoner av AILIM ved anvendelse av medisinske og farmasytiske fremgangsmter (f.eks. et medikament som et monoklonalt antistoff og en lavmolekylr forbindelse). </span>More specifically, an object of the present invention is to reveal biological functions of the new molecule AILIM, which, like "CD28" and "CTLA-4", is considered a molecule that transmits the secondary signal (the costimulatory signal) necessary for the activation of lymphocytes, e.g. T cells, and which control the function of activated lymphocytes, e.g. activated T cells, by working with the signal, and to show connections between the expression of AILIM and diseases, and to provide a method and a pharmaceutical agent that inhibits the development of the various diseases that depend on the expression pattern of AILIM or that treat the diseases by controlling the biological functions of AILIM using medical and pharmaceutical methods (eg, a drug such as a monoclonal antibody and a low molecular weight compound).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">For  oppn de ovenfor beskrevne forml har de foreliggende oppfinnere aktivt utfrt underskelser av humane antistoffer (nrmere bestemt humane, monoklonale antistoffer) rettet mot AILIM fra pattedyr (nrmere bestemt humant AILIM), og som et resultat har de, ved immunisering av transgene mus fremstilt ved anvendelse av genetiske rekombinasjonsteknikker, slik at de danner humane antistoffer med AILIM (nrmere bestemt en cellemembranfraksjon fra celler som uttrykker humant AILIM), som de frste i verden lykkes i  fremstille en rekke monoklonale antistoffer som bindes til humant AILIM, srlig de som bindes til humant AILIM og regulerer signaloverfringen som formidles av humant AILIM. </span>In order to achieve the above-described objects, the present inventors have actively conducted research on human antibodies (more specifically, human monoclonal antibodies) directed against mammalian AILIM (more specifically, human AILIM), and as a result, by immunization of transgenic mice, they have produced using genetic recombination techniques, so as to form human antibodies with AILIM (more specifically, a cell membrane fraction from cells expressing human AILIM), as the first in the world to succeed in producing a series of monoclonal antibodies that bind to human AILIM, in particular those that bind to human AILIM and regulates the signal transduction mediated by human AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ettersom antistoffer (spesielt monoklonale antistoffer) iflge foreliggende oppfinnelse er avledet fra mennesker, induserer de i det hele tatt ikke noen alvorlig immunologisk avvisning grunnet immunogenisitet mot mennesker, HAMA (human antimuseantigenisitet) i verten, noe som har vrt et stort problem (bivirkning) i terapi ved anvendelse av antistoffbaserte farmasytiske midler som omfatter antistoffer avledet fra ikke-humane pattedyr, slik som. mus, og dermed forhyes verdien av antistoff som medisinsk middel dramatisk. </span>Since antibodies (especially monoclonal antibodies) of the present invention are derived from humans, they do not at all induce any serious immunological rejection due to anti-human immunogenicity, HAMA (human anti-mouse antigenicity) in the host, which has been a major problem (side effect) in therapy using antibody-based pharmaceutical agents comprising antibodies derived from non-human mammals, such as. mice, and thus the value of antibody as a medical agent is dramatically increased.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Flgelig er humane antistoffer (nrmere bestemt humane, monoklonale antistoffer) som bindes til AILIM fra pattedyr (nrmere bestemt humant AILIM) iflge foreliggende oppfinnelse, og farmasytiske preparater som omfatter disse humane antistoffene (fortrinnsvis humane, monoklonale antistoffer), anvendbare som medikamenter for kontroll av, uten induksjon av immunologisk avvisning grunnet HAMA i verten, forskjellige fysiologiske reaksjoner forbundet med overfring av det kostimulerende signal til AILIM-uttrykkende celler formidlet av AILIM (f.eks. proliferasjon av AILIM-uttrykkende celler, cytokinproduksjon ved AILIM-uttrykkende celler, immuncytolyse eller apoptose av AILIM-uttrykkende celler og aktivitet for induksjon av antistoffavhengig cytotoksisitet overfor AILIM-uttrykkende celler osv.), og/eller ogs er anvendbare som medikamenter for undertrykkelse eller forebyggelse av utvikling av symptomer og/eller utvikling av forskjellige forstyrrelser forbundet med signal-overfringen som formidles av AILIM, og som medisin for behandling eller forebyggelse av forstyrrelsen. </span>Consequently, human antibodies (more specifically human, monoclonal antibodies) which bind to AILIM from mammals (more specifically human AILIM) according to the present invention, and pharmaceutical preparations comprising these human antibodies (preferably human, monoclonal antibodies), are useful as drugs for the control of , without induction of immunological rejection due to HAMA in the host, various physiological reactions associated with transmission of the costimulatory signal to AILIM-expressing cells mediated by AILIM (eg proliferation of AILIM-expressing cells, cytokine production by AILIM-expressing cells, immunocytolysis or apoptosis of AILIM-expressing cells and activity for the induction of antibody-dependent cytotoxicity against AILIM-expressing cells, etc.), and/or are also useful as drugs for suppressing or preventing the development of symptoms and/or the development of various disorders associated with the signal transmission as before mediated by AILIM, and as medicine for the treatment or prevention of the disorder.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nrmere bestemt kan farmasytiske preparater iflge foreliggende oppfinnelse kontrollere (undertrykke eller stimulere) proliferasjon av AILIM-uttrykkende celler eller AILIM-uttrykkende cellers produksjon av cytokin (f.eks. interferon-y eller interleukin-4 osv.), noe som tillater undertrykkelse av forskjellige patologiske tilstander og behandling eller forebyggelse av forskjellige forstyrrelser som skyldes forskjellige fysiologiske fenomener forbundet med signal-overfringen formidlet av AILIM. </span>More specifically, pharmaceutical preparations according to the present invention can control (suppress or stimulate) proliferation of AILIM-expressing cells or AILIM-expressing cells' production of cytokine (eg, interferon- or interleukin-4, etc.), allowing the suppression of various pathological conditions and the treatment or prevention of various disorders resulting from various physiological phenomena associated with the signal transmission mediated by AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anvendelse av farmasytiske preparater iflge foreliggende oppfinnelse tillater undertrykkelse, forebyggelse og/eller behandling av f.eks. forskjellige forstyrrelser (f.eks. reumatoid artritt multippel sklerose, autoimmun tyreoiditt, allergisk kontaktdermatitt, kronisk inflammatorisk dermatose, f.eks. lichen planus, systemisk lupus erythematosus, insulinavhengig diabetes mellitus, psoriasis osv.) som er klassifisert som autoimmune eller allergiske forstyrrelser (nrmere bestemt autoimmun sykdom og forsinket allergi grunnet cellulr immunitet), artropati (f.eks. reumatoid artritt (RA) og osteoartritt (OA)), inflammasjon (f.eks. hepatitt), "graft versus host"-reaksjon (GVH-reaksjon), "graft versus host"-sykdom (GVHD), immunologisk avvisning etter transplantasjon (homoplastikk eller heteroplastikk) av et vev (vev som hud, hornhinne, ben osv.) eller organ (lever, hjerte, lunge, nyre, bukspyttkjertel osv.), immunrespons utlst av et fremmed antigen eller autoantigen (f.eks. dannelse av antistoffer mot antigenet, celleproliferasjon, produksjon av cytokiner), og forstyrrelser som kan tenkes  skyldes unormal immunitet i tarmen (nrmere bestemt inflammatoriske tarmforstyrrelser (fortrinnsvis klonisk sykdom og ulcers kolitt) og nringsmiddelallergi. </span>Use of pharmaceutical preparations according to the present invention allows the suppression, prevention and/or treatment of e.g. various disorders (eg, rheumatoid arthritis, multiple sclerosis, autoimmune thyroiditis, allergic contact dermatitis, chronic inflammatory dermatosis, eg, lichen planus, systemic lupus erythematosus, insulin-dependent diabetes mellitus, psoriasis, etc.) which are classified as autoimmune or allergic disorders ( specifically autoimmune disease and delayed allergy due to cellular immunity), arthropathy (e.g. rheumatoid arthritis (RA) and osteoarthritis (OA)), inflammation (e.g. hepatitis), "graft versus host" reaction (GVH reaction ), "graft versus host" disease (GVHD), immunological rejection after transplantation (homoplasty or heteroplasty) of a tissue (tissue such as skin, cornea, bone, etc.) or organ (liver, heart, lung, kidney, pancreas, etc. ), immune response triggered by a foreign antigen or autoantigen (e.g. formation of antibodies against the antigen, cell proliferation, production of cytokines), and disorders that can be thought to be due to abnormal immunity in the gut ( more specifically inflammatory bowel disorders (preferably clonic disease and ulcerative colitis) and food allergies.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Videre er det innen feltet suppresj on/behandling av immunologisk avvisning etter transplantasjon av de ovenfor beskrevne vev og organer mulig  forsterke den supprimerende virkning p transplantat avvisning av kjente immunsupprimerende midler ved  benytte det farmasytiske preparat iflge foreliggende oppfinnelse, sammen med medikamenter som er blitt benyttet for suppresjon av immunologisk avvisning ved slik transplantasjonsbehandling. </span>Furthermore, within the field of suppression/treatment of immunological rejection after transplantation of the above-described tissues and organs, it is possible to enhance the suppressive effect on transplant rejection of known immunosuppressive agents by using the pharmaceutical preparation according to the present invention, together with drugs that have been used for suppression of immunological rejection in such transplantation treatment.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det farmasytiske preparat iflge foreliggende oppfinnelse kan videre anvendes for behandling eller forebyggelse av enhver inflammatorisk sykdom hvor forskjellige steroider ville benyttes som antiflogistiske midler. </span>The pharmaceutical preparation according to the present invention can further be used for the treatment or prevention of any inflammatory disease where various steroids would be used as antiphlogistic agents.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det farmasytiske preparat iflge foreliggende oppfinnelse kan benyttes p inflammatorisk sykdom, f.eks. inflammasjon som flge av forskjellige artritter (f.eks. reumatoid artritt, osteoartritt, lungebetennelse, hepatitt (innbefattet viral hepatitt), inflammasjon som flge av infeksise sykdommer, inflammatoriske tarmsykdommer, intestinal enteritt, nefritt (inflammasjon som flge av glomerulonefritt, nefrofibrose), gastritt, angiitt, pankreatitt, peritonitt, bronkitt, myokarditt, cerebritt, inflammasjon ved postiskemisk reperfusjonsskade </span>The pharmaceutical preparation according to the present invention can be used for inflammatory disease, e.g. inflammation due to various arthritis (e.g. rheumatoid arthritis, osteoarthritis, pneumonia, hepatitis (including viral hepatitis), inflammation due to infectious diseases, inflammatory bowel diseases, intestinal enteritis, nephritis (inflammation due to glomerulonephritis, nephrofibrosis), gastritis , angiitis, pancreatitis, peritonitis, bronchitis, myocarditis, cerebritis, inflammation in postischemic reperfusion injury</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(myokardiskemisk reperfusjonsskade), inflammasjon grunnet immunologisk avvisning etter transplantasjon av vev og organer, brannskader, forskjellige hudinflammasjoner (psoriasis, allergisk kontaktdermatitt, lichen planus, som er en kronisk inflammatorisk hudsykdom), inflammasjon ved flerorgansvikt, inflammasjon etter operasjon av PTC A eller PTCR, og inflammasjon forbundet med arteriosklerose, og autoimmun tyreoiditt. </span>(myocardial reperfusion injury), inflammation due to immunological rejection after transplantation of tissues and organs, burns, various skin inflammations (psoriasis, allergic contact dermatitis, lichen planus, which is a chronic inflammatory skin disease), inflammation in multiple organ failure, inflammation after surgery for PTC A or PTCR, and inflammation associated with arteriosclerosis, and autoimmune thyroiditis.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ved anvendelse av en fremgangsmte for identifisering av forbindelser som bindes til AILIM eller AILIM-ligand, som er en fremgangsmte iflge foreliggende oppfinnelse, blir det i tillegg mulig  foreta sk for seleksjon av farmasytiske midler (syntetiske forbindelser eller antistoffer) med mulig aktivitet for behandling av forskjellige sykdommer, ved binding til AILIM eller AILIM-ligander for regulering av signaloverfringen som formidles ved interaksjon mellom disse. </span>When using a method for identifying compounds that bind to AILIM or AILIM ligand, which is a method according to the present invention, it is additionally possible to search for the selection of pharmaceutical agents (synthetic compounds or antibodies) with possible activity for treatment of various diseases, by binding to AILIM or AILIM ligands to regulate the signal transmission mediated by interaction between these.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Foreliggende oppfinnelse er nrmere bestemt oppfinnelsen beskrevet ved de flgende punkter (1) til (21). 1. Humant, monoklonalt antistoff som binder til human AILIM, kjennetegnet ved at det omfatter flgende karakteristika (a) og (b); (a) et variabelt tungkjedeomrde av antistoffet som omfatter enten den ene eller den andre av (I) eller (II); (I) en aminosyresekvens som omfatter aminosyresekvensen fra aminosyrene 20 til 117 iflge SEQ ID NO: 28, eller (II) en aminosyresekvens som omfatter aminosyrene fra posisjon 20 til posisjon 117 i SEQ ID NO: 28 hvorved n til ti aminosyrerester er deletert eller </span>The present invention is more precisely the invention described in the following points (1) to (21). 1. Human monoclonal antibody that binds to human AILIM, characterized in that it comprises the following characteristics (a) and (b); (a) a heavy chain variable region of the antibody comprising either one or the other of (I) or (II); (I) an amino acid sequence comprising the amino acid sequence from amino acids 20 to 117 according to SEQ ID NO: 28, or (II) an amino acid sequence comprising the amino acids from position 20 to position 117 in SEQ ID NO: 28 whereby one to ten amino acid residues have been deleted or</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">substituert, eller til hvilken n til ti aminosyrerester er innsatt eller tilfyd, og </span>substituted, or to which one to ten amino acid residues have been inserted or added, and</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(b) et variabelt lettkjedeomrde av antistoffet som omfatter enten den ene eller den andre av (I) eller (II); (I) en aminosyresekvens som omfatter aminosyresekvensen fra aminosyrene 23 til 116 iflge SEQ ID NO: 30, eller (II) en aminosyresekvens som omfatter aminosyrene fra posisjon 23-116 i SEQ ID NO: 30 i hvilken n til ti aminosyrerester er deletert eller substituert, eller </span>(b) a variable light chain region of the antibody comprising either one or the other of (I) or (II); (I) an amino acid sequence comprising the amino acid sequence from amino acids 23 to 116 according to SEQ ID NO: 30, or (II) an amino acid sequence comprising the amino acids from position 23-116 of SEQ ID NO: 30 in which one to ten amino acid residues are deleted or substituted , or</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">til hvilken n til ti aminosyrerester er innsatt eller tilfyd, </span>to which one to ten amino acid residues have been inserted or added,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">betinget av at nr det variable tungkjedeomrde er ovennevnte (II) av (a) eller det variable lettkjedeomrde er ovennevnte (II) av (b) omfatter antistoffet hvilke som helst av karakteristikaene vist i (i) til (iii); </span>provided that when the heavy chain variable region is the above (II) of (a) or the light chain variable region is the above (II) of (b), the antibody comprises any of the characteristics shown in (i) to (iii);</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(i) en forebyggende aktivitet p en blandet lymfocyttreaksjon, </span>(i) a preventive activity on a mixed lymphocyte reaction;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(ii) en aktivitet for  indusere signaloverfring for  indusere interferon-y, og </span>(ii) an activity to induce signal transduction to induce interferon-, and</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(iii) en aktivitet for  indusere antistoffavhengig cellulr cytotoksisitet overfor AILIM-uttrykkende celler. 2. Humant, monoklonalt antistoff iflge punkt 1, som omfatter flgende karakteristika (a) og (b); (a) et tungkjede polypeptid av antistoffet som omfatter enten den ene eller den andre av (I) eller di); (I) en aminosyresekvens fra aminosyrene 20-470 iflge SEQ ID NO: 28, eller (II) en aminosyresekvens som omfatter aminosyrene fra posisjon 20 til 470 i SEQ ID NO: 28 hvorved n til ti aminosyrerester er deletert eller substituert, eller </span>(iii) an activity to induce antibody-dependent cellular cytotoxicity towards AILIM-expressing cells. 2. Human monoclonal antibody according to point 1, comprising the following characteristics (a) and (b); (a) a heavy chain polypeptide of the antibody comprising either one or the other of (I) or di); (I) an amino acid sequence from amino acids 20-470 according to SEQ ID NO: 28, or (II) an amino acid sequence comprising the amino acids from position 20 to 470 in SEQ ID NO: 28 whereby one to ten amino acid residues have been deleted or substituted, or</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">til hvilken n til ti aminosyrerester er innsatt eller tilfyd, og </span>to which one to ten amino acid residues have been inserted or added, and</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(b) et lettkjede polypeptid av antistoffet omfatter enten den ene eller den andre av flgende (I) eller (II); (I) en aminosyresekvens fra aminosyrene 23-236 iflge SEQ ID NO: 30, eller (II) en aminosyresekvens som omfatter aminosyrene fra posisjon 23 til 236 fra SEQ ID NO: 30 hvorved n til ti aminosyrerester er deletert eller substituert, eller </span>(b) a light chain polypeptide of the antibody comprises either one or the other of the following (I) or (II); (I) an amino acid sequence from amino acids 23-236 according to SEQ ID NO: 30, or (II) an amino acid sequence comprising the amino acids from position 23 to 236 from SEQ ID NO: 30 whereby one to ten amino acid residues have been deleted or substituted, or</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">til hvilken n til ti aminosyrerester er innsatt eller tilfyd, </span>to which one to ten amino acid residues have been inserted or added,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">betinget av at nr tungkjede polypeptidet er ovennevnte (II) av (a) eller lettkjede polypeptidet er ovennevnte (II) av (b), omfatter antistoffet hvilke som helst av karakteristikaene som angitt i (i) til (iii); </span>provided that when the heavy chain polypeptide is the above (II) of (a) or the light chain polypeptide is the above (II) of (b), the antibody comprises any of the characteristics set forth in (i) to (iii);</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(i) en forebyggende aktivitet p en blandet lymfocyttreaksjon, </span>(i) a preventive activity on a mixed lymphocyte reaction;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(ii) en aktivitet for  indusere signaloverfring for  indusere interferon-y, og </span>(ii) an activity to induce signal transduction to induce interferon-, and</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(iii) en aktivitet for  indusere antistoffavhengig cellulr cytotoksisitet overfor AILIM-uttrykkende celler. 3. DNA kjennetegnet ved at det er valgt fra (a) eller (b) nedenfor; a) DNA som koder for en tungkjede variabel region av det humane antistoffet iflge punkt 1, hvor nevnte tungkjede variabel region omfatter aminosyresekvensen fra aminosyrene 20 til 117 fra SEQ ID NO:28; eller b) DNA som koder for en lettkjede variabel region av antistoffet iflge punkt 1, hvor nevnte lettkjede variabel region omfatter aminosyresekvensen fra aminosyrene 23 til 116 </span>(iii) an activity to induce antibody-dependent cellular cytotoxicity towards AILIM-expressing cells. 3. DNA characterized by being selected from (a) or (b) below; a) DNA encoding a heavy chain variable region of the human antibody according to point 1, wherein said heavy chain variable region comprises the amino acid sequence from amino acids 20 to 117 from SEQ ID NO:28; or b) DNA encoding a light chain variable region of the antibody according to point 1, where said light chain variable region comprises the amino acid sequence from amino acids 23 to 116</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">fra SEQ ID NO: 30. </span>from SEQ ID NO: 30.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">4. DNA iflge punkt 3, hvor nevnte tungkjede variabel region omfatter aminosyre sekvensen fra aminosyrene 20 til 470 iflge SEQ ID NO: 28. 5. DNA iflge punkt 4, hvor nevnte lettkjede variabel region omfatter aminosyresekvensen fra aminosyrene 23 til 236 iflge SEQ ID NO: 30. 6. DNA iflge punkt 3, hvor DNA (a) er et DNA som omfatter nukleotidsekvensen fra nukleotidene 126 til 419 iflge SEQ ID NO:27, og hvor DNA (b) er et DNA som omfatter nukleotidsekvensen fra nukleotidene 105 til 386 iflge SEQ ID NO:29. 7. DNA iflge punkt 3, hvor DNA (a) er et DNA som omfatter nukleotidsekvensen fra nukleotidene 69 til 1481 iflge SEQ ID NO: 27, og hvor DNA (b) er et DNA som omfatter nukleotidsekvensen fra nukleotidene 39 til 749 iflge SEQ ID NO: 29. 8. Vektor, kjennetegnet ved at den omfatter DNA iflge hvilke som helst av punktene 3-7. 9. Vektor iflge punkt 8, som omfatter et DNA som omfatter nukleotidsekvensen fra nukleotidene 126 til 419 iflge SEQ ID NO: 27. 10. Vektor iflge punkt 8, som omfatter et DNA som omfatter nukleotidsekvensen fra nukleotidene 69 til 1481 iflge SEQ ID NO: 27. 11. Vektor iflge punkt 8, som omfatter et DNA som omfatter nukleotidsekvensen fra nukleotidene 105 til 386 iflge SEQ ID NO: 29. 12. Vektor iflge punkt 8, som omfatter et DNA som omfatter nukleotidsekvensen fra nukleotidene 39 til 749 iflge SEQ ID NO: 29. 13. Vektor iflge punkt 8, som omfatter et DNA iflge (a) og (b) som flger; a) DNA som omfatter nukleotidsekvensen fra nukleotidene 126 til 419 iflge SEQ ID NO: 27, og b) DNA som omfatter nukleotidsekvensen fra nukleotidene 105 til 386 iflge SEQ ID NO: 29. 14. Vektor iflge punkt 8, som omfatter et DNA iflge (a) og (b) som flger; a) DNA som omfatter nukleotidsekvensen fra nukleotidene 69 til 1481 iflge SEQ ID NO: 27, og b) DNA som omfatter nukleotidsekvensen fra nukleotidene 39 til 749 iflge SEQ ID NO: 29. 15. Celle, kjennetegnet ved at den produserer det humane monoklonale antistoffet iflge punktene 1 eller 2, hvor cellen ikke er en human embryonisk celle. 16. Celle iflge punkt 15, som er en fusjonscelle erholdt ved  fusjonere en B-celle avledet fra et pattedyr som kan danne det humane, monoklonale antistoff og en myelomcelle avledet fra et pattedyr. 17. Genetisk rekombinant ikke-human vert, kjennetegnet ved at den er transformert med en vektor iflge ethvert av punktene 8-14, hvori nevnte vert er avledet fra et pattedyr valgt fra gruppen bestende av kveg, geit, kanin, mus, rotte, hamster og marsvin. </span>4. DNA according to point 3, where said heavy chain variable region comprises the amino acid sequence from amino acids 20 to 470 according to SEQ ID NO: 28. 5. DNA according to point 4, where said light chain variable region comprises the amino acid sequence from amino acids 23 to 236 according to SEQ ID NO : 30. 6. DNA according to point 3, where DNA (a) is a DNA comprising the nucleotide sequence from nucleotides 126 to 419 according to SEQ ID NO:27, and where DNA (b) is a DNA comprising the nucleotide sequence from nucleotides 105 to 386 according to SEQ ID NO:29. 7. DNA according to point 3, where DNA (a) is a DNA comprising the nucleotide sequence from nucleotides 69 to 1481 according to SEQ ID NO: 27, and where DNA (b) is a DNA comprising the nucleotide sequence from nucleotides 39 to 749 according to SEQ ID NO: 29. 8. Vector, characterized in that it comprises DNA according to any of items 3-7. 9. Vector according to point 8, which comprises a DNA comprising the nucleotide sequence from nucleotides 126 to 419 according to SEQ ID NO: 27. 10. Vector according to point 8, which comprises a DNA comprising the nucleotide sequence from nucleotides 69 to 1481 according to SEQ ID NO: 27. 11. Vector according to point 8, which comprises a DNA comprising the nucleotide sequence from nucleotides 105 to 386 according to SEQ ID NO: 29. 12. Vector according to point 8, which comprises a DNA comprising the nucleotide sequence from nucleotides 39 to 749 according to SEQ ID NO: 29. 13. Vector according to point 8, comprising a DNA according to (a) and (b) as follows; a) DNA comprising the nucleotide sequence from nucleotides 126 to 419 according to SEQ ID NO: 27, and b) DNA comprising the nucleotide sequence from nucleotides 105 to 386 according to SEQ ID NO: 29. 14. Vector according to point 8, which comprises a DNA according to ( a) and (b) as follows; a) DNA comprising the nucleotide sequence from nucleotides 69 to 1481 according to SEQ ID NO: 27, and b) DNA comprising the nucleotide sequence from nucleotides 39 to 749 according to SEQ ID NO: 29. 15. Cell, characterized in that it produces the human monoclonal antibody according to items 1 or 2, wherein the cell is not a human embryonic cell. 16. Cell according to point 15, which is a fusion cell obtained by fusing a B cell derived from a mammal capable of forming the human monoclonal antibody and a myeloma cell derived from a mammal. 17. Genetically recombinant non-human host, characterized in that it has been transformed with a vector according to any of items 8-14, wherein said host is derived from a mammal selected from the group consisting of cattle, goat, rabbit, mouse, rat, hamster and guinea pigs.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">18. Genetisk rekombinant vert punkt krav 17, som er en ikke-human pattedyrcelle. </span>18. The genetically recombinant host of claim 17, which is a non-human mammalian cell.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">19. Genetisk rekombinant vert iflge punkt 17, som er et befruktet egg fra et ikke-humant pattedyr. 20. Farmasytisk preparat, kjennetegnet ved at det omfatter det humane antistoffet iflge punktene 1 eller 2 og en farmasytisk akseptabel brer. 21. Anvendelse av antistoffet iflge punktene 1 eller 2, for fremstilling av et farma-sytisk preparat for forebyggelse, behandling eller profylakse av allergi av forsinket type, reumatoid artritt, systemisk lupus erythematosus, psoriasis, insulinavhegig diabetes mellitus, graft-versus-host sykdom, immun-awisning forbundet med transplantasjon eller nefritt. </span>19. Genetic recombinant host according to item 17, which is a fertilized egg from a non-human mammal. 20. Pharmaceutical preparation, characterized in that it comprises the human antibody according to points 1 or 2 and a pharmaceutically acceptable carrier. 21. Use of the antibody according to points 1 or 2, for the production of a pharmaceutical preparation for the prevention, treatment or prophylaxis of delayed-type allergy, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, insulin-dependent diabetes mellitus, graft-versus-host disease , immunodeficiency associated with transplantation or nephritis.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Foreliggende oppfinnelse beskrives i detalj her nedenfor ved definisjon av begreper iflge foreliggende oppfinnelse. </span>The present invention is described in detail here below by definition of terms according to the present invention.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Pattedyr" betyr her menneske, storfe, geit, kanin, mus, rotte, hamster og marsvin; menneske, kanin, rotte, hamster og mus foretrekkes, og spesielt foretrukket er menneske, rotte, hamster og mus. </span>"Mammal" here means human, cattle, goat, rabbit, mouse, rat, hamster and guinea pig; human, rabbit, rat, hamster and mouse are preferred, and particularly preferred are human, rat, hamster and mouse.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Begrepene "pattedyr forskjellige fra mennesker" og "ikke-humane pattedyr", som anvendt her, er synonymer og betyr alle pattedyr som definert ovenfor, bortsett fra menneske. </span>The terms "non-human mammals" and "non-human mammals", as used herein, are synonymous and mean all mammals as defined above, except humans.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Begrepet "aminosyrer", som benyttet her, betyr enhver aminosyre som foreligger i naturen, fortrinnsvis aminosyrene beskrevet iflge det alfabetiske trebokstavsystem eller enbokstavsystem, som vist nedenfor: glysin (Gly/G), alanin (Ala/A), valin ( Val/ V), leucin (Leu/L), isoleucin (Ile/I),
serin (Ser/S), treonin (Thr/T), asparaginsyre (Asp/D), glutaminsyre (Glu/E), asparagin (Asn/N), glutamin (Gln/Q), lysin (Lys/K), arginin (Arg/R), cystein (Cys/C), metionin (Met/M), fenylalanin (Phe/F), tyrosin (Tyr/Y), tryptofan (Trp/W), histidin (His/H), prolin (Pro/P). </span>The term "amino acids", as used herein, means any naturally occurring amino acid, preferably the amino acids described according to the alphabetical three-letter system or one-letter system, as shown below: glycine (Gly/G), alanine (Ala/A), valine (Val/V ), leucine (Leu/L), isoleucine (Ile/I),
serine (Ser/S), threonine (Thr/T), aspartic acid (Asp/D), glutamic acid (Glu/E), asparagine (Asn/N), glutamine (Gln/Q), lysine (Lys/K), arginine (Arg/R), cysteine (Cys/C), methionine (Met/M), phenylalanine (Phe/F), tyrosine (Tyr/Y), tryptophan (Trp/W), histidine (His/H), proline ( Pro/P).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Begrepet "AILIM", som benyttet her, er en forkortelse for aktiveringsinduserbart, lymfocyttimmunmodulerende molekyl, som betegner et molekyl p overflaten av pattedyrceller som har en struktur og funksjon som allerede beskrevet i en tidligere rapport, mer foretrukket et AILIM avledet fra menneske (se f.eks. International Immunology, vol. 12, nr. 1, s. 51-55; aksesjonsbetegnelse i GenBank: BAA82129 (menneske), BAA82128 (rotte), BAA82127 (rottevariant) og BAA82126 (mus)). </span>The term "AILIM", as used herein, is an abbreviation for activation-inducible, lymphocyte immunomodulatory molecule, which denotes a molecule on the surface of mammalian cells having a structure and function as already described in a previous report, more preferably a human-derived AILIM (see f .eg International Immunology, vol. 12, no. 1, pp. 51-55; accession designation in GenBank: BAA82129 (human), BAA82128 (rat), BAA82127 (rat variant) and BAA82126 (mouse)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Alternativt betegnes dette AILIM ogs ICOS (ikke ferdigbehandlet, publisert japansk patentsknad (JP-A) nr. Hei 11-29599, internasjonal patentsknad WO 98/38216) og disse forkortelsene betegner samme molekyl. </span>Alternatively, this AILIM is also referred to as ICOS (unprocessed, Published Japanese Patent Application (JP-A) No. Hei 11-29599, International Patent Application WO 98/38216) and these abbreviations denote the same molecule.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"AILIM-ligand", som anvendt her, betyr et celleoverflatemolekyl som interagerer med det nevnte kostimulerende molekyl "AILIM" (ICOS), og betegnes B7h, B7RP-1, GL50 eller LICOS (Nature, vol. 402, nr. 6763, s. 827-832,1999; Nature Medicine, vol. 5, nr. 12, s. 1365- </span>"AILIM ligand", as used herein, means a cell surface molecule that interacts with said costimulatory molecule "AILIM" (ICOS), and is designated B7h, B7RP-1, GL50 or LICOS (Nature, vol. 402, no. 6763, p .827-832,1999; Nature Medicine, vol. 5, no. 12, pp. 1365-</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1369,1999; J. Immunology, vol. 164, s. 1653-1657,2000; Curr. Biol, vol. 10, nr. 6, s. 333-336, 2000). </span>1369,1999; J. Immunology, vol. 164, pp. 1653-1657, 2000; Curr. Biol, vol. 10, No. 6, pp. 333-336, 2000).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Videre omfatter "AILIM", som anvendt her, ogs et polypeptid med i det vesentlige samme aminosyresekvens som AILIM fra hvert av pattedyrene beskrevet i referansene, og spesielt foretrukket aminosyresekvensen til humant AILIM. Videre omfattes en human AILIM-variant som tilsvarer rotte-AILIM-varianten som allerede er rapportert (aksesjonsbetegnelse i GenBank: BAA82127) ogs av begrepet "AILIM" i foreliggende oppfinnelse. </span>Furthermore, "AILIM", as used herein, also includes a polypeptide having substantially the same amino acid sequence as AILIM from each of the mammals described in the references, and particularly preferably the amino acid sequence of human AILIM. Furthermore, a human AILIM variant corresponding to the rat AILIM variant that has already been reported (accession name in GenBank: BAA82127) is also covered by the term "AILIM" in the present invention.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"AILIM-ligand", som anvendt her, defineres ogs til  ha en tilsvarende betydning som ovenfor. </span>"AILIM ligand", as used herein, is also defined to have a similar meaning as above.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Her betyr "polypeptider med i det vesentlige identisk aminosyresekvens" polypeptidvarianter som beskrevet nedenfor. </span>Here, "polypeptides with substantially identical amino acid sequence" means polypeptide variants as described below.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det vil si at s lenge som disse polypeptidvariantene har biologiske egenskaper som i det vesentlige tilsvarer egenskapene til AILIM av naturlig type (spesielt foretrukket AILIM avledet fra menneske), er de polypeptider iflge foreliggende oppfinnelse. Likes omfattes polypeptider med aminosyresekvensen til AILIM av naturlig type i hvilken flere aminosyrerester, fortrinnsvis 1-10 aminosyrerester, mer foretrukket 1-5 aminosyrerester, er delert og/eller modifisert, og i hvilken flere aminosyrerester, fortrinnsvis 1-10 aminosyrerester, mest foretrukket 1 -5 aminosyrerester, er addert. </span>That is to say, as long as these polypeptide variants have biological properties which essentially correspond to the properties of natural-type AILIM (particularly preferred AILIM derived from humans), they are polypeptides according to the present invention. Likewise, polypeptides with the amino acid sequence of natural type AILIM are included in which several amino acid residues, preferably 1-10 amino acid residues, more preferably 1-5 amino acid residues, are split and/or modified, and in which several amino acid residues, preferably 1-10 amino acid residues, most preferably 1 -5 amino acid residues, are added.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Videre kan det foreligge polypeptidvarianter med flere av disse substitusjonene, delesjonene, modifikasjonene og addisjonene av aminosyrerester i molekylet. </span>Furthermore, there may be polypeptide variants with several of these substitutions, deletions, modifications and additions of amino acid residues in the molecule.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"AILIM-ligand" i foreliggende oppfinnelse er ogs definert til  ha en tilsvarende betydning som ovenfor. </span>"AILIM ligand" in the present invention is also defined to have a similar meaning as above.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AILIM (fortrinnsvis humant AILIM) og AILIM-ligand (fortrinnsvis human AILIM-ligand) i foreliggende oppfinnelse kan i tillegg til ved genrekombinante teknikker fremstilles ved anvendelse av velkjente fremgangsmter innen dette tekniske omrdet, f.eks. ved kjemisk syntese, celledyrking osv., eller ved modifikasjoner av disse fremgangsmtene. </span>AILIM (preferably human AILIM) and AILIM-ligand (preferably human AILIM-ligand) in the present invention can, in addition to gene recombination techniques, be produced using well-known methods within this technical area, e.g. by chemical synthesis, cell culture, etc., or by modifications of these methods.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Slik substitusjon, delesjon eller innfyelse av aminosyrer kan oppns iflge den sedvanlige fremgangsmten (Experimental Medicine: SUPPLEMENT, "Handbook of Genetic Engineering" (1992) osv.). </span>Such substitution, deletion or insertion of amino acids can be achieved according to the usual method (Experimental Medicine: SUPPLEMENT, "Handbook of Genetic Engineering" (1992) etc.).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempler p fremgangsmter for fremstilling av mutante polypeptider som nevnt ovenfor, er setestyrt mutagenese med syntetisk oligonukleotid (dupleks med gap-fremgangsmten), punktmutagenese, hvorved en punktmutasjon innfres tilfeldig ved behandling med nitritt eller sulfitt, fremgangsmten ved hvilken en delesjonsmutant fremstilles med Bal31-enzym og lignende, kassettmutagenese, linkerskanningsfremgangsmten, feilinkorporeringsfremgangs-mten, mistilpasset primer-fremgangsmten, DNA-segmentsyntesefremgangsmten osv. </span>Examples of methods for producing mutant polypeptides as mentioned above are site-directed mutagenesis with synthetic oligonucleotide (duplex with the gap method), point mutagenesis, whereby a point mutation is randomly introduced by treatment with nitrite or sulphite, the method whereby a deletion mutant is produced with Bal31 enzyme and the like, cassette mutagenesis, the linker scanning method, the misincorporation method, the mismatched primer method, the DNA segment synthesis method, etc.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Setestyrt mutagenese med syntetisk oligonukleotid (dupleks med gap-fremgang-mten) kan f.eks. utfres som flger. Omrdet som nskes mutagenisert, klones inn i M13-bakteriofagvektor med ambermutasjon for fremstilling av enkelttrdet bakteriofag-DNA. Deretter lineariseres RF-I-DNA fra en M13-vektor uten ambermutasjon ved restriksjons-enzymbehandling. DNA sammenblandes med det enkelttrdete bakteriofag-DNA nevnt ovenfor, denatureres og hybridiseres, hvorved det dannes "dupleks-DNA med gap". Et syntetisk oligonukleotid med innfrte mutasjoner hybridiseres til dupleks-DNA med gap, og lukket, sirku-lrt, dobbelttrdet DNA fremstilles ved reaksjon med DNA-polymerase og DNA-ligase. E. coli-mutS-celler, som mangler "mismatch"-reparasjonsaktivitet, transfekteres med dette DNA. </span>Site-directed mutagenesis with synthetic oligonucleotide (duplex with the gap-advance method) can e.g. performed as follows. The area that is desired to be mutagenized is cloned into the M13 bacteriophage vector with amber mutation for the production of single-stranded bacteriophage DNA. RF-I DNA is then linearized from an M13 vector without the amber mutation by restriction enzyme treatment. The DNA is mixed with the single-stranded bacteriophage DNA mentioned above, denatured and hybridized, forming "gapped duplex DNA". A synthetic oligonucleotide with introduced mutations is hybridized to gapped duplex DNA, and closed, circular, double-stranded DNA is produced by reaction with DNA polymerase and DNA ligase. E. coli mutS cells, which lack mismatch repair activity, are transfected with this DNA.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">E. co//'-celler uten suppressoraktivitet infiseres med de utvokste bakteriofager, og bare bakteriofager uten ambermutasjon analyseres. </span>E. co//' cells without suppressor activity are infected with the grown bacteriophages, and only bacteriophages without the amber mutation are analyzed.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Fremgangsmten ved hvilken en punktmutasjon innfres med nitritt, anvender f.eks. prinsippet som er nevnt nedenfor. Dersom DNA behandles med nitritt, deamineres baser slik at adenin endres til hypoksantin, cytosin til uracil og guanin til xantin. Dersom deaminert DNA innfres i celler, erstattes "A:T" og "G:C" med "G:C" henholdsvis "A:T", siden hypoksantin, uracil og xantin danner et basepar med cytosin, adenin henholdsvis tymin under DNA-replikasjonen. I praksis hybridiseres enkelttrdete DNA-fragmenter behandlet med nitritt til "dupleks-DNA med gap", hvoretter mutante stammer separeres ved manipulering p samme mte som ved setestyrt mutagenese med syntetisk oligonukleotid (dupleks med gap-fremgangsmten). </span>The method by which a point mutation is introduced with nitrite uses e.g. the principle mentioned below. If DNA is treated with nitrite, bases are deaminated so that adenine changes to hypoxanthine, cytosine to uracil and guanine to xanthine. If deaminated DNA is introduced into cells, "A:T" and "G:C" are replaced by "G:C" and "A:T" respectively, since hypoxanthine, uracil and xanthine form a base pair with cytosine, adenine and thymine respectively during DNA- the replication. In practice, single-stranded DNA fragments treated with nitrite are hybridized to "gap duplex DNA", after which mutant strains are separated by manipulation in the same way as in site-directed mutagenesis with synthetic oligonucleotide (gap duplex method).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I tillegg omfatter "AILIM" her ogs "en del" av dette AILIM. Her betyr "en del" et polypeptid som omfatter enhver delsekvens av den ovenfor definerte AILIM-aminosyresekvens. </span>In addition, "AILIM" here also includes "a part" of this AILIM. Here, "a portion" means a polypeptide comprising any subsequence of the above-defined AILIM amino acid sequence.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Denne del omfatter fortrinnsvis det ekstracellulre omrdet fra det ovenfor definerte AILIM (spesielt foretrukket et humant AILIM) eller enhver del av dette. </span>This part preferably comprises the extracellular region from the above-defined AILIM (especially preferably a human AILIM) or any part thereof.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"AILIM-ligand" i foreliggende oppfinnelse er ogs definert til  ha en tilsvarende betydning som ovenfor. </span>"AILIM ligand" in the present invention is also defined to have a similar meaning as above.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"En del" av dette AILIM (fortrinnsvis det ekstracellulre omrdet i AILIM eller enhver del av dette) kan fremstilles iflge velkjente fremgangsmter innen dette tekniske omrdet, som beskrevet nedenfor, eller iflge modifiserte fremgangsmter ved genetisk rekombinasjonsteknikk eller kjemisk syntese, eller ved egnet klyving av AILIM (spesielt foretrukket et humant AILIM) isolert ved celledyrkingsfremgangsmten ved anvendelse av proteolytiske enzymer osv. </span>A "part" of this AILIM (preferably the extracellular region of AILIM or any part thereof) can be prepared according to methods well known in the art, as described below, or according to modified methods by genetic recombination techniques or chemical synthesis, or by appropriate cleavage of AILIM (particularly preferably a human AILIM) isolated by the cell culture method using proteolytic enzymes, etc.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"En del av AILIM-ligand" kan ogs fremstilles ved fremgangsmter som tilsvarer dem beskrevet ovenfor. </span>"Part of AILIM ligand" can also be prepared by methods corresponding to those described above.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Humant antistoff iflge foreliggende oppfinnelse er et humant antistoff som bindes til det ovenfor definerte AILIM eller en del av dette (spesielt foretrukket et humant avledet AILIM eller en del av dette). Nrmere bestemt betyr dette et humant avledet polyklonalt antistoff (humant, polyklonalt antistoff, humant antiserum) eller et humant avledet monoklonalt antistoff (humant, monoklonalt antistoff). </span>"Human antibody according to the present invention is a human antibody that binds to the above-defined AILIM or a part thereof (especially preferably a human-derived AILIM or a part thereof). More specifically, this means a human-derived polyclonal antibody (human, polyclonal antibody , human antiserum) or a human-derived monoclonal antibody (human monoclonal antibody).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Humant, monoklonalt antistoff iflge foreliggende oppfinnelse er et humant, monoklonalt antistoff som bindes til det ovenfor definerte AILIM eller en del av dette (spesielt foretrukket et humant avledet AILIM eller en del av dette). </span>"Human monoclonal antibody according to the present invention is a human monoclonal antibody that binds to the above-defined AILIM or a part thereof (especially preferably a human-derived AILIM or a part thereof).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nrmere bestemt bestr alle omrder omfattende de variable og konstante omrder i tungkjeden (H-kjeden) og de variable og konstante omrder i lettkjeden (L-kjeden) av humant immunglobulin avledet fra genet som koder for dette humane immunglobulin. Eksempler p L-kjeder er human K-kjede og human X-kjede. </span>More specifically, all areas comprising the variable and constant areas in the heavy chain (H-chain) and the variable and constant areas in the light chain (L-chain) consist of human immunoglobulin derived from the gene that codes for this human immunoglobulin. Examples of L-chains are human K-chain and human X-chain.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Humant, monoklonalt antistoff som bindes til AILIM (spesielt foretrukket et humant avledet AILIM) iflge foreliggende oppfinnelse, eller en del av dette, er et humant, monoklonalt antistoff med egenskaper som definert i punkt 1 og 2 gitt ovenfor. </span>Human monoclonal antibody that binds to AILIM (especially preferably a human derived AILIM) according to the present invention, or a part thereof, is a human monoclonal antibody with properties as defined in points 1 and 2 given above.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nrmere bestemt omfatter det forskjellige humane, monoklonale antistoffer med forskjellige egenskaper og industriell anvendbarhet, som beskrevet i eksempler og figurer nedenfor. </span>More specifically, it includes various human monoclonal antibodies with different properties and industrial applicability, as described in examples and figures below.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En foretrukket utfrelse av humant, monoklonalt antistoff iflge foreliggende oppfinnelse er et humant, monoklonalt antistoff som bindes til AILIM eller en del av dette, som definert i punkt 1 og 2 gitt ovenfor. </span>A preferred embodiment of the human monoclonal antibody according to the present invention is a human monoclonal antibody that binds to AILIM or a part thereof, as defined in points 1 and 2 given above.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den mest foretrukne utfrelse er et humant, monoklonalt antistoff som bindes til humant AILIM, som beskrevet i (1) eller (2). </span>The most preferred embodiment is a human monoclonal antibody that binds to human AILIM, as described in (1) or (2).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Humant, monoklonalt antistoff iflge foreliggende oppfinnelse kan fremstilles ved immunisering av flgende transgene, ikke-humane pattedyr som danner humant antistoff med ethvert av immunogenene (antigenene) beskrevet nedenfor: </span>"Human monoclonal antibody according to the present invention can be prepared by immunizing the following transgenic, non-human mammals that form human antibody with any of the immunogens (antigens) described below:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(a) en naturlig celle eller en kunstig etablert cellelinje som uttrykker det ovenfor nevnte AILIM (spesielt foretrukket et humant avledet AILIM) p celleoverflaten; (b) en genetisk, rekombinant celle, fremstilt ved anvendelse av genetiske rekombinasjonsteknikker, slik at den uttrykker det ovenfor definerte AILIM (spesielt foretrukket et humant avledet AILIM) p celleoverflaten; (c) et cellelysat erholdt ved solubilisering av cellene nevnt ovenfor i (a) eller (b), eller et polypeptidfragment av AILIM (spesielt foretrukket et humant avledet AILIM) renset fra cellelysatet; (d) en genetisk, rekombinant celle, fremstilt ved anvendelse av genetiske rekombinasjonsteknikker, slik at den uttrykker en del av (spesielt foretrukket det ekstracellulre omrdet eller ethvert foretrukket peptid fra dette) det ovenfor definerte AILIM (spesielt foretrukket et humant avledet AILIM) som et lselig polypeptid; (e) en dyrkingssupernatant erholdt ved  dyrke den tidligere nevnte genetiske, rekombinante celle i (d) eller et polypeptid fra det ekstracellulre omrdet (lselig AILIM) i AILIM (spesielt foretrukket et humant avledet AILIM) renset fra dyrkingssupernatanten; eller (f) en del (spesielt foretrukket det ekstracellulre omrdet eller ethvert foretrukket peptid fra dette) fra kjemisk syntetisert AILIM (spesielt foretrukket et humant avledet AILIM). </span>(a) a natural cell or an artificially established cell line expressing the above-mentioned AILIM (especially preferably a human-derived AILIM) on the cell surface; (b) a genetic recombinant cell, prepared using genetic recombination techniques, so that it expresses the above-defined AILIM (especially preferably a human-derived AILIM) on the cell surface; (c) a cell lysate obtained by solubilizing the cells mentioned above in (a) or (b), or a polypeptide fragment of AILIM (particularly preferably a human-derived AILIM) purified from the cell lysate; (d) a genetic, recombinant cell, prepared using genetic recombination techniques, so that it expresses part of (especially preferably the extracellular region or any preferred peptide thereof) the above defined AILIM (especially preferably a human derived AILIM) as a soluble polypeptide; (e) a culture supernatant obtained by culturing the previously mentioned genetic recombinant cell in (d) or a polypeptide from the extracellular region (soluble AILIM) in AILIM (especially preferably a human-derived AILIM) purified from the culture supernatant; or (f) a portion (particularly preferably the extracellular region or any preferred peptide thereof) from chemically synthesized AILIM (particularly preferably a human derived AILIM).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Videre kan det monoklonale antistoff iflge foreliggende oppfinnelse ogs erholdes fra dyrkingssupernatant ved  dyrke en "genetisk, rekombinant vert" [her er verten en eukaryot celle som ikke er et befruktet egg (fortrinnsvis pattedyrceller som CHO, lymfocytter og myelomceller)], som kan fremstilles ved  transformere en vert med cDNA (fortrinnsvis en vektor som inneholder cDNA) som koder for den tunge og den lette kjede fra et slikt humant, monoklonalt antistoff iflge foreliggende oppfinnelse ved anvendelse av genetiske rekombinasjonsteknikker, og som produserer genetisk, rekombinant, humant, monoklonalt antistoff. </span>Furthermore, the monoclonal antibody according to the present invention can also be obtained from culture supernatant by cultivating a "genetic, recombinant host" [here the host is a eukaryotic cell that is not a fertilized egg (preferably mammalian cells such as CHO, lymphocytes and myeloma cells)], which can be prepared by transforming a host with cDNA (preferably a vector containing cDNA) encoding the heavy and light chains of such a human monoclonal antibody of the present invention using genetic recombination techniques, and producing genetic, recombinant, human, monoclonal antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nrmere bestemt kan det monoklonale antistoff iflge foreliggende oppfinnelse erholdes ved  dyrke den genetiske, rekombinante vert beskrevet i de ovenfor nevnte punkter 15 til 16 iflge foreliggende oppfinnelse (her er verten en eukaryot celle som ikke er et befruktet egg (fortrinnsvis pattedyrceller som CHO, lymfocytter og myelomceller)). </span>More specifically, the monoclonal antibody according to the present invention can be obtained by culturing the genetic, recombinant host described in the above-mentioned points 15 to 16 according to the present invention (here the host is a eukaryotic cell which is not a fertilized egg (preferably mammalian cells such as CHO, lymphocytes and myeloma cells)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I tillegg kan det humane, monoklonale antistoff iflge foreliggende oppfinnelse vre et humant, monoklonalt antistoff med en isotype tilhrende IgG (IgGl, IgG2, IgG3 og IgG4), IgH, IgA (IgAl og IgA2), IgD eller IgE. Det monoklonale antistoff tilhrer fortrinnsvis IgG (IgGl, IgG2, IgG3 og IgG4), mer foretrukket IgGl, IgG2 eller IgG4. </span>In addition, the human monoclonal antibody according to the present invention can be a human monoclonal antibody with an isotype belonging to IgG (IgG1, IgG2, IgG3 and IgG4), IgH, IgA (IgAl and IgA2), IgD or IgE. The monoclonal antibody preferably belongs to IgG (IgG1, IgG2, IgG3 and IgG4), more preferably IgG1, IgG2 or IgG4.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det humane, monoklonale antistoff iflge foreliggende oppfinnelse kan fremstilles ved  immunisere et transgent, ikke-humant pattedyr som produserer humant antistoff, f.eks. den transgene mus som produserer humant antistoff beskrevet nedenfor, med ethvert av immunogenene (antigenene) nevnt ovenfor i (a)-(f) iflge en kjent, hyppig anvendt fremstillings-fremgangsmte. </span>The human monoclonal antibody according to the present invention can be prepared by immunizing a transgenic, non-human mammal that produces human antibody, e.g. the transgenic mouse producing human antibody described below, with any of the immunogens (antigens) mentioned above in (a)-(f) according to a known, frequently used production method.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det vil f.eks. si at det transgene, ikke-humane pattedyr som produserer humant antistoff, immuniseres med antigenet i kombinasjon med Freunds adjuvans etter behov. Polyklonalt antistoff kan erholdes fra serum oppsamlet fra det immuniserte dyr. Monoklonalt antistoff kan fremstilles ved  fremstille fusjonsceller (hybridomer) fra de antistoffproduserende cellene som er isolert fra det immuniserte dyr og myelomceller uten autoantistoffproduserende evne, og kloning av hybridomene for seleksjon av en klon som produserer det monoklonale antistoff med en spesifikk affinitet overfor antigenet som ble benyttet for immunisering av pattedyret. </span>It will e.g. say that the transgenic non-human mammal producing human antibody is immunized with the antigen in combination with Freund's adjuvant as needed. Polyclonal antibody can be obtained from serum collected from the immunized animal. Monoclonal antibody can be prepared by preparing fusion cells (hybridomas) from the antibody-producing cells isolated from the immunized animal and myeloma cells without autoantibody-producing ability, and cloning the hybridomas for selection of a clone that produces the monoclonal antibody with a specific affinity for the antigen that was used for immunization of the mammal.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nrmere bestemt kan monoklonalt antistoff fremstilles som beskrevet nedenfor. Det vil si at det transgene, ikke-humane pattedyr som produserer humant antistoff (spesielt foretrukket "en transgen mus som produserer humant antistoff), immuniseres ved  injisere ethvert av immunogenene nevnt ovenfor i (a)-(c) intradermalt, intramuskulrt, intravenst, inn i fotputen eller intraperitonealt n til flere ganger, eller ved  transplantere immunogenet inn i pattedyret. Vanligvis utfres immuniseringer 1-4 ganger med 1-14 dagers mellomrom etter frste immunisering. Antistoffproduserende celler erholdes fra det sledes immuniserte pattedyr i ca. 1 - 5 dager etter siste immunisering. Antall immuniseringer og mellomrommet mellom dem kan arrangeres p egnet vis, avhengig av f.eks. det valgte immunogens egenskaper. </span>More specifically, monoclonal antibody can be prepared as described below. That is, the human antibody-producing transgenic non-human mammal (particularly preferably "a human antibody-producing transgenic mouse) is immunized by injecting any of the immunogens mentioned above in (a)-(c) intradermally, intramuscularly, intravenously , into the footpad or intraperitoneally one to several times, or by transplanting the immunogen into the mammal. Usually, immunizations are carried out 1-4 times at intervals of 1-14 days after the first immunization. Antibody-producing cells are obtained from the thus immunized mammal for about 1 - 5 days after the last immunization The number of immunizations and the interval between them can be arranged as appropriate, depending for example on the properties of the selected immunogen.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Hybridomer som utskiller et humant, monoklonalt antistoff, kan fremstilles iflge fremgangsmten til Kohler og Milstein (Nature, vol. 256, s. 495-497 (1975)) og ved modifikasjoner av denne. Nrmere bestemt fremstilles hybridomer ved  fusjonere antistoffproduserende celler erholdt fra milt, lymfeknute, benmarg eller tonsill fra det humant antistoffproduserende transgene, ikke-humane pattedyr immunisert som nevnt ovenfor, fortrinnsvis fra milt, med myelomer uten autoantistoffproduserende evne, fortrinnsvis avledet fra et pattedyr, slik som mus, rotte, marsvin, hamster, kanin eller menneske, eller mer foretrukket fra en mus, en rotte eller et menneske. </span>Hybridomas secreting a human monoclonal antibody can be prepared according to the method of Kohler and Milstein (Nature, vol. 256, pp. 495-497 (1975)) and by modifications thereof. More specifically, hybridomas are prepared by fusing antibody-producing cells obtained from the spleen, lymph node, bone marrow or tonsil of the human antibody-producing transgenic non-human mammal immunized as mentioned above, preferably from the spleen, with myeloma without autoantibody-producing ability, preferably derived from a mammal, such such as mouse, rat, guinea pig, hamster, rabbit or human, or more preferably from a mouse, rat or human.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">For eksempel kan de museavledede myelomer P3/X63-Ag8.653 (ATCC nr. CRL-1580), P3/NSI/l-Ag4-l (NS-1), P3/X63-Ag8.Ul (P3U1), SP2/0-Agl4 (Sp2/0, Sp2), NSO, PAI, FO eller BW5147, rotteavledet myelom 210RCY3-Ag.2.3, eller de humant avledede myelomer U-266AR1, GM1500-6TG-A1-2, UC729-6, CEM-AGR, D1R11 eller CEM-T15 anvendes som myelom i cellefusjonen. </span>For example, the mouse-derived myelomas P3/X63-Ag8.653 (ATCC No. CRL-1580), P3/NSI/l-Ag4-l (NS-1), P3/X63-Ag8.Ul (P3U1), SP2/ 0-Agl4 (Sp2/0, Sp2), NSO, PAI, FO or BW5147, rat-derived myeloma 210RCY3-Ag.2.3, or the human-derived myelomas U-266AR1, GM1500-6TG-A1-2, UC729-6, CEM- AGR, D1R11 or CEM-T15 are used as myeloma in the cell fusion.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Celler som produserer monoklonale antistoffer (f.eks. hybridomer), kan analyseres ved  dyrke cellene i f.eks. mikrotiterplater, og mle reaktiviteten av dyrkingssupernatanten i brnnene hvor hybridomvekst observeres, overfor immunogenet som ble anvendt for den ovenfor nevnte immunisering, f.eks. ved enzymimmunanalyse, f.eks. radioimmunanalyse (RIA) eller enzymkoblet immunsolventanalyse (ELISA). </span>Cells that produce monoclonal antibodies (e.g. hybridomas) can be analyzed by culturing the cells in e.g. microtiter plates, and measure the reactivity of the culture supernatant in the wells where hybridoma growth is observed, towards the immunogen used for the above-mentioned immunization, e.g. by enzyme immunoassay, e.g. radioimmunoassay (RIA) or enzyme-linked immunosolvent assay (ELISA).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">De monoklonale antistoffene kan produseres fra hybridomer ved  dyrke hybridomene in vitro eller in vivo, f.eks. i ascitesvske hos en mus, en rotte, et marsvin, en hamster eller en kanin, fortrinnsvis en mus eller en rotte, mer foretrukket en mus, og isolere antistoffene fra den resulterende dyrkingssupernatant eller fra ascitesvske fra pattedyret. </span>The monoclonal antibodies can be produced from hybridomas by culturing the hybridomas in vitro or in vivo, e.g. in ascites fluid of a mouse, a rat, a guinea pig, a hamster or a rabbit, preferably a mouse or a rat, more preferably a mouse, and isolating the antibodies from the resulting culture supernatant or from ascites fluid of the mammal.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Monoklonale antistoffer iflge foreliggende oppfinnelse kan fremstilles i stor skala ved flgende fremgangsmte: (1) gener (cDNA osv.) som koder for tungkjeden og lettkjeden fra det monoklonale antistoff, klones fra hybridomene; (2) klonede gener som koder for tungkjede og lettkjede, innsettes i separate vektorer eller i en enkelt vektor for fremstilling av ekspresjonsvektoren; (3) ekspresjonsvektoren overfres til et befruktet egg fra et nsket ikke-humant pattedyr (f.eks. geit); (4) det befruktede egg transfektert med genet transplanteres inn i uterus hos en fostermor for erholdelse av et kimrt, ikke-humant dyr; (5) ved videre paring av den kimre geit med et annet ikke-humant pattedyr frembringes et transgent, ikke-humant pattedyr (storfe, geit, sau eller svin) med gener som koder for tungkjede og lettkjede innfrt i det endogene gen; </span>Monoclonal antibodies according to the present invention can be produced on a large scale by the following method: (1) genes (cDNA etc.) which code for the heavy chain and the light chain from the monoclonal antibody are cloned from the hybridomas; (2) cloned genes encoding heavy chain and light chain are inserted into separate vectors or into a single vector to produce the expression vector; (3) the expression vector is transferred to a fertilized egg of a desired non-human mammal (eg, goat); (4) the fertilized egg transfected with the gene is transplanted into the uterus of a foster mother to obtain a chimeric non-human animal; (5) further mating of the chimeric goat with another non-human mammal produces a transgenic non-human mammal (cattle, goat, sheep or pig) with genes encoding heavy chain and light chain introduced into the endogenous gene;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">og </span>and</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(6) fra melken til det transgene, ikke-humane pattedyr erholdes monoklonalt antistoff avledet fra det humane, monoklonale antistoffgen i stor skala (Nikkei Science, april 1997, s. 78-84). </span>(6) from the milk of the transgenic non-human mammal, monoclonal antibody derived from the human monoclonal antibody gene is obtained on a large scale (Nikkei Science, April 1997, pp. 78-84).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dyrking in vitro av cellene som produserer de monoklonale antistoffene kan utfres avhengig av f.eks. egenskapene til cellene som skal dyrkes, formlet med en analyse-underskelse og de forskjellige betingelsene i dyrkingsfremgangsmten, ved anvendelse av kjente nringsmedier eller ethvert nringsmedium avledet fra et kjent basalmediun for dyrking, opprettholdelse og lagring av hybridomer, for produksjon av monoklonale antistoffer i dyrkingssupernatanten. </span>Cultivation in vitro of the cells producing the monoclonal antibodies can be carried out depending on e.g. the characteristics of the cells to be cultured, the purpose of an analytical study and the various conditions of the culture procedure, using known nutrient media or any nutrient medium derived from a known basal medium for the cultivation, maintenance and storage of hybridomas, for the production of monoclonal antibodies in the culture supernatant.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempler p basalmedier er medier med lav kalsiumkonsentrasjon, slik som Hams F12-medium, MCDB153-medium eller MEM-medium med lav kalsiumkonsentrasjon, og medier med hy kalsiumkonsentrasjon, slik som MCDB104-medium, MEM-medium, D-MEM-medium, RPMI-1640-medium, ASF104-medium eller RD-medium. Basalmediene kan f.eks. inneholde serum, hormoner, cytokiner og/eller forskjellige uorganiske eller organiske forbindelser, avhengig av formlet. </span>Examples of basal media are media with a low calcium concentration, such as Ham's F12 medium, MCDB153 medium or MEM medium with a low calcium concentration, and media with a high calcium concentration, such as MCDB104 medium, MEM medium, D-MEM medium, RPMI -1640 medium, ASF104 medium or RD medium. The basal media can e.g. contain serum, hormones, cytokines and/or various inorganic or organic compounds, depending on the purpose.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Monoklonale antistoffer kan isoleres og renses fra dyrkingssupernatanten eller ascitesvsken nevnt ovenfor ved felling med mettet ammoniumsulfat, ved euglobulinfellings-fremgangsmten, ved kapronsyrefremgangsmten, ved kaprylsyrefremgangsmten, ved ionebytterkromatografi (DEAE eller DE52), og ved affinitetskromatografi ved anvendelse av en antiimmunglobulinkolonne eller en protein A-kolonne. </span>Monoclonal antibodies can be isolated and purified from the culture supernatant or ascites fluid mentioned above by precipitation with saturated ammonium sulfate, by the euglobulin precipitation method, by the caproic acid method, by the caprylic acid method, by ion exchange chromatography (DEAE or DE52), and by affinity chromatography using an anti-immunoglobulin column or a protein A- column.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Humant, monoklonalt antistoff iflge foreliggende oppfinnelse omfatter humane, monoklonale antistoffer som bestr av en tungkjede og/eller en lettkjede i hvilken aminosyresekvensen for hver kjede har n eller flere aminosyrerester delert, substituert eller addert. </span>Human monoclonal antibody according to the present invention comprises human monoclonal antibodies which consist of a heavy chain and/or a light chain in which the amino acid sequence for each chain has one or more amino acid residues split, substituted or added.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Her betyr "flere aminosyrerester" et antall aminosyrer, fortrinnsvis 1-10 aminosyrerester, mer foretrukket 1-5 aminosyrerester. </span>Here, "several amino acid residues" means a number of amino acids, preferably 1-10 amino acid residues, more preferably 1-5 amino acid residues.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En partiell modifisering (delesjon, substitusjon, innfyelse eller addisjon) som beskrevet ovenfor kan innfres i aminosyresekvensen til det humane, monoklonale antistoff iflge foreliggende oppfinnelse ved delvis endring av basesekvensen som koder for aminosyresekvensen. Denne delvise endring av basesekvensen kan innfres ved standardfremgangs-mter som benytter kjent setespesifikk mutageneseteknikk (Proe. Nati. Acad. Sei. USA, vol. 81, 5662-5666,1984). </span>A partial modification (deletion, substitution, insertion or addition) as described above can be introduced into the amino acid sequence of the human monoclonal antibody according to the present invention by partially changing the base sequence that codes for the amino acid sequence. This partial change of the base sequence can be introduced by standard procedures using known site-specific mutagenesis techniques (Proe. Nati. Acad. Sei. USA, vol. 81, 5662-5666, 1984).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Transgent, humant antistoff-produserende ikke-humant pattedyr", fortrinnsvis en humant antistoff-produserende transgen mus, som er en foretrukket utfrelse, kan fremstilles iflge publisert litteratur (Nature Genetics, vol. 7, s. 13-21 (1994); Nature Genetics, vol. 15, s. 146-156, 1997; publisert japansk oversettelse av internasjonalt patentskrift nr. Hei 4-504365; publisert japansk oversettelse av patentskrift nr. Hei 7-509137; Nikkei Science, juni, s. 40-50, 1995; internasjonalt patentskrift nr. WO 94/25585; Nature, vol. 368, s. 856-859,1994; og publisert japansk oversettelse av patentskrift nr. Hei-6-500233 osv.). </span>"Transgenic human antibody-producing non-human mammal", preferably a human antibody-producing transgenic mouse, which is a preferred embodiment, can be prepared according to published literature (Nature Genetics, vol. 7, pp. 13-21 (1994); Nature Genetics, vol. 15, pp. 146-156, 1997; Published Japanese Translation of International Patent Document No. Hei 4-504365; Published Japanese Translation of International Patent Document No. Hei 7-509137; Nikkei Science, June, pp. 40-50 , 1995; International Patent Publication No. WO 94/25585; Nature, vol. 368, pp. 856-859, 1994; and published Japanese translation of Patent Publication No. Hei-6-500233, etc.).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nrmere bestemt kan den humant antistoff-produserende transgene mus f.eks. fremstilles ved anvendelse av teknikker som bestr av flgende trinn: (1) fremstilling av en "knockout"-mus hvis endogene immunglobulintungkjedegen er funksjonelt inaktivert ved  substituere minst en del av genlocus for musens endogene immunglobulintungkjede med et medikamenttoleransemarkrgen (f.eks. et neomycintoleransegen) ved homolog rekombinasjon; (2) fremstilling av en "knockout"-mus hvis endogene immunglobulinlettkjedegen (fortrinnsvis K-kjedegenet) er funksjonelt inaktivert ved at i det minste en del av genlocus for musens endogene immunglobulinlettkjede er erstattet med et medikamenttoleransemarkrgen (f.eks. et neomycintoleransegen) ved homolog rekombinasjon; (3) fremstilling av en transgen mus i hvilken et nsket omrde fra det humane immunglobulintungkjedegenlocus er innfrt i musekromosomet ved anvendelse av en vektor representert ved et kunstig gjrkromosom (YAC), som er i stand til  bre et kjempegen; (4) fremstilling av en transgen mus i hvilken et nsket omrde fra det humane immunglobulinlettkjedegenlocus (fortrinnsvis K-kjedegenet) er innfrt i musekromosomet ved anvendelse av en vektor representert ved et kunstig gjrkromosom (YAC), som er i stand til  bre et kjempegen; og (5) fremstilling av en transgen mus hvis endogene immunglobulintung- og - lettkjedegenloci begge er funksjonelt inaktiverte, og i hvis kromosom de nskede omrder fra det humane immunglobulintung- og -lettkjedegenloci er innfrt, ved  pare "knockout"-mus og transgene mus nevnt ovenfor i punktene (l)-(4) i tilfeldig rekkeflge. </span>More specifically, the human antibody-producing transgenic mouse can e.g. is prepared using techniques consisting of the following steps: (1) producing a "knockout" mouse whose endogenous immunoglobulin heavy chain gene is functionally inactivated by substituting at least a portion of the mouse endogenous immunoglobulin heavy chain gene locus with a drug tolerance marker gene (eg, a neomycin tolerance gene ) by homologous recombination; (2) producing a "knockout" mouse whose endogenous immunoglobulin light chain gene (preferably the K chain gene) is functionally inactivated by replacing at least part of the mouse's endogenous immunoglobulin light chain gene locus with a drug tolerance marker gene (eg, a neomycin tolerance gene) by homologous recombination; (3) production of a transgenic mouse in which a desired region from the human immunoglobulin heavy chain gene locus has been introduced into the mouse chromosome using a vector represented by a yeast artificial chromosome (YAC) capable of carrying a giant gene; (4) production of a transgenic mouse in which a desired region from the human immunoglobulin light chain gene locus (preferably the K chain gene) has been introduced into the mouse chromosome using a vector represented by a yeast artificial chromosome (YAC) capable of carrying a giant gene ; and (5) producing a transgenic mouse whose endogenous immunoglobulin heavy and light chain gene loci are both functionally inactivated, and into whose chromosome the desired regions from the human immunoglobulin heavy and light chain gene loci have been introduced, by mating knockout mice and transgenic mice mentioned above in points (l)-(4) in random order.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den ovenfor beskrevne "knockout"-mus kan fremstilles ved  erstatte det nskede omrdet i musens endogene immunglobulingenlocus med et fremmed markrgen (f.eks. et neomycinresistensgen), basert p homolog rekombinasjon for inaktivering av dette genlocus, slik at det ikke rearrangeres. For inaktivering ved anvendelse av homolog rekombinasjon kan f.eks. en fremgangsmte som betegnes positiv negativ seleksjon (PNS) benyttes (Nikkei Science, mai, s. 52-62,1994). </span>The above-described "knockout" mouse can be produced by replacing the desired region in the endogenous immunoglobulin gene locus of the mouse with a foreign marker gene (eg, a neomycin resistance gene), based on homologous recombination to inactivate this gene locus, so that it is not rearranged. For inactivation using homologous recombination, e.g. a method called positive negative selection (PNS) is used (Nikkei Science, May, pp. 52-62, 1994).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Funksjonell inaktivering av immunglobulintungkjedegenlocus kan f.eks. oppns ved  innfre en skade i en del av J- eller C-omrdet (f.eks. C^-omrdet). Funksjonell inaktivering av immunglobulinlettkjeden (f.eks. K-kjeden) kan f.eks. oppns ved  innfre en skade i en del av J- eller C-omrdet, eller i et omrde som strekker seg over J- og C-omrdet. </span>Functional inactivation of the immunoglobulin heavy chain gene locus can e.g. is achieved by introducing a lesion in a part of the J or C region (eg the C^ region). Functional inactivation of the immunoglobulin light chain (e.g. the K chain) can e.g. is achieved by introducing a damage in part of the J or C area, or in an area that extends over the J and C area.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En transgen mus kan fremstilles iflge fremgangsmten som vanligvis anvendes for fremstilling av et transgent dyr (se f.eks. "Newest Manual of Animal Cell Experiment", LIC press, kapittel 7, s. 361-408, (1990)). Nrmere bestemt kan f.eks. en HPRT-negativ (hypoksantin-guaninfosforibosyltransferasegenmanglende) ES-celle (embryonal stamcelle) avledet fra en normal museblastocyst fusjoneres med gjr som inneholder YAC-vektoren som inneholder genet som koder for det nevnte humane immunglobulintungkjedegenlocus eller - lettkjedegenlocus eller en del av disse og HPRT-genet ved anvendelse av en sferoplastfusjons-fremgangsmte. ES-celler hvor musens endogene gen har ftt integrert det fremmede gen selekteres ved HAT-seleksjonsrfemgangsmten. S mikroinjiseres de analyserte ES-celler inn i et befruktet egg erholdt fra en annen normal mus (blastocyst) (Proe. Nati. Acad. Sei. USA, vol. 77, nr. 12, s. 7380-7384 (1980); US-patent nr. 4 873 191). Blastocysten transplanteres inn i uterus hos en annen normal mus, som fungerer som fostermor. S blir kimre, transgene mus fdt av fostermormusen. Ved  pare de kimre transgene mus med normale mus erholdes heterozygote, transgene mus. Ved  pare de heterozygote, transgene mus med hverandre erholdes homozygote, transgene mus iflge Mendels lover. </span>A transgenic mouse can be prepared according to the method usually used for the preparation of a transgenic animal (see, for example, "Newest Manual of Animal Cell Experiment", LIC press, Chapter 7, pp. 361-408, (1990)). More specifically, e.g. an HPRT-negative (hypoxanthine-guanine phosphoribosyltransferase gene-deficient) ES cell (embryonic stem cell) derived from a normal mouse blastocyst is fused with yeast containing the YAC vector containing the gene encoding said human immunoglobulin heavy chain gene locus or - light chain gene locus or part thereof and HPRT- the gene using a spheroplast fusion method. ES cells in which the mouse's endogenous gene has integrated the foreign gene are selected by the HAT selection method. Then the analyzed ES cells are microinjected into a fertilized egg obtained from another normal mouse (blastocyst) (Proe. Nati. Acad. Sei. USA, vol. 77, no. 12, pp. 7380-7384 (1980); US -patent no. 4 873 191). The blastocyst is transplanted into the uterus of another normal mouse, which acts as a foster mother. Chimeric, transgenic mice are then born to the foster mother mouse. By mating the chimeric transgenic mice with normal mice, heterozygous transgenic mice are obtained. By mating the heterozygous, transgenic mice with each other, homozygous, transgenic mice are obtained according to Mendel's laws.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"En del av et monoklonalt antistoff anvendt i foreliggende oppfinnelse, betyr et delomrde fra det ovenfor nevnte humane, monoklonale antistoff iflge foreliggende oppfinnelse, og omfatter nrmere bestemt F(ab')2, Fab', Fab, Fv (variabelt antistoffragment), </span>"A part of a monoclonal antibody used in the present invention means a partial region from the above-mentioned human monoclonal antibody according to the present invention, and more specifically includes F(ab')2, Fab', Fab, Fv (variable antibody fragment),</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">sFv, dsFv (disulfidstabilisert Fv) eller dAb (enkeltdomeneantistoff) (Exp. Opin. Ther. Patents, vol. 6, nr. 5, s. 441-456 (1996)). </span>sFv, dsFv (disulfide stabilized Fv) or dAb (single domain antibody) (Exp. Opin. Ther. Patents, vol. 6, no. 5, pp. 441-456 (1996)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"F(ab')2" og "Fab"' kan fremstilles ved  behandle immunglobulin (monoklonalt antistoff) med en protease, slik som pepsin eller papain, og betyr et antistoffragment fremstilt ved  klyve immunglobulin nr disulfidbindingene i hengselomrdet som foreligger mellom de to H-kjeder. For eksempel klyver papain IgG oppstrms for disulfidbindingene i hengselomrdene som foreligger mellom de to H-kjedene, slik at det dannes to homologe antistof-fragmenter i hvilke en L-kjede som bestr av Vl(L-kjedens variable omrde) og Cl(L-kjedens konstante omrde), og et H-kjedefragment som bestr av VH (H-kjedens variable omrde) og Cuyl (yl-omrdet i det konstante omrdet i H-kjeden), er sammenbundet via en disulfidbinding i deres C-terminale omrder. Disse to homologe antistofrfagmenter kalles Fab'. Pepsin klyver ogs IgG nedstrms for disulfidbindingene i hengselomrdene som foreligger mellom hver av de to H-kjedene, slik at det dannes et antistoffragment som er noe strre enn de ovenfor nevnte Fab'-fragmentene, og hvori de to ovenfor nevnte Fab' er sammenbundet i hengselomrdet. Dette antistoffragment kalles F(ab')2. </span>"F(ab')2" and "Fab"' can be prepared by treating immunoglobulin (monoclonal antibody) with a protease, such as pepsin or papain, and means an antibody fragment prepared by cleaving immunoglobulin near the disulfide bonds in the hinge region present between the two H chains. For example, papain cleaves IgG upstream of the disulfide bonds in the hinge regions that exist between the two H chains, so that two homologous antibody fragments are formed in which an L chain consists of Vl (the variable region of the L chain) and Cl (L- chain constant region), and a H-chain fragment consisting of VH (H-chain variable region) and Cuyl (yl region in the H-chain constant region), are linked via a disulfide bond in their C-terminal regions. These two homologous antibody fragments are called Fab'. Pepsin also cleaves IgG downstream of the disulfide bonds in the hinge regions that exist between each of the two H chains, so that an antibody fragment is formed that is somewhat larger than the above-mentioned Fab' fragments, and in which the two above-mentioned Fab' are joined in the hinge area. This antibody fragment is called F(ab')2.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Bindingshastighetskonstant (ka)" betyr her en verdi som angir bindingsstyrken (bindingsgraden) for det monoklonale antistoff til mlantigenet, beregnet ut fra antistoff-antigen-reaksjonskinetikken. "Dissosiasjonshastighetskonstant (kd)" betyr en verdi som angir dissosia-sjonsstyrken (-graden) mellom det monoklonale antistoff og mlantigenet. "Dissosiasjonskonstant (Kd)" er en verdi som erholdes ved  dividere "dissosiasjonshastighetskonstanten (kd)" med "bindingshastighetskonstanten (ka)". Disse konstantene anvendes for  representere det monoklonale antistoffs affinitet overfor antigenet og dets nytraliserende aktivitet p antigenet. </span>"Binding rate constant (ka)" here means a value indicating the binding strength (degree of binding) of the monoclonal antibody to the target antigen, calculated from the antibody-antigen reaction kinetics. "Dissociation rate constant (kd)" means a value indicating the strength (degree) of dissociation between the monoclonal antibody and the target antigen. "Dissociation constant (Kd)" is a value obtained by dividing the "dissociation rate constant (kd)" by the "binding rate constant (ka)". These constants are used to represent the affinity of the monoclonal antibody towards the antigen and its neutralizing activity on the antigen.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Disse konstantene kan analyseres iflge forskjellige fremgangsmter, og kan lett analyseres ved anvendelse av et kommersielt analysesett, BiacoreX (Amersham Pharmacia), eller et tilsvarende sett iflge hndboken og den eksperimentelle fremgangsmte som flger med settet, ka-, kd- og Kd-verdiene som erholdes ved anvendelse av settet, uttrykkes i enhetene 1/M-sek, l/sek henholdsvis M (mol). Hyere ka-verdier viser kraftigere antigenbindingsaffinitet for det analyserte monoklonale antistoff, og lavere Kd-verdier viser kraftigere antigennytrali-serende aktivitet for antistoffet. </span>These constants can be analyzed according to various methods, and can be easily analyzed using a commercial assay kit, BiacoreX (Amersham Pharmacia), or an equivalent kit according to the manual and the experimental procedure supplied with the kit, the ka, kd and Kd values which obtained when using the kit, is expressed in the units 1/M-sec, l/sec and M (mol), respectively. Higher ka values show stronger antigen binding affinity for the analyzed monoclonal antibody, and lower Kd values show stronger antigen neutralizing activity for the antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Humant, monoklonalt antistoff iflge foreliggende oppfinnelse omfatter antistoffer med ka-, kd- og Kd-verdier som vist i de flgende punkter (l)-(3): (1) Humant, monoklonalt antistoff som bindes til humant AILIM eller en del av dette med en bindingshastighetskonstant (ka) p 1,0 x 104 (1/M-sek) eller hyere, fortrinnsvis 1,0 x 10&lt;5&gt;(1/M-sek) eller hyere. (2) Humant, monoklonalt antistoff som bindes til humant AILIM eller en del av dette med en dissosiasjonshastighetskonstant (kd) p 1,0 x IO"&lt;4&gt;(l/sek) eller lavere, fortrinnsvis 1,0 x 10"&lt;5&gt;(l/sek) eller lavere. (3) Humant, monoklonalt antistoff som har en reaktivitet overfor humant AILIM eller en del av dette med en dissosiasjonskonstant (Kd) p 1,0 x IO"&lt;7&gt;(M) eller lavere, fortrinnsvis 1,0 x 10"&lt;8&gt;(M) eller lavere, og mer foretrukket 1,0 x IO"&lt;9&gt;(M) eller lavere. </span>Human monoclonal antibody according to the present invention includes antibodies with ka, kd and Kd values as shown in the following points (l)-(3): (1) Human monoclonal antibody that binds to human AILIM or a part thereof with a binding rate constant (ka) of 1.0 x 104 (1/M-sec) or higher, preferably 1.0 x 10&lt;5&gt; (1/M-sec) or higher. (2) Human monoclonal antibody that binds to human AILIM or part thereof with a dissociation rate constant (kd) of 1.0 x 10"&lt;4&gt;(l/sec) or lower, preferably 1.0 x 10"&lt;5 &gt;(l/sec) or lower. (3) Human monoclonal antibody having a reactivity to human AILIM or part thereof with a dissociation constant (Kd) of 1.0 x 10"&lt;7&gt;(M) or lower, preferably 1.0 x 10"&lt;8 &gt;(M) or lower, and more preferably 1.0 x 10"&lt;9&gt;(M) or lower.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I dette tilfellet forventes verdiene for ka, kd og Kd beskrevet ovenfor  variere noe, avhengig av forskjellige betingelser p mletidspunktet med en feilmargin, men med praktisk talt ingen variasjon i verdiene generelt. </span>In this case, the values of ka, kd and Kd described above are expected to vary somewhat, depending on different conditions at the time of measurement with a margin of error, but with practically no variation in the values in general.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Monoklonalt antistoff-produserende celle" eller genetisk, rekombinant, humant, monoklonalt antistoff-produserende "genetisk, rekombinant vert" iflge foreliggende oppfinnelse (her er verten en celle, bortsett fra et befruktet egg) betyr enhver celle som produserer det ovenfor nevnte humane, monoklonale antistoff iflge foreliggende oppfinnelse. </span>"Monoclonal antibody-producing cell" or genetic, recombinant, human, monoclonal antibody-producing "genetic, recombinant host" of the present invention (here, the host is a cell, other than a fertilized egg) means any cell that produces the above-mentioned human, monoclonal antibody according to the present invention.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nrmere bestemt omfatter det f.eks. celler beskrevet i ethvert av de flgende punkter (l)-(3), men er ikke begrenset til disse: (1) en B-celle som produserer humant, monoklonalt antistoff, erholdt ved  immunisere det ovenfor nevnte humant antistoff-produserende, transgene, ikke-humane pattedyr med det ovenfor definerte immunogen (antigen) og erholdelse av cellen fra det immuniserte pattedyr; (2) den ovenfor nevnte fusjonscelle (hybridom), dannet ved fusjon mellom den sledes erholdte monoklonalt antistoff-produserende B-celle og en myelomcelle avledet fra et pattedyr; (3) genetisk, rekombinant, humant, monoklonalt antistoff-produserende genetisk, rekombinant celle erholdt ved  transformere en celle, bortsett fra B-cellen og hybridomen nevnt ovenfor (f.eks. en CHO(kinesisk hamster-ovarium)-celle, BHK(hamsterungenyre)-celle, lymfocytt, f.eks. en myelom), med genet som koder for det humane, monoklonale antistoff (et gen som koder for tungkjeden eller som koder for lettkjeden eller begge gener) isolert fra den humant, monoklonalt antistoff-produserende B-celle eller den humant, monoklonalt antistoff-produserende fusjonscelle (hybridom). </span>More specifically, it includes e.g. cells described in any of the following items (l)-(3), but are not limited to these: (1) a human monoclonal antibody-producing B cell obtained by immunizing the above-mentioned human antibody-producing transgenic , non-human mammals with the above-defined immunogen (antigen) and obtaining the cell from the immunized mammal; (2) the above-mentioned fusion cell (hybridoma), formed by fusion between the monoclonal antibody-producing B cell thus obtained and a myeloma cell derived from a mammal; (3) genetic recombinant human monoclonal antibody-producing genetic recombinant cell obtained by transforming a cell, other than the B cell and the hybridoma mentioned above (eg, a CHO (Chinese Hamster Ovary) cell, BHK (hamster kidney) cell, lymphocyte, e.g. a myeloma), with the gene encoding the human monoclonal antibody (a gene encoding the heavy chain or encoding the light chain or both genes) isolated from the human monoclonal antibody- producing B cell or the human monoclonal antibody-producing fusion cell (hybridoma).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Her betyr den genetiske, rekombinante, humant, monoklonalt antistoffproduserende, genetiske, rekombinante celle nevnt ovenfor i (3) en genetisk, rekombinant celle som produserer genetisk, rekombinant, humant, monoklonalt antistoff dannet av B-cellen beskrevet ovenfor i (1), eller hybridomen nevnt ovenfor i (2). </span>Here, the genetic recombinant human monoclonal antibody-producing genetic recombinant cell mentioned above in (3) means a genetic recombinant cell that produces genetic recombinant human monoclonal antibody formed by the B cell described above in (1), or the hybridoma mentioned above in (2).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Begrepet "vert" i "genetisk, rekombinant vert" iflge foreliggende oppfinnelse omfatter i tillegg til forskjellige pattedyrceller, som beskrevet ovenfor, befruktede egg fra ethvert ikke-humant pattedyr (geit, svin, sau, storfe osv.). Ved  overfre et gen (genet som koder for tungkjeden, genet som koder for lettkjeden eller begge gener) som koder for et monoklonalt antistoff (fortrinnsvis et humant, monoklonalt antistoff) rettet mot humant AILIM iflge foreliggende oppfinnelse inn i dette befruktede egg, kan et genetisk, rekombinant befruktet egg iflge foreliggende oppfinnelse erholdes. Dette genetiske, rekombinante befruktede egg anvendes for fremstilling av transgene dyr for produksjon av det ovenfor nevnte protein fra melken i stor skala (Nikkei Science, april 1997, s. 78-84). </span>The term "host" in "genetic, recombinant host" according to the present invention includes, in addition to various mammalian cells, as described above, fertilized eggs from any non-human mammal (goat, pig, sheep, cattle, etc.). By transferring a gene (the gene encoding the heavy chain, the gene encoding the light chain or both genes) encoding a monoclonal antibody (preferably a human monoclonal antibody) directed against human AILIM according to the present invention into this fertilized egg, a genetically, recombinantly fertilized egg according to the present invention is obtained. This genetic, recombinant fertilized egg is used for the production of transgenic animals for the production of the above-mentioned protein from the milk on a large scale (Nikkei Science, April 1997, pp. 78-84).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"En forbindelse", i foreliggende beskrivelse, nrmere bestemt "en forbindelse med modulerende aktivitet p signaloverfringen som formidles av AILIM", og mer spesifikt betyr "en forbindelse med inhiberende aktivitet p proliferasjonen av AILIM-uttrykkende celler eller inhiberende aktivitet p cytokinproduksjonen av AILIM-uttrykkende celler" en naturlig forbindelse som foreligger i naturen eller en kunstig fremstilt, tilfeldig forbindelse. </span>"A compound", in the present description, more specifically "a compound with modulatory activity on the signal transduction mediated by AILIM", and more specifically means "a compound with inhibitory activity on the proliferation of AILIM-expressing cells or inhibitory activity on the cytokine production of AILIM- expressing cells" a natural compound that exists in nature or an artificially produced, random compound.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Forbindelse" i forbindelse med "forbindelse som bindes til AILIM" og "forbindelse som bindes til AILIM-ligand" betyr her ogs enhver naturlig forbindelse eller enhver kunstig fremstilt forbindelse. </span>"Compound" in the context of "compound that binds to AILIM" and "compound that binds to AILIM ligand" here also means any natural compound or any artificially produced compound.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Her betyr "signaloverfringen som formidles av AILIM" signaloverfringen via AILIM som frer til en endring av en tilfeldig fenotype i de AILIM-uttrykkende cellene (celleproliferasjon, aktivering av celler, inaktivering av celler, apoptose og/eller endret evne til  produsere et tilfeldig cytokin fra AILIM-uttrykkende celler). </span>Here, "the signal transduction mediated by AILIM" means the signal transduction via AILIM that leads to a change of a random phenotype in the AILIM-expressing cells (cell proliferation, activation of cells, inactivation of cells, apoptosis and/or altered ability to produce a random cytokine from AILIM-expressing cells).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Forbindelsen" kan hovedsakelig klassifiseres i "en proteinforbindelse" og "en ikke-proteinforbindelse ". </span>The "compound" can be mainly classified into "a protein compound" and "a non-protein compound".</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempler p "proteinforbindelser" er flgende: polypeptid, antistoff (et polyklonalt antistoff, et monoklonalt antistoff eller en del av et monoklonalt antistoff, og spesielt foretrukket det humane antistoff nevnt ovenfor). </span>Examples of "protein compounds" are the following: polypeptide, antibody (a polyclonal antibody, a monoclonal antibody or part of a monoclonal antibody, and particularly preferably the human antibody mentioned above).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dersom forbindelsen er et antistoff, er forbindelsen fortrinnsvis et monoklonalt antistoff. Dersom forbindelsen er et monoklonalt antistoff, omfatter forbindelsen ikke bare et monoklonalt antistoff avledet fra et ikke-humant pattedyr, men ogs et rekombinant, kimrt, monoklonalt antistoff, et rekombinant, humanisert, monoklonalt antistoff og et humant, monoklonalt antistoff. </span>If the compound is an antibody, the compound is preferably a monoclonal antibody. If the compound is a monoclonal antibody, the compound includes not only a monoclonal antibody derived from a non-human mammal, but also a recombinant chimeric monoclonal antibody, a recombinant humanized monoclonal antibody, and a human monoclonal antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Her er det "rekombinante, kimre, monoklonale antistoff et monoklonalt antistoff fremstilt ved genetisk modifisering, og betyr nrmere bestemt et kimrt antistoff, f.eks. et kimrt, monoklonalt muse-/menneskeantistoff hvis variable omrder er avledet fra immunglobulin fra et ikke-humant pattedyr (mus, rotte, hamster osv.), og hvis konstante omrder er avledet fra humant immunglobulin. </span>Here, the "recombinant chimeric monoclonal antibody" is a monoclonal antibody produced by genetic modification, and specifically means a chimeric antibody, e.g., a chimeric mouse/human monoclonal antibody whose variable regions are derived from immunoglobulin from a non-human mammals (mouse, rat, hamster, etc.), and whose constant regions are derived from human immunoglobulin.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det "humaniserte, monoklonale antistoff (CDR-transplanterte antistoff)" iflge foreliggende oppfinnelse er et monoklonalt antistoff fremstilt ved genetisk modifisering, og betyr nrmere bestemt et humanisert, monoklonalt antistoff hvori en del av eller hele det komplementaritetsbestemmende omrdet i det hypervariable omrdet er avledet fra de komplementaritetsbestemmende omrdet i det hypervariable omrdet i et monoklonalt antistoff fra et ikke-humant pattedyr (mus, rotte, hamster osv.), rammeverksomrdene i det variable omrdet er avledet fra rammeverksomrdene i det variable omrdet i humant immunglobulin, og det konstante omrdet er avledet fra et konstant omrde fra humant immunglobulin. </span>The "humanized, monoclonal antibody (CDR-transplanted antibody)" according to the present invention is a monoclonal antibody produced by genetic modification, and more precisely means a humanized, monoclonal antibody in which part or all of the complementarity-determining region in the hypervariable region is derived from the complementarity-determining region in the hypervariable region of a monoclonal antibody from a non-human mammal (mouse, rat, hamster, etc.), the framework regions of the variable region are derived from the framework regions of the variable region of human immunoglobulin, and the constant region is derived from a constant range from human immunoglobulin.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">De komplementaritetsbestemmende omrder i det hypervariable omrdet foreligger i det hypervariable omrdet i det variable omrdet i et antistoff, og betyr tre omrder som direkte og komplementrt bindes til et antigen (komplementaritetsbestemmende aminosyrerester, CDR1, CDR2 og CDR3). Rammeverksomrdene i det variable omrdet betyr fire relativt konserverte omrder som ligger oppstrms, nedstrms eller mellom de tre komplementaritetsbestemmende omrder (rammeverksomrde, FRI, FR2, FR3 og FR4). </span>The complementarity-determining regions in the hypervariable region are present in the hypervariable region in the variable region in an antibody, and mean three regions that directly and complementarily bind to an antigen (complementarity-determining amino acid residues, CDR1, CDR2 and CDR3). The framework areas in the variable area mean four relatively conserved areas located upstream, downstream or between the three complementarity-determining areas (framework area, FRI, FR2, FR3 and FR4).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Med andre ord betyr et humanisert, monoklonalt antistoff et antistoff i hvilket alle omrder, bortsett fra en del av eller hele det komplementaritetsbestemmende omrdet i det hypervariable omrdet i et monoklonalt antistoff avledet fra et ikke-humant pattedyr, er blitt erstattet med de tilsvarende omrder avledet fra et humant immunglobulin. </span>In other words, a humanized monoclonal antibody means an antibody in which all regions, except for part or all of the complementarity-determining region of the hypervariable region of a monoclonal antibody derived from a non-human mammal, have been replaced with the corresponding regions derived from from a human immunoglobulin.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det konstante omrdet avledet fra humant immunglobulin har aminosyresekvensen som er karakteristisk for hver isotype, f.eks. IgG (IgGl, IgG2, IgG3, IgG4), IgM, IgA, IgD og IgE. Det konstante omrdet i et humanisert, monoklonalt antistoff iflge foreliggende oppfinnelse kan vre et konstant omrde fra et humant immunglobulin som tilhrer enhver isotype. Det er fortrinnsvis det konstante omrdet i humant IgG. Rammeverksomrdene i det konstante omrdet avledet fra humant immunglobulin er ikke spesielt begrensede. </span>The constant region derived from human immunoglobulin has the amino acid sequence characteristic of each isotype, e.g. IgG (IgGl, IgG2, IgG3, IgG4), IgM, IgA, IgD and IgE. The constant region in a humanized monoclonal antibody according to the present invention can be a constant region from a human immunoglobulin belonging to any isotype. It is preferably the constant region of human IgG. The framework regions in the constant region derived from human immunoglobulin are not particularly limited.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dersom forbindelsen iflge foreliggende oppfinnelse er et polypeptid, omfatter forbindelsen flgende: polypeptid, et fragment av polypeptidet (et oligopeptid), et fusjonspolypeptid og et kjemisk modifisert polypeptid. Eksempler p et oligopeptid er et peptid som omfatter 5-30 aminosyrer, fortrinnsvis 5-20 aminosyrer. Den kjemiske modifisering kan utformes avhengig av forskjellige forml, f.eks. forlenget halveringstid i blodet nr det gjelder tilfrsel in vivo, eller forhyet toleranse nr det gjelder degradering eller forhyet absorpsjon i fordyelseskanalen ved oral tilfrsel. </span>If the compound according to the present invention is a polypeptide, the compound comprises the following: polypeptide, a fragment of the polypeptide (an oligopeptide), a fusion polypeptide and a chemically modified polypeptide. Examples of an oligopeptide are a peptide comprising 5-30 amino acids, preferably 5-20 amino acids. The chemical modification can be designed depending on different purposes, e.g. prolonged half-life in the blood in the case of administration in vivo, or increased tolerance in the case of degradation or increased absorption in the digestive tract in the case of oral administration.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempler p polypeptidet er som flger: </span>Examples of the polypeptide are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(1) et polypeptid som omfatter hele eller en del av et ekstracellulrt omrde i </span>(1) a polypeptide comprising all or part of an extracellular region i</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AILIM, </span>AILIM,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(2) et fusjonspolypeptid som omfatter hele eller en del av et ekstracellulrt omrde i AILIM og hele eller en del av et konstant omrde i en immunglobulintungkjede, eller </span>(2) a fusion polypeptide comprising all or part of an extracellular region of AILIM and all or part of a constant region of an immunoglobulin heavy chain, or</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(3) et polypeptid som bindes til AILIM. </span>(3) a polypeptide that binds to AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempler p "ikke-proteinforbindelser" er DNA, RNA og en kjemisk syntetisert forbindelse. </span>Examples of "non-protein compounds" are DNA, RNA and a chemically synthesized compound.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Her betyr "DNA" "DNA som omfatter en delnukleotidsekvens av DNA eller kjemisk modifisert DNA" som er anvendbart som "antisense"-DNA, farmasytisk utformet og basert p en nukleotidsekvens fra DNA (innbefattet cDNA og genomisk DNA) som koder for det ovenfor nevnte AILIM (fortrinnsvis humant AILIM). Nrmere bestemt kan "antisense"-DNA inhibere transkripsjonen av DNA som koder for AILIM til mRNA eller translasjonen av mRNA til et protein ved hybridisere til DNA eller RNA som koder for AILIM. </span>Here, "DNA" means "DNA comprising a partial nucleotide sequence of DNA or chemically modified DNA" which is useful as "antisense" DNA, pharmaceutically formulated and based on a nucleotide sequence from DNA (including cDNA and genomic DNA) encoding the above-mentioned AILIM (preferably human AILIM). More specifically, "antisense" DNA can inhibit the transcription of DNA encoding AILIM into mRNA or the translation of mRNA into a protein by hybridizing to DNA or RNA encoding AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Delnukleotidsekvensen" som det vises til her, angir en delnukleotidsekvens som omfatter et tilfeldig antall nukleotider i et tilfeldig omrde. Delnukleotidsekvensen bestr av 5-100 p hverandre flgende nukleotider, fortrinnsvis 5-70 p hverandre flgende nukleotider, mer foretrukket 5-50 p hverandre flgende nukleotider, og enda mer foretrukket 5-30 p hverandre flgende nukleotider. </span>The "partial nucleotide sequence" referred to herein refers to a partial nucleotide sequence comprising a random number of nucleotides in a random region. The partial nucleotide sequence consists of 5-100 consecutive nucleotides, preferably 5-70 consecutive nucleotides, more preferably 5-50 consecutive nucleotides, and even more preferably 5-30 consecutive nucleotides.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dersom DNA anvendes som et farmasytisk "antisense"-DNA-middel, kan DNA-sekvensen vre delvis kjemisk modifisert for  forlenge halveringstiden (stabiliteten) for konsentrasjonen i blod av DNA tilfrt til pasienter, for  ke permeabiliteten av DNA gjennom den intracytoplasmatiske membran, eller for  ke degraderingsresistensen eller absorpsjonen av det oralt tilfrte DNA i fordyelsesorganene. Den kjemiske modifisering omfatter f.eks. modifisering av fosfatbindingene, ribosene, nukleotidbasene, sukkergruppen, 3'-enden og/eller 5'-enden i DNA-oligonukleotidets struktur. </span>If DNA is used as a pharmaceutical "antisense" DNA agent, the DNA sequence may be partially chemically modified to increase the half-life (stability) of the blood concentration of DNA administered to patients, to increase the permeability of DNA through the intracytoplasmic membrane, or to increase the degradation resistance or absorption of the orally administered DNA in the digestive organs. The chemical modification includes e.g. modification of the phosphate bonds, the riboses, the nucleotide bases, the sugar group, the 3'-end and/or the 5'-end in the structure of the DNA oligonucleotide.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Modifiseringen av fosfatbindingen omfatter f.eks. overfring av n eller flere av bindingene til fosfodiesterbindinger (D-oligo), fosfortioatbindinger, fosforditioatbindinger (S-oligo), metylfosfonat (MP-oligo), fosforamidatbindinger, ikke-fosfatbindinger eller metylfosfon-tioatbindinger, eller kombinasjoner av disse. Modifisering av ribosen omfatter f.eks. overfring til 2'-fluorribose eller 2'-0-metylribose. Modifisering av nukleotidbasen omfatter f.eks. overfring til 5-propynyluracil eller 2-aminoadenin. </span>The modification of the phosphate bond includes e.g. transfer of one or more of the bonds to phosphodiester bonds (D-oligo), phosphorothioate bonds, phosphorodithioate bonds (S-oligo), methylphosphonate (MP-oligo), phosphoramidate bonds, non-phosphate bonds or methylphosphonothioate bonds, or combinations thereof. Modification of the ribose includes e.g. transfer to 2'-fluororibose or 2'-O-methylribose. Modification of the nucleotide base includes e.g. transfer to 5-propynyluracil or 2-aminoadenine.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Her betyr "RNA" "RNA som omfatter en delnukleotidsekvens av RNA eller kjemisk modifisert RNA" som er anvendbart som et farmasytisk "antisense"-RNA-middel, utformet basert p en RNA-nukleotidsekvens som koder for det ovenfor beskrevne AILIM (fortrinnsvis humant AILIM). "Antisense"-RNA kan inhibere transkripsjonen av DNA som koder for AILIM til mRNA eller translasjon av mRNA til et protein ved  hybridisere til DNA eller RNA som koder for AILIM. </span>Here, "RNA" means "RNA comprising a partial nucleotide sequence of RNA or chemically modified RNA" useful as a pharmaceutical "antisense" RNA agent, designed based on an RNA nucleotide sequence encoding the above-described AILIM (preferably human AILIM ). "Antisense" RNA can inhibit the transcription of DNA encoding AILIM into mRNA or translation of mRNA into a protein by hybridizing to DNA or RNA encoding AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Delnukleotidsekvensen" som det vises til her, betegner en delnukleotidsekvens som omfatter et tilfeldig antall nukleotider i et tilfeldig omrde. Delnukleotidsekvensen bestr av 5-100 p hverandre flgende nukleotider, fortrinnsvis 5-70 p hverandre flgende nukleotider, mer foretrukket 5-50 p hverandre flgende nukleotider, og enda mer foretrukket 5-30 p hverandre flgende nukleotider. </span>The "partial nucleotide sequence" referred to herein means a partial nucleotide sequence comprising a random number of nucleotides in a random region. The partial nucleotide sequence consists of 5-100 consecutive nucleotides, preferably 5-70 consecutive nucleotides, more preferably 5-50 consecutive nucleotides, and even more preferably 5-30 consecutive nucleotides.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Antisense"-RNA-sekvensen kan vre delvis kjemisk modifisert for  forlenge halveringstiden (stabiliteten) for konsentrasjonen i blodet av RNA tilfrt til pasienter, for  ke permeabiliteten til RNA gjennom den intracytoplasmatiske membran, eller for  ke degraderingsresistensen eller absorpsjonen av det oralt tilfrte RNA i fordyelsesorganene. Et eksempel p kjemisk modifisering er den kjemisk modifisering som benyttes p det ovenfor beskrevne "antisense"-DNA. </span>The "antisense" RNA sequence may be partially chemically modified to increase the half-life (stability) of the blood concentration of RNA administered to patients, to increase the permeability of the RNA through the intracytoplasmic membrane, or to increase its resistance to degradation or its absorption orally supplied RNA in the digestive organs. An example of chemical modification is the chemical modification used on the "antisense" DNA described above.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempler p "en kjemisk syntetisert forbindelse" er en tilfeldig forbindelse bortsett fra de ovenfor nevnte DNA-, RNA- og proteinforbindelsene, med en molekylvekt p ca. 100 til ca. 1000, fortrinnsvis en forbindelse med molekylvekt p ca. 100 til ca. 800, og mer foretrukket en molekylvekt p ca. 100 til ca. 600. </span>Examples of "a chemically synthesized compound" are a random compound other than the above-mentioned DNA, RNA and protein compounds, with a molecular weight of about 100 to approx. 1000, preferably a compound with a molecular weight of approx. 100 to approx. 800, and more preferably a molecular weight of approx. 100 to approx. 600.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Et "polypeptid" som omfattes av definisjonen p den ovenfor beskrevne "forbindelse", betyr en del (et fragment) av en polypeptidkjede som utgjr AILIM (fortrinnsvis humant AILIM), fortrinnsvis hele eller en del av et ekstracellulrt omrde i polypeptidet som utgjr AILIM (1-5 aminosyrer kan om nskelig vre addert til omrdets N-ende og/eller C-ende). </span>A "polypeptide" covered by the definition of the above-described "compound" means a part (a fragment) of a polypeptide chain that constitutes AILIM (preferably human AILIM), preferably all or part of an extracellular region of the polypeptide that constitutes AILIM ( 1-5 amino acids can, if desired, be added to the N-end and/or C-end of the region).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AILIM som inngr i foreliggende oppfinnelse, er et transmembranmolekyl som trenger gjennom cellemembranen og som omfatter n eller to polypeptidkjeder. </span>AILIM, which forms part of the present invention, is a transmembrane molecule that penetrates the cell membrane and comprises one or two polypeptide chains.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Her betyr et "transmembranprotein" et protein som er forbundet med membranen via et hydrofobt peptidomrde som penetrerer lipiddobbeltlaget i membranen n eller flere ganger, og hvis struktur totalt sett bestr av tre hovedomrder, det vil si det ekstracellulre omrdet, transmembranomrdet og det cytoplasmatiske omrdet, som observert i mange reseptorer og celleoverflatemolekyler. Et slikt transmembranprotein utgjr celleoverflate-reseptormolekyler i form av en monomer, homodimer, heterodimer eller oligomer, med n eller flere andre kjeder med samme eller forskjellig aminosyresekvens. </span>Here, a "transmembrane protein" means a protein that is connected to the membrane via a hydrophobic peptide region that penetrates the lipid bilayer of the membrane one or more times, and whose overall structure consists of three main regions, that is, the extracellular region, the transmembrane region and the cytoplasmic region, as observed in many receptors and cell surface molecules. Such a transmembrane protein constitutes cell surface receptor molecules in the form of a monomer, homodimer, heterodimer or oligomer, with one or more other chains with the same or different amino acid sequence.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Her betyr et "ekstracellulrt omrde" hele eller en del av delstrukturen (delomrdet) i totalstrukturen av det ovenfor nevnte transmembranprotein, hvor delstrukturen foreligger utenfor membranen. Med andre ord betyr det hele eller en del av transmembran-proteinet, bortsett fra det omrdet som inngr i membranen (transmembranomrdet) og omrdet som foreligger i cytoplasmaet og flger etter transmembranomrdet (det cytoplasmatiske omrdet). </span>Here, an "extracellular area" means all or part of the partial structure (partial area) in the overall structure of the above-mentioned transmembrane protein, where the partial structure exists outside the membrane. In other words, it means all or part of the transmembrane protein, except for the area that is part of the membrane (the transmembrane area) and the area that is present in the cytoplasm and follows the transmembrane area (the cytoplasmic area).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Et fusjonspolypeptid" som inngr i den ovenfor definerte "proteinforbindelse", betyr et fusjonspolypeptid som omfatter hele eller en del av et ekstracellulrt omrde i et polypeptid som utgjr AILIM (fortrinnsvis humant AILIM), og "hele eller en del av et konstant omrde i immunglobulintungkjeden (lg, fortrinnsvis humant lg)". Fusjonspolypeptidet er fortrinnsvis et fusjonspolypeptid mellom et ekstracellulrt omrde i AILIM og en del av et konstant omrde fra human IgG-tungkjede, og spesielt foretrukket et fusjonspolypeptid mellom et ekstracellulrt omrde i AILIM og et omrde (Fc) i human IgG-tungkjede som omfatter et hengselomrde, et CH2-domene og et CH3-domene. Som IgG foretrekkes IgGl, og som AILIM foretrekkes AILIM fra menneske, mus eller rotte (fortrinnsvis menneske). </span>"A fusion polypeptide" included in the above-defined "protein compound" means a fusion polypeptide comprising all or part of an extracellular region in a polypeptide constituting AILIM (preferably human AILIM), and "all or part of a constant region in immunoglobulin heavy chain (Ig, preferably human Ig)". The fusion polypeptide is preferably a fusion polypeptide between an extracellular region of AILIM and part of a constant region from human IgG heavy chain, and particularly preferably a fusion polypeptide between an extracellular region of AILIM and a region (Fc) of human IgG heavy chain comprising a hinge region , a CH2 domain and a CH3 domain. As IgG, IgGl is preferred, and as AILIM, AILIM from human, mouse or rat (preferably human) is preferred.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Hele eller en del av et konstant omrde fra human immunglobulin(Ig)-tungkjede", anvendt her, betyr det konstante omrdet eller Fc-omrdet i en humant avledet immunglobulintungkjede (H-kjede), som beskrevet, eller en del av denne. Immunglobulinet kan vre ethvert immunglobulin og tilhre enhver klasse og enhver underklasse. Nrmere bestemt er eksempler p immunglobulinet IgG (IgGl, IgG2, IgG3 og IgG4), IgM, IgA (IgAl og IgA2), IgD og IgE. Immunglobulinet er fortrinnsvis IgG (IgGl, IgG2, IgG3 eller IgG4) eller IgM. Eksempler p spesielt foretrukket immunglobulin iflge foreliggende oppfinnelse er immunglobuliner som tilhrer humant avledet IgG (IgGl, IgG2, IgG3 eller IgG4). </span>"All or part of a human immunoglobulin (Ig) heavy chain constant region", as used herein, means the constant region or Fc region of a human derived immunoglobulin heavy chain (H chain), as described, or part thereof. The immunoglobulin can be any immunoglobulin and belong to any class and any subclass. More specifically, examples of the immunoglobulin are IgG (IgG1, IgG2, IgG3 and IgG4), IgM, IgA (IgAl and IgA2), IgD and IgE. The immunoglobulin is preferably IgG (IgG1, IgG2, IgG3 or IgG4) or IgM. Examples of particularly preferred immunoglobulin according to the present invention are immunoglobulins belonging to human derived IgG (IgG1, IgG2, IgG3 or IgG4).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Immunglobulin har en Y-formet strukturell enhet i hvilken fire kjeder, to homologe lettkjeder (L-kjeder) og to homologe tungkjeder (H-kjeder), er sammenbundet via disulfidbindinger (S-S-bindinger). Lettkjeden bestr av det variable lettkjedeomrdet (Vl) og det konstante lettkjedeomrdet (Cl). Tungkjeden bestr av det variable tungkjedeomrdet (Vh) og det konstante tungkjedeomrdet (Ch). </span>Immunoglobulin has a Y-shaped structural unit in which four chains, two homologous light chains (L chains) and two homologous heavy chains (H chains), are linked via disulfide bonds (S-S bonds). The light chain consists of the variable light chain region (Vl) and the constant light chain region (Cl). The heavy chain consists of the variable heavy chain area (Vh) and the constant heavy chain area (Ch).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tungkjedens konstante omrde bestr av noen domener som har aminosyresekvenser som er typiske for hver klasse (IgG, IgM, IgA, IgD og IgE) og hver underklasse (IgGl, IgG2, IgG3 og IgG4, IgAl og IgA2). </span>The heavy chain constant region consists of some domains that have amino acid sequences typical of each class (IgG, IgM, IgA, IgD and IgE) and each subclass (IgGl, IgG2, IgG3 and IgG4, IgAl and IgA2).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tungkjeden i IgG (IgGl, IgG2, IgG3 og IgG4) bestr av VH, CH1-domenet, hengselomrdet, CH2-domenet og CH3-domenet, i denne rekkeflge fra N-enden. </span>The heavy chain in IgG (IgG1, IgG2, IgG3 and IgG4) consists of the VH, the CH1 domain, the hinge region, the CH2 domain and the CH3 domain, in this order from the N terminus.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">P tilsvarende mte bestr tungkjeden i IgGl av Vh, Cyil-domenet, hengselomrdet, Cyi2-domenet og Cyi3-domenet, i denne rekkeflge fra N-enden. Tungkjeden i IgG2 bestr av VH, Cy2l-domenet, hengselomrdet, Cy22-domenet og Cy23-domenet, i denne rekke-flge fra N-enden. Tungkjeden i IgG3 bestr av VH, Cy3l-domenet, hengselomrdet, Cyj2-domenet og Cy33-domenet, i denne rekkeflge fra N-enden. Tungkjeden i IgG4 bestr av Vh, CyU -domenet, hengselomrdet, Cy42-domenet og Cy43-domenet, i denne rekkeflge fra N-enden. </span>Similarly, the heavy chain in IgG1 consists of Vh, the Cyil domain, the hinge region, the Cyi2 domain and the Cyi3 domain, in this order from the N-terminus. The heavy chain in IgG2 consists of the VH, the Cy21 domain, the hinge region, the Cy22 domain and the Cy23 domain, in this order from the N-terminus. The heavy chain in IgG3 consists of the VH, the Cy3l domain, the hinge region, the Cyj2 domain and the Cy33 domain, in this order from the N terminus. The heavy chain in IgG4 consists of the Vh, the CyU domain, the hinge region, the Cy42 domain and the Cy43 domain, in this order from the N-end.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tungkjeden i IgA bestr av VH, Cal-domenet, hengselomrdet, Ccx2-domenet og Ca3-domenet, i denne rekkeflge fra N-enden. </span>The heavy chain in IgA consists of the VH, the Cal domain, the hinge region, the Ccx2 domain and the Ca3 domain, in this order from the N terminus.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">P tilsvarende mte bestr tungkjeden i IgAl av Vh, Coci 1 -domenet, hengselomrdet, Ccti2-domenet og Coci3-domenet, i denne rekkeflge fra N-enden. Tungkjeden i IgA2 bestr av VH, Co^l-domenet, hengselomrdet, Ca22-domenet og Ca23-domenet, i denne rekke-flge fra N-enden. </span>Similarly, the heavy chain in IgAl consists of Vh, the Coci 1 domain, the hinge region, the Ccti2 domain and the Coci3 domain, in this order from the N-end. The heavy chain in IgA2 consists of the VH, the Co^1 domain, the hinge region, the Ca22 domain and the Ca23 domain, in this order from the N-terminus.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tungkjeden i IgD bestr av Vh, C81-domenet, hengselomrdet, C82-domenet og C83-domenet, i denne rekkeflge fra N-enden. </span>The heavy chain in IgD consists of Vh, the C81 domain, the hinge region, the C82 domain and the C83 domain, in this order from the N-terminus.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tungkjeden i IgM bestr av Vh, C^il-domenet, Cn2-domenet, C^i3-domenet og Cn4-domenet, i denne rekkeflge fra N-enden, og har intet hengselomrde av den type som observeres i IgG, IgA og IgD. </span>The heavy chain in IgM consists of Vh, the C^1 domain, the Cn2 domain, the C^i3 domain, and the Cn4 domain, in this order from the N terminus, and has no hinge region of the type observed in IgG, IgA, and IgD .</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tungkjeden i IgE bestr av Vh, Cel-domenet, Ce2-domenet, Ce3-domenet og Cs4-domenet, i denne rekkeflge fra N-enden, og har intet hengselomrde av den type som observeres i IgG, IgA og IgD. </span>The heavy chain in IgE consists of Vh, the Cel domain, the Ce2 domain, the Ce3 domain and the Cs4 domain, in this order from the N terminus, and has no hinge region of the type observed in IgG, IgA and IgD.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dersom IgG behandles med f.eks. papain, klyves molekylet litt over mot N-enden, bortenfor disulfidbindingene som foreligger i hengselomrdet, og hvor disulfidbindingene sammenbinder de to tungkjedene, slik at det dannes to homologe Fab, hvor et tungkjedefragment bestende av Vh og CH1 er bundet til n lettkjede via en disulfidbinding, og ett Fc, hvor to homologe tungkjedefragmenter bestende av hengselomrdet, CH2-domenet og CH3-domenet er sammenbundet via disulfidbindinger (se "Immunology Illustrated", den opprinnelige 2. utg., Nankodo, s. 65-75 (1992); og "Focus of Newest Medical Science 'Recognition Mechanism of Immune System'", Nankodo, s. 4-7 (1991) osv.). </span>If IgG is treated with e.g. papain, the molecule is cleaved slightly towards the N-end, beyond the disulfide bonds present in the hinge region, and where the disulfide bonds connect the two heavy chains, so that two homologous Fabs are formed, where a heavy chain fragment consisting of Vh and CH1 is bound to one light chain via a disulfide bond , and one Fc, where two homologous heavy chain fragments consisting of the hinge region, the CH2 domain and the CH3 domain are linked via disulfide bonds (see "Immunology Illustrated", the original 2nd ed., Nankodo, pp. 65-75 (1992); and "Focus of Newest Medical Science 'Recognition Mechanism of Immune System'", Nankodo, pp. 4-7 (1991) etc.).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"En del av et konstant omrde fra immunglobulintungkjeden" nevnt ovenfor betyr en del av et konstant omrde fra en immunglobulintungkjede med de strukturelle egenskaper som er nevnt ovenfor, og er fortrinnsvis det konstante omrdet uten Cl-domenet, eller Fc-omrdet. Et spesifikt eksempel p dette er omrdet bestende av hengselomrdet, C2-domenet og C3-domenet fra IgG, IgA og IgD, og er omrdet bestende av C2-domenet, C3-domenet og C4- </span>"A part of a constant region from the immunoglobulin heavy chain" mentioned above means a part of a constant region from an immunoglobulin heavy chain with the structural characteristics mentioned above, and is preferably the constant region without the Cl domain, or the Fc region. A specific example of this is the region consisting of the hinge region, the C2 domain and the C3 domain from IgG, IgA and IgD, and is the region consisting of the C2 domain, the C3 domain and the C4-</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">domenet fra IgM og IgE. Et spesielt foretrukket eksempel p dette er Fc-omrdet i humant avledet IgGl. </span>the domain from IgM and IgE. A particularly preferred example of this is the Fc region of human-derived IgG1.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Fusjonspolypeptidet nevnt ovenfor har den fordel at fusjonspolypeptidet kan renses ekstremt lett ved  anvende affinitetskolonnekromatografi ved utnyttelse av egenskapene til protein A, som bindes spesifikt til immunglobulinfragmentet, siden fusjonspolypeptidet iflge foreliggende oppfinnelse har en del av et konstant omrde (f.eks. Fc) fra et immunglobulin, f.eks. IgG, som nevnt ovenfor, som fusjonspartner. Siden forskjellige antistoffer mot Fc fra forskjellige immunglobuliner er tilgjengelige, kan videre en immunanalyse for fusjonspolypeptidene lett </span>The fusion polypeptide mentioned above has the advantage that the fusion polypeptide can be purified extremely easily by using affinity column chromatography by exploiting the properties of protein A, which binds specifically to the immunoglobulin fragment, since the fusion polypeptide according to the present invention has part of a constant region (e.g. Fc) from an immunoglobulin, e.g. IgG, as mentioned above, as a fusion partner. Since different antibodies against Fc from different immunoglobulins are available, further an immunoassay for the fusion polypeptides can easily</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">utfres med antistoffer mot Fc. </span>performed with antibodies against Fc.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Et polypeptid som bindes til AILIM" inngr i "et polypeptid" som inngr i definisjonen av "forbindelsen" ovenfor. </span>"A polypeptide that binds to AILIM" is included in "a polypeptide" included in the definition of "compound" above.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Spesifikke eksempler p "et polypeptid som bindes til AILIM" er hele eller en del av et polypeptid som utgjr de kjente B7h, B7RP-1, GL50, eller et molekyl betegnet LICOS, som er ligander som interagerer med AILIM (Nature, vol. 402, nr. 6763, s. 827-832, 1999; Nature Medicine, vol. 5, nr. 12, s. 1365-1369,1999; J. Immunology, vol. 164, s. 1653-1657, 2000; Curr. Biol, vol. 10, nr. 6, s. 333-336,2000). </span>Specific examples of "a polypeptide that binds to AILIM" are all or part of a polypeptide constituting the known B7h, B7RP-1, GL50, or a molecule designated LICOS, which are ligands that interact with AILIM (Nature, vol. 402 , No. 6763, pp. 827-832, 1999; Nature Medicine, vol. 5, No. 12, pp. 1365-1369, 1999; J. Immunology, vol. 164, pp. 1653-1657, 2000; Curr. Biol, vol. 10, no. 6, pp. 333-336, 2000).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Polypeptidet er fortrinnsvis et polypeptid som omfatter hele eller en del av et ekstracellulrt omrde fra ligandene nevnt ovenfor (B7h, B7RP-1, GL50, LICOS), eller et fusjonspolypeptid som omfatter polypeptidet og hele eller en del av et konstant omrde fra immunglobulintungkjeden (fortrinnsvis humant immunglobulin). Her har begrepene "et ekstracellulrt omrde" og "et konstant omrde fra immunglobulintungkjeden" samme betydning som ovenfor. </span>The polypeptide is preferably a polypeptide comprising all or part of an extracellular region from the ligands mentioned above (B7h, B7RP-1, GL50, LICOS), or a fusion polypeptide comprising the polypeptide and all or part of a constant region from the immunoglobulin heavy chain (preferably human immunoglobulin). Here, the terms "an extracellular region" and "an immunoglobulin heavy chain constant region" have the same meaning as above.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Polypeptidet, en del av polypeptidet (et fragment) og fusjonspolypeptidet nevnt ovenfor kan fremstilles ikke bare ved rekombinant DNA-teknologi, som nevnt nedenfor, men ogs ved en fremgangsmte som er vel kjent innen faget, slik som en kjemisk syntese-fremgangsmte og en celledyrkingsrfemgangsmte, eller en modifisert utgave av disse. </span>The polypeptide, a part of the polypeptide (a fragment) and the fusion polypeptide mentioned above can be produced not only by recombinant DNA technology, as mentioned below, but also by a method well known in the art, such as a chemical synthesis method and a cell culture procedure method , or a modified version of these.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Antistoffet" iflge foreliggende oppfinnelse kan vre et polyklonalt antistoff (antiserum) eller et monoklonalt antistoff mot AILIM fra et pattedyr (spesielt foretrukket humant AILIM), definert ovenfor, og er fortrinnsvis et monoklonalt antistoff. </span>The "antibody" according to the present invention can be a polyclonal antibody (antiserum) or a monoclonal antibody against AILIM from a mammal (particularly preferred human AILIM), defined above, and is preferably a monoclonal antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nrmere bestemt er antistoffet et antistoff med inhiberende aktivitet p proliferasjon av AILIM-uttrykkende celler ved at det bindes til AILIM, eller inhiberende aktivitet p produksjon av interferon-y eller interleukin-4 ved AILIM-uttrykkende celler via binding til AILIM. </span>More specifically, the antibody is an antibody with inhibitory activity on the proliferation of AILIM-expressing cells by binding to AILIM, or inhibitory activity on the production of interferon-y or interleukin-4 by AILIM-expressing cells via binding to AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Allergi av forsinket type" betyr her allergi som formidles ved cellulr immunitet (fortrinnsvis formidlet av T-celler av Thl-type), det vil si at allergien formidles av T-celler som er sensitivisert med antigen (hukommelses-T-celler som husker antigenet), og betegner enhver allergi hvor det tar ca. 24-48 timer fr den allergiske reaksjon kan pvises, ledsaget av inflammasjon grunnet hukommelses-T-cellen dersom den levende organisme som er sensitivisert med et antigen, igjen settes i forbindelse med det samme antigen. </span>"Delayed-type allergy" here means allergy mediated by cellular immunity (preferably mediated by T cells of the Thl type), i.e. the allergy is mediated by antigen-sensitized T cells (memory T cells that remember the antigen), and denotes any allergy where it takes approx. 24-48 hours before the allergic reaction can be detected, accompanied by inflammation due to the memory T-cell if the living organism that has been sensitized with an antigen is again brought into contact with the same antigen.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Denne allergi av forsinket type omfatter allergi overfor et infeksist, patogent antigen, f.eks. tuberkulinallergi erholdt fra Mycobacterium tuberculosis, en forbigende Jones-Mote-allergi av forsinket type rettet mot en svrt liten mengde protein, kontaktallergi overfor kjemikalier som pikrylklorid eller plantetoksiner som lakk, eller allergi forbundet med transplantatrejeksjon observert ved allotransplantasjon. </span>This delayed-type allergy includes allergy to an infectious, pathogenic antigen, e.g. tuberculin allergy obtained from Mycobacterium tuberculosis, a transient Jones-Mote allergy of the delayed type directed against a very small amount of protein, contact allergy to chemicals such as picryl chloride or plant toxins such as lacquer, or allergy associated with graft rejection observed in allotransplantation.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Farmasytisk preparat" betyr her et preparat som er anvendbart som medikament, og som omfatter som aktive bestanddeler antistoff (fortrinnsvis humant antistoff) som bindes til AILIM (fortrinnsvis humant AILIM) eller en del av dette, eller monoklonalt antistoff (fortrinnsvis humant, monoklonalt antistoff) eller en del av dette, og et "farmasytisk akseptabelt brerstoff. </span>"Pharmaceutical preparation" here means a preparation which can be used as a medicine, and which comprises as active ingredients antibody (preferably human antibody) which binds to AILIM (preferably human AILIM) or a part thereof, or monoclonal antibody (preferably human, monoclonal antibody ) or part thereof, and a "pharmaceutically acceptable carrier.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det "farmasytisk akseptable brerstoff' omfatter en eksipiens, et fortynningsmiddel, et ekspansjonsmiddel, et dekomponeringsmiddel, en stabilisator, et konserveringsmiddel, en buffer, et emulsjonsmiddel, et aromatisk middel, et fargestoff, et stningsmiddel, et viskositetskende middel, et smaksstoff, et lselighetsfremmende middel og andre tilsetnings-stoffer. </span>The "pharmaceutically acceptable carrier" includes an excipient, a diluent, an expanding agent, a disintegrant, a stabilizer, a preservative, a buffer, an emulsifying agent, an aromatic agent, a coloring agent, a sweetening agent, a viscosity increasing agent, a flavoring agent, a solubilizing agent agent and other additives.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ved anvendelse av ett eller flere slike brerstoffer kan et farmasytisk preparat utformes til tabletter, piller, pulvere, granulater, injeksjonslsninger, lsninger, kapsler, drops, eliksirer, suspensjoner, emulsjoner eller siruper. </span>By using one or more such carriers, a pharmaceutical preparation can be formulated into tablets, pills, powders, granules, injection solutions, solutions, capsules, drops, elixirs, suspensions, emulsions or syrups.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det farmasytiske preparat kan tilfres oralt eller parenteralt. Andre former for parenteral tilfrsel omfatter en lsning for ekstern pfring, en stikkpille for rektal tilfrsel og et pessar, foreskrevet ved den sedvanlige fremgangsmten, som omfatter n eller flere aktive bestanddeler. </span>The pharmaceutical preparation can be administered orally or parenterally. Other forms of parenteral administration include a solution for external application, a suppository for rectal administration and a pessary, prescribed by the usual method, which includes one or more active ingredients.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dosen kan variere, avhengig av pasientens alder, kjnn, vekt og symptomer, virkningen av behandlingen, tilfrselsveien, behandlingstidsrommet og hvilken type aktiv bestanddel (polypeptid eller antistoff som nevnt ovenfor) som inngr i det farmasytiske preparat. Vanligvis kan det farmasytiske preparat tilfres en voksen person i en dose p 10^ig til 1000 mg (eller 10^ig til 500 mg) pr. tilfrsel. Avhengig av forskjellige betingelser kan en dose som er mindre enn nevnt ovenfor vre tilstrekkelig i noen tilfeller, mens en dose som er hyere enn nevnt ovenfor kan vre ndvendig i andre tilfeller. </span>The dose may vary, depending on the patient's age, gender, weight and symptoms, the effect of the treatment, the administration route, the treatment period and the type of active ingredient (polypeptide or antibody as mentioned above) that is included in the pharmaceutical preparation. Generally, the pharmaceutical preparation can be administered to an adult in a dose of 10 g to 1000 mg (or 10 g to 500 mg) per supply. Depending on different conditions, a dose less than the above may be sufficient in some cases, while a dose higher than the above may be necessary in other cases.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nrmere bestemt kan injeksjonslsningen fremstilles ved  lse eller suspendere antistoffet i et ikke-toksisk, farmasytisk akseptabelt brerstoff, f.eks. fysiologisk saltvann eller kommersielt tilgjengelig destillert vann for injeksjon, ved justering til en konsentrasjonen p fra 0,1 \ i% antistoff/ml brerstoff til 10 mg antistoff/ml brerstoff. </span>More specifically, the injection solution can be prepared by dissolving or suspending the antibody in a non-toxic, pharmaceutically acceptable carrier, e.g. physiological saline or commercially available distilled water for injection, when adjusted to a concentration of from 0.1% antibody/ml carrier to 10 mg antibody/ml carrier.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den sledes fremstilte injeksjonslsning kan tilfres en menneskelig pasient med behov for behandling i en dose p fra 1 ug til 100 mg/kg kroppsvekt, fortrinnsvis fra 50 ug til 50 mg/kg kroppsvekt, n eller flere ganger daglig. Eksempler p tilfrselsveier er medisinsk egnede tilfrselsveier, slik som intravens injeksjon, subkutan injeksjon, intradermal injeksjon, intramuskulr injeksjon eller intraperitoneal injeksjon, fortrinnsvis intravens injeksjon. </span>The thus prepared injection solution can be administered to a human patient in need of treatment in a dose of from 1 g to 100 mg/kg body weight, preferably from 50 g to 50 mg/kg body weight, one or more times a day. Examples of administration routes are medically suitable administration routes, such as intravenous injection, subcutaneous injection, intradermal injection, intramuscular injection or intraperitoneal injection, preferably intravenous injection.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Injeksjonslsningen kan ogs fremstilles i et ikke-vandig fortynningsmiddel (f.eks. propylenglykol, polyetylenglykol, vegetabilsk olje, slik som olivenolje, og alkoholer, slik som etanol), som en suspensjon eller emulsjon. </span>The injection solution may also be prepared in a non-aqueous diluent (eg, propylene glycol, polyethylene glycol, vegetable oil, such as olive oil, and alcohols, such as ethanol), as a suspension or emulsion.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Injeksjonslsningen kan steriliseres ved filtrering gjennom et filter som ikke slipper igjennom bakterier, ved innblanding av bakteriedrepende midler eller ved bestrling. Injeksjonslsningen kan fremstilles i en form som ferdiggjres fr bruk. Nrmere bestemt kan den frysetrkes til et sterilt, fast preparat og opplses i sterilt, destillert vann for injeksjon eller et annet opplsningsmiddel fr anvendelse. </span>The injection solution can be sterilized by filtering through a filter that does not allow bacteria to pass through, by mixing in bactericidal agents or by irradiation. The injection solution can be prepared in a form that is completed before use. Specifically, it can be lyophilized to a sterile, solid preparation and dissolved in sterile, distilled water for injection or another solvent prior to use.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Farmasytiske preparater som omfatter de humane antistoffene iflge foreliggende oppfinnelse, er anvendbare som farmasytiske preparater som ikke induserer immunologisk avvisning hos verten grunnet HAMA (humant antimuseantistoff), for kontroll av en rekke biologiske reaksjoner (f.eks. proliferasjon av celler som uttrykker AILIM, cytokinproduksjon ved celler som uttrykker AILIM, immuncytolyse eller dd (apoptose) av celler som uttrykker AILIM og andre) som er forbundet med AILIM-formidlet overfring av et kostimulerende signal (sekundrsignal) til AILIM-uttrykkende celler, og/eller som farmasytiske preparater for behandling eller forebyggelse av forskjellige sykdommer ved  undertrykke og inhibere start og/eller utvikling av sykdommer forbundet med AILIM-formidlet signaloverfring. </span>Pharmaceutical preparations comprising the human antibodies according to the present invention are useful as pharmaceutical preparations which do not induce immunological rejection in the host due to HAMA (human anti-mouse antibody), for the control of a number of biological reactions (e.g. proliferation of cells expressing AILIM, cytokine production in the case of cells expressing AILIM, immunocytolysis or death (apoptosis) of cells expressing AILIM and others) associated with AILIM-mediated transmission of a costimulatory signal (secondary signal) to AILIM-expressing cells, and/or as pharmaceutical preparations for treatment or prevention of various diseases by suppressing and inhibiting the onset and/or development of diseases associated with AILIM-mediated signal transduction.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Begrepet "immuncytolyse" betegner her et biologisk fenomen som flger. </span>The term "immunocytolysis" here denotes a biological phenomenon as follows.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cellelysis (cytolyse) kan induseres med et antistoff (fortrinnsvis et cellelyserende antistoff), s vel som ved binding til dreperceller. Det cellelyserende antistoff er et cytotoksisk antistoff som fortrinnsvis har lyserende virkning p celler som immunceller, vevsceller eller spermier. Nr antistoffet bindes til celleoverflateantigenet, har det en cytotoksisk virkning p cellen eller induserer cytolyse i nrvr av komplement. </span>Cell lysis (cytolysis) can be induced with an antibody (preferably a cell-lysing antibody), as well as by binding to killer cells. The cell-lysing antibody is a cytotoxic antibody that preferably has a lysing effect on cells such as immune cells, tissue cells or sperm. When the antibody binds to the cell surface antigen, it has a cytotoxic effect on the cell or induces cytolysis in the presence of complement.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Denne immuncytolyse induseres ved virkningen av komplement sammen med spesifikk binding av antistoffet til celleoverflateantigenet. Antistoffet bundet til overflate-antigenet aktiverer Cl-komplement (Cl). Pflgende celleskadeseter dannes via en serie med komplementfikseringsreaksjoner med komplementer C2 til C9 (C2-C9), hvoretter celleinnholdet frigjres fra cellene og cellene lyserer. </span>This immunocytolysis is induced by the action of complement together with specific binding of the antibody to the cell surface antigen. The antibody bound to the surface antigen activates Cl complement (Cl). Subsequent cell damage sites are formed via a series of complement fixation reactions with complements C2 to C9 (C2-C9), after which the cell contents are released from the cells and the cells lyse.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Begrepet "antistoffavhengig cellulr cytotoksisitet" betegner her en biologisk begivenhet, som ogs forkortes "ADCC", og som er en cytotoksisk virkning p mlceller ved effektorceller, f.eks. lymfocytter, makrofager eller polymorfonuklere leukocytter, som ikke bare krever effektorceller og mlceller, men ogs et antistoff som deltar i induksjon av den cytotoksiske begivenhet. </span>The term "antibody-dependent cellular cytotoxicity" here denotes a biological event, which is also abbreviated "ADCC", and which is a cytotoxic effect on target cells by effector cells, e.g. lymphocytes, macrophages or polymorphonuclear leukocytes, which require not only effector cells and target cells, but also an antibody that participates in the induction of the cytotoxic event.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Begrepet "blandet lymfocyttreaksjon" betyr her et biologisk fenomen, som forkortes "MLR". Reaksjonen betegnes ogs en blandet leukocyttreaksjon. </span>The term "mixed lymphocyte reaction" here means a biological phenomenon, which is abbreviated "MLR". The reaction is also called a mixed leukocyte reaction.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Allogene leukocytter eller lymfocytter avledet fra forskjellige individer sammenblandes og dyrkes i flere dager, noe som tillater blastdannelse av cellene og DNA-syntese i cellene (det vil si celleproliferasjon). Denne reaksjonen betegnes MLR (allogeneisk </span>Allogeneic leukocytes or lymphocytes derived from different individuals are mixed and cultured for several days, allowing blast formation of the cells and DNA synthesis within the cells (ie, cell proliferation). This reaction is called MLR (allogeneic</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">MLR). </span>MLR).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DNA-syntese (celleproliferasjon) kan analyseres ved  stanse proliferasjonen av en av lymfocyttypene. Proliferasjonsstansen kan oppns ved behandling med strling eller mito-mycin. Analysen kan utfres ved  mle mengden DNA syntetisert i den andre lymfocytten. </span>DNA synthesis (cell proliferation) can be analyzed by stopping the proliferation of one of the lymphocyte types. Proliferation arrest can be achieved by treatment with radiation or mitomycin. The analysis can be performed by measuring the amount of DNA synthesized in the second lymphocyte.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mengden syntetisert DNA kan analyseres ved  mle inkorporering av tymidin merket med en radioaktiv isotop, slik som tritium, i cellekjernen. </span>The amount of synthesized DNA can be analyzed by measuring the incorporation of thymidine labeled with a radioactive isotope, such as tritium, into the cell nucleus.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DNA som koder for AILIM (spesielt foretrukket humant AILIM) iflge foreliggende oppfinnelse, kan erholdes iflge en hyppig anvendt fremgangsmte ved  benytte fremgangsmter for kloning av cDNA fra mRNA som koder for AILIM, en fremgangsmte for isolering av genomisk DNA og spleising av dette, en fremgangsmte for fremstilling av DNA ved PCR ved anvendelse av en cDNA-sekvens eller mRNA-sekvens som templat, eller en fremgangsmte for kjemisk syntese av DNA. </span>DNA that codes for AILIM (particularly preferred human AILIM) according to the present invention can be obtained according to a frequently used method by using methods for cloning cDNA from mRNA that codes for AILIM, a method for isolating genomic DNA and splicing it, a method for producing DNA by PCR using a cDNA sequence or mRNA sequence as a template, or a method for chemical synthesis of DNA.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DNA som koder for AILIM-liganden iflge foreliggende oppfinnelse, kan ogs erholdes p samme mte som beskrevet ovenfor. </span>DNA which codes for the AILIM ligand according to the present invention can also be obtained in the same way as described above.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DNA som koder for AILIM (spesielt foretrukket humant AILIM) iflge foreliggende oppfinnelse, kan fremstilles ved  kutte (fordye) DNA som omfatter DNA som koder for AILIM, fremstilt som sdant, med egnede restriksjonsenzymer og etter behov ligere det resulterende DNA-fragment til et linker-DNA eller en merkelapp ved anvendelse av en egnet DNA-polymerase eller lignende. DNA som koder for AILIM-ligand, kan ogs fremstilles p samme mte. </span>DNA encoding AILIM (especially preferred human AILIM) according to the present invention can be prepared by cutting (digesting) DNA comprising DNA encoding AILIM, prepared as such, with suitable restriction enzymes and, if necessary, ligating the resulting DNA fragment into a linker DNA or a tag using a suitable DNA polymerase or the like. DNA encoding AILIM ligand can also be prepared in the same way.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Et eksempel p en fremgangsmte for kloning av cDNA som koder for AILIM (spesielt foretrukket humant AILIM, proteinet vil i det pflgende betegnes proteinet av interesse) fra mRNA, vil vises nedenfor. </span>An example of a method for cloning cDNA encoding AILIM (particularly preferred human AILIM, the protein will be referred to as the protein of interest in the following) from mRNA will be shown below.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Et DNA som koder for AILIM-ligand, kan ogs klones p samme mte. </span>A DNA encoding AILIM ligand can also be cloned in the same way.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Frst fremstilles budbringer-RNA som koder for proteinet av interesse fra vev eller celler som uttrykker og danner proteinet av interesse, mRNA kan fremstilles ved  isolere total-RNA ved en kjent fremgangsmte, f.eks. guanidintiocyanatfremgangsmten (Chirgwin, J.M. et al., Biochemistry, vol. 18, s. 5294, 1979), den varme fenol-fremgangsmten eller AGPC-fremgangsmten, og behandle dette ved affinitetskromatografi med oligo-dT-cellulose eller poly-U-Sepharose. </span>First, messenger RNA that codes for the protein of interest is prepared from tissues or cells that express and form the protein of interest, mRNA can be prepared by isolating total RNA by a known method, e.g. the guanidine thiocyanate method (Chirgwin, J.M. et al., Biochemistry, vol. 18, p. 5294, 1979), the hot phenol method, or the AGPC method, and process this by affinity chromatography with oligo-dT-cellulose or poly-U-Sepharose.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Med det erholdte mRNA som templat syntetiseres s cDNA, f.eks. ved en velkjent fremgangsmte som benytter reverstranskriptase, f.eks. fremgangsmten til Okayama et al. (Mol. Cell. Biol, vol. 2, s. 161 (1982); ibid., vol. 3, s. 280 (1983)) eller fremgangsmten til Hoffman et al. (Gene, vol. 25, s. 263 (1983)), og overfres til dobbelttrdet cDNA. Et cDNA-bibliotek fremstilles ved  transformere E. coli med plasmidvektorer, bakteriofagvektorer eller kosmid-vektorer som brer dette cDNA, eller ved  transfektere E. coli etter pakking in vitro. </span>Using the obtained mRNA as a template, cDNA is then synthesized, e.g. by a well-known method that uses reverse transcriptase, e.g. the method of Okayama et al. (Mol. Cell. Biol, vol. 2, p. 161 (1982); ibid., vol. 3, p. 280 (1983)) or the method of Hoffman et al. (Gene, vol. 25, p. 263 (1983)), and transferred to the double-stranded cDNA. A cDNA library is prepared by transforming E. coli with plasmid vectors, bacteriophage vectors or cosmid vectors carrying this cDNA, or by transfecting E. coli after packaging in vitro.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">De anvendte plasmidvektorer i foreliggende oppfinnelse er ikke begrenset, s lenge de replikeres og opprettholdes i verter. Enhver bakteriofagvektor som kan replikeres i verter, kan ogs anvendes. Eksempler p hyppig anvendte kloningsvektorer er pUC19, XgtlO, Xgtl 1 osv. Dersom vektoren benyttes for immunologisk gjennomsking, som nevnt nedenfor, benyttes fortrinnsvis en vektor med en promoter som kan uttrykke genet som koder for polypeptidet iflge foreliggende oppfinnelse i en vert. </span>The plasmid vectors used in the present invention are not limited, as long as they are replicated and maintained in hosts. Any bacteriophage vector that can replicate in hosts can also be used. Examples of frequently used cloning vectors are pUC19, XgtlO, Xgtl 1, etc. If the vector is used for immunological screening, as mentioned below, a vector with a promoter that can express the gene encoding the polypeptide according to the present invention in a host is preferably used.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">cDNA kan settes inn i et plasmid ved f.eks. fremgangsmten til Maniatis et al. </span>cDNA can be inserted into a plasmid by e.g. the method of Maniatis et al.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(Molecular Cloning, A Laboratory Manual, 2. utgave, Cold Spring Harbor Laboratory, s. 1.53, 1989). cDNA kan settes inn i en bakteriofagvektor ved f.eks. fremgangsmten til Hyunh et al. </span>(Molecular Cloning, A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory, p. 1.53, 1989). cDNA can be inserted into a bacteriophage vector by e.g. the method of Hyunh et al.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(DNA cloning, a practical approach, vol. 1, s. 49 (1985)). Disse fremgangsmtene kan utfres enkelt ved  benytte et kommersielt tilgjengelig kloningssett (f.eks. et produkt fra Takara Shuzo). Det rekombinante plasmid eller bakteriofagvektoren som erholdes p denne mten, innfres egnede vertsceller, slik som en prokaryot (f.eks. E. coli: XLlBlue MRF, DH5a, HB101, MC1061/P3 etc). </span>(DNA cloning, a practical approach, vol. 1, p. 49 (1985)). These procedures can be performed easily using a commercially available cloning kit (eg a product from Takara Shuzo). The recombinant plasmid or bacteriophage vector thus obtained is introduced into suitable host cells, such as a prokaryote (eg E. coli: XLlBlue MRF, DH5a, HB101, MC1061/P3 etc).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempler p fremgangsmter for innfring av et plasmid i en vert er kalsium-kloridfremgangsmten, kalsiumklorid-/rubidiumkloridfremgangsmten beskrevet i Molecular Cloning, A Laboratory Manual (2. utgave, Cold Spring Harbor Laboratory, s. 1.74 (1989)), og elektroporeringsfremgangsmten. Bakteriofagvektorer kan innfres i vertsceller ved f.eks. en fremgangsmte hvor bakteriofag-DNA innfres i dyrkede verter etter pakking in vitro. Pakking in vitro kan lett utfres med et kommersielt tilgjengelig in v/7ro-pakkesett (f.eks. et produkt fra Stratagene eller Amersham). </span>Examples of methods for introducing a plasmid into a host are the calcium chloride method, the calcium chloride/rubidium chloride method described in Molecular Cloning, A Laboratory Manual (2nd ed., Cold Spring Harbor Laboratory, p. 1.74 (1989)), and the electroporation method. Bacteriophage vectors can be introduced into host cells by e.g. a method where bacteriophage DNA is introduced into cultured hosts after packaging in vitro. In vitro packing can be easily performed with a commercially available in vitro packing kit (eg, a product from Stratagene or Amersham).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">cDNA som koder for polypeptidet iflge foreliggende oppfinnelse, kan isoleres fra det sledes fremstilte cDNA-bibliotek iflge fremgangsmten nevnt ovenfor, ved  kombinere generelle cDNA-gj ennomskingsfremgangsmter. </span>The cDNA that codes for the polypeptide according to the present invention can be isolated from the cDNA library thus prepared according to the method mentioned above, by combining general cDNA screening methods.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En klon som omfatter det nskede cDNA, kan f.eks. finnes ved hjelp av en kjent kolonihybridiseringsfremgangsmte (Crunstein et al., Proe. Nati. Acad. Sei., USA, vol. 72, s. 3961 (1975)), eller plakkhybridiseringsfremgangsmten (Molecular Cloning, A Laboratory Manual, 2. utgave, Cold Spring Harbor Laboratory, s. 2.108 (1989)), ved anvendelse av&lt;32&gt;P-merkede, kjemisk syntetiserte oligonukleotider som prober, som tilsvarer aminosyresekvensen til polypeptidet iflge foreliggende oppfinnelse. Alternativt kan en klon med et DNA-fragment som koder for et spesifikt omrde i polypeptidet iflge foreliggende oppfinnelse, pvises ved  amplifisere omrdet ved PCR med syntetiske PCR-primere. </span>A clone comprising the desired cDNA can e.g. found by a known colony hybridization method (Crunstein et al., Proe. Nati. Acad. Sei., USA, vol. 72, p. 3961 (1975)), or the plaque hybridization method (Molecular Cloning, A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory, p. 2,108 (1989)), using&lt;32&gt;P-labeled, chemically synthesized oligonucleotides as probes, which correspond to the amino acid sequence of the polypeptide of the present invention. Alternatively, a clone with a DNA fragment that codes for a specific region in the polypeptide according to the present invention can be detected by amplifying the region by PCR with synthetic PCR primers.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dersom et cDNA-bibliotek fremstilt ved anvendelse av en cDNA-ekspresjonsvektor (f.eks. bakteriofagvektoren XZAPII) anvendes, kan den nskede klon pvises ved en antigen-antistoffreaksjon ved anvendelse av et antistoff rettet mot polypeptidet iflge foreliggende oppfinnelse. En gjennomskingsfremgangsmte som benytter PCR-metoden, anvendes fortrinnsvis dersom mange kloner skal analyseres. </span>If a cDNA library prepared using a cDNA expression vector (e.g. the bacteriophage vector XZAPII) is used, the desired clone can be detected by an antigen-antibody reaction using an antibody directed against the polypeptide according to the present invention. A screening procedure using the PCR method is preferably used if many clones are to be analysed.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nukleotidsekvensen til det sledes erholdte DNA kan bestemmes ved hjelp av Maxam-Gilbert-rfemgangsmten (Maxam et al., Proe. Nati. Acad. Sei., USA, vol. 74, s. 560 </span>The nucleotide sequence of the DNA thus obtained can be determined using the Maxam-Gilbert five-step method (Maxam et al., Proe. Nati. Acad. Sei., USA, vol. 74, p. 560</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(1977)), eller dideoksynukleotidsyntese-kjedetermineringsfremgangsmten med bakteriofag M13 (Sanger et al., Proe. Nati. Acad. Sei., USA, vol. 74, s. 5463-5467 (1977)). Hele eller en del av genet som koder for polypeptidet iflge foreliggende oppfinnelse, kan erholdes ved  kutte klonen erholdt, som nevnt ovenfor, med restriksjonsenzymer osv. DNA som koder for polypeptidet iflge foreliggende oppfinnelse, kan isoleres fra genomisk DNA avledet fra cellene som uttrykker polypeptidet iflge foreliggende oppfinnelse, som nevnt ovenfor, ved flgende fremgangsmter. Slike celler solubiliseres fortrinnsvis med SDS eller proteinase K, og DNA deproteiniseres ved gjentatt fenolekstraksjon. RNA nedbrytes, fortrinnsvis med ribonuklease. Det erholdte DNA kuttes delvis med egnede restriksjonsenzymer, og de erholdte DNA-fragmenter amplifiseres med egnet bakteriofag eller kosmid for dannelse av et bibliotek. Kloner med den nskede sekvens pvises s ved f.eks. anvendelse av radioaktivt merkede DNA-prober, og hele eller en del av genet som koder for polypeptidet iflge foreliggende oppfinnelse, erholdes fra klonene ved kutting med restriksjonsenzym osv. Fremstilling av DNA som koder for proteinet av interesse ved PCR, kan utfres ved  anvende kjent mRNA eller cDNA som koder for proteinet av interesse som templat, iflge en sedvanlig fremgangsmte ("PCR techniques for gene amplification - fundamental and new technologies", KYORITSU SHUPPAN, 1992, osv.). DNA som koder for proteinet av interesse, kan ogs syntetiseres kjemisk ved den sedvanlige fremgangsmte, basert p nukleotidsekvensen som koder for proteinet av interesse. AILIM iflge oppfinnelsen (spesielt foretrukket humant AILIM) eller en del av dette (fortrinnsvis det ekstracellulre omrdet) kan fremstilles som et rekombinant protein iflge en sedvanlig fremgangsmte med hyppig anvendte genetiske rekombinasjonsteknikker, ved anvendelse av DNA erholdt ved kutting av DNA som koder for AILIM (cDNA eller intronholdig genomisk DNA) basert p fremgangsmten illustrert ovenfor med egnede restriksjonsenzymer for erholdelse av et DNA-fragment som koder for AILIM, og s etter behov  ligere det resulterende DNA-fragment til et linker-DNA eller en merkelapp ved anvendelse av en egnet DNA-polymerase eller lignende. AILIM-liganden (spesielt foretrukket den humane AILIM-ligand) eller en del av denne (fortrinnsvis det ekstracellulre omrdet) kan fremstilles p samme mte. Et spesifikt eksempel er vist nedenfor. Nrmere bestemt innsettes DNA fremstilt som beskrevet ovenfor i en vektor som vil beskrives i detalj senere for erholdelse av en ekspresjonsvektor. Ekspresjonsvektoren anvendes s for transformasjon av en vertscelle som beskrevet nedenfor for erholdelse av en transformant. Transformanten dyrkes og tillates  produsere proteinet av interesse i dyrkingssupernatanten. Proteinet av interesse i dyrkingssupernatanten kan lett renses ved anvendelse av kolonnekromatografi eller lignende. Det er ingen spesiell begrensning nr det gjelder type av ekspresjonsvektor som benyttes for fremstilling av det rekombinante AILIM (eller dets ekstracellulre omrde), s lenge som vektoren replikeres og opprettholdes eller dannes autonomt i n av mange verter, f.eks. prokaryote celler og/eller eukaryote celler. Slike ekspresjonsvektorer omfatter plasmidvektorer og bakteriofagvektorer (Cloning Vectors: A Laboratory Manual, Elsevier, New York, 1985). Ekspresjonsvektoren kan lett fremstilles ved  ligere DNA som koder for AILIM (eller dets ekstracellulre omrde) til en vektor for rekombinasjon som er tilgjengelig innen faget (plasmid-DNA og bakteriofag-DNA) ved den sedvanlig fremgangsmten. Spesifikke eksempler p de anvendte vektorer for rekombinasjon er E. co//-avledede plasmider, slik som pBR322, pBR325, pUC12, pUC13 og pUC19, gjravledede plasmider, slik som pSH19 og pSH15, og Bacillus subtilis- avledede plasmider, slik som pUBl 10, pTP5 og pC194. Eksempler p fager er en bakteriofag, slik som bakteriofag X, og et dyre- eller insektvirus (pVL1393, Invitrogen), slik som et retrovirus, et kukoppevirus og nuklert polyhedrosisvirus. Plasmidvektorer er anvendbare dersom et av DNA som koder for AILIM iflge foreliggende oppfinnelse (spesielt foretrukket humant AILIM), eller dets lselige ekstracellulre omrde, skal uttrykkes i en vertscelle slik at AILIM uttrykkes p vertscellens overflate, eller alternativt det lselige ekstracellulr omrdet fra AILIM (spesielt foretrukket humant AILIM) nskes fremstilt. Det er ingen spesielle begrensninger nr det gjelder slike plasmidvektorer, s lenge vektorene kan uttrykke genet som koder for AILIM (fortrinnsvis humant AILIM) eller dets lselige ekstracellulr omrde, og produsere det kodede protein i forskjellige vertsceller, f.eks. prokaryote celler og/eller eukaryote celler. Slike plasmider omfatter f.eks. pMAL C2, pcDNA3.1 (-), pEF-BOS (Nucleic Acid Research, vol. 18, s. 5322,1990, osv.), pME18S ("Handbook for Genetic Engineering", Experimental Medicine, supplement, 1992, osv.) osv. Dersom bakterier, fortrinnsvis E. coli, anvendes som vertsceller, bestr en ekspresjonsvektor generelt av minst et promoter-/operatoromrde, et initieringskodon, DNA som koder for proteinet iflge foreliggende oppfinnelse, et termineringskodon, et terminatoromrde og et replikon. Dersom gjr, dyreceller eller insektceller anvendes som verter, bestr en ekspresjonsvektor fortrinnsvis av minst n promoter, et initieringskodon, DNA som koder for AILIM (spesielt foretrukket humant AILIM) iflge foreliggende oppfinnelse eller dets ekstracellulre omrde, og et termineringskodon. Det kan ogs omfatte DNA som koder for et signalpeptid, en enhancersekvens, 5'- og 3'-ikke-translaterte omrder fra genet som koder for AILIM iflge foreliggende oppfinnelse, spleiseseter, et polyadenyleringssete, et seleksjons-markromrde og et replikon. Ekspresjonsvektoren kan ogs om ndvendig inneholde et gen for genamplifisering (en markr) av hyppig anvendt type. Et promotor-/operatoromrde for ekspresjon av AILIM (spesielt foretrukket humant AILIM) iflge foreliggende oppfinnelse eller dets ekstracellulre omrde i bakterier omfatter en promoter, en operator og en Shine-Dalgarno(SD)-sekvens (f.eks. AAGG). Dersom verten f.eks. er Escherchia, omfatter det fortrinnsvis en Trp-promoter, lac-promoter, recA-promoter, XPL-promoter, lpp-promoter, tac-promoter eller lignende. Eksempler p en promoter for ekspresjon av AILIM (spesielt foretrukket humant AILIM) iflge foreliggende oppfinnelse eller dets ekstracellulre omrde i gjr er PH05-promoter, PGK-promoter, GAP-promoter, ADH-promoter osv. Dersom verten er Bacillus, er eksempler p promotorer SLOI-promoter, SP02-promoter, penP-promoter osv. Dersom verten er en eukaryot celle, slik som en pattedyrcelle, er eksempler p promoter en SV40-avledet promotor, en retroviruspromoter, en varmesjokkpromoter osv. Promotoren er naturligvis ikke begrenset til eksemplene ovenfor. Anvendelse av en enhancer i tillegg kan gi effektiv ekspresjon. </span>(1977)), or the dideoxynucleotide synthesis chain termination method with bacteriophage M13 (Sanger et al., Proe. Nati. Acad. Sei., USA, vol. 74, pp. 5463-5467 (1977)). All or part of the gene encoding the polypeptide of the present invention can be obtained by cutting the clone obtained, as mentioned above, with restriction enzymes, etc. DNA encoding the polypeptide of the present invention can be isolated from genomic DNA derived from the cells expressing the polypeptide according to the present invention, as mentioned above, by the following methods. Such cells are preferably solubilized with SDS or proteinase K, and the DNA is deproteinized by repeated phenol extraction. RNA is degraded, preferably with ribonuclease. The obtained DNA is partially cut with suitable restriction enzymes, and the obtained DNA fragments are amplified with a suitable bacteriophage or cosmid to form a library. Clones with the desired sequence are then detected by e.g. use of radioactively labeled DNA probes, and all or part of the gene that codes for the polypeptide according to the present invention is obtained from the clones by cutting with restriction enzymes, etc. Production of DNA that codes for the protein of interest by PCR can be carried out by using known mRNA or cDNA encoding the protein of interest as a template, according to a customary method ("PCR techniques for gene amplification - fundamental and new technologies", KYORITSU SHUPPAN, 1992, etc.). DNA that codes for the protein of interest can also be synthesized chemically by the usual method, based on the nucleotide sequence that codes for the protein of interest. AILIM according to the invention (particularly preferred human AILIM) or a part thereof (preferably the extracellular region) can be produced as a recombinant protein according to a customary method with frequently used genetic recombination techniques, using DNA obtained by cutting DNA that codes for AILIM ( cDNA or intron-containing genomic DNA) based on the method illustrated above with appropriate restriction enzymes to obtain a DNA fragment encoding AILIM, and then, as needed, ligate the resulting DNA fragment to a linker DNA or a tag using a suitable DNA polymerase or similar. The AILIM ligand (especially preferably the human AILIM ligand) or a part thereof (preferably the extracellular region) can be prepared in the same way. A specific example is shown below. More specifically, DNA prepared as described above is inserted into a vector which will be described in detail later to obtain an expression vector. The expression vector is then used for transformation of a host cell as described below to obtain a transformant. The transformant is grown and allowed to produce the protein of interest in the culture supernatant. The protein of interest in the culture supernatant can be easily purified using column chromatography or the like. There is no particular limitation on the type of expression vector used to produce the recombinant AILIM (or its extracellular region), as long as the vector is replicated and maintained or formed autonomously in one of many hosts, e.g. prokaryotic cells and/or eukaryotic cells. Such expression vectors include plasmid vectors and bacteriophage vectors (Cloning Vectors: A Laboratory Manual, Elsevier, New York, 1985). The expression vector can be easily prepared by ligating DNA encoding AILIM (or its extracellular region) to a vector for recombination available in the art (plasmid DNA and bacteriophage DNA) by the usual method. Specific examples of the vectors used for recombination are E. coli-derived plasmids, such as pBR322, pBR325, pUC12, pUC13 and pUC19, yeast-derived plasmids, such as pSH19 and pSH15, and Bacillus subtilis-derived plasmids, such as pUBl 10 , pTP5 and pC194. Examples of phages are a bacteriophage, such as bacteriophage X, and an animal or insect virus (pVL1393, Invitrogen), such as a retrovirus, a cowpox virus, and nuclear polyhedrosis virus. Plasmid vectors are applicable if one of the DNA that codes for AILIM according to the present invention (especially preferred human AILIM), or its soluble extracellular region, is to be expressed in a host cell so that AILIM is expressed on the surface of the host cell, or alternatively the soluble extracellular region from AILIM (especially preferably human AILIM) is desired to be produced. There are no particular limitations on such plasmid vectors, as long as the vectors can express the gene encoding AILIM (preferably human AILIM) or its soluble extracellular region, and produce the encoded protein in different host cells, e.g. prokaryotic cells and/or eukaryotic cells. Such plasmids include e.g. pMAL C2, pcDNA3.1 (-), pEF-BOS (Nucleic Acid Research, vol. 18, p. 5322, 1990, etc.), pME18S ("Handbook for Genetic Engineering", Experimental Medicine, supplement, 1992, etc. ) etc. If bacteria, preferably E. coli, are used as host cells, an expression vector generally consists of at least one promoter/operator region, an initiation codon, DNA encoding the protein according to the present invention, a termination codon, a terminator region and a replicon. If yeast, animal cells or insect cells are used as hosts, an expression vector preferably consists of at least one promoter, an initiation codon, DNA that codes for AILIM (particularly preferred human AILIM) according to the present invention or its extracellular region, and a termination codon. It may also comprise DNA encoding a signal peptide, an enhancer sequence, 5'- and 3'-untranslated regions from the gene encoding AILIM according to the present invention, splice sites, a polyadenylation site, a selection marker region and a replicon. The expression vector can also, if necessary, contain a gene for gene amplification (a marker) of a frequently used type. A promoter/operator region for expression of AILIM (particularly preferred human AILIM) according to the present invention or its extracellular region in bacteria comprises a promoter, an operator and a Shine-Dalgarno (SD) sequence (eg AAGG). If the host e.g. is Escherchia, it preferably comprises a Trp promoter, lac promoter, recA promoter, XPL promoter, lpp promoter, tac promoter or the like. Examples of a promoter for expression of AILIM (particularly preferred human AILIM) according to the present invention or its extracellular region in yeast are PH05 promoter, PGK promoter, GAP promoter, ADH promoter, etc. If the host is Bacillus, examples of promoters are SLOI promoter, SP02 promoter, penP promoter, etc. If the host is a eukaryotic cell, such as a mammalian cell, examples of the promoter are an SV40-derived promoter, a retrovirus promoter, a heat shock promoter, etc. The promoter is naturally not limited to the above examples . Application of an enhancer in addition can provide effective expression.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Et foretrukket initieringskodon er f.eks. et metioninkodon (ATG). </span>A preferred initiation codon is e.g. a methionine codon (ATG).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Hyppig anvendte termineringskodoner (f.eks. TAG, TGA, TAA osv.) illustrerer et termineringskodon. </span>Frequently used termination codons (eg, TAG, TGA, TAA, etc.) illustrate a termination codon.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Vanlig anvendte, naturlige eller syntetiske terminatorer anvendes som et terminatoromrde. </span>Commonly used natural or synthetic terminators are used as a terminator region.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Et replikon betyr et DNA som kan replikere hele sin DNA-sekvens i vertsceller, og omfatter et naturlig plasmid, et kunstig modifisert plasmid (et DNA-fragment fremstilt fra et naturlig plasmid), et syntetisk plasmid osv. Eksempler p foretrukne plasmider er pBR322 eller kunstige derivater av dette (et DNA-fragment erholdt ved  behandle pBR322 med egnede restriksjonsenzymer) for E. coli, 2^-plasmid fra gjr eller kromosomalt gjr-DNA for gjr, og pRSVneo ATCC 37198, pSV2dhfr ATCC 37145, pdBPV-MMTneo ATCC 37224, pSV2neo ATCC 37149, pSV2bsr osv. for pattedyrceller. </span>A replicon means a DNA that can replicate its entire DNA sequence in host cells, and includes a natural plasmid, an artificially modified plasmid (a DNA fragment prepared from a natural plasmid), a synthetic plasmid, etc. Examples of preferred plasmids are pBR322 or artificial derivatives thereof (a DNA fragment obtained by treating pBR322 with appropriate restriction enzymes) for E. coli, 2^-plasmid from yeast or yeast chromosomal DNA for yeast, and pRSVneo ATCC 37198, pSV2dhfr ATCC 37145, pdBPV-MMTneo ATCC 37224, pSV2neo ATCC 37149, pSV2bsr, etc. for mammalian cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En enhancersekvens, et polyadenyleringssete og et spleisesete av den typen som vanligvis anvendes innen faget, slik som dem avledet fra SV40, kan ogs anvendes. </span>An enhancer sequence, a polyadenylation site and a splice site of the type commonly used in the art, such as those derived from SV40, may also be used.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En vanlig benyttet seleksjonsmarkr kan benyttes iflge den sedvanlige fremgangsmte. Eksempler p slike er resistensgener for antibiotika, slik som tetrasyklin, ampicillin eller kanamycin, og tymidinkinasegenet. </span>A commonly used selection marker can be used according to the customary method. Examples of such are resistance genes for antibiotics, such as tetracycline, ampicillin or kanamycin, and the thymidine kinase gene.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempler p et gen for genamplifisering er dihydrofolatreduktase(DHFR)genet, tymidinkinasegenet, neomycinresistensgenet, glutamatsyntasegenet, adenosindeaminasegenet, ornitindekarboksylasegenet, hygromycin-B-fosfotransferasegenet, </span>Examples of a gene for gene amplification are the dihydrofolate reductase (DHFR) gene, the thymidine kinase gene, the neomycin resistance gene, the glutamate synthase gene, the adenosine deaminase gene, the ornithine decarboxylase gene, the hygromycin B phosphotransferase gene,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">aspartattranskarbamylasegenet osv. </span>the aspartate carbamylase gene, etc.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ekspresjonsvektoren iflge foreliggende oppfinnelse kan fremstilles ved sammen-hengende og sirkulr sammenkobling av minst den ovennevnte promoter, initieringskodonet, DNA som koder for proteinet iflge foreliggende oppfinnelse, termineringskodonet og terminatoromrdet til et egnet replikon. Om nskelig kan egnede DNA-fragmenter (f.eks. linkere, restriksjonsseter for andre restriksjonsenzymer) anvendes ved den sedvanlige fremgangsmten, slik som ved kutting med et restriksjonsenzym eller ligering ved anvendelse av T4-DNA-ligase. </span>The expression vector according to the present invention can be produced by contiguous and circular linking of at least the above-mentioned promoter, the initiation codon, DNA which codes for the protein according to the present invention, the termination codon and the terminator region of a suitable replicon. If desired, suitable DNA fragments (e.g. linkers, restriction sites for other restriction enzymes) can be used by the usual method, such as by cutting with a restriction enzyme or ligation using T4 DNA ligase.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Transformanter iflge foreliggende oppfinnelse kan fremstilles ved  innfre ekspresjonsvektoren nevnt ovenfor i vertsceller. </span>Transformants according to the present invention can be produced by introducing the expression vector mentioned above into host cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Vertsceller som anvendes i foreliggende oppfinnelse, er ikke begrenset s lenge de er forenlige med en ekspresjonsvektor som nevnt ovenfor og kan transformeres. Eksempler p vertsceller er forskjellige celler, slik som naturlige celler eller kunstig etablerte rekombinante celler som vanligvis anvendes innenfor foreliggende oppfinnelses tekniske omrde, f.eks. bakterier ( Escherchia og Bacillus), gjr { Saccharomyces, Pichia osv.), dyreceller eller insektceller. </span>Host cells used in the present invention are not limited as long as they are compatible with an expression vector as mentioned above and can be transformed. Examples of host cells are various cells, such as natural cells or artificially established recombinant cells which are usually used within the technical scope of the present invention, e.g. bacteria (Escherchia and Bacillus), yeast {Saccharomyces, Pichia, etc.), animal cells or insect cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">E. coli eller dyreceller anvendes fortrinnsvis. Spesifikke eksempler er E. coli (DH5cc, DH10B, TB1, HB101, XL2-Blue osv.), museavledede celler (COP, L, C127, Sp2/0, NS-1, NIH 3T3 osv.), rotteavledede celler, hamsteravledede celler (BHK, CHO osv.), apeavledede celler (COSI, COS3, COS7, CV1, Velo etc), og celler avledet fra mennesker (Hela, diploide, fibroblastavledede celler, myelomer, Namalwa-celler osv.). </span>E. coli or animal cells are preferably used. Specific examples are E. coli (DH5cc, DH10B, TB1, HB101, XL2-Blue, etc.), mouse-derived cells (COP, L, C127, Sp2/0, NS-1, NIH 3T3, etc.), rat-derived cells, hamster-derived cells (BHK, CHO etc), monkey derived cells (COSI, COS3, COS7, CV1, Velo etc), and human derived cells (Hela, diploid, fibroblast derived cells, myeloma, Namalwa cells etc).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ekspresjonsvektor kan innfres (transformeres (transduseres)) i vertsceller ved kjente fremgangsmter. </span>An expression vector can be introduced (transformed (transduced)) into host cells by known methods.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Transformasjon kan f.eks. utfres iflge fremgangsmten til Cohen et al. (Proe Nati. Acad. Sei., USA, vol. 69, s. 2110 (1972)), protoplastfremgangsmten (Mol. Gen. Genet., vol. 168, s. 111 (1979)) eller kompetansefremgangsmten (J. Mol. Biol, vol. 56, s. 209 (1971)) dersom vertene er bakterier ( E. coli, Bacillus subtilis osv.), fremgangsmten til Hinnen et al. </span>Transformation can e.g. is performed according to the method of Cohen et al. (Proe Nati. Acad. Sei., USA, vol. 69, p. 2110 (1972)), the protoplast method (Mol. Gen. Genet., vol. 168, p. 111 (1979)) or the competency method (J. Mol. Biol, vol. 56, p. 209 (1971)) if the hosts are bacteria (E. coli, Bacillus subtilis, etc.), the method of Hinnen et al.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(Proe. Nati. Acad. Sei., USA, vol. 75, s. 1927 (1978)) eller litiumfremgangsmten (J. Bacteriol., vol. 153, s. 163 (1983)) dersom verten er Saccharomyces cerevisiae, fremgangsmten til Graham (Virology, vol. 52, s. 456 (1973)) dersom verten er dyreceller, og fremgangsmten til Summers et al. (Mol. Cell. Biol, vol. 3, s. 2156-2165 (1983)) dersom verten er insektceller. </span>(Proe. Nati. Acad. Sei., USA, vol. 75, p. 1927 (1978)) or the lithium method (J. Bacteriol., vol. 153, p. 163 (1983)) if the host is Saccharomyces cerevisiae, the method of Graham (Virology, vol. 52, p. 456 (1973)) if the host is animal cells, and the method of Summers et al. (Mol. Cell. Biol, vol. 3, pp. 2156-2165 (1983)) if the host is insect cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det ekstracellulre omrdet fra AILIM (spesielt foretrukket humant AILIM) iflge foreliggende oppfinnelse (lselig AIILM) kan fremstilles ved  dyrke transformanter (i det pflgende omfatter dette begrep transduktanter) som inneholder en ekspresjonsvektor, fremstilt som beskrevet ovenfor, i nringsmedium. AILIM-ligand kan fremstilles p samme mte. </span>The extracellular region from AILIM (especially preferred human AILIM) according to the present invention (soluble AIILM) can be produced by growing transformants (hereinafter this term includes transductants) containing an expression vector, prepared as described above, in nutrient medium. AILIM ligand can be prepared in the same way.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nringsmediet omfatter fortrinnsvis en karbonkilde, en uorganisk nitrogenkilde eller en organisk nitrogenkilde som er ndvendig for vekst av vertscellene (transformantene). Eksempler p karbonkilder er glukose, dekstran, lselig stivelse og sukrose, og eksempler p uorganiske eller organiske nitrogenkilder er ammoniumsalter, nitrater, aminosyrer, maisblte-vske, pepton, kasein, kjttekstrakt, soyabnnemasse og potetekstrakt. Om nskelig kan de omfatte andre nringsstoffer (f.eks. et uorganisk salt (f.eks. kalsiumklorid, natriumdihydrogen-fosfat og magnesiumklorid)), vitaminer, antibiotika (f.eks. tetrasyklin, neomycin, ampicillin, kanamycin osv.). </span>The nutrient medium preferably comprises a carbon source, an inorganic nitrogen source or an organic nitrogen source which is necessary for growth of the host cells (transformants). Examples of carbon sources are glucose, dextran, soluble starch and sucrose, and examples of inorganic or organic nitrogen sources are ammonium salts, nitrates, amino acids, corn syrup, peptone, casein, meat extract, soybean pulp and potato extract. If desired, they may include other nutrients (eg, an inorganic salt (eg, calcium chloride, sodium dihydrogen phosphate, and magnesium chloride)), vitamins, antibiotics (eg, tetracycline, neomycin, ampicillin, kanamycin, etc.).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dyrkingen utfres ved en fremgangsmte som er kjent innen faget. Dyrkings-betingelser, slik som temperatur, pH i mediet og dyrkingstiden, utvelges p egnet vis, slik at proteinet iflge foreliggende oppfinnelse overproduseres. </span>Cultivation is carried out by a method known in the art. Cultivation conditions, such as temperature, pH in the medium and cultivation time, are selected in a suitable manner, so that the protein according to the present invention is overproduced.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Spesifikke medier og dyrkningsbetingelser som anvendes avhengig av vertscellene, er illustrert nedenfor, men er ikke begrenset til disse. </span>Specific media and culture conditions used depending on the host cells are illustrated below, but are not limited thereto.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dersom verten er bakterier, aktinomyceter, gjr eller filaments sopp, er flytende medier som omfatter nringskildene nevnt ovenfor egnet. Medier med pH 5-8 anvendes fortrinnsvis. </span>If the host is bacteria, actinomycetes, yeast or filamentous fungi, liquid media comprising the nutrient sources mentioned above are suitable. Media with pH 5-8 are preferably used.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dersom verten er E. coli, er eksempler p foretrukne medier LB-medium, M9-medium (Miller et al, Exp. Mol. Genet., Cold Spring Harbor Laboratory, s. 431 (1972)), og YT- medium osv. Ved anvendelse av disse medier kan dyrkingen vanligvis utfres ved 14-43 C i ca. 3-24 timer under lufttilfrsel og omrring, hvis ndvendig. </span>If the host is E. coli, examples of preferred media are LB medium, M9 medium (Miller et al, Exp. Mol. Genet., Cold Spring Harbor Laboratory, p. 431 (1972)), and YT medium, etc. When using these media, cultivation can usually be carried out at 14-43 C for approx. 3-24 hours under air supply and stirring, if necessary.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dersom verten er Bacillus, kan dyrkingen vanligvis utfres ved 30-40 C i ca. 16-96 timer med lufttilfrsel og omrring etter behov. </span>If the host is Bacillus, cultivation can usually be carried out at 30-40 C for approx. 16-96 hours with air supply and stirring as required.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dersom verten er gjr, er et eksempel p medier Burkholders minimalmedium (Bostian, Proe. Nati. Acad. Sei., USA, vol. 77, s. 4505 (1980)). Mediets pH er fortrinnsvis 5-8. Dyrkingen kan vanligvis utfres ved 20-35 C i ca. 14-144 timer med lufttilfrsel og omrring etter behov. </span>If the host is yeast, an example of media is Burkholder's minimal medium (Bostian, Proe. Nati. Acad. Sei., USA, vol. 77, p. 4505 (1980)). The medium's pH is preferably 5-8. Cultivation can usually be carried out at 20-35 C for approx. 14-144 hours with air supply and stirring as required.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dersom verten er en dyrecelle, er eksempler p medier MEM-medium tilsatt ca. 5-20 % ftalt, bovint serum (Science, vol. 122, s. 501 (1952)), DMEM-medium (Virology, vol. 8, s. 396 (1959)), RPMI-1640-medium (J. Am. Med. Assoc, vol. 199, s. 519 (1967)), 199-medium (Proe. Soc. Exp. Biol. Med, vol. 73, s. 1 (1950)), og HamF12-medium osv. Mediets pH er fortrinnsvis ca. 6-8. Dyrkingen kan vanligvis utfres ved ca. 30-40 C i ca. 15-72 timer med lufttilfrsel og omrring etter behov. </span>If the host is an animal cell, examples of media are MEM medium with approx. 5-20% fetal bovine serum (Science, vol. 122, p. 501 (1952)), DMEM medium (Virology, vol. 8, p. 396 (1959)), RPMI-1640 medium (J. Am . Med. Assoc, vol. 199, p. 519 (1967)), 199 medium (Proe. Soc. Exp. Biol. Med, vol. 73, p. 1 (1950)), and HamF12 medium, etc. The medium's The pH is preferably approx. 6-8. Cultivation can usually be carried out at approx. 30-40 C for approx. 15-72 hours with air supply and stirring as required.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dersom verten er en insektcelle, er et eksempel p medium Graces medium tilsatt ftalt, bovint serum (Proe. Nati. Acad. Sei., USA, vol. 82, s. 8404 (1985)). Mediets pH er fortrinnsvis ca. 5-8. Dyrkingen kan vanligvis utfres ved ca. 20-40&lt;*&gt;C i 15-100 timer med luft-tilfrsel og omrring etter behov. </span>If the host is an insect cell, an example of a medium is Grace's medium supplemented with fetal bovine serum (Proe. Nati. Acad. Sei., USA, vol. 82, p. 8404 (1985)). The medium's pH is preferably approx. 5-8. Cultivation can usually be carried out at approx. 20-40&lt;*&gt;C for 15-100 hours with air supply and stirring as required.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det ekstracellulre omrdet (lselig AILIM) i AILIM iflge oppfinnelsen (spesielt foretrukket humant AILIM) kan fremstilles ved  dyrke de ovenfor nevnte transformerte celler (fortrinnsvis en dyrecelle eller E. coli) og tillate sekresjon av proteinet i dyrkingssupernatanten. Nrmere bestemt erholdes et dyrkingsfiltrat (en supernatant) ved f.eks. filtrering eller sentrifugering av den erholdte kultur, og polypeptidet eller polypeptidfragmentet iflge foreliggende oppfinnelse renses og isoleres fra dyrkingsfiltratet ved fremgangsmter som vanligvis anvendes for rensing og isolering av et naturlig eller syntetisk protein. </span>The extracellular region (soluble AILIM) in the AILIM according to the invention (particularly preferred human AILIM) can be produced by culturing the above-mentioned transformed cells (preferably an animal cell or E. coli) and allowing secretion of the protein in the culture supernatant. More specifically, a culture filtrate (a supernatant) is obtained by e.g. filtering or centrifuging the obtained culture, and the polypeptide or polypeptide fragment according to the present invention is purified and isolated from the culture filtrate by methods that are usually used for the purification and isolation of a natural or synthetic protein.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempler p fremgangsmter for isolering og rensing er en fremgangsmte som benytter spesifikk affinitet, f.eks. affinitetskromatografi, en fremgangsmte som benytter lselighet, f.eks. utsalting og felling med et lsningsmiddel, en fremgangsmte som utnytter forskjeller i molekylvekt, slik som dialyse, ultrafiltrering, gelfiltrering og natriumdodecylsulfat-polyakrylamidgelelektroforese, en fremgangsmte som utnytter ladning, slik som ionebytterkromatografi og hydroksylapatittkromatografi, en fremgangsmte som utnytter forskjeller i hydrofobisitet, slik som reversfase-hyytelsesvskekromatografi, og en fremgangsmte som utnytter forskjeller i isoelektrisk punkt, slik som isolektrisk fokusering. </span>Examples of methods for isolation and purification are a method that uses specific affinity, e.g. affinity chromatography, a method that uses solubility, e.g. salting out and precipitation with a solvent, a method that exploits differences in molecular weight, such as dialysis, ultrafiltration, gel filtration, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis, a method that exploits charge, such as ion exchange chromatography and hydroxylapatite chromatography, a method that exploits differences in hydrophobicity, such as reverse phase - high performance liquid chromatography, and a method that exploits differences in isoelectric point, such as isoelectric focusing.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dersom proteinet av interesse foreligger i periplasmaet eller cytoplasmaet fra dyrkede transformanter, hstes frst sopplegemene eller cellene ved en sedvanlig fremgangsmte, slik som filtrering eller sentrifugering, og suspenderes i en egnet buffer. Etter at celle-veggen og/eller cellemembranen er blitt oppbrutt ved en fremgangsmte som lysering, ved ultralydbehandling, lysozymbehandling og frysetrking, erholdes membranfraksjonen som omfatter polypeptidet iflge foreliggende oppfinnelse ved sentrifugering eller filtrering. Membranfraksjonen opplses med en detergent, slik som Triton-XlOO, for erholdelse av en r-ekstrakt. Endelig isoleres og renses polypeptidet eller polypeptidfragmentet fra rekstrakten ved en vanlig fremgangsmte, som illustrert ovenfor. </span>If the protein of interest is present in the periplasm or cytoplasm of cultured transformants, the fungal bodies or cells are first harvested by a customary method, such as filtration or centrifugation, and suspended in a suitable buffer. After the cell wall and/or cell membrane has been broken up by a method such as lysis, by ultrasound treatment, lysozyme treatment and freeze drying, the membrane fraction comprising the polypeptide according to the present invention is obtained by centrifugation or filtration. The membrane fraction is dissolved with a detergent, such as Triton-X100, to obtain a crude extract. Finally, the polypeptide or polypeptide fragment is isolated and purified from the crude extract by a common method, as illustrated above.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I foreliggende oppfinnelse betyr begrepet "ulselig brer" en brer som anvendes for immobilisering av polypeptider ved fysisk absorpsjon eller kjemisk tilkobling. Breren kan f.eks. vre (1) en plate, et reagensrr, et rr eller lignende med et indre rom, en kule, en ball, et filter, en membran eller lignende, fremstilt av vannulselige materialer, innbefattet plast, slik som et polystyrenresin, et polykarbonatresin, et silikonresin eller et nylonresin, eller glass, og (2) ulselige brere som anvendes i affinitetskromatografi, f.eks. en cellulosebrer, en agarosebrer, en polyakrylamidbrer, en dekstranbrer, en polystyrenbrer, en polyvinylalkoholbrer, en polyaminosyrebrer, en pors kiselgelbrer osv. </span>In the present invention, the term "insoluble carrier" means a carrier used for the immobilization of polypeptides by physical absorption or chemical attachment. The carrier can e.g. be (1) a plate, a test tube, a tube or the like with an inner space, a sphere, a ball, a filter, a membrane or the like, made of water-insoluble materials, including plastics, such as a polystyrene resin, a polycarbonate resin, a silicone resin or a nylon resin, or glass, and (2) insoluble supports used in affinity chromatography, e.g. a cellulose support, an agarose support, a polyacrylamide support, a dextran support, a polystyrene support, a polyvinyl alcohol support, a polyamino acid support, a porous silica gel support, etc.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Merkingsforbindelsen som kan gi et pvisbart signal" iflge foreliggende oppfinnelse, omfatter f.eks. et enzym, et fluorescerende materiale, et luminescerende materiale, biotin, avidin eller en radioaktiv isotop, nrmere bestemt enzymer som peroksidase (f.eks. pepperrotperoksidase), alkalinsk fosfatase, (5-D-galaktosidase, glukoseoksidase, glukose-6-fosfatdehydrogenase, alkoholdehydrogenase, malatdehydrogenase, penicillinase, katalase, apoglukoseoksidase, urease, luciferase, acetylcholinesterase osv.; fluorescerende materialer som fluoresceinisotiocyanat, fykobilinprotein, chelateringsmidler for sjeldne jordmetaller, dansyl-klorid, tetrametylrhodaminisotiocyanat osv.; radioaktive isotoper som H, C, I, I osv.; biotin, avidin og luminescerende materiale. </span>"The labeling compound which can give a detectable signal" according to the present invention, comprises e.g. an enzyme, a fluorescent material, a luminescent material, biotin, avidin or a radioactive isotope, more specifically enzymes such as peroxidase (e.g. horseradish peroxidase), alkaline phosphatase, (5-D-galactosidase, glucose oxidase, glucose-6-phosphate dehydrogenase, alcohol dehydrogenase, malate dehydrogenase, penicillinase, catalase, apoglucose oxidase, urease, luciferase, acetylcholinesterase, etc.; fluorescent materials such as fluorescein isothiocyanate, phycobilin protein, rare earth chelating agents, dansyl chloride, tetramethylrhodamine isothiocyanate, etc.; radioactive isotopes such as H, C, I, I, etc. ; biotin, avidin and luminescent material.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Blant disse kan radioaktive isotoper eller fluorescerende materialer gi pvisbart signal selv nr de benyttes alene. Ved benyttelse alene vil derimot enzymer, luminescerende materialer, biotin eller avidin ikke gi pvisbart signal, men nr disse fr reagere med n eller flere forbindelser kan de gi pvisbart signal. Dersom f.eks. merkingsgruppen er et enzym, er minst et substrat ndvendig for pvisningen. Forskjellige substrattyper kan anvendes, avhengig av hvilken fremgangsmte som benyttes for mling av enzymaktiviteten (kolorimetri, fluoro-skopi, fremgangsmter som benytter bioluminescens eller kjemisk luminescens osv.). Dersom f.eks. merkingsgruppen er peroksidase, kan hydrogenperoksid anvendes som substrat. Dersom merkingsgruppen er biotin, anvendes alternativt avidin eller enzymmodifisert avidin vanligvis, men substratet er ikke begrenset til disse. Etter behov kan en rekke luminescerende forbindelser anvendes, avhengig av substratet som skal benyttes. </span>Among these, radioactive isotopes or fluorescent materials can give a detectable signal even when used alone. When used alone, on the other hand, enzymes, luminescent materials, biotin or avidin will not give a detectable signal, but when these are allowed to react with one or more compounds they can give a detectable signal. If e.g. the labeling group is an enzyme, at least one substrate is required for the detection. Different substrate types can be used, depending on the method used for measuring the enzyme activity (colorimetry, fluoroscopy, methods using bioluminescence or chemical luminescence, etc.). If e.g. the labeling group is peroxidase, hydrogen peroxide can be used as substrate. If the labeling group is biotin, alternatively avidin or enzyme-modified avidin is usually used, but the substrate is not limited to these. If necessary, a number of luminescent compounds can be used, depending on the substrate to be used.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Enhver av de ovenfor nevnte merkingsgrupper kan anvendes i foreliggende oppfinnelse. Den foretrukne merking er imidlertid et enzym, slik som peroksidase, eller biotin, idet det tas i betraktning pvisningsflsomhet eller analyseflsomhet, s vel som enkel manipulering. </span>Any of the above-mentioned labeling groups can be used in the present invention. However, the preferred label is an enzyme, such as peroxidase, or biotin, taking into account detection sensitivity or assay sensitivity, as well as ease of manipulation.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En "fremgangsmte for identifisering av en forbindelse som kan bindes til AILIM eller AILIM-ligand" iflge oppfinnelsen, er konstruert basert p immunanalyseprinsippet. </span>A "method for identifying a compound that can bind to AILIM or AILIM ligand" according to the invention is constructed based on the immunoassay principle.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nrmere bestemt kan prinsippene for forskjellige fremgangsmter som beskrevet i Immunoassay (3. utgave, red. Eiji Ishikawa et al., Igakushoin, 1987) benyttes. </span>More specifically, the principles for various procedures as described in Immunoassay (3rd edition, ed. Eiji Ishikawa et al., Igakushoin, 1987) can be used.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempler p prinsipper som fortrinnsvis benyttes, omfatter fast fase-ett antistoff-fremgangsmten, vskefase-to antistoffer-fremgangsmten, fast fase-to antistoffer-fremgangsmten, "sandwich"-fremgangsmten og ettrrsfremgangsmten, som beskrevet i behandlet, publisert japansk patentsknad (JP-B) nr. Hei 2-39747. Videre er et eksempel p analyse-fremgangsmter som benytter antigen-antistoffreaksjoner EMIT-fremgangsmten (enzym-oppformet immunanalyseteknikk), enzymkanaliseringsimmunanalyse, enzymmodulatorformidlet enzymimmunanalyse (EMMIA), enzyminhibitorimmunanalyse, immunenzymometrisk analyse, enzymforsterket immunanalyse og proksimal koblingsimmunanalyse. </span>Examples of principles that are preferably used include the solid phase one antibody method, the liquid phase two antibody method, the solid phase two antibody method, the "sandwich" method, and the one tube method, as described in processed published Japanese patent application (JP- B) No. Hello 2-39747. Furthermore, an example of assay methods using antigen-antibody reactions is the EMIT method (enzyme-mediated immunoassay technique), enzyme channeling immunoassay, enzyme modulator-mediated enzyme immunoassay (EMMIA), enzyme inhibitor immunoassay, immunoenzymometric assay, enzyme-enhanced immunoassay and proximal linkage immunoassay.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I foreliggende oppfinnelse kan ethvert av slike immunanalyseprinsipper utvelges, avhengig av formlet. Idet det tas hensyn til enkel fremgangsmte og/eller konomiske fordeler, og srlig til klinisk anvendelighet, anvendes fortrinnsvis prinsippet for "sandwich"-fremgangsmten, ettrrsfremgangsmten eller fast fase-ett antistoff-fremgangsmten, mer foretrukket "sandwich"-fremgangsmten eller ettrrsfremgangsmten. Spesielt foretrukket er "sandwich"-fremgangsmten ved anvendelse av mikrotiterplater med flere brnner, f.eks. 96-brnners mikrotiterplater, eller ettrrsfremgangsmten ved anvendelse av kuler til hvilket polypeptidet er immobilisert, og hvor det ogs anvendes en motpart merket med et enzym, f.eks. peroksidase, eller med biotin. </span>In the present invention, any of such immunoassay principles can be selected, depending on the purpose. Taking into account simple procedure and/or economic advantages, and especially clinical applicability, the principle of the "sandwich" method, the one-tube method or the solid-phase-one-antibody method is preferably used, more preferably the "sandwich" method or the one-tube method. Particularly preferred is the "sandwich" method using multi-well microtiter plates, e.g. 96-well microtiter plates, or the one-tube method using beads to which the polypeptide is immobilized, and where a counterpart labeled with an enzyme is also used, e.g. peroxidase, or with biotin.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Kort beskrivelse av figurene </span>Brief description of the figures</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 1 viser reaktiviteten for antihumant IgG-antistoff, antihumant IgK-antistoff og antihumant IgFc-antistoff overfor det humane, monoklonale antihumant AILIM-antistoff, analysert ved celle-ELISA med et "flow"-cytometer. </span>Figure 1 shows the reactivity of anti-human IgG antibody, anti-human IgK antibody and anti-human IgFc antibody to the human monoclonal anti-human AILIM antibody, analyzed by cell ELISA with a "flow" cytometer.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Feltene (a)-(l) viser resultater fra analysene angitt nedenfor. </span>Fields (a)-(l) show results from the analyzes indicated below.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Felt (a): resultatet av en analyse hvor biotinmerket antihumant IgG-antistoff som sekundrantistoff var tilsatt i fravr av primrantistoff til en mikroplate hvor villtype-HBP-ALL-celler var utsdd. </span>Panel (a): the result of an assay in which biotin-labelled anti-human IgG antibody as secondary antibody was added in the absence of primary antibody to a microplate on which wild-type HBP-ALL cells were seeded.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Felt (b): resultatet av en analyse hvor biotinmerket antihumant IgK-antistoff som sekundrantistoff var tilsatt i fravr av primrantistoff til en mikroplate hvor villtype-HBP-ALL-celler var utsdd. </span>Panel (b): the result of an assay in which biotin-labelled anti-human IgK antibody as secondary antibody was added in the absence of primary antibody to a microplate on which wild-type HBP-ALL cells were seeded.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Felt (c): resultatet av en analyse hvor biotinmerket antihumant IgFc-antistoff som sekundrantistoff var tilsatt i fravr av primrantistoff til en mikroplate hvor villtype-HBP-ALL-celler var utsdd. </span>Panel (c): the result of an assay in which biotin-labeled anti-human IgFc antibody as secondary antibody was added in the absence of primary antibody to a microplate on which wild-type HBP-ALL cells were seeded.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Felt (d): resultatet av en analyse hvor humant, monoklonalt, antihumant AILIM-antistoff, JMab-136, ble benyttet som primrantistoff, og biotinmerket antihumant IgG-antistoff ble benyttet som sekundrantistoff. </span>Panel (d): the result of an assay where human monoclonal anti-human AILIM antibody, JMab-136, was used as the primary antibody, and biotin-labelled anti-human IgG antibody was used as the secondary antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Felt (e): resultatet av en analyse hvor humant, monoklonalt, antihumant AILIM-antistoff, JMab-136, ble benyttet som primrantistoff, og biotinmerket antihumant IgK-antistoff ble benyttet som sekundrantistoff. </span>Panel (e): the result of an assay where human monoclonal anti-human AILIM antibody, JMab-136, was used as the primary antibody, and biotin-labeled anti-human IgK antibody was used as the secondary antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Felt (f): resultatet av en analyse hvor humant, monoklonalt, antihumant AILIM-antistoff, JMab-136, ble benyttet som primrantistoff, og biotinmerket antihumant IgFc-antistoff ble benyttet som sekundrantistoff. </span>Panel (f): the result of an analysis where human monoclonal anti-human AILIM antibody, JMab-136, was used as primary antibody, and biotin-labeled anti-human IgFc antibody was used as secondary antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Felt (g): resultatet av en analyse hvor humant, monoklonalt, antihumant AILIM-antistoff, JMab-138, ble benyttet som primrantistoff, og biotinmerket antihumant IgG-antistoff ble benyttet som sekundrantistoff. </span>Panel (g): the result of an assay where human monoclonal anti-human AILIM antibody, JMab-138, was used as the primary antibody, and biotin-labeled anti-human IgG antibody was used as the secondary antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Felt (h): resultatet av en analyse hvor humant, monoklonalt, antihumant AILIM-antistoff, JMab-138, ble benyttet som primrantistoff, og biotinmerket antihumant IgK-antistoff ble benyttet som sekundrantistoff. </span>Panel (h): the result of an analysis where human monoclonal anti-human AILIM antibody, JMab-138, was used as primary antibody, and biotin-labelled anti-human IgK antibody was used as secondary antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Felt (i): resultatet av en analyse hvor humant, monoklonalt, antihumant AILIM-antistoff, JMab-138, ble benyttet som primrantistoff, og biotinmerket antihumant IgFc-antistoff ble benyttet som sekundrantistoff. </span>Panel (i): the result of an assay where human monoclonal anti-human AILIM antibody, JMab-138, was used as primary antibody, and biotin-labeled anti-human IgFc antibody was used as secondary antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Felt (j): resultatet av en analyse hvor humant, monoklonalt, antihumant AILIM-antistoff, JMab-139, ble benyttet som primrantistoff, og biotinmerket antihumant IgG-antistoff ble benyttet som sekundrantistoff. </span>Panel (j): the result of an analysis where human monoclonal anti-human AILIM antibody, JMab-139, was used as primary antibody, and biotin-labelled anti-human IgG antibody was used as secondary antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Felt (k): resultatet av en analyse hvor humant, monoklonalt, antihumant AILIM-antistoff, JMab-139, ble benyttet som primrantistoff, og biotinmerket antihumant IgK-antistoff ble benyttet som sekundrantistoff. </span>Panel (k): the result of an assay where human monoclonal anti-human AILIM antibody, JMab-139, was used as primary antibody, and biotin-labelled anti-human IgK antibody was used as secondary antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Felt (1): resultatet av en analyse hvor humant, monoklonalt, antihumant AILIM-antistoff, JMab-139, ble benyttet som primrantistoff, og biotinmerket antihumant IgFc-antistoff ble benyttet som sekundrantistoff. </span>Field (1): the result of an analysis where human, monoclonal, anti-human AILIM antibody, JMab-139, was used as primary antibody, and biotin-labeled anti-human IgFc antibody was used as secondary antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Kurven med pne symboler i hvert felt tilsvarer resultatet av en analyse hvor humant, monoklonalt, anti-KLH-antistoff ble benyttet som kontrollantistoff. </span>The curve with open symbols in each field corresponds to the result of an analysis where human, monoclonal, anti-KLH antibody was used as control antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 2 viser en kalibreringskurve for humant, monoklonalt IgG-antistoff (standardmateriale) analysert ved "sandwich"-ELISA med antihumant IgG-antistoff. </span>Figure 2 shows a calibration curve for human monoclonal IgG antibody (standard material) analyzed by "sandwich" ELISA with anti-human IgG antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir fluorescensintensiteten, og den horisontale akse angir konsentrasjonen av standardmaterialet. </span>The vertical axis indicates the fluorescence intensity, and the horizontal axis indicates the concentration of the standard material.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 3 viser bindingsaktiviteten til forskjellige monoklonale, antihumant AILIM-antistoffer fra mus overfor rekombinante CHO-celler som overuttrykker humant AILIM eller villtype-CHO-celler. </span>Figure 3 shows the binding activity of various mouse monoclonal anti-human AILIM antibodies to recombinant CHO cells overexpressing human AILIM or wild-type CHO cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir fluorescensintensiteten som et ml p bindingsaktiviteten til de rekombinante cellene, og den horisontale akse angir konsentrasjonen av det tilsatte antistoff. </span>The vertical axis indicates the fluorescence intensity as a measure of the binding activity of the recombinant cells, and the horizontal axis indicates the concentration of the added antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Begrepet "CHO" i figuren angir resultatet fra en bindingsanalyse til villtype-CHO-cellen, og "humant" angir </span>The term "CHO" in the figure indicates the result of a binding assay to the wild-type CHO cell, and "human" indicates</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">resultatet fra en bindingsanalyse til den rekombinante CHO-celle som overuttrykker humant </span>the result from a binding assay to the recombinant CHO cell overexpressing human</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AILIM. </span>AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 4 viser bindingsaktiviteten til forskjellige humane, monoklonale antihumant AILIM-antistoffer eller humane, monoklonale anti-KLH-antistoffer som negativ kontroll overfor rekombinante CHO-celler som overuttrykker humant AILIM eller villtype-CHO-celler. </span>Figure 4 shows the binding activity of various human monoclonal anti-human AILIM antibodies or human monoclonal anti-KLH antibodies as a negative control to recombinant CHO cells overexpressing human AILIM or wild-type CHO cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir fluorescensintensiteten som et ml p bindingsaktiviteten til de rekombinante cellene, og den horisontale akse angir konsentrasjonen av det tilsatte antistoff. </span>The vertical axis indicates the fluorescence intensity as a measure of the binding activity of the recombinant cells, and the horizontal axis indicates the concentration of the added antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Begrepet "CHO" i figuren angir resultatet fra en bindingsanalyse til villtype-CHO-cellen, og "humant" angir </span>The term "CHO" in the figure indicates the result of a binding assay to the wild-type CHO cell, and "human" indicates</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">resultatet fra en bindingsanalyse til den rekombinante CHO-celle som overuttrykker humant </span>the result from a binding assay to the recombinant CHO cell overexpressing human</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AILIM. </span>AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 5 viser bindingsaktiviteten til forskjellige humane, monoklonale antihumant AILIM-antistoffer overfor rekombinante CHO-celler som overuttrykker humant AILIM eller villtype-CHO-celler. </span>Figure 5 shows the binding activity of various human monoclonal anti-human AILIM antibodies to recombinant CHO cells overexpressing human AILIM or wild-type CHO cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir fluorescensintensiteten som et ml p bindingsaktiviteten til de rekombinante cellene, og den horisontale akse angir konsentrasjonen av det tilsatte antistoff. </span>The vertical axis indicates the fluorescence intensity as a measure of the binding activity of the recombinant cells, and the horizontal axis indicates the concentration of the added antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Begrepet "CHO" i figuren angir resultatet fra en bindingsanalyse til villtype-CHO-cellen, og "humant" angir </span>The term "CHO" in the figure indicates the result of a binding assay to the wild-type CHO cell, and "human" indicates</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">resultatet fra en bindingsanalyse til den rekombinante CHO-celle som overuttrykker humant </span>the result from a binding assay to the recombinant CHO cell overexpressing human</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AILIM. </span>AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 6 viser bindingsaktiviteten til forskjellige humane, monoklonale antihumant AILIM-antistoffer overfor rekombinante CHO-celler som overuttrykker humant AILIM eller villtype-CHO-celler. </span>Figure 6 shows the binding activity of various human monoclonal anti-human AILIM antibodies to recombinant CHO cells overexpressing human AILIM or wild-type CHO cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir fluorescensintensiteten som et ml p bindingsaktiviteten til de rekombinante cellene, og den horisontale akse angir konsentrasjonen av det tilsatte antistoff. </span>The vertical axis indicates the fluorescence intensity as a measure of the binding activity of the recombinant cells, and the horizontal axis indicates the concentration of the added antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Begrepet "CHO" i figuren angir resultatet fra en bindingsanalyse til villtype-CHO-cellen, og "humant" angir </span>The term "CHO" in the figure indicates the result of a binding assay to the wild-type CHO cell, and "human" indicates</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">resultatet fra en bindingsanalyse til den rekombinante CHO-celle som overuttrykker humant </span>the result from a binding assay to the recombinant CHO cell overexpressing human</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AILIM. </span>AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 7 viser bindingsaktiviteten til monoklonale, antihumant AILIM-antistoffer fra rotte overfor rekombinante CHO-celler som overuttrykker muse-AILIM eller villtype-CHO-celler. </span>Figure 7 shows the binding activity of rat anti-human AILIM monoclonal antibodies to recombinant CHO cells overexpressing mouse AILIM or wild-type CHO cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir fluorescensintensiteten som et ml p bindingsaktiviteten til de rekombinante cellene, og den horisontale akse angir konsentrasjonen av det tilsatte antistoff. </span>The vertical axis indicates the fluorescence intensity as a measure of the binding activity of the recombinant cells, and the horizontal axis indicates the concentration of the added antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Begrepet "CHO" i figuren angir resultatet fra en bindingsanalyse til villtype-CHO-cellen, og "mus" angir resultatet fra en bindingsanalyse til den rekombinante CHO-celle som overuttrykker muse-AILIM. </span>The term "CHO" in the figure denotes the result of a binding assay to the wild-type CHO cell, and "mouse" denotes the result of a binding assay to the recombinant CHO cell overexpressing mouse AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 8 viser bindingsaktiviteten til forskjellige humane, monoklonale antihumant AILIM-antistoffer eller humane, monoklonale, anti-KLH-antistoffer som negativ kontroll overfor rekombinante CHO-celler som overuttrykker muse-AILIM eller villtype-CHO-celler. </span>Figure 8 shows the binding activity of various human monoclonal anti-human AILIM antibodies or human monoclonal anti-KLH antibodies as negative control to recombinant CHO cells overexpressing mouse AILIM or wild-type CHO cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir fluorescensintensiteten som et ml p bindingsaktiviteten til de rekombinante cellene, og den horisontale akse angir konsentrasjonen av det tilsatte antistoff. </span>The vertical axis indicates the fluorescence intensity as a measure of the binding activity of the recombinant cells, and the horizontal axis indicates the concentration of the added antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Begrepet "CHO" i figuren angir resultatet fra en bindingsanalyse til villtype-CHO-cellen, og "mus" angir resultatet fra en bindingsanalyse til den rekombinante CHO-celle som overuttrykker muse-AILIM. </span>The term "CHO" in the figure denotes the result of a binding assay to the wild-type CHO cell, and "mouse" denotes the result of a binding assay to the recombinant CHO cell overexpressing mouse AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 9 viser bindingsaktiviteten til forskjellige humane, monoklonale antihumant AILIM-antistoffer overfor rekombinante CHO-celler som overuttrykker muse-AILIM eller villtype-CHO-celler. </span>Figure 9 shows the binding activity of various human monoclonal anti-human AILIM antibodies to recombinant CHO cells overexpressing mouse AILIM or wild-type CHO cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir fluorescensintensiteten som et ml p bindingsaktiviteten til de rekombinante cellene, og den horisontale akse angir konsentrasjonen av det tilsatte antistoff. </span>The vertical axis indicates the fluorescence intensity as a measure of the binding activity of the recombinant cells, and the horizontal axis indicates the concentration of the added antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Begrepet "CHO" i figuren angir resultatet fra en bindingsanalyse til villtype-CHO-cellen, og "mus" angir resultatet fra en bindingsanalyse til den rekombinante CHO-celle som overuttrykker muse-AILIM. </span>The term "CHO" in the figure denotes the result of a binding assay to the wild-type CHO cell, and "mouse" denotes the result of a binding assay to the recombinant CHO cell overexpressing mouse AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 10 viser bindingsaktiviteten til forskjellige humane, monoklonale antihumant AILIM-antistoffer overfor rekombinante CHO-celler som overuttrykker muse-AILIM eller villtype-CHO-celler. </span>Figure 10 shows the binding activity of various human monoclonal anti-human AILIM antibodies to recombinant CHO cells overexpressing mouse AILIM or wild-type CHO cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir fluorescensintensiteten som et ml p bindingsaktiviteten til de rekombinante cellene, og den horisontale akse angir konsentrasjonen av det tilsatte antistoff. </span>The vertical axis indicates the fluorescence intensity as a measure of the binding activity of the recombinant cells, and the horizontal axis indicates the concentration of the added antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Begrepet "CHO" i figuren angir resultatet fra en bindingsanalyse til villtype-CHO-cellen, og "mus" angir resultatet fra en bindingsanalyse til den rekombinante CHO-celle som overuttrykker muse-AILIM. </span>The term "CHO" in the figure denotes the result of a binding assay to the wild-type CHO cell, and "mouse" denotes the result of a binding assay to the recombinant CHO cell overexpressing mouse AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 11 viser bindingsaktiviteten til forskjellige monoklonale, antirotte-AILIM-antistoffer fra mus overfor rekombinante CHO-celler som overuttrykker rotte-AILIM eller villtype-CHO-celler. </span>Figure 11 shows the binding activity of various mouse anti-rat AILIM monoclonal antibodies to recombinant CHO cells overexpressing rat AILIM or wild-type CHO cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir fluorescensintensiteten som et ml p bindingsaktiviteten til de rekombinante cellene, og den horisontale akse angir konsentrasjonen av det tilsatte antistoff. </span>The vertical axis indicates the fluorescence intensity as a measure of the binding activity of the recombinant cells, and the horizontal axis indicates the concentration of the added antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Begrepet "CHO" i figuren angir resultatet fra en bindingsanalyse til villtype-CHO-cellen, og "rotte" angir resultatet fra en bindingsanalyse til den rekombinante CHO-celle som overuttrykker rotte-AILIM. </span>The term "CHO" in the figure denotes the result of a binding assay to the wild-type CHO cell, and "rat" denotes the result of a binding assay to the recombinant CHO cell overexpressing rat AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 12 viser bindingsaktiviteten til forskjellige humane, monoklonale antihumant AILIM-antistoffer eller humane, monoklonale, anti-KLH-antistoffer som negativ kontroll overfor rekombinante CHO-celler som overuttrykker rotte-AILIM eller villtype-CHO-celler. </span>Figure 12 shows the binding activity of various human monoclonal anti-human AILIM antibodies or human monoclonal anti-KLH antibodies as a negative control to recombinant CHO cells overexpressing rat AILIM or wild-type CHO cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir fluorescensintensiteten som et ml p bindingsaktiviteten til de rekombinante cellene, og den horisontale akse angir konsentrasjonen av det tilsatte antistoff. </span>The vertical axis indicates the fluorescence intensity as a measure of the binding activity of the recombinant cells, and the horizontal axis indicates the concentration of the added antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Begrepet "CHO" i figuren angir resultatet fra en bindingsanalyse til villtype-CHO-cellen, og "rotte" angir resultatet fra en bindingsanalyse til den rekombinante CHO-celle som overuttrykker rotte-AILIM. </span>The term "CHO" in the figure denotes the result of a binding assay to the wild-type CHO cell, and "rat" denotes the result of a binding assay to the recombinant CHO cell overexpressing rat AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 13 viser bindingsaktiviteten til forskjellige humane, monoklonale antihumant AILIM-antistoffer overfor rekombinante CHO-celler som overuttrykker rotte-AILIM eller villtype-CHO-celler. </span>Figure 13 shows the binding activity of various human monoclonal anti-human AILIM antibodies to recombinant CHO cells overexpressing rat AILIM or wild-type CHO cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir fluorescensintensiteten som et ml p bindingsaktiviteten til de rekombinante cellene, og den horisontale akse angir konsentrasjonen av det tilsatte antistoff. </span>The vertical axis indicates the fluorescence intensity as a measure of the binding activity of the recombinant cells, and the horizontal axis indicates the concentration of the added antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Begrepet "CHO" i figuren angir resultatet fra en bindingsanalyse til villtype-CHO-cellen, og "rotte" angir resultatet fra en bindingsanalyse til den rekombinante CHO-celle som overuttrykker rotte-AILIM. </span>The term "CHO" in the figure denotes the result of a binding assay to the wild-type CHO cell, and "rat" denotes the result of a binding assay to the recombinant CHO cell overexpressing rat AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 14 viser bindingsaktiviteten til forskjellige </span>Figure 14 shows the binding activity of different</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">humane, monoklonale antihumant AILIM-antistoffer overfor rekombinante CHO-celler som overuttrykker rotte-AILIM eller villtype-CHO-celler. </span>human monoclonal anti-human AILIM antibodies to recombinant CHO cells overexpressing rat AILIM or wild-type CHO cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir fluorescensintensiteten som et ml p bindingsaktiviteten til de rekombinante cellene, og den horisontale akse angir konsentrasjonen av det tilsatte antistoff. </span>The vertical axis indicates the fluorescence intensity as a measure of the binding activity of the recombinant cells, and the horizontal axis indicates the concentration of the added antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Begrepet "CHO" i figuren angir resultatet fra en bindingsanalyse til villtype-CHO-cellen, og "rotte" angir resultatet fra en bindingsanalyse til den rekombinante CHO-celle som overuttrykker rotte-AILIM. </span>The term "CHO" in the figure denotes the result of a binding assay to the wild-type CHO cell, and "rat" denotes the result of a binding assay to the recombinant CHO cell overexpressing rat AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 15 viser proliferasjonsaktiviteten til T-celler avledet fra en normal, frisk person, "donor A", i en analyse av virkningen av forskjellige monoklonale, antihumant AILIM-antistoffer fra mus p overfringen av det kostimulerende signal, ved anvendelse av en mikroplate belagt med monoklonalt, antihumant CD3-antistoff sammen med monoklonalt, antihumant AILIM-antistoff fra mus. </span>Figure 15 shows the proliferative activity of T cells derived from a normal, healthy individual, "donor A", in an analysis of the effect of various mouse anti-human AILIM monoclonal antibodies on the transmission of the costimulatory signal, using a microplate coated with monoclonal anti-human CD3 antibody together with mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av monoklonalt, antihumant AILIM-antistoff fra mus. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 16 viser proliferasjonsaktiviteten til T-celler avledet fra en normal, frisk person, "donor A", i en analyse av virkningen av forskjellige monoklonale, antihumant AILIM-antistoffer p overfringen av det kostimulerende signal, ved anvendelse av en mikroplate belagt med monoklonalt, antihumant CD3-antistoff sammen med humant, monoklonalt, antihumant AILIM-antistoff. </span>Figure 16 shows the proliferative activity of T cells derived from a normal, healthy individual, "donor A", in an analysis of the effect of different monoclonal anti-human AILIM antibodies on the transmission of the costimulatory signal, using a microplate coated with monoclonal, antihuman CD3 antibody together with human monoclonal antihuman AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [ 1H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av humant, monoklonalt, antihumant AILIM-antistoff. </span>The vertical axis indicates the amount of cellular incorporation of [  1 H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 17 viser proliferasjonsaktiviteten til T-celler avledet fra en normal, frisk person, "donor B", i en analyse av virkningen av forskjellige monoklonale, antihumant AILIM-antistoffer fra mus p overfringen av det kostimulerende signal, ved anvendelse av en mikroplate belagt med monoklonalt, antihumant CD3-antistoff sammen med monoklonalt, antihumant AILIM-antistoff fra mus. </span>Figure 17 shows the proliferative activity of T cells derived from a normal, healthy individual, "donor B", in an analysis of the effect of various mouse anti-human AILIM monoclonal antibodies on the transmission of the costimulatory signal, using a microplate coated with monoclonal anti-human CD3 antibody together with mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av monoklonalt, antihumant AILIM-antistoff fra mus. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "JHC1" resultatet av en analyse hvor monoklonalt, antihumant CETP-antistoff ble anvendt som negativ kontroll i stedet for det monoklonale, antihumant AILIM-antistoff fra mus. </span>In this figure, "JHC1" indicates the result of an assay in which the monoclonal anti-human CETP antibody was used as a negative control in place of the monoclonal anti-human AILIM antibody from mouse.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 18 viser proliferasjonsaktiviteten til T-celler avledet fra en normal, frisk person, "donor B", i en analyse av virkningen av forskjellige humane, monoklonale antihumant AILIM-antistoffer p overfringen av det kostimulerende signal, ved anvendelse av en mikroplate belagt med monoklonalt, antihumant CD3-antistoff sammen med humant, monoklonalt, antihumant AILIM-antistoff. </span>Figure 18 shows the proliferative activity of T cells derived from a normal healthy person, "donor B", in an analysis of the effect of different human monoclonal anti-human AILIM antibodies on the transmission of the costimulatory signal, using a microplate coated with monoclonal , anti-human CD3 antibody together with human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av humant, monoklonalt, antihumant AILIM-antistoff. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "anti-KLH" resultatet av en analyse hvor humant, monoklonalt, anti-KLH-antistoff ble anvendt som negativ kontroll i stedet for det humane, monoklonale antihumant AILIM-antistoff. </span>In this figure, "anti-KLH" indicates the result of an assay in which human monoclonal anti-KLH antibody was used as a negative control in place of the human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 19 viser proliferasjonsaktiviteten til T-celler avledet fra en normal, frisk person, "donor B", i en analyse av virkningen av forskjellige humane, monoklonale antihumant AILIM-antistoffer p overfringen av det kostimulerende signal, ved anvendelse av en mikroplate belagt med monoklonalt, antihumant CD3-antistoff sammen med humant, monoklonalt, antihumant AILIM-antistoff. </span>Figure 19 shows the proliferative activity of T cells derived from a normal healthy person, "donor B", in an analysis of the effect of different human monoclonal anti-human AILIM antibodies on the transmission of the costimulatory signal, using a microplate coated with monoclonal , anti-human CD3 antibody together with human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av humant, monoklonalt, antihumant AILIM-antistoff. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "anti-KLH" resultatet av en analyse hvor humant, monoklonalt, anti-KLH-antistoff ble anvendt som negativ kontroll i stedet for det humane, monoklonale antihumant AILIM-antistoff. </span>In this figure, "anti-KLH" indicates the result of an assay in which human monoclonal anti-KLH antibody was used as a negative control in place of the human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 20 viser proliferasjonsaktiviteten til T-celler avledet fra en normal, frisk person, "donor C", i en analyse av virkningen av forskjellige monoklonale, antihumant AILIM-antistoffer fra mus p overfringen av det kostimulerende signal, ved anvendelse av en mikroplate belagt med monoklonalt, antihumant CD3-antistoff sammen med monoklonalt, antihumant AILIM-antistoff fra mus. </span>Figure 20 shows the proliferative activity of T cells derived from a normal, healthy individual, "donor C", in an analysis of the effect of various mouse anti-human AILIM monoclonal antibodies on the transmission of the costimulatory signal, using a microplate coated with monoclonal anti-human CD3 antibody together with mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av monoklonalt, antihumant AILIM-antistoff fra mus. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "JHC1" resultatet av en analyse hvor monoklonalt, antihumant CETP-antistoff ble anvendt som negativ kontroll i stedet for det monoklonale, antihumant AILIM-antistoff fra mus. </span>In this figure, "JHC1" indicates the result of an assay in which the monoclonal anti-human CETP antibody was used as a negative control in place of the monoclonal anti-human AILIM antibody from mouse.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 21 viser proliferasjonsaktiviteten til T-celler avledet fra en normal, frisk person, "donor C", i en analyse av virkningen av forskjellige humane, monoklonale antihumant AILIM-antistoffer p overfringen av det kostimulerende signal, ved anvendelse av en mikroplate belagt med monoklonalt, antihumant CD3-antistoff sammen med humant, monoklonalt, antihumant AILIM-antistoff. </span>Figure 21 shows the proliferative activity of T cells derived from a normal healthy individual, "donor C", in an analysis of the effect of different human monoclonal anti-human AILIM antibodies on the transmission of the costimulatory signal, using a microplate coated with monoclonal , anti-human CD3 antibody together with human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av humant, monoklonalt, antihumant AILIM-antistoff. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "anti-KLH" resultatet av en analyse hvor humant, monoklonalt, anti-KLH-antistoff ble anvendt som negativ kontroll i stedet for det humane, monoklonale antihumant AILIM-antistoff. </span>In this figure, "anti-KLH" indicates the result of an assay in which human monoclonal anti-KLH antibody was used as a negative control in place of the human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"124": humant, monoklonalt, antihumant AILIM-antistoff, JMabl24. </span>"124": human, monoclonal, anti-human AILIM antibody, JMabl24.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"126": humant, monoklonalt, antihumant AILIM-antistoff, JMabl26. </span>"126": human, monoclonal, anti-human AILIM antibody, JMabl26.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"127": humant, monoklonalt, antihumant AILIM-antistoff, JMabl27. </span>"127": human, monoclonal, anti-human AILIM antibody, JMabl27.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 22 viser proliferasjonsaktiviteten til T-celler avledet fra en normal, frisk person, "donor C", i en analyse av virkningen av forskjellige humane, monoklonale antihumant AILIM-antistoffer p overfringen av det kostimulerende signal, ved anvendelse av en mikroplate belagt med monoklonalt, antihumant CD3-antistoff sammen med humant, monoklonalt, antihumant AILIM-antistoff. </span>Figure 22 shows the proliferative activity of T cells derived from a normal healthy individual, "donor C", in an analysis of the effect of different human monoclonal anti-human AILIM antibodies on the transmission of the costimulatory signal, using a microplate coated with monoclonal , anti-human CD3 antibody together with human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av humant, monoklonalt, antihumant AILIM-antistoff. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "anti-KLH" resultatet av en analyse hvor humant, monoklonalt, anti-KLH-antistoff ble anvendt som negativ kontroll i stedet for det humane, monoklonale antihumant AILIM-antistoff. </span>In this figure, "anti-KLH" indicates the result of an assay in which human monoclonal anti-KLH antibody was used as a negative control in place of the human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"128": humant, monoklonalt, antihumant AILIM-antistoff, JMabl28. </span>"128": human, monoclonal, anti-human AILIM antibody, JMabl28.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"135": humant, monoklonalt, antihumant AILIM-antistoff, JMabl35. </span>"135": human, monoclonal, anti-human AILIM antibody, JMabl35.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"136": humant, monoklonalt, antihumant AILIM-antistoff, JMabl36. </span>"136": human, monoclonal, anti-human AILIM antibody, JMabl36.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 23 viser proliferasjonsaktiviteten til T-celler avledet fra en normal, frisk person, "donor C", i en analyse av virkningen av forskjellige humane, monoklonale antihumant AILIM-antistoffer p overfringen av det kostimulerende signal, ved anvendelse av en mikroplate belagt med monoklonalt, antihumant CD3-antistoff sammen med humant, monoklonalt, antihumant AILIM-antistoff. </span>Figure 23 shows the proliferative activity of T cells derived from a normal, healthy individual, "donor C", in an analysis of the effect of different human monoclonal anti-human AILIM antibodies on the transmission of the costimulatory signal, using a microplate coated with monoclonal , anti-human CD3 antibody together with human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av humant, monoklonalt, antihumant AILIM-antistoff. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "anti-KLH" resultatet av en analyse hvor humant, monoklonalt, anti-KLH-antistoff ble anvendt som negativ kontroll i stedet for det humane, monoklonale antihumant AILIM-antistoff. </span>In this figure, "anti-KLH" indicates the result of an assay in which human monoclonal anti-KLH antibody was used as a negative control in place of the human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"137": humant, monoklonalt, antihumant AILIM-antistoff, JMabl37. </span>"137": human, monoclonal, anti-human AILIM antibody, JMabl37.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"138": humant, monoklonalt, antihumant AILIM-antistoff, JMabl38. </span>"138": human, monoclonal, anti-human AILIM antibody, JMabl38.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"139": humant, monoklonalt, antihumant AILIM-antistoff, JMabl39. </span>"139": human, monoclonal, anti-human AILIM antibody, JMabl39.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 24 viser proliferasjonsaktiviteten til T-celler avledet fra en normal, frisk person, "donor C", i en analyse av virkningen av forskjellige humane, monoklonale antihumant AILIM-antistoffer p overfringen av det kostimulerende signal, ved anvendelse av en mikroplate belagt med monoklonalt, antihumant CD3-antistoff sammen med humant, monoklonalt, antihumant AILIM-antistoff. </span>Figure 24 shows the proliferative activity of T cells derived from a normal healthy individual, "donor C", in an analysis of the effect of different human monoclonal anti-human AILIM antibodies on the transmission of the costimulatory signal, using a microplate coated with monoclonal , anti-human CD3 antibody together with human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av humant, monoklonalt, antihumant AILIM-antistoff. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "anti-KLH" resultatet av en analyse hvor humant, monoklonalt, anti-KLH-antistoff ble anvendt som negativ kontroll i stedet for det humane, monoklonale antihumant AILIM-antistoff. </span>In this figure, "anti-KLH" indicates the result of an assay in which human monoclonal anti-KLH antibody was used as a negative control in place of the human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"140": humant, monoklonalt, antihumant AILIM-antistoff, JMabl40. </span>"140": human, monoclonal, anti-human AILIM antibody, JMabl40.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"141": humant, monoklonalt, antihumant AILIM-antistoff, JMabl41. </span>"141": human monoclonal anti-human AILIM antibody, JMabl41.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 25 viser proliferasjonsaktiviteten til T-celler avledet fra en normal, frisk person, "donor D", i en analyse av virkningen av forskjellige monoklonale, antihumant AILIM-antistoffer fra mus p overfringen av det kostimulerende signal, ved anvendelse av en mikroplate belagt med monoklonalt, antihumant CD3-antistoff sammen med monoklonalt, antihumant AILIM-antistoff fra mus. </span>Figure 25 shows the proliferative activity of T cells derived from a normal healthy individual, "donor D", in an analysis of the effect of different mouse anti-human AILIM monoclonal antibodies on the transmission of the costimulatory signal, using a microplate coated with monoclonal anti-human CD3 antibody together with mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av monoklonalt, antihumant AILIM-antistoff fra mus. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "JHC1" resultatet av en analyse hvor monoklonalt, antihumant CETP-antistoff ble anvendt som negativ kontroll i stedet for det monoklonale, antihumant AILIM-antistoff fra mus. </span>In this figure, "JHC1" indicates the result of an assay in which the monoclonal anti-human CETP antibody was used as a negative control in place of the monoclonal anti-human AILIM antibody from mouse.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 26 viser proliferasjonsaktiviteten til T-celler avledet fra en normal, frisk person, "donor D", i en analyse av virkningen av forskjellige humane, monoklonale antihumant AILIM-antistoffer p overfringen av det kostimulerende signal, ved anvendelse av en mikroplate belagt med monoklonalt, antihumant CD3-antistoff sammen med humant, monoklonalt, antihumant AILIM-antistoff. </span>Figure 26 shows the proliferative activity of T cells derived from a normal healthy individual, "donor D", in an analysis of the effect of different human monoclonal anti-human AILIM antibodies on the transmission of the costimulatory signal, using a microplate coated with monoclonal , anti-human CD3 antibody together with human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av humant, monoklonalt, antihumant AILIM-antistoff. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "anti-KLH" resultatet av en analyse hvor humant, monoklonalt, anti-KLH-antistoff ble anvendt som negativ kontroll i stedet for det humane, monoklonale antihumant AILIM-antistoff. </span>In this figure, "anti-KLH" indicates the result of an assay in which human monoclonal anti-KLH antibody was used as a negative control in place of the human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"124": humant, monoklonalt, antihumant AILIM-antistoff, JMabl24. </span>"124": human, monoclonal, anti-human AILIM antibody, JMabl24.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"126": humant, monoklonalt, antihumant AILIM-antistoff, JMabl26. </span>"126": human, monoclonal, anti-human AILIM antibody, JMabl26.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"127": humant, monoklonalt, antihumant AILIM-antistoff, JMabl27. </span>"127": human, monoclonal, anti-human AILIM antibody, JMabl27.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 27 viser proliferasjonsaktiviteten til T-celler avledet fra en normal, frisk person, "donor D", i en analyse av virkningen av forskjellige humane, monoklonale antihumant AILIM-antistoffer p overfringen av det kostimulerende signal, ved anvendelse av en mikroplate belagt med monoklonalt, antihumant CD3-antistoff sammen med humant, monoklonalt, antihumant AILIM-antistoff. </span>Figure 27 shows the proliferative activity of T cells derived from a normal healthy individual, "donor D", in an analysis of the effect of different human monoclonal anti-human AILIM antibodies on the transmission of the costimulatory signal, using a microplate coated with monoclonal , anti-human CD3 antibody together with human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av monoklonalt, antihumant AILIM-antistoff fra mus. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "anti-KLH" resultatet av en analyse hvor humant, monoklonalt, anti-KLH-antistoff ble anvendt som negativ kontroll i stedet for det humane, monoklonale antihumant AILIM-antistoff. </span>In this figure, "anti-KLH" indicates the result of an assay in which human monoclonal anti-KLH antibody was used as a negative control in place of the human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"128": humant, monoklonalt, antihumant AILIM-antistoff, JMabl28. </span>"128": human, monoclonal, anti-human AILIM antibody, JMabl28.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"135": humant, monoklonalt, antihumant AILIM-antistoff, JMabl35. </span>"135": human, monoclonal, anti-human AILIM antibody, JMabl35.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"136": humant, monoklonalt, antihumant AILIM-antistoff, JMabl36. </span>"136": human, monoclonal, anti-human AILIM antibody, JMabl36.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 28 viser proliferasjonsaktiviteten til T-celler avledet fra en normal, frisk person, "donor D", i en analyse av virkningen av forskjellige humane, monoklonale antihumant AILIM-antistoffer p overfringen av det kostimulerende signal, ved anvendelse av en mikroplate belagt med monoklonalt, antihumant CD3-antistoff sammen med humant, monoklonalt, antihumant AILIM-antistoff. </span>Figure 28 shows the proliferative activity of T cells derived from a normal, healthy individual, "donor D", in an analysis of the effect of different human monoclonal anti-human AILIM antibodies on the transmission of the costimulatory signal, using a microplate coated with monoclonal , anti-human CD3 antibody together with human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [ 1H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av humant, monoklonalt, antihumant AILIM-antistoff. </span>The vertical axis indicates the amount of cellular incorporation of [  1 H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "anti-KLH" resultatet av en analyse hvor humant, monoklonalt, anti-KLH-antistoff ble anvendt som negativ kontroll i stedet for det humane, monoklonale antihumant AILIM-antistoff. </span>In this figure, "anti-KLH" indicates the result of an assay in which human monoclonal anti-KLH antibody was used as a negative control in place of the human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"137": humant, monoklonalt, antihumant AILIM-antistoff, JMabl37. </span>"137": human, monoclonal, anti-human AILIM antibody, JMabl37.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"138": humant, monoklonalt, antihumant AILIM-antistoff, JMabl38. </span>"138": human, monoclonal, anti-human AILIM antibody, JMabl38.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"139": humant, monoklonalt, antihumant AILIM-antistoff, JMabl39. </span>"139": human, monoclonal, anti-human AILIM antibody, JMabl39.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 29 viser proliferasjonsaktiviteten til T-celler avledet fra en normal, frisk person, "donor D", i en analyse av virkningen av forskjellige humane, monoklonale antihumant AILIM-antistoffer p overfringen av det kostimulerende signal, ved anvendelse av en mikroplate belagt med monoklonalt, antihumant CD3-antistoff sammen med humant, monoklonalt, antihumant AILIM-antistoff. </span>Figure 29 shows the proliferative activity of T cells derived from a normal, healthy individual, "donor D", in an analysis of the effect of different human monoclonal anti-human AILIM antibodies on the transmission of the costimulatory signal, using a microplate coated with monoclonal , anti-human CD3 antibody together with human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av humant, monoklonalt, antihumant AILIM-antistoff. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "anti-KLH" resultatet av en analyse hvor humant, monoklonalt, anti-KLH-antistoff ble anvendt som negativ kontroll i stedet for det humane, monoklonale antihumant AILIM-antistoff. </span>In this figure, "anti-KLH" indicates the result of an assay in which human monoclonal anti-KLH antibody was used as a negative control in place of the human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"140": humant, monoklonalt, antihumant AILIM-antistoff, JMabl40. </span>"140": human, monoclonal, anti-human AILIM antibody, JMabl40.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"141": humant, monoklonalt, antihumant AILIM-antistoff, JMabl41. </span>"141": human monoclonal anti-human AILIM antibody, JMabl41.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 30 viser proliferasjonsaktiviteten til T-celler avledet fra en normal, frisk person, "donor E", i en analyse av virkningen av forskjellige monoklonale, antihumant AILIM-antistoffer fra mus p overfringen av det kostimulerende signal, ved anvendelse av en mikroplate belagt med monoklonalt, antihumant CD3-antistoff sammen med monoklonalt, antihumant AILIM-antistoff fra mus. </span>Figure 30 shows the proliferative activity of T cells derived from a normal healthy individual, "donor E", in an analysis of the effect of different mouse anti-human AILIM monoclonal antibodies on the transmission of the costimulatory signal, using a microplate coated with monoclonal anti-human CD3 antibody together with mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av monoklonalt, antihumant AILIM-antistoff fra mus. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "JHC1" resultatet av en analyse hvor monoklonalt, antihumant CETP-antistoff ble anvendt som negativ kontroll i stedet for det monoklonale, antihumant AILIM-antistoff fra mus. </span>In this figure, "JHC1" indicates the result of an assay in which the monoclonal anti-human CETP antibody was used as a negative control in place of the monoclonal anti-human AILIM antibody from mouse.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 31 viser proliferasjonsaktiviteten til T-celler avledet fra en normal, frisk person, "donor E", i en analyse av virkningen av forskjellige humane, monoklonale antihumant AILIM-antistoffer p overfringen av det kostimulerende signal, ved anvendelse av en mikroplate belagt med monoklonalt, antihumant CD3-antistoff sammen med humant, monoklonalt, antihumant AILIM-antistoff. </span>Figure 31 shows the proliferative activity of T cells derived from a normal healthy individual, "donor E", in an analysis of the effect of different human monoclonal anti-human AILIM antibodies on the transmission of the costimulatory signal, using a microplate coated with monoclonal , anti-human CD3 antibody together with human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av humant, monoklonalt, antihumant AILIM-antistoff. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "anti-KLH" resultatet av en analyse hvor humant, monoklonalt, anti-KLH-antistoff ble anvendt som negativ kontroll i stedet for det humane, monoklonale antihumant AILIM-antistoff. </span>In this figure, "anti-KLH" indicates the result of an assay in which human monoclonal anti-KLH antibody was used as a negative control in place of the human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"124": humant, monoklonalt, antihumant AILIM-antistoff, JMabl24. </span>"124": human, monoclonal, anti-human AILIM antibody, JMabl24.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"126": humant, monoklonalt, antihumant AILIM-antistoff, JMabl26. </span>"126": human, monoclonal, anti-human AILIM antibody, JMabl26.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"127": humant, monoklonalt, antihumant AILIM-antistoff, JMabl27. </span>"127": human, monoclonal, anti-human AILIM antibody, JMabl27.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 32 viser proliferasjonsaktiviteten til T-celler avledet fra en normal, frisk person, "donor E", i en analyse av virkningen av forskjellige humane, monoklonale antihumant AILIM-antistoffer p overfringen av det kostimulerende signal, ved anvendelse av en mikroplate belagt med monoklonalt, antihumant CD3-antistoff sammen med humant, monoklonalt, antihumant AILIM-antistoff. </span>Figure 32 shows the proliferative activity of T cells derived from a normal, healthy individual, "donor E", in an analysis of the effect of different human monoclonal anti-human AILIM antibodies on the transmission of the costimulatory signal, using a microplate coated with monoclonal , anti-human CD3 antibody together with human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av humant, monoklonalt, antihumant AILIM-antistoff. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "anti-KLH" resultatet av en analyse hvor humant, monoklonalt, anti-KLH-antistoff ble anvendt som negativ kontroll i stedet for det humane, monoklonale antihumant AILIM-antistoff. </span>In this figure, "anti-KLH" indicates the result of an assay in which human monoclonal anti-KLH antibody was used as a negative control in place of the human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"128": humant, monoklonalt, antihumant AILIM-antistoff, JMabl28. </span>"128": human, monoclonal, anti-human AILIM antibody, JMabl28.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"135": humant, monoklonalt, antihumant AILIM-antistoff, JMabl35. </span>"135": human, monoclonal, anti-human AILIM antibody, JMabl35.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"136": humant, monoklonalt, antihumant AILIM-antistoff, JMabl36. </span>"136": human, monoclonal, anti-human AILIM antibody, JMabl36.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 33 viser proliferasjonsaktiviteten til T-celler avledet fra en normal, frisk person, "donor E", i en analyse av virkningen av forskjellige humane, monoklonale antihumant AILIM-antistoffer p overfringen av det kostimulerende signal, ved anvendelse av en mikroplate belagt med monoklonalt, antihumant CD3-antistoff sammen med humant, monoklonalt, antihumant AILIM-antistoff. </span>Figure 33 shows the proliferative activity of T cells derived from a normal healthy individual, "donor E", in an analysis of the effect of different human monoclonal anti-human AILIM antibodies on the transmission of the costimulatory signal, using a microplate coated with monoclonal , anti-human CD3 antibody together with human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av humant, monoklonalt, antihumant AILIM-antistoff. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "anti-KLH" resultatet av en analyse hvor humant, monoklonalt, anti-KLH-antistoff ble anvendt som negativ kontroll i stedet for det humane, monoklonale antihumant AILIM-antistoff. </span>In this figure, "anti-KLH" indicates the result of an assay in which human monoclonal anti-KLH antibody was used as a negative control in place of the human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"137": humant, monoklonalt, antihumant AILIM-antistoff, JMabl37. </span>"137": human, monoclonal, anti-human AILIM antibody, JMabl37.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"138": humant, monoklonalt, antihumant AILIM-antistoff, JMabl38. </span>"138": human, monoclonal, anti-human AILIM antibody, JMabl38.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"139": humant, monoklonalt, antihumant AILIM-antistoff, JMabl39. </span>"139": human, monoclonal, anti-human AILIM antibody, JMabl39.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 34 viser proliferasjonsaktiviteten til T-celler avledet fra en normal, frisk person, "donor E", i en analyse av virkningen av forskjellige humane, monoklonale antihumant AILIM-antistoffer p overfringen av det kostimulerende signal, ved anvendelse av en mikroplate belagt med monoklonalt, antihumant CD3-antistoff sammen med humant, monoklonalt, antihumant AILIM-antistoff. </span>Figure 34 shows the proliferative activity of T cells derived from a normal healthy individual, "donor E", in an analysis of the effect of different human monoclonal anti-human AILIM antibodies on the transmission of the costimulatory signal, using a microplate coated with monoclonal , anti-human CD3 antibody together with human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av humant, monoklonalt, antihumant AILIM-antistoff. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "anti-KLH" resultatet av en analyse hvor humant, monoklonalt, anti-KLH-antistoff ble anvendt som negativ kontroll i stedet for det humane, monoklonale antihumant AILIM-antistoff. </span>In this figure, "anti-KLH" indicates the result of an assay in which human monoclonal anti-KLH antibody was used as a negative control in place of the human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"140": humant, monoklonalt, antihumant AILIM-antistoff, JMabl40. </span>"140": human, monoclonal, anti-human AILIM antibody, JMabl40.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"141": humant, monoklonalt, antihumant AILIM-antistoff, JMabl41. </span>"141": human monoclonal anti-human AILIM antibody, JMabl41.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 35 viser proliferasjonsaktiviteten til T-celler avledet fra en normal, frisk person, "donor D", i en analyse av virkningen av forskjellige monoklonale, antihumant AILIM-antistoffer fra mus p overfringen av det kostimulerende signal nr en lsning av monoklonalt, antihumant AILIM-antistoff fra mus (i vskefase) ble tilsatt alene til en mikroplate belagt med monoklonalt, antihumant CD3-antistoff. </span>Figure 35 shows the proliferative activity of T cells derived from a normal healthy individual, "donor D", in an analysis of the effect of different mouse monoclonal anti-human AILIM antibodies on the transmission of the costimulatory signal when a solution of monoclonal anti-human AILIM -antibody from mouse (in liquid phase) was added alone to a microplate coated with monoclonal anti-human CD3 antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av monoklonalt, antihumant AILIM-antistoff fra mus. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "JHC1" resultatet av en analyse hvor monoklonalt, antihumant CETP-antistoff ble anvendt som negativ kontroll i stedet for det monoklonale, antihumant AILIM-antistoff fra mus. </span>In this figure, "JHC1" indicates the result of an assay in which the monoclonal anti-human CETP antibody was used as a negative control in place of the monoclonal anti-human AILIM antibody from mouse.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 36 viser proliferasjonsaktiviteten til T-celler avledet fra en normal, frisk person, "donor D", i en analyse av virkningen av forskjellige humane, monoklonale antihumant AILIM-antistoffer p overfringen av det kostimulerende signal nr en lsning av humant, monoklonalt, antihumant AILIM-antistoff (i vskefase) ble tilsatt alene til en mikroplate belagt med monoklonalt, antihumant CD3-antistoff. </span>Figure 36 shows the proliferative activity of T cells derived from a normal, healthy individual, "donor D", in an analysis of the effect of different human monoclonal anti-human AILIM antibodies on the transmission of the costimulatory signal when a solution of human, monoclonal, anti-human AILIM antibody (in liquid phase) was added alone to a microplate coated with monoclonal anti-human CD3 antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av humant, monoklonalt, antihumant AILIM-antistoff. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "anti-KLH" resultatet av en analyse hvor humant, monoklonalt, anti-KLH-antistoff ble anvendt som negativ kontroll i stedet for det humane, monoklonale antihumant AILIM-antistoff. </span>In this figure, "anti-KLH" indicates the result of an assay in which human monoclonal anti-KLH antibody was used as a negative control in place of the human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"124": humant, monoklonalt, antihumant AILIM-antistoff, JMabl24. </span>"124": human, monoclonal, anti-human AILIM antibody, JMabl24.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"125": humant, monoklonalt, antihumant AILIM-antistoff, JMabl25. </span>"125": human, monoclonal, anti-human AILIM antibody, JMabl25.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"126": humant, monoklonalt, antihumant AILIM-antistoff, JMabl26. </span>"126": human, monoclonal, anti-human AILIM antibody, JMabl26.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 37 viser proliferasjonsaktiviteten til T-celler avledet fra en normal, frisk person, "donor D", i en analyse av virkningen av forskjellige humane, monoklonale antihumant AILIM-antistoffer p overfringen av det kostimulerende signal nr en lsning av humant, monoklonalt, antihumant AILIM-antistoff (i vskefase) ble tilsatt alene til en mikroplate belagt med monoklonalt, antihumant CD3-antistoff. </span>Figure 37 shows the proliferative activity of T cells derived from a normal, healthy individual, "donor D", in an analysis of the effect of different human monoclonal anti-human AILIM antibodies on the transmission of the costimulatory signal when a solution of human, monoclonal, anti-human AILIM antibody (in liquid phase) was added alone to a microplate coated with monoclonal anti-human CD3 antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av humant, monoklonalt, antihumant AILIM-antistoff. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "anti-KLH" resultatet av en analyse hvor humant, monoklonalt, anti-KLH-antistoff ble anvendt som negativ kontroll i stedet for det humane, monoklonale antihumant AILIM-antistoff. </span>In this figure, "anti-KLH" indicates the result of an assay in which human monoclonal anti-KLH antibody was used as a negative control in place of the human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"128": humant, monoklonalt, antihumant AILIM-antistoff, JMabl28. </span>"128": human, monoclonal, anti-human AILIM antibody, JMabl28.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"135": humant, monoklonalt, antihumant AILIM-antistoff, JMabl35. </span>"135": human, monoclonal, anti-human AILIM antibody, JMabl35.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"136": humant, monoklonalt, antihumant AILIM-antistoff, JMabl36. </span>"136": human, monoclonal, anti-human AILIM antibody, JMabl36.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 38 viser proliferasjonsaktiviteten til T-celler avledet fra en normal, frisk person, "donor D", i en analyse av virkningen av forskjellige humane, monoklonale antihumant AILIM-antistoffer p overfringen av det kostimulerende signal nr en lsning av humant, monoklonalt, antihumant AILIM-antistoff (i vskefase) ble tilsatt alene til en mikroplate belagt med monoklonalt, antihumant CD3-antistoff. </span>Figure 38 shows the proliferative activity of T cells derived from a normal, healthy individual, "donor D", in an analysis of the effect of different human monoclonal anti-human AILIM antibodies on the transmission of the costimulatory signal when a solution of human, monoclonal, anti-human AILIM antibody (in liquid phase) was added alone to a microplate coated with monoclonal anti-human CD3 antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av humant, monoklonalt, antihumant AILIM-antistoff. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "anti-KLH" resultatet av en analyse hvor humant, monoklonalt, anti-KLH-antistoff ble anvendt som negativ kontroll i stedet for det humane, monoklonale antihumant AILIM-antistoff. </span>In this figure, "anti-KLH" indicates the result of an assay in which human monoclonal anti-KLH antibody was used as a negative control in place of the human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"137": humant, monoklonalt, antihumant AILIM-antistoff, JMabl37. </span>"137": human, monoclonal, anti-human AILIM antibody, JMabl37.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"138": humant, monoklonalt, antihumant AILIM-antistoff, JMabl38. </span>"138": human, monoclonal, anti-human AILIM antibody, JMabl38.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"139": humant, monoklonalt, antihumant AILIM-antistoff, JMabl39. </span>"139": human, monoclonal, anti-human AILIM antibody, JMabl39.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 39 viser proliferasjonsaktiviteten til T-celler avledet fra en normal, frisk person, "donor D", i en analyse av virkningen av forskjellige humane, monoklonale antihumant AILIM-antistoffer p overfringen av det kostimulerende signal nr en lsning av humant, monoklonalt, antihumant AILIM-antistoff (i vskefase) ble tilsatt alene til en mikroplate belagt med monoklonalt, antihumant CD3-antistoff. </span>Figure 39 shows the proliferative activity of T cells derived from a normal, healthy individual, "donor D", in an analysis of the effect of different human monoclonal anti-human AILIM antibodies on the transmission of the costimulatory signal when a solution of human, monoclonal, anti-human AILIM antibody (in liquid phase) was added alone to a microplate coated with monoclonal anti-human CD3 antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [ 1H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av humant, monoklonalt, antihumant AILIM-antistoff. </span>The vertical axis indicates the amount of cellular incorporation of [  1 H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "anti-KLH" resultatet av en analyse hvor humant, monoklonalt, anti-KLH-antistoff ble anvendt som negativ kontroll i stedet for det humane, monoklonale antihumant AILIM-antistoff. </span>In this figure, "anti-KLH" indicates the result of an assay in which human monoclonal anti-KLH antibody was used as a negative control in place of the human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"140": humant, monoklonalt, antihumant AILIM-antistoff, JMabl40. </span>"140": human, monoclonal, anti-human AILIM antibody, JMabl40.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"141": humant, monoklonalt, antihumant AILIM-antistoff, JMabl41. </span>"141": human monoclonal anti-human AILIM antibody, JMabl41.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 40 viser mengden IFN-y dannet i dyrkingssupernatanten fra T-celler avledet fra en normal, frisk person, "donor B", dyrket i en mikroplate belagt med monoklonalt, antihumant AILIM-antistoff fra mus sammen med monoklonalt, antihumant CD3-antistoff. </span>Figure 40 shows the amount of IFN- produced in the culture supernatant from T cells derived from a normal, healthy individual, "donor B", cultured in a microplate coated with mouse monoclonal anti-human AILIM antibody together with monoclonal anti-human CD3 antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir konsentrasjonen av IFN-y, og den horisontale akse angir konsentrasjonen av det monoklonale, antihumant AILIM-antistoff fra mus. </span>The vertical axis indicates the concentration of IFN-, and the horizontal axis indicates the concentration of the mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "JHC1" resultatet av en analyse hvor monoklonalt, antihumant CETP-antistoff ble anvendt som negativ kontroll i stedet for det monoklonale, antihumant AILIM-antistoff fra mus. </span>In this figure, "JHC1" indicates the result of an assay in which the monoclonal anti-human CETP antibody was used as a negative control in place of the monoclonal anti-human AILIM antibody from mouse.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 41 viser mengden IFN-y dannet i dyrkingssupernatanten fra T-celler avledet fra en normal, frisk person, "donor B", dyrket i en mikroplate belagt med humant, monoklonalt, antihumant AILIM-antistoff sammen med monoklonalt, antihumant CD3-antistoff. </span>Figure 41 shows the amount of IFN- produced in the culture supernatant from T cells derived from a normal, healthy individual, "donor B", cultured in a microplate coated with human monoclonal anti-human AILIM antibody together with monoclonal anti-human CD3 antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir konsentrasjonen av IFN-y, og den horisontale akse angir konsentrasjonen av det monoklonale, antihumant AILIM-antistoff fra mus. </span>The vertical axis indicates the concentration of IFN-, and the horizontal axis indicates the concentration of the mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "anti-KLH" resultatet av en analyse hvor humant, monoklonalt, anti-KLH-antistoff ble anvendt som negativ kontroll i stedet for det humane, monoklonale antihumant AILIM-antistoff. </span>In this figure, "anti-KLH" indicates the result of an assay in which human monoclonal anti-KLH antibody was used as a negative control in place of the human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 42 viser mengden IFN-y dannet i dyrkingssupernatanten fra T-celler avledet fra en normal, frisk person, "donor B", dyrket i en mikroplate belagt med humant, monoklonalt, antihumant AILIM-antistoff sammen med monoklonalt, antihumant CD3-antistoff. </span>Figure 42 shows the amount of IFN- produced in the culture supernatant from T cells derived from a normal, healthy individual, "donor B", cultured in a microplate coated with human monoclonal anti-human AILIM antibody together with monoclonal anti-human CD3 antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir konsentrasjonen av IFN-y, og den horisontale akse angir konsentrasjonen av det monoklonale, antihumant AILIM-antistoff fra mus. </span>The vertical axis indicates the concentration of IFN-, and the horizontal axis indicates the concentration of the mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "anti-KLH" resultatet av en analyse hvor humant, monoklonalt, anti-KLH-antistoff ble anvendt som negativ kontroll i stedet for det humane, monoklonale antihumant AILIM-antistoff. </span>In this figure, "anti-KLH" indicates the result of an assay in which human monoclonal anti-KLH antibody was used as a negative control in place of the human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 43 viser mengden IFN-y dannet i dyrkingssupernatanten fra T-celler avledet fra en normal, frisk person, "donor C", dyrket i en mikroplate belagt med monoklonalt, antihumant AILIM-antistoff fra mus sammen med monoklonalt, antihumant CD3-antistoff. </span>Figure 43 shows the amount of IFN- produced in the culture supernatant from T cells derived from a normal, healthy individual, "donor C", cultured in a microplate coated with mouse monoclonal anti-human AILIM antibody together with monoclonal anti-human CD3 antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir konsentrasjonen av IFN-y, og den horisontale akse angir konsentrasjonen av det monoklonale, antihumant AILIM-antistoff fra mus. </span>The vertical axis indicates the concentration of IFN-, and the horizontal axis indicates the concentration of the mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "JHC1" resultatet av en analyse hvor monoklonalt, antihumant CETP-antistoff ble anvendt som negativ kontroll i stedet for det monoklonale, antihumant AILIM-antistoff fra mus. </span>In this figure, "JHC1" indicates the result of an assay in which the monoclonal anti-human CETP antibody was used as a negative control in place of the monoclonal anti-human AILIM antibody from mouse.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 44 viser mengden IFN-y dannet i dyrkingssupernatanten fra T-celler avledet fra en normal, frisk person, "donor C", dyrket i en mikroplate belagt med humant, monoklonalt, antihumant AILIM-antistoff sammen med monoklonalt, antihumant CD3-antistoff. </span>Figure 44 shows the amount of IFN- produced in the culture supernatant from T cells derived from a normal, healthy individual, "donor C", cultured in a microplate coated with human monoclonal anti-human AILIM antibody together with monoclonal anti-human CD3 antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir konsentrasjonen av IFN-y, og den horisontale akse angir konsentrasjonen av det monoklonale, antihumant AILIM-antistoff fra mus. </span>The vertical axis indicates the concentration of IFN-, and the horizontal axis indicates the concentration of the mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "anti-KLH" resultatet av en analyse hvor humant, monoklonalt anti-KLH-antistoff ble anvendt som negativ kontroll i stedet for det humane, monoklonale antihumant AILIM-antistoff. </span>In this figure, "anti-KLH" indicates the result of an assay in which human monoclonal anti-KLH antibody was used as a negative control in place of the human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"124": humant, monoklonalt, antihumant AILIM-antistoff, JMabl24. </span>"124": human, monoclonal, anti-human AILIM antibody, JMabl24.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"125": humant, monoklonalt, antihumant AILIM-antistoff, JMabl25. </span>"125": human, monoclonal, anti-human AILIM antibody, JMabl25.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"126": humant, monoklonalt, antihumant AILIM-antistoff, JMabl26. </span>"126": human, monoclonal, anti-human AILIM antibody, JMabl26.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 45 viser mengden IFN-y dannet i dyrkingssupernatanten fra T-celler avledet fra en normal, frisk person, "donor C", dyrket i en mikroplate belagt med humant, monoklonalt, antihumant AILIM-antistoff sammen med monoklonalt, antihumant CD3-antistoff. </span>Figure 45 shows the amount of IFN- produced in the culture supernatant from T cells derived from a normal healthy person, "donor C", cultured in a microplate coated with human monoclonal anti-human AILIM antibody together with monoclonal anti-human CD3 antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir konsentrasjonen av IFN-y, og den horisontale akse angir konsentrasjonen av det monoklonale, antihumant AILIM-antistoff fra mus. </span>The vertical axis indicates the concentration of IFN-, and the horizontal axis indicates the concentration of the mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "anti-KLH" resultatet av en analyse hvor humant, monoklonalt anti-KLH-antistoff ble anvendt som negativ kontroll i stedet for det humane, monoklonale antihumant AILIM-antistoff. </span>In this figure, "anti-KLH" indicates the result of an assay in which human monoclonal anti-KLH antibody was used as a negative control in place of the human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"128": humant, monoklonalt, antihumant AILIM-antistoff, JMabl28. </span>"128": human, monoclonal, anti-human AILIM antibody, JMabl28.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"135": humant, monoklonalt, antihumant AILIM-antistoff, JMabl35. </span>"135": human, monoclonal, anti-human AILIM antibody, JMabl35.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"136": humant, monoklonalt, antihumant AILIM-antistoff, JMabl36. </span>"136": human, monoclonal, anti-human AILIM antibody, JMabl36.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 46 viser mengden IFN-y dannet i dyrkingssupernatanten fra T-celler avledet fra en normal, frisk person, "donor C", dyrket i en mikroplate belagt med humant, monoklonalt, antihumant AILIM-antistoff sammen med monoklonalt, antihumant CD3-antistoff. </span>Figure 46 shows the amount of IFN- produced in the culture supernatant from T cells derived from a normal, healthy individual, "donor C", cultured in a microplate coated with human monoclonal anti-human AILIM antibody together with monoclonal anti-human CD3 antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir konsentrasjonen av IFN-y, og den horisontale akse angir konsentrasjonen av det monoklonale, antihumant AILIM-antistoff fra mus. </span>The vertical axis indicates the concentration of IFN-, and the horizontal axis indicates the concentration of the mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "anti-KLH" resultatet av en analyse hvor humant, monoklonalt anti-KLH-antistoff ble anvendt som negativ kontroll i stedet for det humane, monoklonale antihumant AILIM-antistoff. </span>In this figure, "anti-KLH" indicates the result of an assay in which human monoclonal anti-KLH antibody was used as a negative control in place of the human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"137": humant, monoklonalt, antihumant AILIM-antistoff, JMabl37. </span>"137": human, monoclonal, anti-human AILIM antibody, JMabl37.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"138": humant, monoklonalt, antihumant AILIM-antistoff, JMabl38. </span>"138": human, monoclonal, anti-human AILIM antibody, JMabl38.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"139": humant, monoklonalt, antihumant AILIM-antistoff, JMabl39. </span>"139": human, monoclonal, anti-human AILIM antibody, JMabl39.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 47 viser mengden IFN-y dannet i dyrkingssupernatanten fra T-celler avledet fra en normal, frisk person, "donor C", dyrket i en mikroplate belagt med humant, monoklonalt, antihumant AILIM-antistoff sammen med monoklonalt, antihumant CD3-antistoff. </span>Figure 47 shows the amount of IFN- produced in the culture supernatant from T cells derived from a normal, healthy individual, "donor C", cultured in a microplate coated with human monoclonal anti-human AILIM antibody together with monoclonal anti-human CD3 antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir konsentrasjonen av IFN-y, og den horisontale akse angir konsentrasjonen av det monoklonale, antihumant AILIM-antistoff fra mus. </span>The vertical axis indicates the concentration of IFN-, and the horizontal axis indicates the concentration of the mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "anti-KLH" resultatet av en analyse hvor humant, monoklonalt anti-KLH-antistoff ble anvendt som negativ kontroll i stedet for det humane, monoklonale antihumant AILIM-antistoff. </span>In this figure, "anti-KLH" indicates the result of an assay in which human monoclonal anti-KLH antibody was used as a negative control in place of the human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"140": humant, monoklonalt, antihumant AILIM-antistoff, JMabl40. </span>"140": human, monoclonal, anti-human AILIM antibody, JMabl40.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"141": humant, monoklonalt, antihumant AILIM-antistoff, JMabl41. </span>"141": human monoclonal anti-human AILIM antibody, JMabl41.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 48 viser den inhiberende virkning p T-celleproliferasjonen ved dyrking av T-celler fra en normal, frisk person, "donor A", med PBMC fra en normal, frisk person, "donor D", ved forskjellige analyseprver i en proliferasjonsanalyse for T-celler via den blandede lymfocyttreaksjon (MLR). </span>Figure 48 shows the inhibitory effect on T-cell proliferation when culturing T-cells from a normal, healthy person, "donor A", with PBMC from a normal, healthy person, "donor D", at different assay samples in a proliferation assay for T -cells via the mixed lymphocyte reaction (MLR).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsnivet, og den horisontale akse viser konsentrasjonen av analyseprvene. </span>The vertical axis indicates the amount of incorporation of [&lt;3&gt;H]thymidine as a measure of the level of cell proliferation, and the horizontal axis shows the concentration of the assay samples.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Betegnelsene i figuren angir flgende: </span>The designations in the figure indicate the following:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"CD80 + 86": en blanding av anti-CD80-antistoff og anti-CD86-antistoff. "mlgGl": monoklonalt, antihumant CD34/IgGl-antistoff fra mus. </span>"CD80 + 86": a mixture of anti-CD80 antibody and anti-CD86 antibody. "mlgGl": mouse monoclonal anti-human CD34/IgGl antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"CTLA4-Ig": kimrt, humant CTLA4-IgFc-molekyl. </span>"CTLA4-Ig": chimeric human CTLA4-IgFc molecule.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"SA12": monoklonalt, antihumant AILIM-antistoff fra mus. </span>"SA12": mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 49 viser den inhiberende virkning p T-celleproliferasjonen ved dyrking av T-celler fra en normal, frisk person, "donor A", med PBMC fra en normal, frisk person, "donor D", av forskjellige humane, monoklonale antihumant AILIM-antistoffer i en proliferasjonsanalyse for T-celler via den blandede lymfocyttreaksjon (MLR). </span>Figure 49 shows the inhibitory effect on T-cell proliferation by culturing T-cells from a normal, healthy person, "donor A", with PBMCs from a normal, healthy person, "donor D", of different human monoclonal anti-human AILIM- antibodies in a proliferation assay for T cells via the mixed lymphocyte reaction (MLR).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsnivet, og den horisontale akse viser konsentrasjonen av analyseprvene. </span>The vertical axis indicates the amount of incorporation of [&lt;3&gt;H]thymidine as a measure of the level of cell proliferation, and the horizontal axis shows the concentration of the assay samples.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Anti-KLH": humant, monoklonalt, anti-KLH-antistoff som en negativ kontroll. "JMab-124": humant, monoklonalt, antihumant AILIM-antistoff, JMabl24. "126": humant, monoklonalt, antihumant AILIM-antistoff, JMabl26. </span>"Anti-KLH": human, monoclonal, anti-KLH antibody as a negative control. "JMab-124": human, monoclonal, anti-human AILIM antibody, JMabl24. "126": human, monoclonal, anti-human AILIM antibody, JMabl26.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"127": humant, monoklonalt, antihumant AILIM-antistoff, JMabl27. </span>"127": human, monoclonal, anti-human AILIM antibody, JMabl27.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"128": humant, monoklonalt, antihumant AILIM-antistoff, JMabl28. </span>"128": human, monoclonal, anti-human AILIM antibody, JMabl28.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"135": humant, monoklonalt, antihumant AILIM-antistoff, JMabl35. </span>"135": human, monoclonal, anti-human AILIM antibody, JMabl35.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"136": humant, monoklonalt, antihumant AILIM-antistoff, JMabl36. </span>"136": human, monoclonal, anti-human AILIM antibody, JMabl36.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"137": humant, monoklonalt, antihumant AILIM-antistoff, JMabl37. </span>"137": human, monoclonal, anti-human AILIM antibody, JMabl37.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 50 viser den inhiberende virkning p T-celleproliferasjonen ved dyrking av T-celler fra en normal, frisk person, "donor D", med PBMC fra en normal, frisk person, "donor </span>Figure 50 shows the inhibitory effect on T cell proliferation when culturing T cells from a normal, healthy person, "donor D", with PBMC from a normal, healthy person, "donor</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">B", ved forskjellige analyseprver i en proliferasjonsanalyse for T-celler via den blandede lymfocyttreaksjon (MLR). </span>B", by different test samples in a proliferation assay for T cells via the mixed lymphocyte reaction (MLR).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsnivet, og den horisontale akse viser konsentrasjonen av analyseprvene. </span>The vertical axis indicates the amount of incorporation of [&lt;3&gt;H]thymidine as a measure of the level of cell proliferation, and the horizontal axis shows the concentration of the assay samples.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Betegnelsene i figuren angir flgende: </span>The designations in the figure indicate the following:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"CD80 + 86": en blanding av anti-CD80-antistoff og anti-CD86-antistoff. "mlgGl": monoklonalt, antihumant CD34/IgGl-antistoff fra mus. "CTLA4-Ig": kimrt, humant CTLA4-IgFc-molekyl. </span>"CD80 + 86": a mixture of anti-CD80 antibody and anti-CD86 antibody. "mlgGl": mouse monoclonal anti-human CD34/IgGl antibody. "CTLA4-Ig": chimeric human CTLA4-IgFc molecule.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"SA 12": monoklonalt, antihumant AILIM-antistoff fra mus. </span>"SA 12": mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 51 viser den inhiberende virkning p T-celleproliferasjonen ved dyrking av T-celler fra en normal, frisk person, "donor D", med PBMC fra en normal, frisk person, "donor B", av forskjellige humane, monoklonale antihumant AILIM-antistoffer i en proliferasjonsanalyse for T-celler via den blandede lymfocyttreaksjon (MLR). </span>Figure 51 shows the inhibitory effect on T-cell proliferation when culturing T-cells from a normal, healthy person, "donor D", with PBMCs from a normal, healthy person, "donor B", of different human monoclonal anti-human AILIM- antibodies in a proliferation assay for T cells via the mixed lymphocyte reaction (MLR).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsnivet, og den horisontale akse viser konsentrasjonen av analyseprvene. </span>The vertical axis indicates the amount of incorporation of [&lt;3&gt;H]thymidine as a measure of the level of cell proliferation, and the horizontal axis shows the concentration of the assay samples.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Anti-KLH": humant, monoklonalt, anti-KLH-antistoff som en negativ kontroll. "JMab-124": humant, monoklonalt, antihumant AILIM-antistoff, JMabl24. "126": humant, monoklonalt, antihumant AILIM-antistoff, JMabl26. </span>"Anti-KLH": human, monoclonal, anti-KLH antibody as a negative control. "JMab-124": human, monoclonal, anti-human AILIM antibody, JMabl24. "126": human monoclonal anti-human AILIM antibody, JMabl26.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"127": humant, monoklonalt, antihumant AILIM-antistoff, JMabl27. </span>"127": human, monoclonal, anti-human AILIM antibody, JMabl27.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"128": humant, monoklonalt, antihumant AILIM-antistoff, JMabl28. </span>"128": human, monoclonal, anti-human AILIM antibody, JMabl28.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"135": humant, monoklonalt, antihumant AILIM-antistoff, JMabl35. </span>"135": human, monoclonal, anti-human AILIM antibody, JMabl35.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"136": humant, monoklonalt, antihumant AILIM-antistoff, JMabl36. </span>"136": human, monoclonal, anti-human AILIM antibody, JMabl36.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"137": humant, monoklonalt, antihumant AILIM-antistoff, JMabl37. </span>"137": human, monoclonal, anti-human AILIM antibody, JMabl37.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 52 viser den inhiberende virkning p T-celleproliferasjonen ved dyrking av T-celler fra en normal, frisk person, "donor C", med PBMC fra en normal, frisk person, "donor A", ved forskjellige analyseprver i en proliferasjonsanalyse for T-celler via den blandede lymfocyttreaksjon (MLR). </span>Figure 52 shows the inhibitory effect on T-cell proliferation by culturing T-cells from a normal, healthy person, "donor C", with PBMC from a normal, healthy person, "donor A", at different assay samples in a proliferation assay for T -cells via the mixed lymphocyte reaction (MLR).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsnivet, og den horisontale akse viser konsentrasjonen av analyseprvene. </span>The vertical axis indicates the amount of incorporation of [&lt;3&gt;H]thymidine as a measure of the level of cell proliferation, and the horizontal axis shows the concentration of the assay samples.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Betegnelsene i figuren angir flgende: </span>The designations in the figure indicate the following:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"CD80 + 86": en blanding av anti-CD80-antistoff og anti-CD86-antistoff. "mlgGl": monoklonalt, antihumant CD34/IgGl-antistoff fra mus. "CTLA4-Ig": kimrt, humant CTLA4-IgFc-molekyl. </span>"CD80 + 86": a mixture of anti-CD80 antibody and anti-CD86 antibody. "mlgGl": mouse monoclonal anti-human CD34/IgGl antibody. "CTLA4-Ig": chimeric human CTLA4-IgFc molecule.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"SA12": monoklonalt, antihumant AILIM-antistoff fra mus. </span>"SA12": mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 53 viser den inhiberende virkning p T-celleproliferasjonen ved dyrking av T-celler fra en normal, frisk person, "donor C", med PBMC fra en normal, frisk person, "donor A", av forskjellige humane, monoklonale antihumant AILIM-antistoffer i en proliferasjonsanalyse for T-celler via den blandede lymfocyttreaksjon (MLR). </span>Figure 53 shows the inhibitory effect on T-cell proliferation when culturing T-cells from a normal, healthy person, "donor C", with PBMC from a normal, healthy person, "donor A", of different human monoclonal anti-human AILIM- antibodies in a proliferation assay for T cells via the mixed lymphocyte reaction (MLR).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden inkorporering av [ 1H]tymidin som et ml p celleproliferasjonsnivet, og den horisontale akse viser konsentrasjonen av analyseprvene. </span>The vertical axis indicates the amount of incorporation of [1H]thymidine as a measure of the level of cell proliferation, and the horizontal axis shows the concentration of the assay samples.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Anti-KLH": humant, monoklonalt, anti-KLH-antistoff som en negativ kontroll. "JMab-124": humant, monoklonalt, antihumant AILIM-antistoff, JMabl24. "126": humant, monoklonalt, antihumant AILIM-antistoff, JMabl26. </span>"Anti-KLH": human, monoclonal, anti-KLH antibody as a negative control. "JMab-124": human, monoclonal, anti-human AILIM antibody, JMabl24. "126": human, monoclonal, anti-human AILIM antibody, JMabl26.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"127": humant, monoklonalt, antihumant AILIM-antistoff, JMabl27. </span>"127": human, monoclonal, anti-human AILIM antibody, JMabl27.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"128": humant, monoklonalt, antihumant AILIM-antistoff, JMabl28. </span>"128": human, monoclonal, anti-human AILIM antibody, JMabl28.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"135": humant, monoklonalt, antihumant AILIM-antistoff, JMabl35. </span>"135": human, monoclonal, anti-human AILIM antibody, JMabl35.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"136": humant, monoklonalt, antihumant AILIM-antistoff, JMabl36. </span>"136": human, monoclonal, anti-human AILIM antibody, JMabl36.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"137": humant, monoklonalt, antihumant AILIM-antistoff, JMabl37. </span>"137": human, monoclonal, anti-human AILIM antibody, JMabl37.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 54 viser den inhiberende virkning p T-celleproliferasjonen ved dyrking av T-celler fra en normal, frisk person, "donor E", med PBMC fra en normal, frisk person, "donor G", ved forskjellige analyseprver i en proliferasjonsanalyse for T-celler via den blandede lymfocyttreaksjon (MLR). </span>Figure 54 shows the inhibitory effect on T-cell proliferation by culturing T-cells from a normal, healthy person, "donor E", with PBMC from a normal, healthy person, "donor G", at different assay samples in a proliferation assay for T -cells via the mixed lymphocyte reaction (MLR).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsnivet, og den horisontale akse viser konsentrasjonen av analyseprvene. </span>The vertical axis indicates the amount of incorporation of [&lt;3&gt;H]thymidine as a measure of the level of cell proliferation, and the horizontal axis shows the concentration of the assay samples.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Betegnelsene i figuren angir flgende: </span>The designations in the figure indicate the following:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Kontroll-mlgG": monoklonalt, antihumant CD34/IgGl-antistoff fra mus. "CD80 + 86 Ab": en blanding av anti-CD80-antistoff og anti-CD86-antistoff. "SA 12": monoklonalt, antihumant AILIM-antistoff fra mus. </span>"Control mlgG": mouse monoclonal anti-human CD34/IgG1 antibody. "CD80 + 86 Ab": a mixture of anti-CD80 antibody and anti-CD86 antibody. "SA 12": mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"CTLA4-Ig": kimrt, humant CTLA4-IgFc-molekyl. </span>"CTLA4-Ig": chimeric human CTLA4-IgFc molecule.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 55 viser den inhiberende virkning p T-celleproliferasjonen ved dyrking av T-celler fra en normal, frisk person, "donor E", med PBMC fra en normal, frisk person, "donor G", av forskjellige humane, monoklonale antihumant AILIM-antistoffer i en proliferasjonsanalyse for T-celler via den blandede lymfocyttreaksjon (MLR). </span>Figure 55 shows the inhibitory effect on T-cell proliferation when culturing T-cells from a normal, healthy person, "donor E", with PBMCs from a normal, healthy person, "donor G", of different human monoclonal anti-human AILIM- antibodies in a proliferation assay for T cells via the mixed lymphocyte reaction (MLR).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsnivet, og den horisontale akse viser konsentrasjonen av analyseprvene. </span>The vertical axis indicates the amount of incorporation of [&lt;3&gt;H]thymidine as a measure of the level of cell proliferation, and the horizontal axis shows the concentration of the assay samples.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Anti-KLH": humant, monoklonalt, anti-KLH-antistoff som en negativ kontroll. "JMab-136": humant, monoklonalt, antihumant AILIM-antistoff, JMabl36. "138": humant, monoklonalt, antihumant AILIM-antistoff, JMabl38. </span>"Anti-KLH": human, monoclonal, anti-KLH antibody as a negative control. "JMab-136": human, monoclonal, anti-human AILIM antibody, JMabl36. "138": human, monoclonal, anti-human AILIM antibody, JMabl38.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"139": humant, monoklonalt, antihumant AILIM-antistoff, JMabl39. </span>"139": human, monoclonal, anti-human AILIM antibody, JMabl39.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"140": humant, monoklonalt, antihumant AILIM-antistoff, JMabl40. </span>"140": human, monoclonal, anti-human AILIM antibody, JMabl40.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"141": humant, monoklonalt, antihumant AILIM-antistoff, JMabl41. </span>"141": human monoclonal anti-human AILIM antibody, JMabl41.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 56 viser den inhiberende virkning p T-celleproliferasjonen ved dyrking av T-celler fra en normal, frisk person, "donor F", med PBMC fra en normal, frisk person, "donor E", ved forskjellige analyseprver i en proliferasjonsanalyse for T-celler via den blandede lymfocyttreaksjon (MLR). </span>Figure 56 shows the inhibitory effect on T-cell proliferation when culturing T-cells from a normal, healthy person, "donor F", with PBMC from a normal, healthy person, "donor E", at different assay samples in a proliferation assay for T -cells via the mixed lymphocyte reaction (MLR).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden inkorporering av [ 1H]tymidin som et ml p celleproliferasjonsnivet, og den horisontale akse viser konsentrasjonen av analyseprvene. </span>The vertical axis indicates the amount of incorporation of [1H]thymidine as a measure of the level of cell proliferation, and the horizontal axis shows the concentration of the assay samples.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Betegnelsene i figuren angir flgende: </span>The designations in the figure indicate the following:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Kontroll-mlgG": monoklonalt, antihumant CD34/IgGl-antistoff fra mus. "CD80 + 86 Ab": en blanding av anti-CD80-antistoff og anti-CD86-antistoff. "SA12": monoklonalt, antihumant AILIM-antistoff fra mus. </span>"Control mlgG": mouse monoclonal anti-human CD34/IgG1 antibody. "CD80 + 86 Ab": a mixture of anti-CD80 antibody and anti-CD86 antibody. "SA12": mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"CTLA4-Ig": kimrt, humant CTLA4-IgFc-molekyl. </span>"CTLA4-Ig": chimeric human CTLA4-IgFc molecule.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 57 viser den inhiberende virkning p T-celleproliferasjonen ved dyrking av T-celler fra en normal, frisk person, "donor F", med PBMC fra en normal, frisk person, "donor E", ved forskjellige analyseprver i en proliferasjonsanalyse for T-celler via den blandede lymfocyttreaksjon (MLR). </span>Figure 57 shows the inhibitory effect on T-cell proliferation by culturing T-cells from a normal, healthy person, "donor F", with PBMC from a normal, healthy person, "donor E", at different assay samples in a proliferation assay for T -cells via the mixed lymphocyte reaction (MLR).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsnivet, og den horisontale akse viser konsentrasjonen av analyseprvene. </span>The vertical axis indicates the amount of incorporation of [&lt;3&gt;H]thymidine as a measure of the level of cell proliferation, and the horizontal axis shows the concentration of the assay samples.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Betegnelsene i figuren angir flgende: </span>The designations in the figure indicate the following:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Anti-KLH": humant, monoklonalt, anti-KLH-antistoff som en negativ kontroll. "JMab-136": humant, monoklonalt, antihumant AILIM-antistoff, JMabl36. "138": humant, monoklonalt, antihumant AILIM-antistoff, JMabl38. </span>"Anti-KLH": human, monoclonal, anti-KLH antibody as a negative control. "JMab-136": human, monoclonal, anti-human AILIM antibody, JMabl36. "138": human, monoclonal, anti-human AILIM antibody, JMabl38.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"139": humant, monoklonalt, antihumant AILIM-antistoff, JMabl39. </span>"139": human, monoclonal, anti-human AILIM antibody, JMabl39.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"140": humant, monoklonalt, antihumant AILIM-antistoff, JMabl40. </span>"140": human, monoclonal, anti-human AILIM antibody, JMabl40.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"141": humant, monoklonalt, antihumant AILIM-antistoff, JMabl41. </span>"141": human monoclonal anti-human AILIM antibody, JMabl41.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 58 viser den inhiberende virkning p T-celleproliferasjonen ved dyrking av T-celler fra en normal, frisk person, "donor G", med PBMC fra en normal, frisk person, "donor F", ved forskjellige analyseprver i en proliferasjonsanalyse for T-celler via den blandede lymfocyttreaksjon (MLR). </span>Figure 58 shows the inhibitory effect on T-cell proliferation when culturing T-cells from a normal, healthy person, "donor G", with PBMC from a normal, healthy person, "donor F", at different assay samples in a proliferation assay for T -cells via the mixed lymphocyte reaction (MLR).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsnivet, og den horisontale akse viser konsentrasjonen av analyseprvene. </span>The vertical axis indicates the amount of incorporation of [&lt;3&gt;H]thymidine as a measure of the level of cell proliferation, and the horizontal axis shows the concentration of the assay samples.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Betegnelsene i figuren angir flgende: </span>The designations in the figure indicate the following:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Kontroll-mlgG": monoklonalt, antihumant CD34/IgGl-antistoff fra mus. "CD80 + 86 Ab": en blanding av anti-CD80-antistoff og anti-CD86-antistoff. "SA12": monoklonalt, antihumant AILIM-antistoff fra mus. </span>"Control mlgG": mouse monoclonal anti-human CD34/IgG1 antibody. "CD80 + 86 Ab": a mixture of anti-CD80 antibody and anti-CD86 antibody. "SA12": mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"CTLA4-Ig": kimrt, humant CTLA4-IgFc-molekyl. </span>"CTLA4-Ig": chimeric human CTLA4-IgFc molecule.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 59 viser den inhiberende virkning p T-celleproliferasjonen ved dyrking av T-celler fra en normal, frisk person, "donor G", med PBMC fra en normal, frisk person, "donor F", ved forskjellige analyseprver i en proliferasjonsanalyse for T-celler via den blandede lymfocyttreaksjon (MLR). </span>Figure 59 shows the inhibitory effect on T-cell proliferation by culturing T-cells from a normal, healthy person, "donor G", with PBMC from a normal, healthy person, "donor F", at different assay samples in a proliferation assay for T -cells via the mixed lymphocyte reaction (MLR).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden inkorporering av [ H]tymidin som et ml p celleproliferasjonsnivet, og den horisontale akse viser konsentrasjonen av analyseprvene. </span>The vertical axis indicates the amount of incorporation of [ H]thymidine as a measure of the level of cell proliferation, and the horizontal axis shows the concentration of the assay samples.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Betegnelsene i figuren angir flgende: </span>The designations in the figure indicate the following:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Anti-KLH": humant, monoklonalt, anti-KLH-antistoff som en negativ kontroll. </span>"Anti-KLH": human, monoclonal, anti-KLH antibody as a negative control.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"JMab-136": humant, monoklonalt, antihumant AILIM-antistoff, JMabl36. "138": humant, monoklonalt, antihumant AILIM-antistoff, JMabl38. </span>"JMab-136": human, monoclonal, anti-human AILIM antibody, JMabl36. "138": human, monoclonal, anti-human AILIM antibody, JMabl38.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"139": humant, monoklonalt, antihumant AILIM-antistoff, JMabl39. </span>"139": human, monoclonal, anti-human AILIM antibody, JMabl39.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"140": humant, monoklonalt, antihumant AILIM-antistoff, JMabl40. </span>"140": human, monoclonal, anti-human AILIM antibody, JMabl40.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"141": humant, monoklonalt, antihumant AILIM-antistoff, JMabl41. </span>"141": human monoclonal anti-human AILIM antibody, JMabl41.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 60 viser den inhiberende virkning av forskjellige kontrollanalyseforbindelser p proliferasjon av T-celler i en analyse som benytter den blandede lymfocyttreaksjon (MLR). T-celler fra en normal, frisk person, "donor A", ble dyrket sammen med PBMC fra en normal, frisk person, "donor D", som p forhnd var dyrket i nrvr av kimrt, humant CTLA4-Ig-molekyl. </span>Figure 60 shows the inhibitory effect of various control assay compounds on the proliferation of T cells in an assay using the mixed lymphocyte reaction (MLR). T cells from a normal healthy person, "donor A", were co-cultured with PBMCs from a normal, healthy person, "donor D", which had been previously cultured in the presence of chimeric human CTLA4-Ig molecule.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av analyseforbindelser. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of analyte compounds.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Betegnelsene i figuren angir flgende: </span>The designations in the figure indicate the following:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"CD80 + 86": en blanding av anti-CD80-antistoff og anti-CD86-antistoff. "mlgGl": monoklonalt, antihumant CD34/IgGl-antistoff fra mus. </span>"CD80 + 86": a mixture of anti-CD80 antibody and anti-CD86 antibody. "mlgGl": mouse monoclonal anti-human CD34/IgGl antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"SA12": monoklonalt, antihumant AILIM-antistoff fra mus. </span>"SA12": mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 61 viser den inhiberende virkning av forskjellige </span>Figure 61 shows the inhibitory effect of different</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">humane, monoklonale antihumant AILIM-antistoffer p proliferasjon av T-celler i en analyse som benytter den blandede lymfocyttreaksjon (MLR). T-celler fra en normal, frisk person, "donor A", ble dyrket sammen med PBMC fra en normal, frisk person, "donor D", som p forhnd var dyrket i nrvr av kimrt, humant CTLA4-Ig-molekyl. </span>human monoclonal anti-human AILIM antibodies on T-cell proliferation in an assay using the mixed lymphocyte reaction (MLR). T cells from a normal healthy person, "donor A", were co-cultured with PBMCs from a normal, healthy person, "donor D", which had been previously cultured in the presence of chimeric human CTLA4-Ig molecule.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av analyseforbindelser. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of analyte compounds.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Anti-KLH": humant, monoklonalt, anti-KLH-antistoff som en negativ kontroll. "JMab-124": humant, monoklonalt, antihumant AILIM-antistoff, JMabl24. "126": humant, monoklonalt, antihumant AILIM-antistoff, JMabl26. </span>"Anti-KLH": human, monoclonal, anti-KLH antibody as a negative control. "JMab-124": human, monoclonal, anti-human AILIM antibody, JMabl24. "126": human, monoclonal, anti-human AILIM antibody, JMabl26.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"127": humant, monoklonalt, antihumant AILIM-antistoff, JMabl27. </span>"127": human, monoclonal, anti-human AILIM antibody, JMabl27.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"128": humant, monoklonalt, antihumant AILIM-antistoff, JMabl28. </span>"128": human, monoclonal, anti-human AILIM antibody, JMabl28.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"135": humant, monoklonalt, antihumant AILIM-antistoff, JMabl35. </span>"135": human, monoclonal, anti-human AILIM antibody, JMabl35.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"136": humant, monoklonalt, antihumant AILIM-antistoff, JMabl36. </span>"136": human, monoclonal, anti-human AILIM antibody, JMabl36.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"137": humant, monoklonalt, antihumant AILIM-antistoff, JMabl37. </span>"137": human, monoclonal, anti-human AILIM antibody, JMabl37.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 62 viser den inhiberende virkning av forskjellige kontrollanalyseforbindelser p proliferasjon av T-celler i en analyse som benytter den blandede lymfocyttreaksjon (MLR). T-celler fra en normal, frisk person, "donor D", ble dyrket sammen med PBMC fra en normal, frisk person, "donor B", som p forhnd var dyrket i nrvr av kimrt, humant CTLA4-Ig-molekyl. </span>Figure 62 shows the inhibitory effect of various control assay compounds on proliferation of T cells in an assay using the mixed lymphocyte reaction (MLR). T cells from a normal healthy person, "donor D", were co-cultured with PBMCs from a normal, healthy person, "donor B", which had been previously cultured in the presence of chimeric human CTLA4-Ig molecule.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [ 1H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av analyseforbindelser. </span>The vertical axis indicates the amount of cellular incorporation of [  1 H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of test compounds.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Betegnelsene i figuren angir flgende: </span>The designations in the figure indicate the following:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"CD80 + 86": en blanding av anti-CD80-antistoff og anti-CD86-antistoff. "mlgGl": monoklonalt, antihumant CD34/IgGl-antistoff fra mus. </span>"CD80 + 86": a mixture of anti-CD80 antibody and anti-CD86 antibody. "mlgGl": mouse monoclonal anti-human CD34/IgGl antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"SA12": monoklonalt, antihumant AILIM-antistoff fra mus. </span>"SA12": mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 63 viser den inhiberende virkning av forskjellige </span>Figure 63 shows the inhibitory effect of different</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">humane, monoklonale antihumant AILIM-antistoffer p proliferasjon av T-celler i en analyse som benytter den blandede lymfocyttreaksjon (MLR). T-celler fra en normal, frisk person, "donor D", ble dyrket sammen med PBMC fra en normal, frisk person, "donor B", som p forhnd var dyrket i nrvr av kimrt, humant CTLA4-Ig-molekyl. </span>human monoclonal anti-human AILIM antibodies on T-cell proliferation in an assay using the mixed lymphocyte reaction (MLR). T cells from a normal healthy person, "donor D", were co-cultured with PBMCs from a normal, healthy person, "donor B", which had been previously cultured in the presence of chimeric human CTLA4-Ig molecule.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av analyseforbindelser. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of analyte compounds.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Anti-KLH": humant, monoklonalt, anti-KLH-antistoff som en negativ kontroll. "JMab-124": humant, monoklonalt, antihumant AILIM-antistoff, JMabl24. "126": humant, monoklonalt, antihumant AILIM-antistoff, JMabl26. </span>"Anti-KLH": human, monoclonal, anti-KLH antibody as a negative control. "JMab-124": human, monoclonal, anti-human AILIM antibody, JMabl24. "126": human, monoclonal, anti-human AILIM antibody, JMabl26.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"127": humant, monoklonalt, antihumant AILIM-antistoff, JMabl27. </span>"127": human, monoclonal, anti-human AILIM antibody, JMabl27.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"128": humant, monoklonalt, antihumant AILIM-antistoff, JMabl28. </span>"128": human, monoclonal, anti-human AILIM antibody, JMabl28.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"135": humant, monoklonalt, antihumant AILIM-antistoff, JMabl35. </span>"135": human, monoclonal, anti-human AILIM antibody, JMabl35.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"136": humant, monoklonalt, antihumant AILIM-antistoff, JMabl36. </span>"136": human, monoclonal, anti-human AILIM antibody, JMabl36.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"137": humant, monoklonalt, antihumant AILIM-antistoff, JMabl37. </span>"137": human, monoclonal, anti-human AILIM antibody, JMabl37.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 64 viser den inhiberende virkning av forskjellige </span>Figure 64 shows the inhibitory effect of different</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">kontrollanalyseforbindelser p proliferasjon av T-celler i en analyse som benytter den blandede lymfocyttreaksjon (MLR). T-celler fra en normal, frisk person, "donor C", ble dyrket sammen med PBMC fra en normal, frisk person, "donor A", som p forhnd var dyrket i nrvr av kimrt, humant CTLA4-Ig-molekyl. </span>control assay compounds on proliferation of T cells in an assay using the mixed lymphocyte reaction (MLR). T cells from a normal, healthy person, "donor C", were co-cultured with PBMC from a normal, healthy person, "donor A", which had been previously cultured in the presence of chimeric human CTLA4-Ig molecule.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av analyseforbindelser. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of analyte compounds.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Betegnelsene i figuren angir flgende: </span>The designations in the figure indicate the following:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"CD80 + 86": en blanding av anti-CD80-antistoff og anti-CD86-antistoff. "mlgGl": monoklonalt, antihumant CD34/IgGl-antistoff fra mus. </span>"CD80 + 86": a mixture of anti-CD80 antibody and anti-CD86 antibody. "mlgGl": mouse monoclonal anti-human CD34/IgGl antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"SA 12": monoklonalt, antihumant AILIM-antistoff fra mus. </span>"SA 12": mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 65 viser den inhiberende virkning av forskjellige </span>Figure 65 shows the inhibitory effect of different</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">humane, monoklonale antihumant AILIM-antistoffer p proliferasjon av T-celler i en analyse som benytter den blandede lymfocyttreaksjon (MLR). T-celler fra en normal, frisk person, </span>human monoclonal anti-human AILIM antibodies on T-cell proliferation in an assay using the mixed lymphocyte reaction (MLR). T cells from a normal, healthy person,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"donor C", ble dyrket sammen med PBMC fra en normal, frisk person, "donor A", som p forhnd var dyrket i nrvr av kimrt, humant CTLA4-Ig-molekyl. </span>"donor C", was co-cultured with PBMC from a normal, healthy person, "donor A", which had previously been cultured in the presence of chimeric human CTLA4-Ig molecule.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av analyseforbindelser. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of analyte compounds.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Anti-KLH": humant, monoklonalt, anti-KLH-antistoff som en negativ kontroll. "JMab-124": humant, monoklonalt, antihumant AILIM-antistoff, JMabl24. "126": humant, monoklonalt, antihumant AILIM-antistoff, JMabl26. </span>"Anti-KLH": human, monoclonal, anti-KLH antibody as a negative control. "JMab-124": human, monoclonal, anti-human AILIM antibody, JMabl24. "126": human, monoclonal, anti-human AILIM antibody, JMabl26.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"127": humant, monoklonalt, antihumant AILIM-antistoff, JMabl27. </span>"127": human, monoclonal, anti-human AILIM antibody, JMabl27.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"128": humant, monoklonalt, antihumant AILIM-antistoff, JMabl28. </span>"128": human, monoclonal, anti-human AILIM antibody, JMabl28.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"135": humant, monoklonalt, antihumant AILIM-antistoff, JMabl35. </span>"135": human, monoclonal, anti-human AILIM antibody, JMabl35.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"136": humant, monoklonalt, antihumant AILIM-antistoff, JMabl36. </span>"136": human, monoclonal, anti-human AILIM antibody, JMabl36.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"137": humant, monoklonalt, antihumant AILIM-antistoff, JMabl37. </span>"137": human, monoclonal, anti-human AILIM antibody, JMabl37.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 66 viser den inhiberende virkning av forskjellige </span>Figure 66 shows the inhibitory effect of different</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">kontrollanalyseforbindelser p proliferasjon av T-celler i en analyse som benytter den blandede lymfocyttreaksjon (MLR). T-celler fra en normal, frisk person, "donor E", ble dyrket sammen med PBMC fra en normal, frisk person, "donor G", som p forhnd var dyrket i nrvr av kimrt, humant CTLA4-Ig-molekyl. </span>control assay compounds on proliferation of T cells in an assay using the mixed lymphocyte reaction (MLR). T cells from a normal healthy person, "donor E", were co-cultured with PBMCs from a normal, healthy person, "donor G", which had been previously cultured in the presence of chimeric human CTLA4-Ig molecule.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av analyseforbindelser. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of analyte compounds.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Betegnelsene i figuren angir flgende: </span>The designations in the figure indicate the following:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Kontroll-mlgG": monoklonalt, antihumant CD34/IgGl-antistoff fra mus. "CD80 + 86 Ab": en blanding av anti-CD80-antistoff og anti-CD86-antistoff. "SA12": monoklonalt, antihumant AILIM-antistoff fra mus. </span>"Control mlgG": mouse monoclonal anti-human CD34/IgG1 antibody. "CD80 + 86 Ab": a mixture of anti-CD80 antibody and anti-CD86 antibody. "SA12": mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 67 viser den inhiberende virkning av forskjellige </span>Figure 67 shows the inhibitory effect of different</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">humane, monoklonale antihumant AILIM-antistoffer p proliferasjon av T-celler i en analyse som benytter den blandede lymfocyttreaksjon (MLR). T-celler fra en normal, frisk person, "donor E", ble dyrket sammen med PBMC fra en normal, frisk person, "donor G", som p forhnd var dyrket i nrvr av kimrt, humant CTLA4-Ig-molekyl. </span>human monoclonal anti-human AILIM antibodies on T-cell proliferation in an assay using the mixed lymphocyte reaction (MLR). T cells from a normal healthy person, "donor E", were co-cultured with PBMCs from a normal, healthy person, "donor G", which had been previously cultured in the presence of chimeric human CTLA4-Ig molecule.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [ H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av analyseforbindelser. </span>The vertical axis indicates the amount of cellular incorporation of [ H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of test compounds.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Anti-KLH": humant, monoklonalt, anti-KLH-antistoff som en negativ kontroll. "JMab-136": humant, monoklonalt, antihumant AILIM-antistoff, JMabl36. "138": humant, monoklonalt, antihumant AILIM-antistoff, JMabl38. </span>"Anti-KLH": human, monoclonal, anti-KLH antibody as a negative control. "JMab-136": human, monoclonal, anti-human AILIM antibody, JMabl36. "138": human, monoclonal, anti-human AILIM antibody, JMabl38.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"139": humant, monoklonalt, antihumant AILIM-antistoff, JMabl39. </span>"139": human, monoclonal, anti-human AILIM antibody, JMabl39.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"140": humant, monoklonalt, antihumant AILIM-antistoff, JMabl40. </span>"140": human, monoclonal, anti-human AILIM antibody, JMabl40.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"141": humant, monoklonalt, antihumant AILIM-antistoff, JMabl41. </span>"141": human monoclonal anti-human AILIM antibody, JMabl41.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 68 viser den inhiberende virkning av forskjellige </span>Figure 68 shows the inhibitory effect of different</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">kontrollanalyseforbindelser p proliferasjon av T-celler i en analyse som benytter den blandede lymfocyttreaksjon (MLR). T-celler fra en normal, frisk person, "donor G", ble dyrket sammen med PBMC fra en normal, frisk person, "donor F", som p forhnd var dyrket i nrvr av kimrt, humant CTLA4-Ig-molekyl. </span>control assay compounds on proliferation of T cells in an assay using the mixed lymphocyte reaction (MLR). T cells from a normal healthy person, "donor G", were co-cultured with PBMCs from a normal, healthy person, "donor F", which had been previously cultured in the presence of chimeric human CTLA4-Ig molecule.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av analyseforbindelser. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of analyte compounds.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Betegnelsene i figuren angir flgende: </span>The designations in the figure indicate the following:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Kontroll-mlgG": monoklonalt, antihumant CD34/IgGl-antistoff fra mus. "CD80 + 86 Ab": en blanding av anti-CD80-antistoff og anti-CD86-antistoff. "SA12": monoklonalt, antihumant AILIM-antistoff fra mus. </span>"Control mlgG": mouse monoclonal anti-human CD34/IgG1 antibody. "CD80 + 86 Ab": a mixture of anti-CD80 antibody and anti-CD86 antibody. "SA12": mouse monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 69 viser den inhiberende virkning av forskjellige </span>Figure 69 shows the inhibitory effect of different</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">humane, monoklonale antihumant AILIM-antistoffer p proliferasjon av T-celler i en analyse som benytter den blandede lymfocyttreaksjon (MLR). T-celler fra en normal, frisk person, "donor G", ble dyrket sammen med PBMC fra en normal, frisk person, "donor F", som p forhnd var dyrket i nrvr av kimrt, humant CTLA4-Ig-molekyl. </span>human monoclonal anti-human AILIM antibodies on T-cell proliferation in an assay using the mixed lymphocyte reaction (MLR). T cells from a normal healthy person, "donor G", were co-cultured with PBMCs from a normal, healthy person, "donor F", which had been previously cultured in the presence of chimeric human CTLA4-Ig molecule.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av analyseforbindelser. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of analyte compounds.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Andre betegnelser er som flger: </span>Other designations are as follows:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Anti-KLH": humant, monoklonalt, anti-KLH-antistoff som en negativ kontroll. "JMab-136": humant, monoklonalt, antihumant AILIM-antistoff, JMabl36. "138": humant, monoklonalt, antihumant AILIM-antistoff, JMabl38. </span>"Anti-KLH": human, monoclonal, anti-KLH antibody as a negative control. "JMab-136": human, monoclonal, anti-human AILIM antibody, JMabl36. "138": human, monoclonal, anti-human AILIM antibody, JMabl38.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"139": humant, monoklonalt, antihumant AILIM-antistoff, JMabl39. </span>"139": human, monoclonal, anti-human AILIM antibody, JMabl39.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"140": humant, monoklonalt, antihumant AILIM-antistoff, JMabl40. </span>"140": human, monoclonal, anti-human AILIM antibody, JMabl40.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"141": humant, monoklonalt, antihumant AILIM-antistoff, JMabl41. </span>"141": human monoclonal anti-human AILIM antibody, JMabl41.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 70 viser den ADCC-induserende aktivitet av forskjellige humane, monoklonale antihumant AILIM-antistoffer og kontrollantistoffer ved anvendelse av villtype-CHO-celler som mlceller. </span>Figure 70 shows the ADCC-inducing activity of various human monoclonal anti-human AILIM antibodies and control antibodies using wild-type CHO cells as target cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir graden av cytotoksisitet grunnet antistoffets ADCC-induserende aktivitet, og den horisontale akse angir konsentrasjonen av antistoff. </span>The vertical axis indicates the degree of cytotoxicity due to the antibody's ADCC-inducing activity, and the horizontal axis indicates the concentration of antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 71 viser den ADCC-induserende aktivitet av forskjellige humane, monoklonale antihumant AILIM-antistoffer og kontrollantistoff ved anvendelse av rekombinante CHO-celler som overuttrykker humant AILIM som mlceller. </span>Figure 71 shows the ADCC-inducing activity of various human monoclonal anti-human AILIM antibodies and control antibody using recombinant CHO cells overexpressing human AILIM as target cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir omfanget av celleskader grunnet antistoffets ADCC-induserende aktivitet, og den horisontale akse angir konsentrasjonen av antistoff. </span>The vertical axis indicates the extent of cell damage due to the antibody's ADCC-inducing activity, and the horizontal axis indicates the concentration of antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 72 viser den inhiberende virkning av anti-AILIM-antistoff p forsinket allergi. </span>Figure 72 shows the inhibitory effect of anti-AILIM antibody on delayed allergy.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir arealet av det rde omrdet, benyttet som ml p pbegynt forsinket allergi, og den horisontale akse angir typen analyseprve som ble gitt til forsksdyrene. </span>The vertical axis indicates the area of the red area, used as a measure of onset delayed allergy, and the horizontal axis indicates the type of test sample given to the test animals.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 73 viser proliferasjonsaktiviteten av ape-T-celler i en analyse for  bestemme virkningen av forskjellige </span>Figure 73 shows the proliferative activity of monkey T cells in an assay to determine the effect of various</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">humane, monoklonale antihumant AILIM-antistoffer p overfringen av det kostimulerende signal, ved anvendelse av en mikroplate belagt med humant, monoklonalt, antihumant AILIM-antistoff sammen med monoklonalt, antihumant CD3-antistoff. </span>human monoclonal antihuman AILIM antibodies on the transmission of the costimulatory signal, using a microplate coated with human monoclonal antihuman AILIM antibody together with monoclonal antihuman CD3 antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av det humane, monoklonale antihumant AILIM-antistoff. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of the human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne figuren angir "anti-KLH" resultatet av en analyse hvor humant, monoklonalt, anti-KLH-antistoff ble anvendt som negativ kontroll i stedet for det humane, monoklonale antihumant AILIM-antistoff. </span>In this figure, "anti-KLH" indicates the result of an assay in which human monoclonal anti-KLH antibody was used as a negative control in place of the human monoclonal anti-human AILIM antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 74 viser den inhiberende aktivitet av det negative kontrollantistoff p binding mellom lselig AILIM (hB7h-IgFc) og lselig AILIM (AILIM-IgFc) i forskjellige konsentrasjoner. </span>Figure 74 shows the inhibitory activity of the negative control antibody on binding between soluble AILIM (hB7h-IgFc) and soluble AILIM (AILIM-IgFc) at different concentrations.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir absorbansen som et ml p den inhiberende aktivitet, og den horisontale akse angir konsentrasjonen av lselig AILIM. </span>The vertical axis indicates the absorbance as a measure of the inhibitory activity, and the horizontal axis indicates the concentration of soluble AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 75 viser den inhiberende aktivitet av anti-AILIM-antistoff p bindingen mellom lselig AILIM-ligand (hB7h-IgFc) og lselig AILIM (AILIM-IgFc) i forskjellige konsentrasjoner. </span>Figure 75 shows the inhibitory activity of anti-AILIM antibody on the binding between soluble AILIM ligand (hB7h-IgFc) and soluble AILIM (AILIM-IgFc) at different concentrations.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir absorbansen som et ml p den inhiberende aktivitet, og den horisontale akse angir konsentrasjonen av lselig AILIM. </span>The vertical axis indicates the absorbance as a measure of the inhibitory activity, and the horizontal axis indicates the concentration of soluble AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 76 viser den inhiberende aktivitet av anti-AILIM-antistoff i forskjellige konsentrasjoner p bindingen mellom lselig AILIM-ligand (hB7h-IgFc) og lselig AILIM (AILIM-IgFc). </span>Figure 76 shows the inhibitory activity of anti-AILIM antibody at different concentrations on the binding between soluble AILIM ligand (hB7h-IgFc) and soluble AILIM (AILIM-IgFc).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir absorbansen som et ml p den inhiberende aktivitet, og den horisontale akse angir konsentrasjonen av lselig AILIM. </span>The vertical axis indicates the absorbance as a measure of the inhibitory activity, and the horizontal axis indicates the concentration of soluble AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 77 viser den inhiberende aktivitet av forskjellige humane, monoklonale antihumant AILIM-antistoffer p proliferasjon av humane T-celler i en analyse for bestemmelse av virkningen p overfringen av det kostimulerende signal ved anvendelse av en mikroplate belagt med lselig human AILIM-ligand (hB7h-IgFc) sammen med monoklonalt, antihumant CD3-antistoff. </span>Figure 77 shows the inhibitory activity of various human monoclonal anti-human AILIM antibodies on the proliferation of human T cells in an assay to determine the effect on the transmission of the costimulatory signal using a microplate coated with soluble human AILIM ligand (hB7h- IgFc) together with monoclonal anti-human CD3 antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av antistoff. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Figur 78 viser den inhiberende aktivitet av forskjellige humane, monoklonale antihumant AILIM-antistoffer p proliferasjon av ape-T-celler i en analyse for bestemmelse av virkningen p overfringen av det kostimulerende signal ved anvendelse av en mikroplate belagt med lselig human AILIM-ligand (hB7h-IgFc) sammen med monoklonalt, antihumant CD3-antistoff. </span>Figure 78 shows the inhibitory activity of various human monoclonal anti-human AILIM antibodies on the proliferation of monkey T cells in an assay to determine the effect on the transmission of the costimulatory signal using a microplate coated with soluble human AILIM ligand (hB7h -IgFc) together with monoclonal anti-human CD3 antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den vertikale akse angir mengden cellulr inkorporering av [&lt;3&gt;H]tymidin som et ml p celleproliferasjonsgraden, og den horisontale akse angir konsentrasjonen av antistoff. </span>The vertical axis indicates the amount of cellular incorporation of [&lt;3&gt;H]thymidine as a measure of the degree of cell proliferation, and the horizontal axis indicates the concentration of antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den beste mte  utfre oppfinnelsen p </span>The best way to carry out the invention</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Foreliggende oppfinnelse illustreres i nrmere detalj nedenfor ved henvisning til eksempler. </span>The present invention is illustrated in more detail below by reference to examples.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempel 1 </span>Example 1</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Fremstilling av immunogen </span>Preparation of immunogen</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1.1 Fremstilling av rekombinante celler som uttrykker humant AILIM </span>1.1 Preparation of recombinant cells expressing human AILIM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">To typer av rekombinante celler (CHO-celler og HPB-ALL-celler) som overuttrykker humant AILIM, ble fremstilt iflge fremgangsmten beskrevet i tidligere patentsknader (JP-A nr. Hei 11-29599 og WO 98/38216), s vel som i en tidligere rapport (Int. Immunology, vol. 12, nr. 1, s. 51-55, 2000) av en av de foreliggende oppfinnere, Tezuka. Nrmere bestemt er fremgangsmten som flger: Et cDNA (aksesjonsbetegnelse i GenBank: AB023135 (cDNA); BAA82129 (aminosyre)) som inneholder fullengde-ORF som koder for humant AILIM, ble innsatt i vektoren pEF-neo. Den resulterende rekombinante ekspresjonsvektor ble s innfrt i kinesisk hamster-ovariumceller (CHO-celler) og celler fra en human tymomlinje, HPB-ALL, iflge en hyppig anvendt fremgangsmte ved anvendelse av elektroporering (960 jiF, 320 V) med en Gene Pulser (BioRad). Cellene ble dyrket i RPMI-1640-medium tilsatt geneticin (0,8 mg/ml, GIBCO-BRL) og 10 % FCS for seleksjon av medikamentresistente, transformerte celler. </span>Two types of recombinant cells (CHO cells and HPB-ALL cells) overexpressing human AILIM were prepared according to the method described in previous patent applications (JP-A No. Hei 11-29599 and WO 98/38216), as well as in a previous report (Int. Immunology, vol. 12, no. 1, pp. 51-55, 2000) by one of the present inventors, Tezuka. More specifically, the procedure is as follows: A cDNA (accession name in GenBank: AB023135 (cDNA); BAA82129 (amino acid)) containing the full-length ORF encoding human AILIM was inserted into the vector pEF-neo. The resulting recombinant expression vector was then introduced into Chinese hamster ovary cells (CHO cells) and cells from a human thymoma line, HPB-ALL, according to a commonly used method using electroporation (960 jiF, 320 V) with a Gene Pulser (BioRad ). The cells were grown in RPMI-1640 medium supplemented with geneticin (0.8 mg/ml, GIBCO-BRL) and 10% FCS for selection of drug-resistant, transformed cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1.2 Seleksjon av rekombinante HPB- ALL- celler som overuttrykker humant AILIM </span>1.2 Selection of recombinant HPB-ALL cells overexpressing human AILIM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En kultur av de medikamentresistente HPB-ALL-cellene selektert i 1.1 beskrevet ovenfor ble sentrifugert for erholdelse av nedsentrifugerte celler. Et monoklonalt, antihumant AILIM-antistoff fra mus, betegnet "SA 12" (monoklonalt, antihumant JTT-1 antigenantistoff fra mus), etablert og rapportert tidligere (JP-A 11-29599 (eksempel 12) og WO 98/38216 (eksempel 12)) av de foreliggende oppfinnere, ble tilsatt til de nedsentrifugerte cellene (konsentrasjon: antistofflsning (10 ug/ml) fortynnet med EDTA-B SA/PB S ble tilsatt i et forhold p 100fil/10&lt;5&gt;celler). Den resulterende blanding ble inkubert ved 4 C i 30 minutter. Cellene ble vasket to ganger med det ovenfor nevnte EDTA-BSA/PBS (200 fil), hvoretter fykoerytrinmerket streptavidin (SA-PE, 100 fil av en 500 ganger fortynnet lsning) ble tilsatt til disse. Den resulterende blanding ble inkubert ved 4 C i 30 minutter. Etter inkubasjonen ble cellene vasket tre ganger med EDTA-BSA/PBS, og cellesuspensjoner ble fremstilt. </span>A culture of the drug-resistant HPB-ALL cells selected in 1.1 described above was centrifuged to obtain centrifuged cells. A mouse monoclonal anti-human AILIM antibody, designated "SA 12" (mouse monoclonal anti-human JTT-1 antigen antibody), established and reported previously (JP-A 11-29599 (Example 12) and WO 98/38216 (Example 12 )) of the present inventors, was added to the down-centrifuged cells (concentration: antibody solution (10 g/ml) diluted with EDTA-B SA/PB S was added at a ratio of 100 l/10&lt;5 &gt;cells). The resulting mixture was incubated at 4C for 30 minutes. The cells were washed twice with the above-mentioned EDTA-BSA/PBS (200 l), after which phycoerythrin-labeled streptavidin (SA-PE, 100 l of a 500-fold diluted solution) was added to them. The resulting mixture was incubated at 4C for 30 minutes. After the incubation, the cells were washed three times with EDTA-BSA/PBS, and cell suspensions were prepared.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ekspresjonsnivet av humant AILIM i cellene i suspensjonene ble analysert i et "flow"-cytometer, FACSort (Beckton-Dichinson), for seleksjon av rekombinante HPB-ALL-celler som overuttrykker humant AILIM. De selekterte cellene ble dyrket til konfluens i RPMI-1640-medium tilsatt 10 % FCS og G418 (1 mg/ml). </span>The expression level of human AILIM in the cells in the suspensions was analyzed in a flow cytometer, FACSort (Beckton-Dichinson), for selection of recombinant HPB-ALL cells overexpressing human AILIM. The selected cells were grown to confluence in RPMI-1640 medium supplemented with 10% FCS and G418 (1 mg/ml).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1.3 Seleksjon av rekombinante CHO- celler som overuttrykker humant AILIM </span>1.3 Selection of recombinant CHO cells overexpressing human AILIM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En kultur av de medikamentresistente CHO-cellene selektert i 1.1 beskrevet ovenfor ble sentrifugert for erholdelse av nedsentrifugerte celler. Det ovenfor nevnte monoklonale, antihumant AILIM-antistoff SA12 fra mus, merket med FITC, ble tilsatt til de nedsentrifugerte cellene (antistofflsning (100 jxg/ml) fortynnet med EDTA-BSA/PBS). Den resulterende blanding ble inkubert ved 4 C i 30 minutter. Cellene ble vasket med det ovenfor nevnte EDTA-BSA/PBS, hvoretter cellesuspensjoner ble fremstilt ved tilsetning av EDTA-BSA/PBS (500 fil) til de nedsentrifugerte cellene. </span>A culture of the drug-resistant CHO cells selected in 1.1 described above was centrifuged to obtain centrifuged cells. The above-mentioned mouse monoclonal anti-human AILIM antibody SA12, labeled with FITC, was added to the down-centrifuged cells (antibody solution (100 g/ml) diluted with EDTA-BSA/PBS). The resulting mixture was incubated at 4C for 30 minutes. The cells were washed with the above-mentioned EDTA-BSA/PBS, after which cell suspensions were prepared by adding EDTA-BSA/PBS (500 l) to the down-centrifuged cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ekspresjonsnivet av humant AILIM i cellene i suspensjonen ble analysert i et "flow"-cytometer, FACSort (Beckton-Dichinson), for seleksjon av rekombinante HPB-ALL-celler som overuttrykker humant AILIM. De selekterte cellene ble dyrket til konfluens i RPMI-1640-medium tilsatt 10 % FCS og G418 (1 mg/ml). </span>The expression level of human AILIM in the cells in the suspension was analyzed in a flow cytometer, FACSort (Beckton-Dichinson), for selection of recombinant HPB-ALL cells overexpressing human AILIM. The selected cells were grown to confluence in RPMI-1640 medium supplemented with 10% FCS and G418 (1 mg/ml).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1.4. Fremstilling av immunogen fra HPB- ALL- celler som overuttrykker humant </span>1.4. Production of immunogen from HPB-ALL cells overexpressing human</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AILIM </span>AILIM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">HPB-ALL-cellene som overuttrykte humant AILIM, erholdt i 1.2 beskrevet ovenfor, ble sentrifugert. De nedsentrifugerte cellene ble vasket fire ganger med fosfatbuffer (PBS, Nikken Seibutsu) og s resuspendert i en proteaseinhibitorholdig buffer (tilsatt 25 mM HEPES (pH 7,4), 10 mM MgCb, 0,25 M sukrose, og proteaseinhibitor (10 U/ml aprotinin, 2 fig/ml pepstatin, 50 fig/ml leupeptin og 0,35 mg/ml PMSF)). Cellesuspensjonen ble behandlet i en homogenisator av Potter-type og sentrifugert ved lav hastighet (1500 rpm ved 4 "C i 10 minutter). Den resulterende supernatant ble underkastet ultrasentirfugering (100 000 g ved 4 ''C i 1 time). Den nedsentrifugerte membranfraksjon ble gjenvunnet og suspendert i fosfatbuffer (konsentrasjonen av membranfraksjonen ble justert slik at 1 ml PBS inneholder membranfraksjonen avledet fra 1 x IO&lt;7&gt;celler). Suspensjonen ble lagret ved -80 C. Suspensjonen som inneholdt cellemembranfraksjonen, ble anvendt som antigen (immunogen) for fremstilling av humant antistoff iflge foreliggende oppfinnelse, som vil beskrives senere. </span>The HPB-ALL cells overexpressing human AILIM, obtained in 1.2 described above, were centrifuged. The down-centrifuged cells were washed four times with phosphate buffer (PBS, Nikken Seibutsu) and then resuspended in a protease inhibitor-containing buffer (added 25 mM HEPES (pH 7.4), 10 mM MgCb, 0.25 M sucrose, and protease inhibitor (10 U/ ml aprotinin, 2 g/ml pepstatin, 50 g/ml leupeptin and 0.35 mg/ml PMSF)). The cell suspension was processed in a Potter-type homogenizer and centrifuged at low speed (1500 rpm at 4 "C for 10 minutes). The resulting supernatant was subjected to ultracentrifugation (100,000 g at 4 "C for 1 hour). The down-centrifuged membrane fraction was recovered and suspended in phosphate buffer (the concentration of the membrane fraction was adjusted so that 1 ml of PBS contains the membrane fraction derived from 1 x 10&lt;7&gt; cells). The suspension was stored at -80 C. The suspension containing the cell membrane fraction was used as antigen (immunogen ) for the production of human antibody according to the present invention, which will be described later.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1.5 Fremstilling av immunogen fra CHO- celler som overuttrykker humant AILIM </span>1.5 Production of immunogen from CHO cells overexpressing human AILIM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CHO-cellene som overuttrykker humant AILIM, erholdt i 1.3 ovenfor, ble fordelt med en skrape og sentrifugert. De nedsentrifugerte cellene ble vasket fire ganger med fosfatbuffer (PBS, Nikken Seibutsu) og s resuspendert i en proteaseinhibitorholdig buffer </span>The CHO cells overexpressing human AILIM obtained in 1.3 above were distributed with a scraper and centrifuged. The centrifuged cells were washed four times with phosphate buffer (PBS, Nikken Seibutsu) and then resuspended in a protease inhibitor-containing buffer</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(inneholdende 25 mM HEPES (pH 7,4), 10 mM MgCl2, 0,25 M sukrose, og proteaseinhibitor (10 U/ml aprotinin, 2 ug/ml pepstatin, 50 ug/ml leupeptin og 0,35 mg/ml PMSF)). Cellesuspensjonen ble behandlet i en homogenisator av Potter-type og sentrifugert ved lav hastighet (1500 rpm ved 4 C i 10 minutter). Den resulterende supernatant ble underkastet ultrasentrifugering (100 000 g ved 4 C i 1 time). Den nedsentrifugerte membranfraksjon ble gjenvunnet og suspendert i fosfatbuffer (konsentrasjonen av membranfraksjonen ble justert slik at 1 ml PBS inneholder membranfraksjon avledet fra 1 x IO&lt;7&gt;celler). Suspensjonen ble lagret ved -80 C. Suspensjonen som inneholdt cellemembranfraksjonen, ble anvendt som antigen (immunogen) for fremstilling av humant antistoff iflge foreliggende oppfinnelse, som vil beskrives senere. </span>(containing 25 mM HEPES (pH 7.4), 10 mM MgCl2, 0.25 M sucrose, and protease inhibitor (10 U/ml aprotinin, 2 g/ml pepstatin, 50 g/ml leupeptin and 0.35 mg/ml PMSF )). The cell suspension was processed in a Potter-type homogenizer and centrifuged at low speed (1500 rpm at 4 C for 10 minutes). The resulting supernatant was subjected to ultracentrifugation (100,000 g at 4C for 1 hour). The centrifuged-down membrane fraction was recovered and suspended in phosphate buffer (the concentration of the membrane fraction was adjusted so that 1 ml of PBS contains membrane fraction derived from 1 x 10&lt;7&gt; cells). The suspension was stored at -80 C. The suspension containing the cell membrane fraction was used as antigen (immunogen) for the production of human antibody according to the present invention, which will be described later.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempel 2 </span>Example 2</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Fremstilling av hybridom som danner humant, monoklonalt, antihumant AILIM- antistoff </span>Production of hybridoma producing human monoclonal anti-human AILIM antibody</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I dette eksempel ble fremstilling av monoklonalt antistoff utfrt iflge en typisk fremgangsmte som beskrevet i Experimental Medicine (supplement), Handbook for Cell Technology (red. T. Kuroki et al., Yodosha, s. 66-74,1992), og Experimental Manual for Monoclonal Antibody (T. Ando et al., Kodansha, 1991). </span>In this example, production of monoclonal antibody was carried out according to a typical procedure as described in Experimental Medicine (supplement), Handbook for Cell Technology (ed. T. Kuroki et al., Yodosha, pp. 66-74, 1992), and Experimental Manual for Monoclonal Antibody (T. Ando et al., Kodansha, 1991).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cellemembranfraksjon fremstilt fra rekombinante celler som overuttrykker humant AILIM, erholdt i eksempel 1, ble anvendt som immunogen for humant AILIM. </span>Cell membrane fraction prepared from recombinant cells overexpressing human AILIM, obtained in Example 1, was used as immunogen for human AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dyrene som ble immunisert, var transgene mus som danner humant antistoff, </span>The animals that were immunized were transgenic mice that produce human antibody,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">fremstilt ved fremgangsmten beskrevet ovenfor (Nature Genetics, vol. 7, s. 13-21, 1994; Nature Genetics, vol. 15, s. 146-156,1997; publisert japansk oversettelse av internasjonal patentsknad nr. Hei 4-504365; publisert japansk oversettelse av internasjonal patentsknad nr. Hei 7-509137; Nikkei Science, juni, s. 40-50,1995, osv.). </span>produced by the method described above (Nature Genetics, vol. 7, pp. 13-21, 1994; Nature Genetics, vol. 15, pp. 146-156, 1997; published Japanese translation of International Patent Application No. Hei 4-504365; published Japanese Translation of International Patent Application No. Hi 7-509137; Nikkei Science, June, pp. 40-50, 1995, etc.).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mikroplater med flere brnner ble anvendt for dyrking av celler. </span>Multi-well microplates were used for growing cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2.1 Immunisering og fremstilling av h&lt;y&gt;bridom </span>2.1 Immunization and production of h&lt;y&gt;bridom</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Et av de to immunogenene (100fil/mus/tilfrsel), fremstilt i 1.4 (avledet fra HPB-ALL) og i 1.5 (avledet fra CHO) beskrevet ovenfor, ble gitt til de ovenfor nevnte humant antistoff-produserende, transgene mus. Immunogenet ble injisert sammen med Freunds komplette adjuvans (ICN/CAPPEL) i fotputen som primrimmunisering (dag 0). </span>One of the two immunogens (100 l/mouse/supply), prepared in 1.4 (derived from HPB-ALL) and in 1.5 (derived from CHO) described above, was administered to the above-mentioned human antibody-producing transgenic mice. The immunogen was injected together with Freund's complete adjuvant (ICN/CAPPEL) into the foot pad as primary immunization (day 0).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Etter primrimmuniseringen ble et av de to immunogenene i tillegg injisert i fotputen med 1 ukes mellomrom som sekundr- og/eller tertirimmunisering. P samme mte ble injeksjonen utfrt videre for den endelige immunisering 2 dager fr fremstilling av lymfocytter, som beskrives nedenfor. </span>After the primary immunization, one of the two immunogens was additionally injected into the foot pad at 1-week intervals as secondary and/or tertiary immunization. Similarly, the injection was carried out further for the final immunization 2 days before the preparation of lymphocytes, as described below.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">To dager etter siste immunisering ble lymfocytter fremstilt fra subinguinale og subgenuale lymfeknuter og milt fra de immuniserte transgene mus. Lymfocytter og musemyelomceller P3/X63-AG8.653 (ATCC nr. CRL-1580) ble sammenblander ved et forhold p 5:1, og polyetylenglykol 1500 (Boehringer Mannheim) ble tilsatt som fusjonsmiddel. Blandingen ble s fortynnet med 10 volumer serumfritt basalmedium EX-CELL301 (JRH Bioscience). Deretter ble celleblandingen vasket med basalmedium og suspendert i HAT-medium (11 basalmedium tilsatt 13,61 mg hypoksantin, 176 fig aminopterin og 3,88 mg av tymidin). Cellene ble utsdd i 96-brnners mikroplater og dyrket i 10-14 dager for fullfring av cellefusjonen. Cellefusjonsbehandlingen ga mange hybridomer. </span>Two days after the last immunization, lymphocytes were prepared from subinguinal and subgenual lymph nodes and spleens of the immunized transgenic mice. Lymphocytes and mouse myeloma cells P3/X63-AG8.653 (ATCC No. CRL-1580) were mixed at a ratio of 5:1, and polyethylene glycol 1500 (Boehringer Mannheim) was added as a fusion agent. The mixture was then diluted with 10 volumes of serum-free basal medium EX-CELL301 (JRH Bioscience). Then the cell mixture was washed with basal medium and suspended in HAT medium (11 basal medium added 13.61 mg of hypoxanthine, 176 g of aminopterin and 3.88 mg of thymidine). The cells were seeded in 96-well microplates and cultured for 10-14 days to complete cell fusion. The cell fusion treatment produced many hybridomas.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2.2 Analyse av humane, monoklonalt antistoff- produserende hybridomer </span>2.2 Analysis of human monoclonal antibody-producing hybridomas</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En rekke hybridomer fremstilt i 2.1 beskrevet ovenfor ble analysert ved celle-ELISA, som beskrevet nedenfor, for seleksjon av hybridomer som som danner humant, monoklonalt antistoff mot humant AILIM. </span>A number of hybridomas prepared in 2.1 described above were analyzed by cell ELISA, as described below, for the selection of hybridomas which produce human monoclonal antibody against human AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">De rekombinante HPB-ALL-cellene og de rekombinante CHO-cellene som overuttrykker humant AILIM, og som er beskrevet ovenfor, ble utsdd i brnner i 96-brnners ELISA-mikroplater (1 x IO&lt;5&gt;celler/brnn). Cellene ble inkubert ved 37 C i 2 dager. </span>The recombinant HPB-ALL cells and the recombinant CHO cells overexpressing human AILIM described above were seeded into wells of 96-well ELISA microplates (1 x 10&lt;5&gt; cells/well). The cells were incubated at 37C for 2 days.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Deretter ble supernatanten fra hver brnn fjernet, og prver av supernatant fra hver av hybridomkulturene ble tilsatt (50fil/brnn), og blandingen ble inkubert i 1 time. Etter fullfrt reaksjon ble lsningen fjernet, og hver brnn ble vasket tre ganger med PBS tilsatt 1 % BSA (Sigma). </span>Then the supernatant from each well was removed, and samples of supernatant from each of the hybridoma cultures were added (50 l/well), and the mixture was incubated for 1 hour. After completion of the reaction, the solution was removed, and each well was washed three times with PBS supplemented with 1% BSA (Sigma).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Deretter ble peroksidasekonjugert antihumant immunglobulin(Fc)-antistoff fra geit (50 fil av 2000 ganger fortynnet serum pr. brnn, American Corex, 1 % BSA/PBS) tilsatt til hver brnn for pvisning av tungkjeden fra humant immunglobulin (humant, monoklonalt antistoff) i hybridomsupernatanten. Blandingen ble inkubert ved romtemperatur i 1 time. </span>Next, peroxidase-conjugated goat anti-human immunoglobulin (Fc) antibody (50 l of 2000-fold diluted serum per well, American Corex, 1% BSA/PBS) was added to each well for detection of human immunoglobulin heavy chain (human monoclonal antibody) in the hybridoma supernatant. The mixture was incubated at room temperature for 1 hour.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Videre ble peroksidasekonjugert antihumant immunglobulin K-kjedeantistoff fra geit (50 fil av 2000 ganger fortynnet serum pr. brnn) tilsatt til hver brnn for pvisning av lettkjeden fra humant immunglobulin (humant, monoklonalt antistoff) i hybridomsupernatanten. Blandingen ble inkubert ved romtemperatur i 15 minutter. </span>Furthermore, peroxidase-conjugated anti-human immunoglobulin K-chain antibody from goat (50 l of 2000-fold diluted serum per well) was added to each well for detection of the light chain from human immunoglobulin (human, monoclonal antibody) in the hybridoma supernatant. The mixture was incubated at room temperature for 15 minutes.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Antihumant IgFc-antistoff eller antihumant IgK-antistoff ble fjernet fra brnnene i mikroplatene, hvoretter platene ble vasket tre ganger med PBS tilsatt 1 % BSA. Tetrametylbenzidin (3,3',5,5'-tetrametylbenzidin (TMB), 100fil/brnn, BIO-RAD) ble tilsatt til hver brnn, og den resulterende blanding ble inkubert ved romtemperatur i 15 minutter. </span>Antihuman IgFc antibody or antihuman IgK antibody was removed from the wells of the microplates, after which the plates were washed three times with PBS supplemented with 1% BSA. Tetramethylbenzidine (3,3',5,5'-tetramethylbenzidine (TMB), 100 l/well, BIO-RAD) was added to each well, and the resulting mixture was incubated at room temperature for 15 minutes.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Deretter ble 1 N H2SO4tilsatt til hver brnn (50 jil/brnn) for  stoppe reaksjonen. Reaksjonen ble mlt ved mling av absorbansen ved en blgelengde p 450 nm ved hjelp av en mikroplateleser (modell 3550 mikroplateleser, BIO-RAD). </span>Then 1 N H 2 SO 4 was added to each well (50 l/well) to stop the reaction. The reaction was measured by measuring the absorbance at a wavelength of 450 nm using a microplate reader (model 3550 microplate reader, BIO-RAD).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Et kontroll-ELISA-eksperiment ble utfrt p samme mte som beskrevet ovenfor ved anvendelse av flgende reagenser: (1) villtype-HPB-ALL-celler i stedet for rekombinante HPB-ALL-celler som uttrykker humant AILIM; (2) villtype-CHO-celler i stedet for rekombinante CHO-celler som uttrykker humant AILIM; (3) monoklonale antistoffer fra mus mot humant AILIM (SA12 eller SG430, JP-A 11-29599 (eksempel 12) og WO 98/38216 (eksempel 12)) i stedet for hybridomsupernatant; (4) humant, monoklonalt antistoff mot KLH ("keyhole limpef-hemocyanin, PIERCE) i stedet for hybridomsupernatant </span>A control ELISA experiment was performed in the same manner as described above using the following reagents: (1) wild-type HPB-ALL cells instead of recombinant HPB-ALL cells expressing human AILIM; (2) wild-type CHO cells instead of recombinant CHO cells expressing human AILIM; (3) mouse monoclonal antibodies against human AILIM (SA12 or SG430, JP-A 11-29599 (Example 12) and WO 98/38216 (Example 12)) instead of hybridoma supernatant; (4) human monoclonal antibody against KLH ("keyhole limpef-hemocyanin, PIERCE) instead of hybridoma supernatant</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det humane, monoklonale anti-KLH-antistoff ble fremstilt iflge fremgangsmten beskrevet ovenfor i 2.1, ved immunisering av de ovenfor nevnte humant antistoff-produserende, transgene mus med KLH ("keyhole limpet"-hemocyanin, PIERCE). </span>The human monoclonal anti-KLH antibody was prepared according to the method described above in 2.1, by immunization of the above-mentioned human antibody-producing transgenic mice with KLH ("keyhole limpet" hemocyanin, PIERCE).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mange hybridomer som dannet humant, monoklonalt antistoff som kunne bindes til humant AILIM, ble selektert ved analysen. </span>Many hybridomas that produced human monoclonal antibody that could bind to human AILIM were selected in the analysis.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2.3 Primrkloning av hybridomer </span>2.3 Primary cloning of hybridomas</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mange typer av hybridommonokloner ble etablert fra de forskjellige hybridomene (utgangscellelinjene) som var selektert i 2.2 beskrevet ovenfor. Disse dannet humant, monoklonalt antistoff mot humant AILIM, vist ved flgende analysefremgangsmte. </span>Many types of hybridoma monoclonals were established from the different hybridomas (starting cell lines) selected in 2.2 described above. These formed human monoclonal antibody against human AILIM, shown by the following assay procedure.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Hybridomene selektert i 2.2 beskrevet ovenfor ble utsdd i 24-brnners mikroplater. Antallet hybridomceller i hver brnn ble bestemt ved pipettering. Deretter ble 10 % ftalt kalveserum (FCS, Trace Bioscience PTY), 1 % penicillin/streptomycin (Sigma), 1 % HT-supplement (GIBCO-BRL) og 2,5 % T-STIM kultursupplement (Collaborative Biomedical Products) tilsatt til EX-CELL301-medium (JRH Bioscience) som inneholdt 4,0 mM L-glutamin og lipid. Det resulterende modifiserte medium ble anvendt for fortynning av hybridomer til 1 x 10&lt;4&gt;celler/ml, og cellene ble suspendert i hver brnn. </span>The hybridomas selected in 2.2 described above were seeded in 24-well microplates. The number of hybridoma cells in each well was determined by pipetting. Then, 10% fetal calf serum (FCS, Trace Bioscience PTY), 1% penicillin/streptomycin (Sigma), 1% HT supplement (GIBCO-BRL), and 2.5% T-STIM culture supplement (Collaborative Biomedical Products) were added to EX -CELL301 medium (JRH Bioscience) containing 4.0 mM L-glutamine and lipid. The resulting modified medium was used to dilute hybridomas to 1 x 10&lt;4&gt;cells/ml, and the cells were suspended in each well.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cellesuspensjonen (300 fil eller 600 fil) i hver brnn ble tilsatt og blandet godt med det modifiserte medium (150 ml eller 300 ml), hvoretter et 200 ml uttak av cellesuspensjonen ble tilsatt til brnner i flere 96-brnners mikroplater, slik at hver brnn inneholdt 4 hybridomceller. Det ovenfor nevnte modifiserte medium (50 ml eller 100 ml) ble tilsatt til den gjenvrende cellesuspensjon og blandet godt, og den resulterende cellesuspensjon ble s tilsatt til hver brnn i andre nyfremstilte 96-brnners mikroplater, slik at hver brnn inneholdt 2 hybridomceller. </span>The cell suspension (300 l or 600 l) in each well was added and mixed well with the modified medium (150 ml or 300 ml), after which a 200 ml aliquot of the cell suspension was added to wells in several 96-well microplates, so that each well contained 4 hybridoma cells. The above-mentioned modified medium (50 ml or 100 ml) was added to the remaining cell suspension and mixed well, and the resulting cell suspension was then added to each well of other freshly prepared 96-well microplates, so that each well contained 2 hybridoma cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cellene ble dyrket i 1-2 uker. Etter dyrkingen ble enkeltkolonier avledet fra en enkelt hybridom funnet i mange brnner. </span>The cells were cultured for 1-2 weeks. After cultivation, single colonies derived from a single hybridoma were found in many wells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Med celle-ELISA, som beskrevet ovenfor i 2.2, ble det bekreftet at humant, monoklonalt antistoff mot humant AILIM ble dannet i dyrkingssupernatanten i hver brnn som inneholdt en koloni. </span>By cell ELISA, as described above in 2.2, it was confirmed that human monoclonal antibody against human AILIM was formed in the culture supernatant of each well containing a colony.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2.4 Sekundrkloning av h&lt;y&gt;bridomer </span>2.4 Secondary cloning of hybridomas</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Subkloning (sekundrkloning) av de forskjellige hybridomkloner erholdt i 2.3 ovenfor ble utfrt iflge fremgangsmten beskrevet ovenfor i 2.3. </span>Subcloning (secondary cloning) of the various hybridoma clones obtained in 2.3 above was carried out according to the method described above in 2.3.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Celletettheten i hver brnn i en 96-brnners mikroplate ble justert til 1 celle/brnn i det foreliggende eksperiment. </span>The cell density in each well of a 96-well microplate was adjusted to 1 cell/well in the present experiment.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Analysen ga mange hybridommonokloner som dannet humant, monoklonalt antistoff mot humant AILIM. Noen av klonene var som beskrevet nedenfor: </span>The analysis yielded many hybridoma monoclonals that produced human monoclonal antibody against human AILIM. Some of the clones were as described below:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(Klonnavn) </span>(clone name)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AIF34 (JMabl24), AIF182 (JMab-126), AIF348 (JMab-127), </span>AIF34 (JMabl24), AIF182 (JMab-126), AIF348 (JMab-127),</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AIF620 (JMab-128), AIF1052 (JMab-135), AIH5D3 (JMab-136), AIH386 (JMab-137), AII289 (JMab-138), AII394 (JMab-139), AII488 (JMab-140), AIJ40 (JMab-141). </span>AIF620 (JMab-128), AIF1052 (JMab-135), AIH5D3 (JMab-136), AIH386 (JMab-137), AII289 (JMab-138), AII394 (JMab-139), AII488 (JMab-140), AIJ40 (JMab-141).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Navnene gitt ovenfor benyttes gjennomgende i foreliggende patentsknad, nrmere bestemt i alle eksempler beskrevet nedenfor, innbefattet foreliggende eksempel, og i figurene og tabellene som inneholder analyseresultatene erholdt i dette eksempel. </span>The names given above are used throughout in the present patent application, more specifically in all examples described below, including the present example, and in the figures and tables containing the analysis results obtained in this example.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempel 3 </span>Example 3</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Analyse av egenskapene til monoklonalt antistoff </span>Analysis of the properties of monoclonal antibody</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">3.1 Analyse av tungkjede og lettkjede </span>3.1 Analysis of heavy chain and light chain</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ved anvendelse av ELISA og "flow"-cytometri som beskrevet nedenfor, ble det bekreftet at det monoklonale antistoff mot humant AILIM som ble dannet av hver av hybridomklonene, klonet som beskrevet i 2.4 ovenfor, faktisk var et humant, monoklonalt antistoff. </span>Using ELISA and flow cytometry as described below, it was confirmed that the monoclonal antibody to human AILIM produced by each of the hybridoma clones cloned as described in 2.4 above was indeed a human monoclonal antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">De rekombinante HPB-ALL-cellene som overuttrykker humant AILIM, fremstilt i eksempel 1, ble utsdd i brnnene i en mikroplate med V-formet brnn (3 x IO&lt;4&gt;celler/brnn). Cellene ble dyrket ved 37 C i RPMI-1640-medium tilsatt 10 % FCS. </span>The recombinant HPB-ALL cells overexpressing human AILIM, prepared in Example 1, were seeded into the wells of a V-shaped well microplate (3 x 10&lt;4&gt; cells/well). The cells were grown at 37C in RPMI-1640 medium supplemented with 10% FCS.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Etter fullfrt dyrking ble platen sentrifugert (ved 1800 rpm i 2 minutter) for ned-sentrifugering av cellene, hvoretter supernatanten ble fjernet. Dyrkingssupernatant (50fil/brnn) fra hver av hybridomene klonet i 2.4, beskrevet ovenfor, monoklonalt, antihumant AILIM-antistoff fra mus SA12 (2fig/50fil) eller alternativt humant, monoklonalt anti-KLH-antistoff (50fil/brnn) som kontrollantistoff ble tilsatt til hver brnn. Blandingen fikk reagere i 30 minutter i et kjleskap. Etter reaksjonen ble prvelsningen fjernet, og hver brnn ble vasket med fosfatbuffer (0,5 % BSA-PBS tilsatt 5 mM EDTA). </span>After completion of cultivation, the plate was centrifuged (at 1800 rpm for 2 minutes) to down-centrifuge the cells, after which the supernatant was removed. Culture supernatant (50 l/well) from each of the hybridomas cloned in 2.4, described above, monoclonal anti-human AILIM antibody from mouse SA12 (2 l/50 l) or alternatively human monoclonal anti-KLH antibody (50 l/well) as control antibody was added to each well. The mixture was allowed to react for 30 minutes in a refrigerator. After the reaction, the sample solution was removed, and each well was washed with phosphate buffer (0.5% BSA-PBS added to 5 mM EDTA).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Deretter ble et av sekundrantistoffene beskrevet nedenfor tilsatt til hver brnn (fortynnet 1000 ganger med den ovenfor beskrevne fosfatbuffer og tilsatt i en mengde p </span>Then one of the secondary antibodies described below was added to each well (diluted 1000 times with the phosphate buffer described above and added in an amount of</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">50fil/brnn) for suspendering av cellene. Suspensjonen fikk reagere i 30 minutter i et kjleskap.
(Sekundrantistoff): biotinmerket, antihumant IgG-antistoff (Zymed); </span>50 cells/well) for suspending the cells. The suspension was allowed to react for 30 minutes in a refrigerator.
(Secondary antibody): biotin-labeled, anti-human IgG antibody (Zymed);</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">biotinmerket, antihumant IgG-antistoff (Protos); </span>biotin-labeled anti-human IgG antibody (Protos);</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">biotinmerket, antihumant IgFc-antistoff (EY Laboratories) eller biotinmerket, antihumant IgK-antistoff (Vector). </span>biotin-labeled anti-human IgFc antibody (EY Laboratories) or biotin-labeled anti-human IgK antibody (Vector).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Etter reaksjonen ble sekundrantistoffet fjernet, og brnnene i platen ble vasket med den ovenfor nevnte fosfatbuffer. S ble fykoerytirnmerket streptavidin (streptavidin-PE, Pharmingen, fortynnet 500 ganger med den ovenfor nevnte fosfatbuffer og tilsatt i en mengde p 50fil/brnn) tilsatt til hver brnn. Blandingen fikk reagere i 30 minutter i et kjleskap. Etter reaksjonen ble brnnene vasket med den ovenfor nevnte fosfatbuffer. Den ovenfor nevnte fosfatbuffer ble s tilsatt til brnnene (200fil/brnn) for suspendering av cellene. </span>After the reaction, the secondary antibody was removed, and the wells in the plate were washed with the above-mentioned phosphate buffer. Then phycoerythrin-labeled streptavidin (streptavidin-PE, Pharmingen, diluted 500 times with the above-mentioned phosphate buffer and added in an amount of 50 l/well) was added to each well. The mixture was allowed to react for 30 minutes in a refrigerator. After the reaction, the wells were washed with the above-mentioned phosphate buffer. The above-mentioned phosphate buffer was then added to the wells (200 l/well) to suspend the cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Prvene ble analysert for  bestemme reaktiviteten av det monoklonale, antihumant AILIM-antistoff i dyrkingssupernatanten fra hver av hybridomklonene overfor HPB-ALL-cellene som overuttrykker humant AILIM i hver brnn. </span>The samples were analyzed to determine the reactivity of the monoclonal anti-human AILIM antibody in the culture supernatant from each of the hybridoma clones to the HPB-ALL cells overexpressing human AILIM in each well.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Kontrollanalyser ble utfrt p samme mte som beskrevet ovenfor ved anvendelse av flgende reagenser: (1) villtype-HPB-ALL-celler i stedet for rekombinante HPB-ALL-celler som overuttrykker humant AILIM; (2) humant, monoklonalt antistoff mot KLH ("keyhole limpef-hemocyanin, PIERCE) i stedet for hybridomsupernatant. </span>Control assays were performed in the same manner as described above using the following reagents: (1) wild-type HPB-ALL cells instead of recombinant HPB-ALL cells overexpressing human AILIM; (2) human monoclonal antibody against KLH ("keyhole limpef-hemocyanin, PIERCE) instead of hybridoma supernatant.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det humane, monoklonale anti-KLH-antistoff ble fremstilt iflge fremgangsmten beskrevet ovenfor i 2.1, ved immunisering av de ovenfor nevnte humant antistoff-produserende, transgene mus med KLH ("keyhole limpef-hemocyanin, PIERCE). </span>The human monoclonal anti-KLH antibody was prepared according to the method described above in 2.1, by immunization of the above-mentioned human antibody-producing, transgenic mice with KLH ("keyhole limpef-hemocyanin, PIERCE).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Basert p resultatet ble det bekreftet at alle hybridomklonene beskrevet ovenfor i 2.4 var humane, monoklonale antistoffer som bestod av en humant avledet tungkjede og en humant avledet K-lettkjede. </span>Based on the result, it was confirmed that all the hybridoma clones described above in 2.4 were human monoclonal antibodies consisting of a human-derived heavy chain and a human-derived K light chain.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Et eksempel p resultatene er vist i figur 1, som omfatter analyseresultatet for hybridomklonene AIH5D3 (JMab-136), AII289 (JMab-138) og AII394 (JMab-139). </span>An example of the results is shown in Figure 1, which includes the analysis result for the hybridoma clones AIH5D3 (JMab-136), AII289 (JMab-138) and AII394 (JMab-139).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">3.2 Isotvping av humant, monoklonalt antistoff </span>3.2 Isolation of human monoclonal antibody</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Isotypen ble bestemt for hvert av de humane, monoklonale antihumant AILIM-antistoffene som ble dannet av hybridomene klonet i 2.4 og analysert i 3.1 ovenfor. Bestemmel-sen ble utfrt ved anvendelse av et "Human Monoclonal Antibody Isotyping Kit" (American Qualex) iflge den eksperimentelle fremgangsmte som flger med settet. </span>The isotype was determined for each of the human monoclonal anti-human AILIM antibodies generated from the hybridomas cloned in 2.4 and analyzed in 3.1 above. The determination was carried out using a "Human Monoclonal Antibody Isotyping Kit" (American Qualex) according to the experimental procedure provided with the kit.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Alle de humane, monoklonale antihumant AILIM-antistoffene ble bestemt  vre IgG2/K. </span>All of the human monoclonal anti-human AILIM antibodies were determined to be IgG2/K.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempel 4 </span>Example 4</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Fremstilling av humant, monoklonalt antistoff mot humant AILIM ( humant, monoklonalt, antihumant AILIM- antistoff) i stor skala og rensing av dette </span>Production of human, monoclonal antibody against human AILIM (human, monoclonal, anti-human AILIM antibody) on a large scale and purification of this</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">4.1 Fremgangsmte 1 </span>4.1 Procedure 1</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Celler fra hver hybridomklonene som dannet humant, monoklonalt, antihumant AILIM-antistoff, fremstilt i 2.4 ovenfor, ble tilsatt til en vevsdyrkingsflaske (50 ml, FALCON) og dyrket i ASF104-medium (Ajinomoto) tilsatt 10 % "Ultra Low Bovine" IgG-FBS (GIBCO-BRL) til konfluens under en atmosfre med 5 % CO2ved 37 C. </span>Cells from each of the hybridoma clones producing human monoclonal anti-human AILIM antibody, prepared in 2.4 above, were added to a tissue culture flask (50 ml, FALCON) and cultured in ASF104 medium (Ajinomoto) supplemented with 10% "Ultra Low Bovine" IgG- FBS (GIBCO-BRL) to confluence under an atmosphere of 5% CO2 at 37 C.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Deretter ble hele dyrkingsvsken overfrt til en ny vevsdyrkingsflaske (750 ml, FALCON), og cellene ble dyrket i ASF104-medium (Ajinomoto) tilsatt 10 % "Ultra Low Bovine" IgG-FBS (GIBCO-BRL) til konfluent under en atmosfre med 5 % C02ved 37 C. </span>Then, the entire culture fluid was transferred to a new tissue culture flask (750 ml, FALCON), and the cells were cultured in ASF104 medium (Ajinomoto) supplemented with 10% "Ultra Low Bovine" IgG-FBS (GIBCO-BRL) to confluency under an atmosphere of 5 % C02 at 37 C.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Etter 10-20 dagers dyrking ble dyrkingssupernatant fra hver hybridom gjenvunnet og overfrt til et 50 ml konisk polypropylenrr (FALCON). Rret ble sentrifugert ved 500 x g i 5 minutter. </span>After 10-20 days of culture, culture supernatant from each hybridoma was recovered and transferred to a 50 ml conical polypropylene tube (FALCON). The tube was centrifuged at 500 x g for 5 minutes.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den resulterende supernatant ble s filtrert gjennom en steriliseringsfilterenhet (NALGEN), og filtratet ble gjenvunnet. </span>The resulting supernatant was then filtered through a sterilizing filter unit (NALGEN) and the filtrate was recovered.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Filtratet ble psatt en HiTrap protein G-kolonne ("HiTrap affinity column Protein G", Amersham Pharmacia) som p forhnd var ekvilibrert med fosfatbuffer (30 ml) ved en gjennomstrmningshastighet p 3 ml/minutt. </span>The filtrate was applied to a HiTrap protein G column ("HiTrap affinity column Protein G", Amersham Pharmacia) which had previously been equilibrated with phosphate buffer (30 ml) at a flow rate of 3 ml/minute.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Deretter ble kolonnen vasket med fosfatbuffer (20 ml), hvoretter antistoffet av interesse ble eluert ved  sette 100 mM sitratbuffer (pH 2,0) p kolonnen ved en gjennom-strmningshastighet p ca. 1 ml/minutt. Den eluerte lsning ble s nytralisert med en lsning (pH 9,0) med 750 mM Tris-HCl og filtrert gjennom et filter (Millipore) for  fjerne den hvite utfelling. Det resulterende filtrat ble dialysert mot fosfatbuffer (over natten) og filtrert gjennom et filter (Millipore). P denne mten ble renset humant, monoklonalt anti-AILIM-antistoff erholdt fra hver av hybridomcellelinjene. </span>The column was then washed with phosphate buffer (20 ml), after which the antibody of interest was eluted by applying 100 mM citrate buffer (pH 2.0) to the column at a flow rate of approx. 1 ml/minute. The eluted solution was then neutralized with a solution (pH 9.0) of 750 mM Tris-HCl and filtered through a filter (Millipore) to remove the white precipitate. The resulting filtrate was dialyzed against phosphate buffer (overnight) and filtered through a filter (Millipore). In this way, purified human monoclonal anti-AILIM antibody was obtained from each of the hybridoma cell lines.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Proteinskonsentrasjonen ble bestemt ut fra absorbansen ved 280 nm ved anvendelse av et spektrofotometer (lA2go= 1,41 mg/ml). </span>The protein concentration was determined from the absorbance at 280 nm using a spectrophotometer (1A2go = 1.41 mg/ml).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">4.2 Fremgangsmte 2 </span>4.2 Procedure 2</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Celler fra hver av hybridomklonene som var blitt fremstilt i 2.4 ovenfor, ble kondisjonert i ASF104-medium (Ajinomoto) tilsatt 10 % "Ultra Low Bovine" IgG-FBS (GIBCO-BRL) (1-2 x IO&lt;6&gt;celler/ml for hver prve) og utsdd og dyrket i "Integra Cell Line 1000" (INTEGRA CL1000, INTEGRA BIOSCIENCE). Etter 7-10 dagers dyrking, da celletettheten hadde ndd lx 10&lt;8&gt;celler/ml, ble supernatant fra hver hybridomkultur gjenvunnet. </span>Cells from each of the hybridoma clones prepared in 2.4 above were conditioned in ASF104 medium (Ajinomoto) supplemented with 10% "Ultra Low Bovine" IgG-FBS (GIBCO-BRL) (1-2 x 10&lt;6&gt;cells/ml for each sample) and seeded and cultured in "Integra Cell Line 1000" (INTEGRA CL1000, INTEGRA BIOSCIENCE). After 7-10 days of culture, when the cell density had reached lx 10&lt;8&gt;cells/ml, supernatant from each hybridoma culture was recovered.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Hver av dyrkingssupernatantene ble psatt en HiTrap protein G-kolonne ("HiTrap affinity column Protein G", Amersham Pharmacia) som p forhnd var ekvilibrert med fosfatbuffer (30 ml) ved en gjennomstrmningshastighet p 3 ml/minutt. </span>Each of the culture supernatants was applied to a HiTrap protein G column ("HiTrap affinity column Protein G", Amersham Pharmacia) previously equilibrated with phosphate buffer (30 ml) at a flow rate of 3 ml/minute.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Deretter ble kolonnen vasket med fosfatbuffer (20 ml), hvoretter 100 mM sitratbuffer (pH 2,0) ble psatt kolonnen ved en gjennomstrmningshastighet p ca. 1 ml/minutt for eluering av antistoffet. S ble en lsning (pH 9,0) med 750 mM Tris-HCl tilsatt for nytralisering av den eluerte lsning, og den resulterende lsning ble filtrert gjennom et filter (Millipore) for  fjerne den hvite utfelling. Det resulterende filtrat ble dialysert mot fosfatbuffer (over natten) og s filtrert gjennom et filter (Millipore). P denne mten ble renset humant, monoklonalt anti-AILIM-antistoff erholdt fra hver av hybridomcellelinjene. </span>The column was then washed with phosphate buffer (20 ml), after which 100 mM citrate buffer (pH 2.0) was applied to the column at a flow rate of approx. 1 ml/minute for elution of the antibody. Then a solution (pH 9.0) of 750 mM Tris-HCl was added to neutralize the eluted solution, and the resulting solution was filtered through a filter (Millipore) to remove the white precipitate. The resulting filtrate was dialyzed against phosphate buffer (overnight) and then filtered through a filter (Millipore). In this way, purified human monoclonal anti-AILIM antibody was obtained from each of the hybridoma cell lines.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempel 5 </span>Example 5</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Reaktivitet av humant, monoklonalt, antihumant AILIM- antistoff overfor humant AILIM, og kryssreaktivitet med AILIM fra mus og rotte </span>Reactivity of human monoclonal anti-human AILIM antibody to human AILIM, and cross-reactivity with mouse and rat AILIM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Forskjellige rensede humane, monoklonale antihumant AILIM-antistoffer erholdt ovenfor ble analysert for reaktivitet overfor humant AILIM, s vel som for kryssreaktivitet med AILIM fra mus og rotte, ved anvendelse av celle-ELISA-fremgangsmten. </span>Various purified human monoclonal anti-human AILIM antibodies obtained above were analyzed for reactivity with human AILIM, as well as for cross-reactivity with mouse and rat AILIM, using the cell ELISA method.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5.1 Etablering av et ELISA- system for bestemmelse av IgG- antistoffkonsentrasjonen og fremstilling av kalibreringskurver </span>5.1 Establishment of an ELISA system for determining the IgG antibody concentration and preparation of calibration curves</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Siden alle de ovenfor nevnte rensede humane, monoklonale antihumant AILIM-antistoffene var IgG(IgG2)-antistoff, ble det etablert et ELISA-system for bestemmelse av IgG-antistoffkonsentrasjonen. </span>Since all of the above-mentioned purified human monoclonal anti-human AILIM antibodies were IgG(IgG2) antibody, an ELISA system was established to determine the IgG antibody concentration.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Antihumant IgG(Fc)-antistoff fra geit (1,2 fig/ml i PBS, 100 fil/brnn, Organon Teknika) ble tilsatt til hver av brnnene i en 96-brnners ELISA-mikroplate (Nunc). Platen ble inkubert ved romtemperatur i 2 timer for adsorpsjon av anti-IgG(Fc)-antistoffet til mikroplaten. Deretter ble supernatanten fjernet, og platen ble vasket tre ganger med fosfatbuffer (PBS) tilsatt 0,05 % Tween 20. Et blokkeringsmiddel (PBS tilatt 0,5 % bovint serumalbumin (BSA) og 0,1 % Tween 20) ble tilsatt til brnnene (200fil/brnn), og platen ble inkubert ved romtemperatur i 2 timer for blokkering av anti-IgG(Fc)-antistoff-frie seter p platen. Blokkeringsreagenset ble s fjernet, og brnnene ble vasket to ganger med PBS. </span>Goat antihuman IgG(Fc) antibody (1.2 g/ml in PBS, 100 l/well, Organon Teknika) was added to each well of a 96-well ELISA microplate (Nunc). The plate was incubated at room temperature for 2 hours for adsorption of the anti-IgG(Fc) antibody to the microplate. Then the supernatant was removed and the plate was washed three times with phosphate buffer (PBS) supplemented with 0.05% Tween 20. A blocking agent (PBS supplemented with 0.5% bovine serum albumin (BSA) and 0.1% Tween 20) was added to the wells. (200 l/well), and the plate was incubated at room temperature for 2 hours to block anti-IgG(Fc) antibody-free sites on the plate. The blocking reagent was then removed and the wells were washed twice with PBS.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Humant avledet IgG2-antistoff (50 fil/brnn, bindingssetet), som ble anvendt som standardantistoff, ble tilsatt i forskjellige konsentrasjoner (0-100 ng/ml) til brnner i platen, og platen ble inkubert ved romtemperatur i 2 timer. Overskuddet av standardantistofflsning ble fjernet, og brnnene ble vasket tre ganger med fosfatbuffer tilsatt 0,05 % Tween 20. </span>Human-derived IgG2 antibody (50 l/well, binding site), which was used as a standard antibody, was added at various concentrations (0-100 ng/ml) to wells of the plate, and the plate was incubated at room temperature for 2 hours. The excess standard antibody solution was removed, and the wells were washed three times with phosphate buffer supplemented with 0.05% Tween 20.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Deretter ble peroksidasekonjugert antihumant IgG/ic-antistoff fra geit tilsatt til hver brnn (fortynnet 4000 ganger, 100 jil/brnn, Protos), og platen ble inkubert ved romtemperatur i 1 time. </span>Then, peroxidase-conjugated goat anti-human IgG/ic antibody was added to each well (diluted 4000-fold, 100 l/well, Protos), and the plate was incubated at room temperature for 1 hour.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Supernatanten ble fjernet, og mikroplate ble vasket tre ganger med fosfatbuffer tilsatt 0,05 % Tween 20. En buffer som tilsatt substrat (sammensetning: ortofenylendiamin (O-fenylendiamin, OPD, 20 mg)/sitrat-fosfatbuffer (pH 5,0, 50 mi)/vandig lsning av 30 % hydrogenperoksid (15fil)) ble tilsatt til brnnene (100fil/brnn), og platen ble inkubert ved romtemperatur i ca. 7 minutter. </span>The supernatant was removed, and the microplate was washed three times with phosphate buffer supplemented with 0.05% Tween 20. A buffer as added substrate (composition: orthophenylenediamine (O-phenylenediamine, OPD, 20 mg)/citrate-phosphate buffer (pH 5.0, 50 ml)/aqueous solution of 30% hydrogen peroxide (15 l)) was added to the wells (100 l/well), and the plate was incubated at room temperature for approx. 7 minutes.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Deretter ble 2 M svovelsyre tilsatt til hver av brnnene (50fil/brnn) for  stoppe reaksjonen. Kalibreringskurver ble fremstilt (figur 2) basert p absorbansverdiene mlt ved en blgelengde p 490 nm ved anvendelse av en mikroplateleser. </span>Then 2 M sulfuric acid was added to each of the wells (50 l/well) to stop the reaction. Calibration curves were prepared (Figure 2) based on the absorbance values measured at a wavelength of 490 nm using a microplate reader.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Kontrollanalyser ble utfrt med dyrkingsmedium alene eller BSA-lsning alene som analyseforbindelse, p samme mte som beskrevet ovenfor. </span>Control assays were performed with culture medium alone or BSA solution alone as assay compound, in the same manner as described above.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5.2 Analyse av reaktiviteten av forskjellige rensede humane, monoklonale antihumant AILIM- antistoffer overfor humant AILIM.s vel som for kryssreaktivitet med AILIM fra mus og rotte </span>5.2 Analysis of the reactivity of various purified human monoclonal anti-human AILIM antibodies to human AILIM, as well as for cross-reactivity with mouse and rat AILIM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5.2.1 Fremstilling av reagenser </span>5.2.1 Preparation of reagents</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Reagensene som skulle benyttes i denne celle-ELISA, ble fremstilt som flger: 5.2.1.1 Fremstilling av rekombinante CHO- celler som overuttrykker muse- AILIM </span>The reagents to be used in this cell ELISA were prepared as follows: 5.2.1.1 Preparation of recombinant CHO cells overexpressing mouse AILIM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Rekombinante CHO-celler som overuttrykker muse-AILIM, ble fremstilt og erholdt p samme mte som beskrevet ovenfor i 1.1 og 1.3. </span>Recombinant CHO cells overexpressing mouse AILIM were prepared and obtained in the same manner as described above in 1.1 and 1.3.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">cDNA (aksesjonsbetegnelse i GenBank: AB023132 (cDNA), BAA82126 (aminosyre)) inneholdende fullengde-ORF for muse-AILIM ble innsatt i vektoren pEF-neo, hvoretter den resulterende rekombinante ekspresjonsvektor ble innfrt i kinesisk hamster-ovariumceller (CHO-celler) ved en hyppig anvendt fremgangsmte for elektroporering (960fiF, 320 V) ved anvendelse av en Gene Pulser (BioRad). Cellene ble dyrket i RPMI-1640-medium tilsatt geneticin (0,8 mg/ml, GIBCO-BRL) og 10 % FCS for seleksjon av medikamentresistente, transformerte celler, hvorved det ble erholdt rekombinante CHO-celler som overuttrykker muse-AILIM. </span>cDNA (GenBank accession number: AB023132 (cDNA), BAA82126 (amino acid)) containing the full-length ORF of mouse AILIM was inserted into the vector pEF-neo, after which the resulting recombinant expression vector was introduced into Chinese hamster ovary cells (CHO cells) by a frequently used method of electroporation (960F, 320 V) using a Gene Pulser (BioRad). The cells were grown in RPMI-1640 medium supplemented with geneticin (0.8 mg/ml, GIBCO-BRL) and 10% FCS for selection of drug-resistant, transformed cells, whereby recombinant CHO cells overexpressing mouse AILIM were obtained.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5.2.1.2 Fremstilling av rekombinante CHO- celler som overuttrykker rotte- AILIM </span>5.2.1.2 Production of recombinant CHO cells overexpressing rat AILIM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Rekombinante CHO-celler som overuttrykker rotte-AILIM, ble fremstilt og erholdt p samme mte som beskrevet ovenfor i 1.1 og 1.3. </span>Recombinant CHO cells overexpressing rat AILIM were prepared and obtained in the same manner as described above in 1.1 and 1.3.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Et cDNA (aksesjonsbetegnelse i GenBank: AB023134 (cDNA), BAA82128 (aminosyre)) som inneholder fullengde-ORF for rotte-AILIM, ble innsatt i vektoren pEF-neo, hvoretter den resulterende rekombinante ekspresjonsvektor ble innfrt i kinesisk hamster-ovariumceller (CHO-celler) ved en hyppig anvendt fremgangsmte for elektroporering (960fiF, 320 V) ved anvendelse av en Gene Pulser (BioRad). Cellene ble dyrket i RPMI-1640-medium tilsatt geneticin (0,8 mg/ml, GIBCO-BRL) og 10 % FCS for seleksjon av medikamentresistente, transformerte celler, hvorved det ble erholdt rekombinante CHO-celler som overuttrykker rotte-AILIM. </span>A cDNA (GenBank accession number: AB023134 (cDNA), BAA82128 (amino acid)) containing the full-length ORF of rat AILIM was inserted into the vector pEF-neo, after which the resulting recombinant expression vector was introduced into Chinese hamster ovary cells (CHO- cells) by a frequently used method of electroporation (960F, 320 V) using a Gene Pulser (BioRad). The cells were grown in RPMI-1640 medium supplemented with geneticin (0.8 mg/ml, GIBCO-BRL) and 10% FCS for selection of drug-resistant, transformed cells, whereby recombinant CHO cells overexpressing rat AILIM were obtained.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5.2.1.3 Fremstilling av monoklonalt antistoff mot muse- AILIM </span>5.2.1.3 Production of monoclonal antibody against mouse AILIM</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">De rekombinante CHO-cellene som overuttrykker muse- AILIM, fremstilt i 5.2.1.1 ovenfor, ble homogenisert og underkastet ultrasentirfugering (100 000 x g). Det cellemembran-fraksjonholdige nedsentrifugerte materialet ble gjenvunnet og suspendert i PBS. Den resulterende cellemembranfraksjon ble injisert i fotputen hos Wistar rotter sammen med Freunds komplette adjuvans for primrimmunisering (dag 0). Cellemembranfraksjonsantigenet ble videre gitt til rottene i fotputen p dag 7, dag 14 og dag 28 etter primrimmuniseringen. Lymfeknute-celler ble oppsamlet fra dyrene 2 dager etter siste immunisering. </span>The recombinant CHO cells overexpressing mouse AILIM, prepared in 5.2.1.1 above, were homogenized and subjected to ultracentrifugation (100,000 x g). The cell membrane fraction-containing centrifuged material was recovered and suspended in PBS. The resulting cell membrane fraction was injected into the foot pad of Wistar rats together with Freund's complete adjuvant for primary immunization (day 0). The cell membrane fraction antigen was further administered to the rats in the foot pad on day 7, day 14 and day 28 after the primary immunization. Lymph node cells were collected from the animals 2 days after the last immunization.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Lymfeknutecellene og musemyelomceller PAI (JCR nr. BOI 13; Res. Disclosure, vol. 217, s. 155,1982) ble sammenblandet i et forhold p 5:1. Cellene ble fusjonert ved anvendelse av polyetylenglykol 4000 (Boehringer Mannheim) som et fusjonsmiddel for fremstilling av hybridomer som danner monoklonalt antistoff. Seleksjon av hybridomene ble utfrt ved  dyrke dem i ASF104-medium (Ajinomoto) tilsatt HAT, 10 % ftalt kalveserum og aminopterin. </span>The lymph node cells and mouse myeloma cells PAI (JCR No. BOI 13; Res. Disclosure, vol. 217, p. 155, 1982) were mixed in a ratio of 5:1. The cells were fused using polyethylene glycol 4000 (Boehringer Mannheim) as a fusion agent for the preparation of monoclonal antibody forming hybridomas. Selection of the hybridomas was performed by growing them in ASF104 medium (Ajinomoto) supplemented with HAT, 10% fetal calf serum and aminopterin.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Reaktiviteten overfor muse-AILIM av det monoklonale rotteantistoff i dyrking-supernatanten fra hver av hybridomene ble bestemt ved  la dyrkingssupernatanten reagere med de ovenfor nevnte CHO-celler som uttrykker muse-AILIM, og s mle fluorescensintensiteten av cellene farget med FITC-merket anti-rotte- IgG (Cappel) i et EPICS-ELITE "flow"-cytometer. Analysen ga flere hybridomer som dannet monoklonalt antistoff med reaktivitet mot muse-AILIM. </span>The reactivity to mouse AILIM of the rat monoclonal antibody in the culture supernatant from each hybridoma was determined by reacting the culture supernatant with the above-mentioned CHO cells expressing mouse AILIM, and then measuring the fluorescence intensity of the cells stained with FITC-labeled anti- rat IgG (Cappel) in an EPICS-ELITE "flow" cytometer. The analysis yielded several hybridomas that produced monoclonal antibody with reactivity against mouse AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Blant disse var en hybridomlinje som ble betegnet "B10.5". Celler fra denne hybridom ble injisert intraperitonealt (IO&lt;6-&gt;IO&lt;7&gt;celler/0,5 ml/mus) til ICR-nu/nu-mus (hunner, 7-8-uker gamle). 10-20 dager etter injeksjonen ble ascitesvske oppsamlet fra musene ved laparotomi under bedvelse iflge en hyppig anvendt fremgangsmte. Det monoklonale antimuse-AILIM-antistoff fra rotte, B10.5 (IgGl), ble fremstilt fra ascitesvsken i stor skala. </span>Among these was a hybridoma line designated "B10.5". Cells from this hybridoma were injected intraperitoneally (10&lt;6-&gt;10&lt;7&gt;cells/0.5 ml/mouse) into ICR-nu/nu mice (females, 7-8 weeks old). 10-20 days after the injection, ascites fluid was collected from the mice by laparotomy under anesthesia according to a frequently used procedure. The rat anti-mouse AILIM monoclonal antibody, B10.5 (IgG1), was prepared from the ascites fluid on a large scale.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5.2.2 Reaktiviteten av antistoffet overfor AILIM fra menneske, mus og rotte </span>5.2.2 The reactivity of the antibody against AILIM from humans, mice and rats</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Konsentrasjon av humant, monoklonalt, antihumant AILIM-antistoff og kontrollantistoff som skulle anvendes i ELISA-analysen beskrevet nedenfor, ble bestemt basert p ELISA-analysen og kalibreringskurvene beskrevet i 5.1 ovenfor. </span>Concentration of human, monoclonal, anti-human AILIM antibody and control antibody to be used in the ELISA assay described below was determined based on the ELISA assay and calibration curves described in 5.1 above.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Celler (7 x 10&lt;3&gt;celler/brnn) av de rekombinante CHO-cellene som overuttrykker humant AILIM, fremstilt i eksempel 1, de rekombinante CHO-cellene som overuttrykker muse-AILIM, fremstilt i 5.2.1.1 ovenfor, og de rekombinante CHO-cellene som overuttrykker rotte-AILIM, fremstilt i 5.2.1.2 ovenfor, ble utsdd i brnner i 96-brnners ELISA-mikroplater og dyrket til konfluens ved 37 "C. </span>Cells (7 x 10&lt;3&gt;cells/well) of the recombinant CHO cells overexpressing human AILIM, prepared in Example 1, the recombinant CHO cells overexpressing mouse AILIM, prepared in 5.2.1.1 above, and the recombinant CHO - cells overexpressing rat AILIM, prepared in 5.2.1.2 above, were seeded into wells of 96-well ELISA microplates and grown to confluence at 37C.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Deretter ble supernatanten fjernet, hvoretter et av de rensede humane, monoklonale antihumant AILIM-antistoffene eller kontrollantistoffet fremstilt ovenfor ble tilsatt til hver brnn (antistoffkonsentrasjoner: antistoff med 200fig/ml ble fortynnet, med PBS tilsatt 1 % BSA, 3 ganger, 32 ganger, 3&lt;3&gt;ganger, 3&lt;4&gt;ganger, 3&lt;5&gt;ganger, 3&lt;6&gt;ganger, 37 ganger, 38 ganger, 3&lt;9&gt;ganger, 3&lt;10&gt;ganger, 3&lt;11&gt;ganger og 3&lt;12&gt;ganger) i en mengde p 50fil/brnn, og platene fikk reagere ved romtemperatur i 2 timer. Lsningene med monoklonalt antistoff ble fjernet, og brnnene ble vasket tre ganger med fosfatbuffer tilsatt 1 % BSA (Sigma). </span>Then the supernatant was removed, after which one of the purified human monoclonal anti-human AILIM antibodies or the control antibody prepared above was added to each well (antibody concentrations: antibody at 200 g/ml was diluted, with PBS supplemented with 1% BSA, 3 times, 32 times, 3&lt;3&gt;times, 3&lt;4&gt;times, 3&lt;5&gt;times, 3&lt;6&gt;times, 37 times, 38 times, 3&lt;9&gt;times, 3&lt;10&gt;times, 3&lt;11&gt;times and 3&lt; 12 times) in an amount of 50 fil/well, and the plates were allowed to react at room temperature for 2 hours. The monoclonal antibody solutions were removed, and the wells were washed three times with phosphate buffer supplemented with 1% BSA (Sigma).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Deretter ble pepperrotperoksidasekonjugert, antihumant IgG(Fc)-antistoff tilsatt til hver brnn (fortynnet 1000 ganger, 50 (il/brnn, American Qualex), og platene ble inkubert ved romtemperatur i 1 time. </span>Then, horseradish peroxidase-conjugated, antihuman IgG(Fc) antibody was added to each well (diluted 1000-fold, 50 (l/well, American Qualex), and the plates were incubated at room temperature for 1 hour.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Overskudd av den merkede antistofflsning ble fjernet, og mikroplatene ble vasket tre ganger med fosfatbuffer tilsatt 1 % BSA. Buffer tilsatt substrat (sammensetning: ortofenylendiamin (O-fenylendiamin, OPD, 20 mg)/sitrat-fosfatbuffer (pH 5,0,50 ml)/vandig lsning av 30 % hydrogenperoksid (15 |4.1 ble tilsatt til hver brnn (100^l/brnn), og platene ble inkubert ved romtemperatur i ca. 7 minutter. </span>Excess of the labeled antibody solution was removed, and the microplates were washed three times with phosphate buffer supplemented with 1% BSA. Buffer added substrate (composition: orthophenylenediamine (O-phenylenediamine, OPD, 20 mg)/citrate-phosphate buffer (pH 5.0.50 ml)/aqueous solution of 30% hydrogen peroxide (15 |4.1 was added to each well (100^ l/well), and the plates were incubated at room temperature for about 7 minutes.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Deretter ble 2 M svovelsyre tilsatt til brnnene (50 (il/brnn) for  stoppe reaksjonen. Absorbansen ble mlt ved en blgelengde p 490 nm ved anvendelse av en mikroplateleser (Bio-Rad). </span>Then, 2 M sulfuric acid was added to the wells (50 (l/well) to stop the reaction. The absorbance was measured at a wavelength of 490 nm using a microplate reader (Bio-Rad).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">For evaluering av de ovenfor nevnte antistoffer ble en kontroll-ELISA-analyse utfrt p samme mte som beskrevet ovenfor med flgende kontrollantistoffer: (1) det monoklonale museantistoff SA 12 eller SG430 rettet mot humant AILIM (JP-A 11-29599 (eksempel 12) og WO 98/38216 (eksempel 12)); (2) det monoklonale rotteantistoff B10.5 rettet mot muse-AILIM (5.2.1.3, beskrevet ovenfor); (3) monoklonalt museantistoff JTT2 mot rotte-AILIM (monoklonalt antistoff produsert av en hybridom som ble deponert internasjonalt den 11. oktober 1996 under den internasjonale aksesjonsbetegnelse FERM BP-5708 hos the National Institute of Bioscience and Human-Technology, The Agency of Industrial Science and Technology, The Ministry of International Trade and Industry)), som er en internasjonal deponeringsautoritet under Budapest-konvensjonen; JP-A 11-29599 (eksemplene 1 og 2) og WO 98/38216 (eksemplene 1 og 2)); (4) det ovenfor fremstilte humane, monoklonale antistoff mot KLH ("keyhole limpef-hemocyanin, PIERCE) i stedet for hybridomsupernatant. </span>For evaluation of the above-mentioned antibodies, a control ELISA assay was performed in the same manner as described above with the following control antibodies: (1) the mouse monoclonal antibody SA 12 or SG430 directed against human AILIM (JP-A 11-29599 (Example 12) and WO 98/38216 (Example 12)); (2) the rat monoclonal antibody B10.5 directed against mouse AILIM (5.2.1.3, described above); (3) mouse monoclonal antibody JTT2 against rat AILIM (monoclonal antibody produced by a hybridoma deposited internationally on October 11, 1996 under the international accession number FERM BP-5708 at the National Institute of Bioscience and Human-Technology, The Agency of Industrial Science and Technology, The Ministry of International Trade and Industry)), which is an international depository authority under the Budapest Convention; JP-A 11-29599 (Examples 1 and 2) and WO 98/38216 (Examples 1 and 2)); (4) the above prepared human monoclonal antibody against KLH ("keyhole limpef-hemocyanin, PIERCE) instead of hybridoma supernatant.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Kontroll-ELISA-eksperimentet ble utfrt p samme mte som beskrevet ovenfor ved anvendelse av villtype-CHO-cellene vist nedenfor i stedet for rekombinante CHO-celler som uttrykker AILIM. </span>The control ELISA experiment was performed in the same manner as described above using the wild-type CHO cells shown below instead of recombinant CHO cells expressing AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatene er vist i figurene 3-14. </span>The results are shown in Figures 3-14.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Basert p det oppndde resultat ble den 50 % effektive konsentrasjon (ED50:ng/ml) beregnet som et ml p reaktiviteten av de humane, monoklonale antihumant AILIM-antistoffene overfor humant AILIM (rekombinante CHO-celler som overuttrykker humant AILIM), muse-AILIM (rekombinante CHO-celler som overuttrykker muse-AILIM), eller rotte-AILIM (rekombinante CHO-celler som overuttrykker rotte-AILIM). Resultatene oppndd ved beregningen er vist nedenfor. </span>Based on the obtained result, the 50% effective concentration (ED50:ng/ml) was calculated as a measure of the reactivity of the human monoclonal anti-human AILIM antibodies against human AILIM (recombinant CHO cells overexpressing human AILIM), mouse AILIM (recombinant CHO cells overexpressing mouse AILIM), or rat AILIM (recombinant CHO cells overexpressing rat AILIM). The results obtained by the calculation are shown below.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">( A) ED50 for CHO som overuttrykker humant AILIM: </span>(A) ED50 for CHO overexpressing human AILIM:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AIF34 (JMab-124): 5,3 ng/ml </span>AIF34 (JMab-124): 5.3 ng/ml</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AIF182 (JMab-126): 3,6 ng/ml </span>AIF182 (JMab-126): 3.6 ng/ml</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AIF348 (JMab-127): 9,1 ng/ml </span>AIF348 (JMab-127): 9.1 ng/ml</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AIF620 (JMab-128): 10,1 ng/ml </span>AIF620 (JMab-128): 10.1 ng/ml</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AIF1052 (JMab-135): 2,0 ng/ml </span>AIF1052 (JMab-135): 2.0 ng/ml</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AIH5D3 (JMab-136): 7,5 ng/ml </span>AIH5D3 (JMab-136): 7.5 ng/ml</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AIH386 (JMab-137): 9,6 ng/ml </span>AIH386 (JMab-137): 9.6 ng/ml</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AII289 (JMab-138): 10,5 ng/ml </span>AII289 (JMab-138): 10.5 ng/ml</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AII394 (JMab-139): 10,6 ng/ml </span>AII394 (JMab-139): 10.6 ng/ml</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AII488 (JMab-140): 11,0 ng/ml </span>AII488 (JMab-140): 11.0 ng/ml</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AU 40 (JMab-141): 3,7 ng/ml </span>AU 40 (JMab-141): 3.7 ng/ml</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SA 12: 1,8 ng/ml </span>SA 12: 1.8 ng/ml</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SG430: 1,2 ng/ml </span>SG430: 1.2 ng/ml</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">( B) ED50 for CHO som overuttrykker muse- AILIM: </span>(B) ED50 for CHO overexpressing mouse AILIM:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AIF34 (JMab-124): 42 ng/ml </span>AIF34 (JMab-124): 42 ng/ml</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AIF348 (JMab-127): 81 ng/ml </span>AIF348 (JMab-127): 81 ng/ml</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AIF620 (JMab-128): 100 ng/ml </span>AIF620 (JMab-128): 100 ng/ml</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AII289 (JMab-138): 53 ng/ml </span>AII289 (JMab-138): 53 ng/ml</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AII394 (JMab-139): 60 ng/ml </span>AII394 (JMab-139): 60 ng/ml</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AII488 (JMab-140): 70 ng/ml </span>AII488 (JMab-140): 70 ng/ml</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">( C) ED50 for CHO som overuttrykker rotte- AILIM: </span>(C) ED50 for CHO overexpressing rat AILIM:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AIF34 (JMab-124): 45 ng/ml </span>AIF34 (JMab-124): 45 ng/ml</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AIF348 (JMab-127): 62 ng/ml </span>AIF348 (JMab-127): 62 ng/ml</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AIF620 (JMab-128): 97 ng/ml </span>AIF620 (JMab-128): 97 ng/ml</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AII289 (JMab-138): 57 ng/ml </span>AII289 (JMab-138): 57 ng/ml</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AII394 (JMab-139): 90 ng/ml </span>AII394 (JMab-139): 90 ng/ml</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AII488 (JMab-140): 90 ng/ml. </span>AII488 (JMab-140): 90 ng/ml.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatene viste at de humane, monoklonale antihumant AILIM-antistoffene iflge foreliggende oppfinnelse viste signifikant hy spesifisitet overfor humant AILIM. </span>The results showed that the human, monoclonal anti-human AILIM antibodies according to the present invention showed significantly high specificity towards human AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det viste seg videre at seks typer av humant, monoklonalt, antihumant AILIM-antistoff (vist ovenfor i (B) og (C)) reagerer med bde muse-AILIM og rotte-AILIM (bindingsevne, kryssreaktivitet). </span>It was further shown that six types of human monoclonal anti-human AILIM antibody (shown above in (B) and (C)) react with both mouse AILIM and rat AILIM (binding ability, cross-reactivity).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempel 6 </span>Example 6</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Bestemmelse av affinitet og nytraliserende aktivitet av humant, monoklonalt, antihumant AILIM- antistoff overfor antigenet ( humant AILIM) </span>Determination of affinity and neutralizing activity of human, monoclonal, anti-human AILIM antibody towards the antigen (human AILIM)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Assosiasjonshastighetskonstanten (ka), dissosiasjonshastighetskonstanten (kd) og dissosiasjonskonstanten (Kd) for reaksjonen mellom hvert av de rensede humane, monoklonale antihumant AILIM-antistoffene fremstilt ovenfor og humant AILIM ble bestemt ved anvendelse av et kommersielt tilgjengelig sett Biacore X (Amersham Pharmacia). </span>The association rate constant (ka), dissociation rate constant (kd) and dissociation constant (Kd) of the reaction between each of the purified human monoclonal anti-human AILIM antibodies prepared above and human AILIM were determined using a commercially available Biacore X kit (Amersham Pharmacia).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">6.1 Fremstilling av antigen for immobilisering til sensorbrikken </span>6.1 Preparation of antigen for immobilization to the sensor chip</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Antigen som skulle immobiliseres til sensorbrikken i settet, ble fremstilt som et rekombinant, kimrt antigen (i det pflgende betegnet "humant AILIM-IgFc"), som bestr av det ekstracellulre omrdet fra humant AILIM og det konstante omrdet (Fc) fra human IgGl. </span>Antigen to be immobilized to the sensor chip in the kit was prepared as a recombinant, chimeric antigen (hereinafter referred to as "human AILIM-IgFc"), which consists of the extracellular region from human AILIM and the constant region (Fc) from human IgG1.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Humant AILIM-IgFc ble fremstilt ved videre rensing av antigenet erholdt iflge fremgangsmten beskrevet i de tidligere patentsknader (JP-A 11-29599 (eksempel 16 (2)) og WO 98/38216 (eksempel 16 (2)) av en av de foreliggende oppfinnere, Tezuka. </span>Human AILIM-IgFc was prepared by further purification of the antigen obtained according to the method described in the previous patent applications (JP-A 11-29599 (Example 16 (2)) and WO 98/38216 (Example 16 (2)) of one of the present inventors, Tezuka.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dyrkingssupernatant fra rekombinante celler som danner humant AILIM-IgFc, ble psatt en HiTrap protein G-kolonne ("Hitrap affinity column Protein G", Amersham-Pharmacia) som p forhnd var ekvilibrert med fosfatbuffer (30 ml) ved en gjennomstrmningshastighet p 3 ml/minutt for adsorpsjon av humant AILIM-IgFc i dyrkingssupernatanten til kolonnen. </span>Culture supernatant from recombinant cells producing human AILIM-IgFc was applied to a HiTrap protein G column ("Hitrap affinity column Protein G", Amersham-Pharmacia) previously equilibrated with phosphate buffer (30 ml) at a flow rate of 3 ml/ minute for adsorption of human AILIM-IgFc in the culture supernatant to the column.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Deretter ble kolonnen vasket med fosfatbuffer (20 ml), hvoretter 100 mM sitratbuffer (pH 2,0) ble psatt kolonnen ved en gjennomstrmningshastighet p ca. 1 ml/minutt for eluering av humant AILIM-IgFc. Den eluerte lsning ble s nytralisert med en lsning (pH 9,0) med 750 mM Tris-HCl og dialysert mot fosfatbuffer (over natten). Den dialyserte lsning ble s filtrert gjennom et filter (Millipore). P denne mten ble renset antihumant AILIM-IgFc erholdt. </span>The column was then washed with phosphate buffer (20 ml), after which 100 mM citrate buffer (pH 2.0) was applied to the column at a flow rate of approx. 1 ml/minute for elution of human AILIM-IgFc. The eluted solution was then neutralized with a solution (pH 9.0) of 750 mM Tris-HCl and dialyzed against phosphate buffer (overnight). The dialyzed solution was then filtered through a filter (Millipore). In this way, purified antihuman AILIM-IgFc was obtained.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Proteinskonsentrasjon ble beregnet ut fra absorbansen ved 280 nm ved anvendelse av et spektrofotometer (1A280= 1 mg/ml). Konsentrasjon av humant AILIM-IgFc ble bestemt til 0,28mg/ml. </span>Protein concentration was calculated from the absorbance at 280 nm using a spectrophotometer (1A280= 1 mg/ml). Concentration of human AILIM-IgFc was determined to be 0.28mg/ml.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Renset kimrt protein bestende av det ekstracellulre omrdet fra rotte-AILIM og det konstante omrdet (Fc) fra humant IgGl (rotte-AILIM-IgFc, JP-A 11-29599 (eksempel 16 (2)) og WO 98/38216 (eksempel 16 (2)) ble ogs fremstilt iflge fremgangsmten beskrevet ovenfor. Konsentrasjonen av det erholdte rotte-AILIM-IgFc ble bestemt til 0,45 mg/ml. </span>Purified chimeric protein consisting of the extracellular region of rat AILIM and the constant region (Fc) of human IgG1 (rat AILIM-IgFc, JP-A 11-29599 (Example 16 (2)) and WO 98/38216 (Example 16 (2)) was also prepared according to the method described above.The concentration of the obtained rat AILIM-IgFc was determined to be 0.45 mg/ml.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">6.2 Bestemmelse av affinitet og nytraliserende aktivitet </span>6.2 Determination of affinity and neutralizing activity</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Bortsett fra immobilisering av antigen (humant AILIM-IgFc) til sensorbrikken, som er beskrevet nedenfor, var de eksperimentelle fremgangsmter basert p instruksjons-hndboken og den eksperimentelle fremgangsmte som medflger det kommersielt tilgjengelige analysesett Biacore X (Amersham-Pharmacia). </span>Except for the immobilization of antigen (human AILIM-IgFc) to the sensor chip, which is described below, the experimental procedures were based on the instruction manual and the experimental procedure included with the commercially available assay kit Biacore X (Amersham-Pharmacia).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">HBS-buffer (tilsatt 0,01 M HEPES, 0,15 M NaCl, 3 mM EDTA og 0,005 % detergent P20 (pH 7,0)) fikk renne gjennom en "Flow Cell-1" som fulgte med settet ved en gjennomstrmningshastighet p 5 ul/minutt. Deretter ble en lsning (15 |xl) inneholdende 0,005 M NHS (N-hydroksysuksinimid) og 0,2 M EDC (N-etyl-N'-(dimetylaminopropyl)karbodiimid) tilsatt for aktivering av karboksylgruppene i CM belagt p overflaten av sensorbrikken. </span>HBS buffer (supplemented with 0.01 M HEPES, 0.15 M NaCl, 3 mM EDTA and 0.005% detergent P20 (pH 7.0)) was run through a "Flow Cell-1" supplied with the kit at a flow rate of 5 ul/minute. Then, a solution (15 l) containing 0.005 M NHS (N-hydroxysuccinimide) and 0.2 M EDC (N-ethyl-N'-(dimethylaminopropyl)carbodiimide) was added to activate the carboxyl groups in the CM coated on the surface of the sensor chip.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Deretter ble 23 fil humant AILIM-IgFc-lsning (10fig/ml, opplst i 10 mM natriumacetatbuffer (pH 5,0)) tilsatt for immobilisering av humant AILIM-IgFc til sensorbrikken. Deretter ble ikke-reagerte, aktiverte karboksylgrupper blokkert ved tilsetning av 35 fil 1 M etanolaminhydroklorid. Mengden av humant AILIM-IgFc immobilisert ved immobiliserings-behandlingen utfrt to ganger var 2444 RU (resonansenheter) henholdsvis 2213 RU. Enheten RU tilsvarer masse pr. enhetsareal, 1 RU = 1 pg/mm . </span>Then, 23 l of human AILIM-IgFc solution (10g/ml, dissolved in 10 mM sodium acetate buffer (pH 5.0)) was added to immobilize human AILIM-IgFc to the sensor chip. Then, unreacted, activated carboxyl groups were blocked by the addition of 35 l of 1 M ethanolamine hydrochloride. The amount of human AILIM-IgFc immobilized by the immobilization treatment performed twice was 2444 RU (resonance units) and 2213 RU, respectively. The unit RU corresponds to mass per unit area, 1 RU = 1 pg/mm .</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">"Flow Cell-2", som er en referansegjennomstrmningscelle, ble behandlet ved blokkeringsbehandlingen i fravr av humant AILIM-IgFc p samme mte som beskrevet ovenfor. </span>"Flow Cell-2", which is a reference flow cell, was treated by the blocking treatment in the absence of human AILIM-IgFc in the same manner as described above.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Fosfatbuffer fikk strmme gjennom gjennomstrmningscellen (sensorbrikken) ved en gjennomstrmningshastighet p 20fil/minutt, og hvert av de rensede humane, monoklonale antihumant AILIM-antistoffene fremstilt i eksemplet ovenfor ble tilsatt til denne (10-50fig/ml, 60 fil). </span>Phosphate buffer was allowed to flow through the flow cell (sensor chip) at a flow rate of 20 l/minute, and each of the purified human monoclonal anti-human AILIM antibodies prepared in the above example was added to this (10-50g/ml, 60 l).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Standardbetingelser for mlingen var: assosiasjonsfase i 3 minutter og dissosiasjonsfase i 10 minutter. Mengden antistoff bundet til og frigjort fra antigenet ble mlt over tid for erholdelse av et sensorgram. Dissosiasjon av antistoff fra antigenet ble oppndd ved  la PBS strmme gjennom sensorbrikken ved en gjennomstrmningshastighet p 20 (4.1/minutt. </span>Standard conditions for the measurement were: association phase for 3 minutes and dissociation phase for 10 minutes. The amount of antibody bound to and released from the antigen was measured over time to obtain a sensorgram. Dissociation of antibody from the antigen was achieved by allowing PBS to flow through the sensor chip at a flow rate of 20 (4.1/min.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Basert p de resulterende sensorgramresultater ble assosiasjonshastighetskonstanten (ka), dissosiasjonshastighetskonstanten (kd) og dissosiasjonskonstanten (Kd, Kd = kd/ka) beregnet ved anvendelse av den analytiske programvare (BIAevaluation 3.0), som medflger settet. </span>Based on the resulting sensorgram results, the association rate constant (ka), the dissociation rate constant (kd) and the dissociation constant (Kd, Kd = kd/ka) were calculated using the analytical software (BIAevaluation 3.0), which is included in the kit.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Affinitet og nytralisering aktivitet av de monoklonale museantistoff ene SA 12 og SG430 rettet mot humant AILIM, fremstilt i eksemplet beskrevet ovenfor, ble ogs analysert p samme mte som beskrevet ovenfor. </span>Affinity and neutralization activity of the mouse monoclonal antibodies SA 12 and SG430 directed against human AILIM, prepared in the example described above, were also analyzed in the same way as described above.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">De erholdte verdier er vist nedenfor. </span>The obtained values are shown below.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Resultatene viser at alle de humane, monoklonale antihumant AILIM-antistoffene og de monoklonale antihumant AILIM-antistoffene fra mus viser markant hy bindingsaffinitet og nytraliserende aktivitet p humant AILIM. </span>
The results show that all the human monoclonal anti-human AILIM antibodies and the monoclonal anti-human AILIM antibodies from mice show markedly high binding affinity and neutralizing activity on human AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempel 7 </span>Example 7</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Aktivitet av humant, monoklonalt. antihumant AILIM- antistoff p overfringen av det kostimulerende signal i humane T- celler </span>Activity of human, monoclonal. antihuman AILIM antibody on the transmission of the costimulatory signal in human T cells</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det ble analysert hvorvidt de humane, monoklonale antihumant AILIM-antistoffene iflge foreliggende oppfinnelse hadde evnen til  kontrollere (forsterke og/eller inhibere) humane T-celleresponser (produksjon av cytokiner, slik som IFN-y og IL-4, celleproliferasjon osv.), med andre ord hvorvidt antistoffene viste regulatorisk aktivitet p cellulr overfring av det AILIM-formidlede, kostimulerende signal. Analysen ble utfrt basert p mengden cytokiner (IFN-y og IL-4) dannet i humane T-celler s vel som proliferasjonsgraden av humane T-celler som ml. </span>It was analyzed whether the human monoclonal anti-human AILIM antibodies according to the present invention had the ability to control (enhance and/or inhibit) human T-cell responses (production of cytokines, such as IFN- and IL-4, cell proliferation, etc.) , in other words, whether the antibodies showed regulatory activity on cellular transmission of the AILIM-mediated costimulatory signal. The analysis was performed based on the amount of cytokines (IFN- and IL-4) formed in human T cells as well as the proliferation rate of human T cells as targets.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">7.1 Fortynning av antistoff </span>7.1 Dilution of antibody</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det monoklonale antihumant CD3-antistoff OKT3 (ATCC CRL-8001) ble fortynnet med fosfatbuffer (PBS) til en sluttkonsentrasjon p 8 mg/ml. </span>The monoclonal anti-human CD3 antibody OKT3 (ATCC CRL-8001) was diluted with phosphate buffer (PBS) to a final concentration of 8 mg/ml.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Hvert av de forskjellige humane, monoklonale antihumant AILIM-antistoffene fremstilt ovenfor ble fortynnet med PBS til en sluttkonsentrasjon p 40fig/ml. Antistoff-lsningene ble videre fortynnet med PBS for fremstilling av forskjellige konsentrasjoner av antistoff (40 (ig/ml-0,0049 ng/ml). </span>Each of the different human monoclonal anti-human AILIM antibodies prepared above was diluted with PBS to a final concentration of 40 g/ml. The antibody solutions were further diluted with PBS to prepare different concentrations of antibody (40 (g/ml-0.0049 ng/ml).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">7.2 Belegging av mikroplate med antistoff </span>7.2 Coating of microplate with antibody</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Hver brnn i 96-brnners mikroplater ble belagt med (1) monoklonalt, antihumant CD3-antistoff OKT3 (8 ng/ml, 25 fil i hver brnn) og et av de forskjellige humane, monoklonale antihumant AILIM-antistoffene (40 (4g/ml-0,0049 (Ag/ml, 25 (4.1 i hver brnn), eller (2) monoklonalt, antihumant CD3-antistoff OKT3 (8 (lg/ml, 25 (4.1 i hver brnn) alene. Platene ble inkubert ved 37 C i 2 timer. Deretter ble antistofflsningene fjernet, og brnnene ble vasket tre ganger med PBS. Etter vask ble RPMI-1640-medium tilsatt 10 % FCS tilsatt til hver brnn (100 (il/brnn), og platene ble inkubert ved 37&lt;*&gt;C i 1 time. P denne mten ble brnnene i platene belagt med antistoffer nevnt ovenfor i (1) eller (2). </span>Each well in 96-well microplates was coated with (1) monoclonal anti-human CD3 antibody OKT3 (8 ng/ml, 25 l in each well) and one of the different human monoclonal anti-human AILIM antibodies (40 (4g/ml -0.0049 (Ag/ml, 25 (4.1 in each well), or (2) monoclonal anti-human CD3 antibody OKT3 (8 (lg/ml, 25 (4.1 in each well)) alone. Plates were incubated at 37 C for 2 hours. Then the antibody solutions were removed, and the wells were washed three times with PBS. After washing, RPMI-1640 medium supplemented with 10% FCS was added to each well (100 (l/well), and the plates were incubated at 37&lt;* &gt;C for 1 hour In this way the wells of the plates were coated with antibodies mentioned above in (1) or (2).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Kontrolleksperimenter ble utfrt p samme mte ved anvendelse av plater belagt med flgende monoklonale antistoffer som kontrollantistoffer i stedet for de humane, monoklonale antihumant AILIM-antistoffene. (1) det monoklonale museantistoff SA 12 eller SG430 rettet mot humant AILIM (JP-A 11-29599 (eksempel 12) og WO 98/38216 (eksempel 12)); (2) det monoklonale antihumant CETP-antistoff JHC1 fra mus (ogs betegnet JMabl09, JP-A 9-20800); og (3) humant, monoklonalt anti-KLH-antistoff (ogs betegnet JMab23, det ovenfor nevnte eksempel). </span>Control experiments were performed in the same manner using plates coated with the following monoclonal antibodies as control antibodies instead of the human anti-human AILIM monoclonal antibodies. (1) the mouse monoclonal antibody SA 12 or SG430 directed against human AILIM (JP-A 11-29599 (Example 12) and WO 98/38216 (Example 12)); (2) the mouse monoclonal anti-human CETP antibody JHC1 (also designated JMabl09, JP-A 9-20800); and (3) human monoclonal anti-KLH antibody (also designated JMab23, the above example).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mikroplatene belagt med antistoff ble anvendt i flgende analyser. </span>The microplates coated with antibody were used in the following analyses.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">7.3 Fremstilling av en suspensjon av humane T- celler </span>7.3 Preparation of a suspension of human T cells</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Perifert blod ble oppsamlet fra normale, friske personer (5 personer, donorer A, B, C, D og E). Fraksjonen som inneholdt mononuklere celler, ble fremstilt ved tetthetsgradientsentrifugering ved anvendelse av "LymphoPrep" (Nycomed). Humane T-celler ble separert fra den humane mononuklere cellefraksjon iflge bruksanvisningen ved anvendelse av et Pan-T-celleisoleringssett (Miltenyi) og en magnetisk sorterer. T-celletallet ble bestemt ved anvendelse av et hemacytometer. Humane T-celler ble suspendert i RPMI-1640-medium tilsatt 10 % FCS for fremstilling av en suspensjon av humane T-celler (lx IO&lt;6&gt;celler/ml). </span>Peripheral blood was collected from normal, healthy subjects (5 subjects, donors A, B, C, D and E). The fraction containing mononuclear cells was prepared by density gradient centrifugation using "LymphoPrep" (Nycomed). Human T cells were separated from the human mononuclear cell fraction according to the instructions for use using a Pan-T cell isolation kit (Miltenyi) and a magnetic sorter. The T-cell count was determined using a hemacytometer. Human T cells were suspended in RPMI-1640 medium supplemented with 10% FCS to prepare a suspension of human T cells (1x 10&lt;6&gt; cells/ml).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">7.4 Celledyrking </span>7.4 Cell cultivation</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(1) Dyrking ved anvendelse av en mikroplate belagt med antihumant CD3- antistoff og antihumant AILIM antistoff </span>(1) Cultivation using a microplate coated with anti-human CD3 antibody and anti-human AILIM antibody</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Human T-cellesuspensjon (donor A, B, C, D eller E, 100 (il/brnn, 1 x IO&lt;5&gt;celler/brnn) ble tilsatt til hver brnn i mikroplaten belagt med antistoffene nevnt ovenfor, og platen ble inkubert ved 37&lt;*&gt;C i 3 dager i en CCvinkubator. </span>Human T-cell suspension (donor A, B, C, D or E, 100 (l/well, 1 x 10&lt;5&gt; cells/well) was added to each well of the microplate coated with the antibodies mentioned above, and the plate was incubated at 37&lt;*&gt;C for 3 days in a CCwin incubator.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Etter dyrkingen ble uttak av de resulterende dyrkingssupernatanter (50 (il) lagret ved -20 C og s anvendt i analysen beskrevet senere (analyse for IFN-y). Etter uttak av prver av dyrkingssupernatantene ble mikroplatene anvendt i flgende analyse. </span>After the cultivation, samples of the resulting culture supernatants (50 l) were stored at -20 C and then used in the analysis described later (analysis for IFN-). After sampling the culture supernatants, the microplates were used in the following analysis.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(2) Dyrking ved anvendelse av en mikroplate belagt med antihumant CD3- antistoff alene </span>(2) Cultivation using a microplate coated with anti-human CD3 antibody alone</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Human T-cellesuspensjon (donor D, 100 (il/brnn, 1 x 10&lt;5&gt;celler/brnn) ble tilsatt til brnnene i mikroplatene belagt med det ovenfor nevnte antistoff, hvoretter et av de forskjellige humane, monoklonale antihumant AILIM-antistoffene ble tilsatt (25 (il antistoff med 40 (ig/ml-0,0049 (lg/ml). Platene ble inkubert ved 37&lt;*&gt;C i 3 dager i en CCVinkubator. </span>Human T-cell suspension (donor D, 100 (l/well, 1 x 10&lt;5&gt;cells/well) was added to the wells of the microplates coated with the above-mentioned antibody, after which one of the different human, monoclonal anti-human AILIM antibodies was added (25 (l) antibody at 40 (g/ml-0.0049 (g/ml). The plates were incubated at 37&lt;*&gt;C for 3 days in a CCVincubator.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">7.5 Bestemmelse av T- cellenes proliferasjonsaktivitet </span>7.5 Determination of the proliferation activity of the T cells</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Metyl [&lt;3&gt;H]tymidin (0,5 (iCi/brnn, Amersham-Pharmacia) ble tilsatt til hver av brnnene i platene etter inkuberingen, og platene ble inkubert ved 37&lt;*&gt;C i 6 timer i en CO2-inkubator. Etter inkuberingen ble cellene oppfanget p GF/C-filtre (Packard) ved anvendelse av en cellehster. Filtrene ble s trket ved 40&lt;*&gt;C i 3 timer eller lenger, hvoretter "Microscinti 0" </span>Methyl [&lt;3&gt;H]thymidine (0.5 (iCi/well, Amersham-Pharmacia) was added to each of the wells of the plates after the incubation, and the plates were incubated at 37&lt;*&gt;C for 6 hours in a CO2 incubator . After the incubation, the cells were collected on GF/C filters (Packard) using a cell harvester. The filters were then dried at 40&lt;*&gt;C for 3 hours or longer, after which "Microscinti 0"</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(20 (il/brnn, Packard) ble tilsatt.&lt;3&gt;H-radioaktiviteten inkorporert i cellene oppfanget p filtrene ble mlt med en (}-teller (TOP COUNT) for analyse av T-celleproliferasjonsgraden etter dyrking. </span>(20 (l/well, Packard) was added. The &lt;3&gt;H radioactivity incorporated into the cells captured on the filters was measured with a (} counter (TOP COUNT) for analysis of the T-cell proliferation rate after cultivation.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatene er vist i figurene 15-39. </span>The results are shown in figures 15-39.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatene fra denne analysen viste at humane T-celler hadde signifikant proliferasjon, avhengig av konsentrasjonen av celler nr mikroplatene var belagt med monoklonalt, antihumant AILIM-antistoff (humant, monoklonalt antistoff eller monoklonalt antistoff fra mus) sammen med antihumant CD3-antistoff. Det var videre noen forskjeller mellom donorene nr det gjaldt celleproliferasjonsgraden. </span>The results of this assay showed that human T cells had significant proliferation, depending on the concentration of cells, when the microplates were coated with monoclonal anti-human AILIM antibody (human monoclonal antibody or mouse monoclonal antibody) together with anti-human CD3 antibody. There were also some differences between the donors when it came to the degree of cell proliferation.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Derimot vokste humane T-celler ikke signifikant nr platene var belagt med antihumant CD3-antistoff alene, og monoklonalt, antihumant AILIM-antistoff (humant, monoklonalt antistoff eller monoklonalt antistoff fra mus) i lsning (vskefase) ble benyttet under dyrking av cellene. </span>In contrast, human T cells did not grow significantly when the plates were coated with anti-human CD3 antibody alone, and monoclonal anti-human AILIM antibody (human, monoclonal antibody or mouse monoclonal antibody) in solution (liquid phase) was used during cultivation of the cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">7.6 Kvantifisering av IFN- y i dyrkingssupernatant fra T- celler </span>7.6 Quantification of IFN- in culture supernatant from T cells</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">For T-cellekulturene (donorer B og C) beskrevet i (1) i 7.4 ble mengden IFN-y i dyrkingssupernatantene bestemt med et kommersielt tilgjengelig humant IFN-y ELISA-sett (Amersham-Pharmacia, Endogen). </span>For the T cell cultures (donors B and C) described in (1) in 7.4, the amount of IFN- in the culture supernatants was determined with a commercially available human IFN- ELISA kit (Amersham-Pharmacia, Endogen).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatene er vist i figurene 40-47. </span>The results are shown in Figures 40-47.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatene av denne analysen viste at produksjonen av IFN-y kte signifikant, avhengig av konsentrasjonen av monoklonalt, antihumant AILIM-antistoff (humant, monoklonalt antistoff eller monoklonalt antistoff fra mus). </span>The results of this assay showed that the production of IFN- increased significantly, depending on the concentration of monoclonal anti-human AILIM antibody (human monoclonal antibody or mouse monoclonal antibody).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempel 8 </span>Example 8</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Regulatorisk virkning av humant, monoklonalt, antihumant AILIM- antistoff p den blandede lvmfocyttreaksion ( MLR) </span>Regulatory effect of human monoclonal anti-human AILIM antibody on the mixed lymphocyte reaction (MLR)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det ble analysert hvorvidt de humane, monoklonale antihumant AILIM-antistoffene iflge foreliggende oppfinnelse kunne kontrollere (forsterke og/eller inhibere) T-celleresponser (produksjon av cytokiner, slik som IFN-y og IL-4, celleproliferasjon osv.), med andre ord om de kunne regulere overfringen av det AILIM-formidlede, kostimulerende signal inn i celler, ved analyse av virkningen (nrmere bestemt DNA-syntese i cellene) p T-celleproliferasjonen forbundet med den allogene blandede lymfocyttreaksjon (allogen MLR) som et ml. </span>It was analyzed whether the human, monoclonal anti-human AILIM antibodies according to the present invention could control (enhance and/or inhibit) T-cell responses (production of cytokines, such as IFN- and IL-4, cell proliferation, etc.), in other words whether they could regulate the transmission of the AILIM-mediated costimulatory signal into cells, by analyzing the effect (specifically DNA synthesis in the cells) on the T-cell proliferation associated with the allogeneic mixed lymphocyte reaction (allogeneic MLR) as a target.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">8.1 Fremstilling av humane PBMC og T- celler </span>8.1 Production of human PBMC and T cells</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Perifert blod (200 ml) oppsamlet fra normale, friske personer (7 personer, donorer A, B, C, D, E, F og G) ble lagt over lag med "LymphoPrep" (15 ml, Nycomed) i sentrifugerar (50 ml, Falcon). Etter sentrifugering (ved 1600 rpm i 10 minutter) ble de mellomliggende sjikt gjenvunnet. Gjenvunne celler ble fortynnet to ganger eller mer med fosfatbuffer og s sentrifugert (ved 1800 rpm i 10 minutter). P denne mten ble PBMC (mononuklere celler fra perifert blod, 2 x 108-5 x 108 celler) fremstilt. Celletallet ble bestemt ved anvendelse av et hemacytometer. Et uttak av cellene som skulle benyttes i MLR-analysen (1,08 x 10&lt;8&gt;celle/9 mikroplater) ble tatt ut og inkubert p is. De gjenvrende celler ble anvendt for separasjon av T-celler, som beskrevet nedenfor. </span>Peripheral blood (200 ml) collected from normal healthy subjects (7 subjects, donors A, B, C, D, E, F and G) was overlaid with "LymphoPrep" (15 ml, Nycomed) in centrifuge tubes (50 ml , Falcon). After centrifugation (at 1600 rpm for 10 minutes) the intermediate layers were recovered. Recovered cells were diluted twofold or more with phosphate buffer and then centrifuged (at 1800 rpm for 10 minutes). In this way, PBMC (peripheral blood mononuclear cells, 2 x 10 8 -5 x 10 8 cells) were prepared. The cell count was determined using a hemacytometer. An aliquot of the cells to be used in the MLR analysis (1.08 x 10&lt;8&gt;cell/9 microplates) was taken out and incubated on ice. The remaining cells were used for separation of T cells, as described below.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Pan-T-isoleringssett (Miltenyi) ble anvendt for separasjon av T-celler fra PBMC. Iflge veiledningen vedlagt settet ble gjenvrende PBMC tilsatt til lsningen som fulgte med settet, og lsningen ble inkubert. Deretter ble cellene vasket med PBS tilsatt 5 mM EDTA og 0,5 % BSA og s resuspendert i PBS. Cellesuspensjonen ble deretter psatt en positiv seleksjons-kolonne VS+ (Miltenyi Biotech) ekvilibrert med PBS, og den ikke-adsorberte fraksjon ble gjenvunnet. S ble PBS psatt kolonnen, og vaskelsningen ble gjenvunnet. Den samme behandling ble gjentatt n gang. De gjenvunne lsninger ble sltt sammen for erholdelse av en T-cellefraksjon. Etter sentrifugering av T-cellefraksjonen ble cellene resuspendert i PBS. Celletallet av de resulterende T-celler ble bestemt ved anvendelse av et hemacytometer. Cellene ble anvendt i den pflgende analyse. </span>Pan-T isolation kit (Miltenyi) was used for separation of T cells from PBMC. According to the instructions provided with the kit, the remaining PBMCs were added to the solution provided with the kit and the solution was incubated. The cells were then washed with PBS supplemented with 5 mM EDTA and 0.5% BSA and then resuspended in PBS. The cell suspension was then applied to a positive selection column VS+ (Miltenyi Biotech) equilibrated with PBS, and the non-adsorbed fraction was recovered. PBS was then applied to the column, and the washing solution was recovered. The same treatment was repeated once. The recovered solutions were combined to obtain a T-cell fraction. After centrifugation of the T-cell fraction, the cells were resuspended in PBS. The cell count of the resulting T cells was determined using a hemacytometer. The cells were used in the subsequent analysis.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">8.2 Den blandede lvmfocyttreaksion ( MLR) </span>8.2 The mixed lymphocyte reaction (MLR)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Som beskrevet ovenfor, er to signalveier, n mellom CD28 og CD80(B7-l)/CD86(B7-2) og den andre mellom CTLA4 og CD80(B7-l)/CD86(B7-2), for hvilke relativt detaljert analyse tidligere er blitt utfrt, kjent som kostimulerende signalveier som er ndvendige for aktivering av lymfocytter som T-celler osv. </span>As described above, two signaling pathways, one between CD28 and CD80(B7-l)/CD86(B7-2) and the other between CTLA4 and CD80(B7-l)/CD86(B7-2), for which relatively detailed analysis have previously been carried out, known as costimulatory signaling pathways that are necessary for the activation of lymphocytes such as T cells, etc.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nrmere bestemt kan proliferasjon av T-celler som respons p en blandet lymfocyttreaksjon (MLR) induseres via signaloverfringen gjennom disse to kjente reaksjonsveiene. </span>More specifically, proliferation of T cells in response to a mixed lymphocyte reaction (MLR) can be induced via the signal transmission through these two known reaction pathways.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ved anvendelse av forbindelsene angitt nedenfor, ble sledes en analyse iflge foreliggende oppfinnelse utfrt for  analysere (1) inhibering av MLR ved  blokkere den CTLA4-formidlede reaksjonsvei; (2) inhibering av MLR ved  blokkere den CD80(B7-l)/CD86(B7-2)-formidlede signalvei; (3) inhibering av MLR ved  blokkere bde den CTLA4-formidlede reaksjonsvei og den CD80(B7-l)/CD86(B7-2)-formidlede signalvei; (4) inhibering av MLR ved  blokkere den tertire signalvei forbundet med AILIM; og (5) inhibering av MLR ved  blokkering bde den CTLA4-formidlede reaksjonsvei og den AILIM-formidlede reaksjonsvei. </span>Thus, using the compounds set forth below, an assay according to the present invention was performed to analyze (1) inhibition of MLR by blocking the CTLA4-mediated pathway; (2) inhibition of MLR by blocking the CD80(B7-1)/CD86(B7-2)-mediated signaling pathway; (3) inhibition of MLR by blocking both the CTLA4-mediated pathway and the CD80(B7-1)/CD86(B7-2)-mediated signaling pathway; (4) inhibition of MLR by blocking the tertiary signaling pathway associated with AILIM; and (5) inhibition of MLR by blocking both the CTLA4-mediated pathway and the AILIM-mediated pathway.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Flgende analyseforbindelser ble anvendt. </span>The following assay compounds were used.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(1) humant, monoklonalt, antihumant AILIM-antistoff (fremstilt i eksemplet beskrevet ovenfor); (2) monoklonalt, antihumant AILIM-antistoff SA12 fra mus (det samme som i eksemplet ovenfor); (3) humant, monoklonalt anti-KLH-antistoff (negativ kontroll, det samme som i eksemplet ovenfor); (4) IgG-antistoff fra mus (antihumant CD34, negativ kontroll, Immunotech); (5) en blanding av monoklonalt, antihumant CD80-antistoff (Pharmingen) og monoklonalt, antihumant CD86-antistoff (Pharmingen); og </span>(1) human monoclonal anti-human AILIM antibody (prepared in the example described above); (2) mouse monoclonal anti-human AILIM antibody SA12 (same as in the example above); (3) human monoclonal anti-KLH antibody (negative control, the same as in the above example); (4) mouse IgG antibody (antihuman CD34, negative control, Immunotech); (5) a mixture of monoclonal anti-human CD80 antibody (Pharmingen) and monoclonal anti-human CD86 antibody (Pharmingen); and</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(6) kimrt, humant CTLA4-IgFc-molekyl (Ancell). </span>(6) chimeric human CTLA4-IgFc molecule (Ancell).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den blandede lymfocyttreaksjon (MLR) ble utfrt p flgende seks kombinasjoner ved anvendelse av PBMC og T-celler fremstilt fra donorene beskrevet ovenfor i 8.1. </span>The mixed lymphocyte reaction (MLR) was performed on the following six combinations using PBMC and T cells prepared from the donors described above in 8.1.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(i) T-celler (donor A)/PBMC (donor D) </span>(i) T cells (donor A)/PBMC (donor D)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(ii) T-celler (donor D)/PBMC (donor B) </span>(ii) T cells (donor D)/PBMC (donor B)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(iii) T-celler (donor C)/PBMC (donor A) </span>(iii) T cells (donor C)/PBMC (donor A)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(iv) T-celler (donor E)/PBMC (donor G) </span>(iv) T cells (donor E)/PBMC (donor G)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(v) T-celler (donor F)/PBMC (donor E) </span>(v) T cells (donor F)/PBMC (donor E)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(vi) T-celler (donor G)/PBMC (donor F). </span>(vi) T cells (donor G)/PBMC (donor F).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Konsentrasjonen av PBMC og T-celler som skulle anvendes i analysen, ble justert som beskrevet nedenfor. </span>The concentration of PBMC and T cells to be used in the analysis was adjusted as described below.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">PBMC ble suspendert i PBS og s overfrt til dyrkingsskler (60 mm). Cellene ble behandlet med rntgenstrling (50 Gy) med en irradiator (Hitachi MEDICO). Cellene ble gjenvunnet, sentrifugert og tilsatt til RPMI-1640-medium tilsatt 10 % FCS. Celletallet ble justert til 2 x 10&lt;5&gt;celler/50 pl. </span>PBMC were suspended in PBS and then transferred to culture dishes (60 mm). The cells were treated with X-ray radiation (50 Gy) with an irradiator (Hitachi MEDICO). The cells were recovered, centrifuged and added to RPMI-1640 medium supplemented with 10% FCS. The cell number was adjusted to 2 x 10&lt;5&gt; cells/50 l.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">De resulterende T-celler fra hver donor ble ogs tilsatt til RPMI-1640-medium tilsatt 10 % FCS, og celletallet ble justert til 1 x IO&lt;5&gt;celler/50 (il. </span>The resulting T cells from each donor were also added to RPMI-1640 medium supplemented with 10% FCS, and the cell number was adjusted to 1 x 10 cells/50 (l.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">8.2.1 Inhibering av MLR med humant, monoklonalt, antihumant AILIM- antistoff </span>8.2.1 Inhibition of MLR by human monoclonal anti-human AILIM antibody</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">RPMI-1640-medium tilsatt 10 % FCS ble tilsatt til hver brnn i en 96-brnners mikroplate med U-formede brnner. En lsning av humant, monoklonalt, antihumant AILIM-antistoff eller monoklonalt, antihumant AILIM-antistoff SA12 fra mus ble fortynnet med RPMI-1640-medium tilsatt 10 % FCS for fremstilling av lsninger med forskjellige konsentrasjoner av antistoffet. Fortynnede antistofflsninger ble tilsatt til brnnene (sluttkonsentrasjon: 0, 0,31, 1,25, 5 og 20 (lg/ml). Deretter ble T-celler (50 jxl) tilsatt til brnnene. Platen ble inkubert ved 37 C i 1 time i en C02-inkubator (NAPCO). Etter fullfrt reaksjon ble PBMC (50 (il) avledet fra en annen donor tilsatt til brnnene for innledning av MLR. </span>RPMI-1640 medium supplemented with 10% FCS was added to each well of a 96-well microplate with U-shaped wells. A solution of human monoclonal anti-human AILIM antibody or mouse monoclonal anti-human AILIM antibody SA12 was diluted with RPMI-1640 medium supplemented with 10% FCS to prepare solutions with different concentrations of the antibody. Diluted antibody solutions were added to the wells (final concentration: 0, 0.31, 1.25, 5 and 20 (lg/ml). Then T cells (50 l) were added to the wells. The plate was incubated at 37 C for 1 hour in a CO2 incubator (NAPCO). After completion of the reaction, PBMC (50 (l) derived from another donor were added to the wells to initiate MLR.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dersom MLR ble utfrt ved anvendelse av et antistoff forskjellig fra humant, antihumant AILIM-antistoff (beskrevet ovenfor i (3)-(6)) som analyseforbindelse, fikk T-celler avledet fra en annen donor reagere etter inkubering av PBMC med analyseforbindelsen. </span>If MLR was performed using an antibody other than human, anti-human AILIM antibody (described above in (3)-(6)) as assay compound, T cells derived from another donor were allowed to react after incubation of PBMC with the assay compound.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">P den femte dyrkingsdagen ble tritiummerket tymidin (&lt;3&gt;H-tymidin, 20 fil, 1fiCi/brnn) fortynnet med RPMI-1640-medium tilsatt 10 % FCS tilsatt til hver brnn. Dyrkingen ble fortsatt i n dag. Etter avsluttet dyrking ble cellene hstet ved anvendelse av en cellehster (Packard).&lt;3&gt;H-radioaktiviteten inkorporert i cellene ble mlt i en (}-teller (TOP COUNT, Packard) for analyse av T-celleproliferasjonsgraden etter dyrkingen. </span>On the fifth day of culture, tritium-labeled thymidine (&lt;3&gt;H-thymidine, 20 l, 1 Ci/well) diluted with RPMI-1640 medium supplemented with 10% FCS was added to each well. Cultivation was continued for one day. After completion of cultivation, the cells were harvested using a cell harvester (Packard).&lt;3&gt;H radioactivity incorporated into the cells was measured in a (-) counter (TOP COUNT, Packard) for analysis of the T-cell proliferation rate after cultivation.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatene er vist i figurene 48-59. </span>The results are shown in figures 48-59.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">8.2.2 Inhibering av MLR med humant, monoklonalt, antihumant AILIM- antistoff i et MLR- svstem hvor den CTLA4- formidlede signalvei tidligere var blokkert </span>8.2.2 Inhibition of MLR with human, monoclonal, anti-human AILIM antibody in an MLR system where the CTLA4-mediated signaling pathway was previously blocked</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">RPMI-1640-medium tilsatt 10 % FCS ble tilsatt til hver brnn i en 96-brnners mikroplate med U-formede brnner. En lsning av humant, monoklonalt, antihumant AILIM-antistoff eller det monoklonale antihumant AILIM-antistoff SA 12 fra mus ble fortynnet med RPMI-1640-medium tilsatt 10 % FCS for fremstilling av lsninger med forskjellige konsentrasjoner av antistoffet. De fortynnede antistofflsninger ble tilsatt til brnnene (sluttkonsentrasjon: 0, 0,31, 1,25, 5 og 20fig/ml). Deretter ble T-celler (50 ml) tilsatt til brnnene. Platen ble inkubert ved 37 C i 1 time i en C02-inkubator (NAPCO). </span>RPMI-1640 medium supplemented with 10% FCS was added to each well of a 96-well microplate with U-shaped wells. A solution of human monoclonal anti-human AILIM antibody or the mouse monoclonal anti-human AILIM antibody SA 12 was diluted with RPMI-1640 medium supplemented with 10% FCS to prepare solutions with different concentrations of the antibody. The diluted antibody solutions were added to the wells (final concentration: 0, 0.31, 1.25, 5 and 20 g/ml). Then T cells (50 ml) were added to the wells. The plate was incubated at 37C for 1 hour in a CO 2 incubator (NAPCO).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I tillegg til dyrking av T-cellene ble PBMC (i RPMI-1640-medium tilsatt 10 % FCS) avledet fra andre donorer dyrket uavhengig etter tilsetning av humant CTLA4-IgFc til PBMC. Dyrkingen ble utfrt ved 37&lt;*&gt;C i 1 time i en C02-inkubator (NAPCO). Konsentrasjonen av CTLA4-IgFc ble justert til 20 (Ag/ml ved start av MLR. </span>In addition to culturing the T cells, PBMC (in RPMI-1640 medium supplemented with 10% FCS) derived from other donors were cultured independently after addition of human CTLA4-IgFc to PBMC. Cultivation was carried out at 37&lt;*&gt;C for 1 hour in a CO 2 incubator (NAPCO). The concentration of CTLA4-IgFc was adjusted to 20 (Ag/ml at the start of MLR.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Deretter ble PBMC (50 (il) tilsatt til T-cellekulturen beskrevet ovenfor for start av </span>Then PBMC (50 (l) were added to the T cell culture described above to start the</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">MLR. </span>MLR.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dersom MLR ble utfrt ved anvendelse av et annet antistoff enn humant, antihumant AILIM-antistoff (beskrevet ovenfor i (3)-(5)) som analyseforbindelse, fikk T-celler avledet fra en annen donor reagere etter inkubering av PBMC, dyrket i nrvr av CTLA4-IgFc, med analyseforbindelsen. </span>If MLR was performed using an antibody other than human, anti-human AILIM antibody (described above in (3)-(5)) as assay compound, T cells derived from another donor were allowed to react after incubation of PBMC, cultured in the presence of CTLA4-IgFc, with the assay compound.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">P den femte dyrkingsdagen ble tritiummerket tymidin (&lt;3&gt;H-tymidin, 20 (il, 1fiCi/brnn) fortynnet med RPMI-1640-medium tilsatt 10 % FCS tilsatt til hver brnn. Dyrkingen ble fortsatt i n dag. Etter avsluttet dyrking ble cellene hstet ved anvendelse av en cellehster (Packard).&lt;3&gt;H-radioaktiviteten inkorporert i cellene ble mlt i en (5-teller (TOP COUNT, Packard) for analyse av T-celleproliferasjonsgraden etter dyrkingen. </span>On the fifth day of culture, tritium-labeled thymidine (&lt;3&gt;H-thymidine, 20 (l, 1Ci/well) diluted with RPMI-1640 medium supplemented with 10% FCS was added to each well. Cultivation was continued for one day. After completion of culture, the cells were harvested using a cell harvester (Packard).&lt;3&gt;H radioactivity incorporated into the cells was measured in a (5-counter (TOP COUNT, Packard) for analysis of the T-cell proliferation rate after the cultivation.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatene er vist i figurene 60-69. </span>The results are shown in figures 60-69.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatene erholdt fra de to analysene beskrevet ovenfor kan oppsummeres som flger: (1) CTLA4-IgFc blokkerer den CTLA-4-formidlede signaloverfring, og inhiberer derved T-celleproliferasjonen indusert ved den allogene MLR. (2) Anti-CD80-antistoff og anti-CD86-antistoff inhiberer signaloverfring formidlet av CD80/CD86, som er en
ligand for CTLA4 og CD28, hvorved T-celleproliferasjonen som induseres ved den allogene MLR, inhiberes. (3) Et monoklonalt antistoff mot humant AILIM gir, i likhet med CTLA4-IgFc, anti-CD80- og anti-CD86-antistoff, signifikant inhibering av T-celleproliferasjonen indusert ved den allogene MLR forbundet med den AILIM-formidlede signaloverfring p en antistoff-konsentrasjonsavhengig mte. </span>The results obtained from the two assays described above can be summarized as follows: (1) CTLA4-IgFc blocks the CTLA-4-mediated signal transduction, thereby inhibiting the T-cell proliferation induced by the allogeneic MLR. (2) Anti-CD80 antibody and anti-CD86 antibody inhibit signal transduction mediated by CD80/CD86, which is a
ligand for CTLA4 and CD28, whereby the T-cell proliferation induced by the allogeneic MLR is inhibited. (3) A monoclonal antibody against human AILIM, like CTLA4-IgFc, anti-CD80 and anti-CD86 antibody, significantly inhibits the T-cell proliferation induced by the allogeneic MLR associated with the AILIM-mediated signaling on an antibody -concentration-dependent manner.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Med andre ord viser disse resultatene at en tertir reaksjonsvei formidlet av AILIM og liganden derav i tillegg til de kjente reaksjonsveiene formidlet av CTLA4/CD80/CD86 og av CD28/CD80/CD86 foreligger som en kostimulerende signalvei som er ndvendig for T-celleaktivering, s vel som at den AILIM-formidlede signalvei inhiberes av antistoff mot AILIM. </span>In other words, these results show that a tertiary reaction pathway mediated by AILIM and its ligand in addition to the known reaction pathways mediated by CTLA4/CD80/CD86 and by CD28/CD80/CD86 exists as a costimulatory signaling pathway that is necessary for T cell activation, so as well as that the AILIM-mediated signaling pathway is inhibited by antibody against AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dette peker videre p muligheten for at den AILIM-formidlede reaksjonsveis bidrag til signaloverfringen kan vre sammenlignbar med bidragene til den CTLA4/CD80/CD86-formidlede reaksjonsvei og den CD28/CD80/CD86-formidlede reaksjonsvei. </span>This further points to the possibility that the contribution of the AILIM-mediated pathway to signal transduction may be comparable to the contributions of the CTLA4/CD80/CD86-mediated pathway and the CD28/CD80/CD86-mediated pathway.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempel 9 </span>Example 9</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Virkning av humant, monoklonalt. antihumant AILIM- antistoff p induksjon av antistoffavhengig cellulr cvtotoksisitet ( ADCC) </span>Effect of human, monoclonal. antihuman AILIM antibody on induction of antibody-dependent cellular cytotoxicity (ADCC)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Biologiske aktiviteter som skyldes antistoffer omfatter induksjon av antistoffavhengig cellulr cytotoksisitet (ADCC). ADCC er en cytotoksisk aktivitet som krever antistoff i tillegg til effektorceller og mlceller, og som induserer skader p mlceller via effektorceller, slik som lymfocytter, makrofager eller polymorfonuklere leukocytter. </span>Biological activities due to antibodies include the induction of antibody-dependent cellular cytotoxicity (ADCC). ADCC is a cytotoxic activity that requires antibody in addition to effector cells and target cells, and which induces damage to target cells via effector cells, such as lymphocytes, macrophages or polymorphonuclear leukocytes.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Virkningen av det monoklonale antihumant AILIM-antistoff iflge foreliggende oppfinnelse p induksjon av ADCC ble analysert som flger:&lt;51&gt;Cr (0,1 mCi/106 celler, Amersham-Pharmacia) ble tilsatt til en kultur av rekombinante HPB-ALL-celler som overuttrykker humant AILIM, fremstilt i eksemplet beskrevet ovenfor, og blandingen ble inkubert ved 37 C i 2 timer. Cellene ble vasket tte ganger med RPMI-1640-medium. De sledes erholdte isotopmerkede celler ble anvendt som mlceller. </span>The effect of the monoclonal anti-human AILIM antibody of the present invention on the induction of ADCC was analyzed as follows:&lt;51&gt;Cr (0.1 mCi/10 6 cells, Amersham-Pharmacia) was added to a culture of recombinant HPB-ALL cells which overexpressing human AILIM, prepared in the example described above, and the mixture was incubated at 37C for 2 hours. The cells were washed eight times with RPMI-1640 medium. The isotope-labeled cells thus obtained were used as target cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Kontrolleksperimenter ble utfrt ved anvendelse av humane villtype-HPB-ALL-celler som kontrollceller, merket med isotop som p samme mte som beskrevet ovenfor. </span>Control experiments were performed using human wild-type HPB-ALL cells as control cells, isotopically labeled as described above.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ved anvendelse av "Lymphosepar I" (IBL) ble PBMC-fraksjoner separert fra perifert blod oppsamlet fra normale, friske personer. De resulterende humane PBMC ble anvendt som </span>Using "Lymphosepar I" (IBL), PBMC fractions were separated from peripheral blood collected from normal, healthy subjects. The resulting human PBMCs were used as</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">effektorceller. </span>effector cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mlcellene (1 x IO&lt;4&gt;celler/brnn, 25 (il/brnn) ble utsdd i hver brnn i en 96-brnners mikroplate (Nunc) med U-formede brnner. Deretter ble n av flere forskjellige konsentrasjoner av humant, monoklonalt, antihumant AILIM-antistoff fortynnet med RPMI-1640-medium tilsatt 5 % FBS (0,0001-1,0 ng/ml, 25 (U/brnn), medium alene (25 (U/brnn) eller 1 % Nonidet P-40 (25fil/brnn; detergent med cellelyserende aktivitet) tilsatt til hver brnn, og platen ble inkubert ved romtemperatur i 20 minutter. </span>The target cells (1 x 10&lt;4&gt; cells/well, 25 (l/well) were seeded into each well of a 96-well microplate (Nunc) with U-shaped wells. Then one of several different concentrations of human, monoclonal, antihuman AILIM antibody diluted with RPMI-1640 medium supplemented with 5% FBS (0.0001-1.0 ng/ml, 25 (U/well), medium alone (25 (U/well) or 1% Nonidet P-40 (25 l/well; detergent with cell lysing activity) added to each well, and the plate was incubated at room temperature for 20 minutes.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dyrkingen ble utfrt ved anvendelse av monoklonalt, antihumant CD3-antistoff OKT3 (ATCC CRL-8001) som positivt kontrollantistoff i stedet for antihumant AILIM-antistoff, p samme mte som beskrevet ovenfor. </span>Cultivation was performed using monoclonal anti-human CD3 antibody OKT3 (ATCC CRL-8001) as positive control antibody instead of anti-human AILIM antibody, in the same manner as described above.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Deretter ble effektorceller (E/T-forhold = 50, 1 x 10&lt;5&gt;celler/brnn, 50 fil/brnn) tilsatt til hver brnn, og platen ble inkubert ved 37 "C i 16 timer under en atmosfre med 5 % CO2i en inkubator. </span>Then, effector cells (E/T ratio = 50, 1 x 10&lt;5&gt;cells/well, 50 fil/well) were added to each well and the plate was incubated at 37C for 16 hours under an atmosphere of 5% CO2i an incubator.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Etter dyrkingen ble prvene sentrifugert (ved 1500 rpm ved 4 "C i 10 minutter). Den resulterende supernatant ble gjenvunnet. Radioaktiviteten i supernatanten ble mlt med en y-teller. Radioaktiviteten representerer mengden51 Cr frigjort fra celler til dyrkingssupernatanten p grunn av cellemembranskader grunnet ADCC. </span>After the cultivation, the samples were centrifuged (at 1500 rpm at 4 "C for 10 minutes). The resulting supernatant was recovered. The radioactivity in the supernatant was measured with a y-counter. The radioactivity represents the amount of 51 Cr released from cells into the culture supernatant due to cell membrane damage due to ADCC .</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Prosent cellemembranskader (prosent cellelysis) grunnet ADCC indusert med anti-AILIM-antistoff eller anti-CD3-antistoff ble bestemt idet det ble antatt at radioaktiviteten observert med medium alene tilsvarer 0 % nr det gjelder cellemembranskader (0) og at radioaktiviteten med Nonidet tilsvarer 100 % nr det gjelder cellemembranskader. </span>Percent cell membrane damage (percent cell lysis) due to ADCC induced with anti-AILIM antibody or anti-CD3 antibody was determined assuming that the radioactivity observed with medium alone corresponds to 0% in terms of cell membrane damage (0) and that the radioactivity with Nonidet corresponds to 100 % when it comes to cell membrane damage.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatene er vist i figurene 70 og 71. </span>The results are shown in Figures 70 and 71.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatet av analysen viser at humant, monoklonalt, antihumant AILIM-antistoff iflge foreliggende oppfinnelse viste ADCC-induserende aktivitet p en konsentrasjonsavhengig mte. </span>The result of the analysis shows that human, monoclonal, anti-human AILIM antibody according to the present invention showed ADCC-inducing activity in a concentration-dependent manner.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempel 10 </span>Example 10</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Bestemmelse av gensekvens og aminosyresekvens for humant, monoklonalt, antihumant AILIM-antistoff og analyse av disse </span>Determination of gene sequence and amino acid sequence for human, monoclonal, anti-human AILIM antibody and analysis of these</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Sekvensen av cDNA som koder for tungkjeder, s vel som cDNA som koder for lettkjeder fra de forskjellige humane, monoklonale antihumant AILIM-antistoffene fremstilt i eksemplet beskrevet ovenfor, ble bestemt som beskrevet nedenfor. Strukturelle egenskaper hos genene ble ogs analysert. </span>The sequence of cDNA encoding heavy chains, as well as cDNA encoding light chains from the various human monoclonal anti-human AILIM antibodies prepared in the example described above, was determined as described below. Structural properties of the genes were also analyzed.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ved anvendelse av "Quick Prep mRNA Purification Kit" (Amersham-Pharmacia) ble PolyA&lt;+&gt;RNA ekstrahert og renset fra hver av hybridomene (kloner: AIH5D3 (JMab-136), AII289 (JMab-138) og AII394 (JMab-139)), som danner humant, monoklonalt antistoff mot humant AILIM, fremstilt i eksemplet beskrevet ovenfor. </span>Using the "Quick Prep mRNA Purification Kit" (Amersham-Pharmacia), PolyA&lt;+&gt;RNA was extracted and purified from each of the hybridomas (clones: AIH5D3 (JMab-136), AII289 (JMab-138) and AII394 (JMab-139 )), which produces human monoclonal antibody against human AILIM, prepared in the example described above.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Hybridomcellene ble suspendert i en cellelyseringsbuffer (lyseringsbuffer), og lysert ved anvendelse av en kanyle. Oligo (dT)-resin ble tilsatt til det solubiliserte materialet, og blandingen ble ristet forsiktig. Deretter ble oligo (dT)-resinet vasket, hvoretter PolyA&lt;+&gt;RNA ble eluert med elueringsbuffer. Eluert polyA&lt;+&gt;RNA ble utfelt med etanol og lst i Tris-EDTA-buffer. Konsentrasjonen av det erholdte polyA&lt;+&gt;RNA ble bestemt ut fra absorbansen ved en blgelengde p 260 nm. </span>The hybridoma cells were suspended in a cell lysis buffer (lysis buffer), and lysed using a needle. Oligo (dT) resin was added to the solubilized material and the mixture was shaken gently. Next, the oligo (dT) resin was washed, after which the PolyA&lt;+&gt;RNA was eluted with elution buffer. Eluted polyA&lt;+&gt;RNA was precipitated with ethanol and dissolved in Tris-EDTA buffer. The concentration of the obtained polyA&lt;+&gt;RNA was determined from the absorbance at a wavelength of 260 nm.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dobbelttrdet cDNA ble syntetisert ved anvendelse av polyA&lt;+&gt;RNA som templat iflge M-MLV-reverstranskriptasefremgangsmten med et kommersielt tilgjengelig cDNA-syntesesett (GIBCO-BRL) og syntetisk oligo-DNA-Notl-T (SEQ ID NO: 1) som primer. </span>Double-stranded cDNA was synthesized using polyA&lt;+&gt;RNA as template according to the M-MLV reverse transcriptase method with a commercially available cDNA synthesis kit (GIBCO-BRL) and synthetic oligo-DNA-Notl-T (SEQ ID NO: 1) as primer .</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nrmere bestemt ble enkelttrdet cDNA syntetisert i en lsning (ca. 50 jol) som inneholdt polyA&lt;+&gt;RNA (ca. 5fig) renset fra hybridomene som templat, primeren (ca. 400 pmol) og M-MLV- reverstranskriptase ved 37&lt;*&gt;C i 1 time. Deretter ble dNTP, DNA-polymerase I, RNaseH, DNA-ligase, buffer og destillert vann tilsatt til reaksjonsLsningen (4fil), og blandingen ble inkubert ved 16 C i 2 timer for syntese av dobbelttrdet cDNA. Det resulterende dobbelttrdede cDNA ble ekstrahert med fenol/kloroform og s utfelt med etanol. </span>More specifically, single-stranded cDNA was synthesized in a solution (approx. 50 l) containing polyA&lt;+&gt;RNA (approx. 5fig) purified from the hybridomas as template, the primer (approx. 400 pmol) and M-MLV reverse transcriptase at 37&lt;* &gt;C for 1 hour. Then dNTP, DNA polymerase I, RNaseH, DNA ligase, buffer and distilled water were added to the reaction solution (4 l), and the mixture was incubated at 16 C for 2 hours for synthesis of double-stranded cDNA. The resulting double-stranded cDNA was extracted with phenol/chloroform and then precipitated with ethanol.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Deretter ble EcoRI-linker-DNA (ca. 300 pmol) og DNA-ligase ("Ligastion High", 33 ml, TOYOBO) tilsatt til en lsning som inneholdt det dobbelttrdede cDNA i TE-buffer (ca. 50fil), og blandingen ble inkubert ved 16 C i ca. 80 minutter for ligering av linker-DNA til cDNA. Det anvendte linker-DNA var et dobbelttrdet DNA som bestod av oligo-DNA (20 adp, SEQ ID NO: 2) og oligo-DNA (24 adp, SEQ ID NO: 3), som var blitt 5'-fosforylert og hybridisert til hverandre ved anvendelse av en hyppig anvendt fremgangsmte. </span>Then, EcoRI linker DNA (about 300 pmol) and DNA ligase ("Ligastion High", 33 ml, TOYOBO) were added to a solution containing the double-stranded cDNA in TE buffer (about 50 l), and the mixture was incubated at 16 C for approx. 80 minutes for ligation of linker DNA to cDNA. The linker DNA used was a double-stranded DNA consisting of oligo-DNA (20 adp, SEQ ID NO: 2) and oligo-DNA (24 adp, SEQ ID NO: 3), which had been 5'-phosphorylated and hybridized to each other using a frequently used method.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DNA-ligeringsblandingen ble ekstrahert med fenol/kloroform og utfelt med etanol. Det resulterende DNA ble deretter kuttet med et kommersielt tilgjengelig restriksjonsenzym Noti (TOYOBO) og inkubert med en kommersielt tilgjengelig ATP-lsning (GIBCO-BRL) og T4-kinase (TOYOBO) ved 37&lt;*&gt;C i 30 minutter for fosforylering av 5'-enden. </span>The DNA ligation mixture was extracted with phenol/chloroform and precipitated with ethanol. The resulting DNA was then cut with a commercially available restriction enzyme Noti (TOYOBO) and incubated with a commercially available ATP solution (GIBCO-BRL) and T4-kinase (TOYOBO) at 37&lt;*&gt;C for 30 minutes for phosphorylation of 5' - the end.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det resulterende DNA ble utfelt med etanol og s fraksjonert ved polyakrylamid-gelelektroforese. En gelbit som inneholdt DNA p fra ca. 500 bp til 2000 bp ble kuttet ut. Utkuttingen fra gelen ble utfrt mens DNA farget med etidiumbromid ble synliggjort ved bestrling med UV-lys i en fotografisk innretning. </span>The resulting DNA was precipitated with ethanol and then fractionated by polyacrylamide gel electrophoresis. A piece of gel that contained DNA from approx. 500 bp to 2000 bp were excised. The excision from the gel was carried out while DNA stained with ethidium bromide was visualized by irradiation with UV light in a photographic device.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den utkuttede gel ble knust og suspendert i TE-buffer. Suspensjonen ble sentrifugert, og den resulterende supernatant ble gjenvunnet. </span>The excised gel was crushed and suspended in TE buffer. The suspension was centrifuged and the resulting supernatant was recovered.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det gjenvunne DNA ble ligert til en kommersielt tilgjengelig bakteriofag lambda-vektor XEXcell (0,25 fig, Amersham Pharmacia) i nrvr av kommersielt tilgjengelig DNA-ligase ("Ligation High", TOYOBO) (ved 16 C i 30 minutter). I neste trinn ble det ligerte DNA pakket i bakteriofag lambda ved anvendelse av et kommersielt tilgjengelig bakteriofag lambda-pakkesett, Gigapack III Gold (STRATAGENE), og de resulterende bakteriofagpartikler ble anvendt for infeksjon av E. co//-NM522 som vert for fremstilling av et cDNA-bibliotek. Alle manipulasjoner ble utfrt iflge den eksperimentelle veiledning som medflger settet. </span>The recovered DNA was ligated to a commercially available bacteriophage lambda vector XEXcell (0.25 g, Amersham Pharmacia) in the presence of commercially available DNA ligase ("Ligation High", TOYOBO) (at 16C for 30 minutes). In the next step, the ligated DNA was packaged into bacteriophage lambda using a commercially available bacteriophage lambda packaging kit, Gigapack III Gold (STRATAGENE), and the resulting bacteriophage particles were used for infection of E. co//-NM522 as a host for the production of a cDNA library. All manipulations were performed according to the experimental instructions provided with the kit.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">cDNA-biblioteket ble deretter gjennomskt ved en plakk-hybridiseringsfremgangsmte (Maniatis et al., "Molecular Cloning: A Labolatory Manual", Cold Spring Harbor Laboratory, Cold Spring Harbor, New York) som flger: cDNA-biblioteket (lx 10&lt;4-&gt;plakk) ble utsdd p agarskler, og replikafiltre ble fremstilt ved anvendelse av Hybond-N nylonmembraner (Amersham Pharmacia). Disse replikafiltrene ble analysert ved hybridisering med prober merket ved anvendelse av y32P-ATP i en hybridiseringsbuffer iflge plakkhybridiseringsfremgangsmten. De anvendte prober var HIGLC (SEQ ID NO: 4) for antistofflettkjeden og NHCc2 (SEQ ID NO: 5) for antistofftungkjeden. Isolering av enkeltplakk ble utfrt fra de positive klonene erholdt i primrsket og sekundrsket. </span>The cDNA library was then screened by a plaque hybridization procedure (Maniatis et al., "Molecular Cloning: A Laboratory Manual", Cold Spring Harbor Laboratory, Cold Spring Harbor, New York) as follows: the cDNA library (lx 10&lt;4- &gt;plaque) were plated on agar plates, and replicate filters were prepared using Hybond-N nylon membranes (Amersham Pharmacia). These replica filters were analyzed by hybridization with probes labeled using  32 P-ATP in a hybridization buffer according to the plaque hybridization method. The probes used were HIGLC (SEQ ID NO: 4) for the antibody light chain and NHCc2 (SEQ ID NO: 5) for the antibody heavy chain. Isolation of single plaques was performed from the positive clones obtained in the primary and secondary screening.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Antistofftungkjede og antistofflettkjede ble amplifisert ved PCR med en enkelt PCR-primer og et Taq-PCR-sett (TAKARA) ved anvendelse av bakteriofagsuspensjon fra hver av de positive kloner som templat-DNA. Primerparet anvendt for antistofflettkjeden var ExcellE (SEQ ID NO: 6) og ckll7 (SEQ ID NO: 7), og primerparet anvendt for antistofftungkjeden var ExcellE (SEQ ID NO: 6) og NHCc2 (SEQ ID NO: 5). De resulterende PCR-produkter ble fraksjonert iflge en sedvanlig fremgangsmte ved anvendelse av agarosegelelektroforese. Gelbiter som inneholdt DNA p ca. 600 bp, tilsvarende tungkjede og lettkjede, ble kuttet ut. Nukleotidsekvensen til DNA renset fra gelen ble analysert ved anvendelse av et DNA-sekvenseringsinstrument (373A, PE-Applied Biosystems), ABI PRISM Sequencing Software (PE-Applied Biosystems) og ABI PRISM Auto Assembler (PE-Applied Biosystems). DNA fra hver av de positive klonene ble vist  ha en tilstrekkelig lang nukleotidsekvens. </span>Antibody heavy chain and antibody light chain were amplified by PCR with a single PCR primer and a Taq-PCR kit (TAKARA) using bacteriophage suspension from each of the positive clones as template DNA. The primer pair used for the antibody light chain was ExcellE (SEQ ID NO: 6) and ckll7 (SEQ ID NO: 7), and the primer pair used for the antibody heavy chain was ExcellE (SEQ ID NO: 6) and NHCc2 (SEQ ID NO: 5). The resulting PCR products were fractionated according to a conventional method using agarose gel electrophoresis. Gel pieces containing DNA of approx. 600 bp, corresponding to heavy chain and light chain, were cut out. The nucleotide sequence of DNA purified from the gel was analyzed using a DNA sequencing instrument (373A, PE-Applied Biosystems), ABI PRISM Sequencing Software (PE-Applied Biosystems), and ABI PRISM Auto Assembler (PE-Applied Biosystems). DNA from each of the positive clones was shown to have a sufficiently long nucleotide sequence.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Bakteriofag-X fra plakk av hver positiv klon ble benyttet for infeksjon av E. coli-NP66 for in v/vo-utkutting av plasmid-DNA av interesse, og de resulterende filamentse bakteriofager ble utsdd i ampicillinholdige skler for erholdelse av kolonier. Deretter ble plasmid-DNA gjenvunnet og renset fra koloniene ved en sedvanlig fremgangsmte, og E. coli-JM109 ble transformerte med plasmidene. Deretter ble de transformerte cellene utsdd p ampicillinholdige nringsagarskler for dannelse av kolonier. </span>Bacteriophage-X from plaques of each positive clone was used to infect E. coli NP66 for in v/vo excision of plasmid DNA of interest, and the resulting filamentous bacteriophages were plated in ampicillin-containing dishes to obtain colonies. Subsequently, plasmid DNA was recovered and purified from the colonies by a conventional method, and E. coli-JM109 was transformed with the plasmids. Then, the transformed cells were plated on ampicillin-containing nutrient agar plates to form colonies.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En suspensjon i ampicillinholdig LB-medium avledet fra bakterier fra hver koloni ble overfrt til et flytende nringsmedium, og bakteriene ble dyrket ved 37 C i 24 timer. Bakteriene ble hstet fra kulturen, hvoretter plasmid-DNA ble renset med et plasmidrensesett (Quiagen). Hvert plasmid-DNA ble kuttet med restriksjonsenzymene EcoRI/Notl for  bekrefte nrvr av vektor-DNA og innskudds-DNA (tungkjede-cDNA eller lettkjede-cDNA). </span>A suspension in ampicillin-containing LB medium derived from bacteria from each colony was transferred to a liquid nutrient medium, and the bacteria were grown at 37C for 24 h. The bacteria were harvested from the culture, after which plasmid DNA was purified with a plasmid purification kit (Quiagen). Each plasmid DNA was cut with the restriction enzymes EcoRI/NotI to confirm the presence of vector DNA and insert DNA (heavy chain cDNA or light chain cDNA).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nukleotidsekvensen til cDNA som koder for tungkjede og lettkjede i antistoffet, innsatt i de rensede plasmider, ble bestemt ved en sedvanlig fremgangsmte ved anvendelse av et DNA-sekvenseringsinstrument (377A, PE-Applied Biosystems), ABI PRISM Sequencing Software (PE-Applied Biosystems) og ABI PRISM Auto Assembler (PE-Applied Biosystems). </span>The nucleotide sequence of the cDNA encoding the heavy chain and light chain of the antibody, inserted into the purified plasmids, was determined by a conventional method using a DNA sequencing instrument (377A, PE-Applied Biosystems), ABI PRISM Sequencing Software (PE-Applied Biosystems) and ABI PRISM Auto Assembler (PE-Applied Biosystems).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Primerne som ble anvendt for sekvensbestemmelsen var som flger. </span>The primers used for the sequence determination were as follows.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Primere anvendt for bestemmelse av sekvensen til tungkjede- cDNA: </span>Primers used for determining the sequence of heavy chain cDNA:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">M13R-primer (SEQ ID NO: 8, STRATAGENE), ExcellE (SEQ ID NO: 6), 136H (SEQ ID NO: 9), 138/9H (SEQ ID NO: 10), AILIMHC1 (SEQ ID NO: 11), HCcl (SEQ ID NO: 12), NHCc2 (SEQ ID NO: 5), HCc7 (SEQ ID NO: 13), HCc8 (SEQ ID NO: 14), HCc3 (SEQ ID NO: 15), HCc4 (SEQ ID NO: 16), HCc6 (SEQ ID NO: 17), HIGHC (SEQ ID NO: 18), HCc9 (SEQ ID NO: 19), HCc5 (SEQ ID NO: 20) og polyA (SEQ ID NO: 21). </span>M13R primer (SEQ ID NO: 8, STRATAGENE), ExcellE (SEQ ID NO: 6), 136H (SEQ ID NO: 9), 138/9H (SEQ ID NO: 10), AILIMHC1 (SEQ ID NO: 11) , HCcl (SEQ ID NO: 12), NHCc2 (SEQ ID NO: 5), HCc7 (SEQ ID NO: 13), HCc8 (SEQ ID NO: 14), HCc3 (SEQ ID NO: 15), HCc4 (SEQ ID NO: 16), HCc6 (SEQ ID NO: 17), HIGHC (SEQ ID NO: 18), HCc9 (SEQ ID NO: 19), HCc5 (SEQ ID NO: 20) and polyA (SEQ ID NO: 21).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Primere anvendt for bestemmelse av sekvensen til lettkjede- cDNA: </span>Primers used for determining the sequence of light chain cDNA:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">M13R-primer (SEQ ID NO: 8, STRATAGENE), ExcellE (SEQ ID NO: 6), AILIMLC1 (SEQ ID NO: 22), AILIMLC2 (SEQ ID NO: 23), LCcl (SEQ ID NO: 24), ckl 17 (SEQ ID NO: 7), HIGLC (SEQ ID NO: 4), LCc2 (SEQ ID NO: 25), HIK (SEQ ID NO: 26), og polyA(SEQ ID NO: 21). </span>M13R primer (SEQ ID NO: 8, STRATAGENE), ExcellE (SEQ ID NO: 6), AILIMLC1 (SEQ ID NO: 22), AILIMLC2 (SEQ ID NO: 23), LCcl (SEQ ID NO: 24), ckl 17 (SEQ ID NO: 7), HIGLC (SEQ ID NO: 4), LCc2 (SEQ ID NO: 25), HIK (SEQ ID NO: 26), and polyA (SEQ ID NO: 21).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Sekvenslisten vist nedenfor inneholder cDNA-sekvensen som koder for tungkjede og cDNA-sekvensen som koder for lettkjede i det humane, monoklonale antistoff mot humant AILIM som dannes av hver av hybridomene nevnt ovenfor, s vel som aminosyresekvenser utledet fra cDNA-sekvensene. </span>The sequence listing shown below contains the cDNA sequence encoding the heavy chain and the cDNA sequence encoding the light chain of the human monoclonal antibody to human AILIM produced by each of the hybridomas mentioned above, as well as amino acid sequences derived from the cDNA sequences.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Klon AIH5D3 ( JMab- 136) </span>Clone AIH5D3 (JMab-136)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tungkjede </span>Heavy chain</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DNA-sekvens: SEQ ID NO: 27 (signalsekvens: nukleotider nr. 69-125, V-omrde: nukleotider nr. 126-419). </span>DNA sequence: SEQ ID NO: 27 (signal sequence: nucleotides no. 69-125, V region: nucleotides no. 126-419).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Aminosyresekvens: SEQ ID NO: 28 (omfattende signalsekvens: aminosyrer nr. 1-19, variabelt omrde: aminosyrer nr. 20-118). </span>Amino acid sequence: SEQ ID NO: 28 (comprehensive signal sequence: amino acids No. 1-19, variable region: amino acids No. 20-118).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Lettkjede </span>Light chain</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DNA-sekvens: SEQ ID NO: 29 (signalsekvens: nukleotider nr. 39-104, V-omrde: nukleotider nr. 105-386). </span>DNA sequence: SEQ ID NO: 29 (signal sequence: nucleotides no. 39-104, V region: nucleotides no. 105-386).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Aminosyresekvens: SEQ ID NO: 30 (omfattende signalsekvens: aminosyrer nr. 1-22, variabelt omrde: aminosyrer nr. 23-116). </span>Amino acid sequence: SEQ ID NO: 30 (comprehensive signal sequence: amino acids No. 1-22, variable region: amino acids No. 23-116).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Klon AII289 ( JMab- 138) </span>Clone AII289 (JMab-138)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tungkjede </span>Heavy chain</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DNA-sekvens: SEQ ID NO: 31 (omfattende signalsekvens: nukleotider nr. 94-150, V-omrde: nukleotider nr. 151-441). </span>DNA sequence: SEQ ID NO: 31 (comprehensive signal sequence: nucleotides no. 94-150, V region: nucleotides no. 151-441).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Aminosyresekvens: SEQ ID NO: 32 (omfattende signalsekvens: aminosyrer nr. 1-19, variabelt omrde: aminosyrer nr. 20-116). </span>Amino acid sequence: SEQ ID NO: 32 (comprehensive signal sequence: amino acids No. 1-19, variable region: amino acids No. 20-116).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Lettkjede </span>Light chain</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DNA-sekvens: SEQ ID NO: 33 (omfattende signalsekvens: nukleotider nr. 28-87, V-omrde: nukleotider nr. 88-375). </span>DNA sequence: SEQ ID NO: 33 (comprehensive signal sequence: nucleotides no. 28-87, V region: nucleotides no. 88-375).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Aminosyresekvens: SEQ ID NO: 34 (omfattende signalsekvens: aminosyrer nr. 1-20, variabelt omrde: aminosyrer nr. 21-116). </span>Amino acid sequence: SEQ ID NO: 34 (comprehensive signal sequence: amino acids No. 1-20, variable region: amino acids No. 21-116).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Klon AII394 ( JMab- 139) </span>Clone AII394 (JMab-139)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tungkjede </span>Heavy chain</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DNA-sekvens: SEQ ID NO: 35 (signalsekvens: nukleotider nr. 96-152, V-omrde: nukleotider nr. 153-443). </span>DNA sequence: SEQ ID NO: 35 (signal sequence: nucleotides no. 96-152, V region: nucleotides no. 153-443).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Aminosyresekvens: SEQ ID NO: 36 (omfattende signalsekvens: aminosyrer nr. 1-19, variabelt omrde: aminosyrer nr. 20-116). </span>Amino acid sequence: SEQ ID NO: 36 (comprehensive signal sequence: amino acids No. 1-19, variable region: amino acids No. 20-116).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Lettkjede </span>Light chain</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DNA-sekvens: SEQ ID NO: 37 (signalsekvens: nukleotider nr. 33-92, V-omrde: nukleotider nr. 93-380). </span>DNA sequence: SEQ ID NO: 37 (signal sequence: nucleotides no. 33-92, V region: nucleotides no. 93-380).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Aminosyresekvens: SEQ ID NO: 38 (omfattende signalsekvens: aminosyrer nr. 1-20, variabelt omrde: aminosyrer nr. 21-116). </span>Amino acid sequence: SEQ ID NO: 38 (comprehensive signal sequence: amino acids No. 1-20, variable region: amino acids No. 21-116).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ved  anvende programvare for analyse av gensekvenser ble biblioteket V BASE Sequence for gener for variable omrder i </span>By using gene sequence analysis software, the library V BASE Sequence for genes for variable regions i</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">humane immunglobuliner, konstruert av Tomlinson et al. (Immunol. Today, vol. 16, nr. 5, s. 237-242, 1995), gjennomskt for hver av DNA-sekvensene bestemt her. </span>human immunoglobulins, constructed by Tomlinson et al. (Immunol. Today, vol. 16, no. 5, pp. 237-242, 1995), screened for each of the DNA sequences determined herein.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatene viste at V-omrdegenene for tungkjede og lettkjede i de ovenfor nevnte humane, monoklonale antistoffene bestod av flgende segmenter: </span>The results showed that the V region genes for heavy chain and light chain in the above-mentioned human monoclonal antibodies consisted of the following segments:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tungkjede- V- omrdegen </span>Heavy chain V-region gene</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">klon AIH5D3 (JMab-136): 1-02 </span>clone AIH5D3 (JMab-136): 1-02</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">klon AII289 (JMab-138): 3-13 </span>clone AII289 (JMab-138): 3-13</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">klon AII394 (JMab-139): 3-13. </span>clone AII394 (JMab-139): 3-13.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Lettkjede- V- omrdegen </span>Light chain V region gene</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">klon AIH5D3 (JMab-136): L5 </span>clone AIH5D3 (JMab-136): L5</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">klon AII289 (JMab-138): A27 </span>clone AII289 (JMab-138): A27</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">klon AII394 (JMab-139): A27. </span>clone AII394 (JMab-139): A27.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempel 11 </span>Example 11</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Inhiberende virkning av humant, monoklonalt, antihumant AILIM- antistoff p hypersensitivitet av forsinket type ( DTH") </span>Inhibitory effect of human monoclonal anti-human AILIM antibody on delayed-type hypersensitivity (DTH")</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det biologiske immunresponssystem, hvis funksjon er  fjerne skadelige antigener (patogene mikroorganismer, slik som virus, bakterier og parasitter, fremmedlegemer osv.) fra kroppen, kan grovt sett deles i kongenital immunitet og ervervet immunitet. </span>The biological immune response system, whose function is to remove harmful antigens (pathogenic microorganisms, such as viruses, bacteria and parasites, foreign bodies, etc.) from the body, can roughly be divided into congenital immunity and acquired immunity.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den frste er et elimineringssystem basert p uspesifikk gjenkjenning som omfatter fagocytose ved fagocytter (polymorfonuklere leukocytter, monocytter, makrofager osv.), angrep av naturlige dreperceller (NK-celler), opsonisering av antigen ved komplement osv. </span>The first is an elimination system based on nonspecific recognition that includes phagocytosis by phagocytes (polymorphonuclear leukocytes, monocytes, macrophages, etc.), attack by natural killer cells (NK cells), opsonization of antigen by complement, etc.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det siste system, den ervervede immunrespons, er et elimineringssystem via lymfocytter (hovedsakelig T-celler og B-celler) som har ervervet spesifisitet (aktivering) over antigenet. </span>The last system, the acquired immune response, is an elimination system via lymphocytes (mainly T cells and B cells) that have acquired specificity (activation) over the antigen.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Videre kan den ervervede immunrespons grovt sett oppdeles i cellulr immunitet og humoral immunitet. </span>Furthermore, the acquired immune response can be roughly divided into cellular immunity and humoral immunity.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I motsetning til den antistoffavhengige humorale immunitet er den cellulre immunitet en immunrespons som generelt uttrykkes ved direkte virkning av T-celler p et ml-antigen. Den cellulre immunitet vites  inng i immunresponsen mot virus eller tumorer, immunresponser indusert etter transplantasjon av vev eller organer, hypersensitivitet overfor visse medikamenter og noen autoimmune sykdommer. </span>In contrast to the antibody-dependent humoral immunity, the cellular immunity is an immune response that is generally expressed by the direct action of T cells on a target antigen. Cellular immunity is known to be part of the immune response against viruses or tumors, immune responses induced after transplantation of tissues or organs, hypersensitivity to certain drugs and some autoimmune diseases.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det mest typiske fenomen tilhrende den cellulre immunitet er den velkjente tuberkulinallergi (nesten synonym med tuberkulinhypersensitivitet). Tuberkulinallergi er en forsinket allergi som utlses ved infeksjon med tuberkelbasiller. Allergien skyldes infeksjonen med tuberkelbasiller og kan induseres ved  utlse en immunrespons ved intrakutan injeksjon i kroppen av tuberkulinprotein dannet i dyrkingssupernatant fra tuberkelbasiller. </span>The most typical phenomenon associated with cellular immunity is the well-known tuberculin allergy (almost synonymous with tuberculin hypersensitivity). Tuberculin allergy is a delayed allergy that is triggered by infection with tubercle bacilli. The allergy is caused by the infection with tubercle bacilli and can be induced by triggering an immune response by intracutaneous injection into the body of tuberculin protein formed in culture supernatant from tubercle bacilli.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Forsinket allergi er en allergi som formidles av T-celler (hukommelses-T-celler som "husker" antigenet) sensitivisert med et antigen. Allergien kalles "forsinket type", siden det tar 24-48 timer for en kropp som er sensitivisert med antigenet  uttrykke en allergisk respons med inflammasjon, indusert av hukommelses-T-cellen nr den igjen kommer i kontakt med antigenet. </span>Delayed allergy is an allergy mediated by T cells (memory T cells that "remember" the antigen) sensitized with an antigen. The allergy is called "delayed type", since it takes 24-48 hours for a body sensitized with the antigen to express an allergic response with inflammation, induced by the memory T cell when it comes into contact with the antigen again.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Fenomenet tuberkulinallergi, som er representativ for forsinkede allergier, er generelt blitt utnyttet i "tuberkulinprven" for diagnose av hvorvidt sensitivisering ved infeksjon med tuberkelbasiller allerede er blitt etablert i et dyr. Nrmere bestemt utfres analysen som flger: Renset tuberkulin (renset proteinderivat, PPD, 0,1 ml derivat med 0,05 fig/0,1 ml (2,5 TU) for generell diagnostisk anvendelse), som er tuberkulinprotein renset fra en kultur av tuberkelbasiller, tilfres intrakutant til et dyr; hovedaksen for rdhet i huden p injeksjonssetet mles 48 timer etter injeksjonen, og nrvr av en tuberkelbasillinfeksjon kan diagnostiseres basert p mling av hovedaksen. Dersom hovedaksen for rdheten er mindre enn 4 mm, er individet negativt; dersom aksen ligger innenfor omrdet 4-9 mm, er individet en falsk positiv; og dersom aksen er 10 mm eller lenger, anses individet som positivt. </span>The phenomenon of tuberculin allergy, which is representative of delayed allergies, has generally been exploited in the "tuberculin test" for the diagnosis of whether sensitization by infection with tubercle bacilli has already been established in an animal. Specifically, the assay is performed as follows: Purified tuberculin (purified protein derivative, PPD, 0.1 ml derivative with 0.05 fig/0.1 ml (2.5 TU) for general diagnostic use), which is tuberculin protein purified from a culture of tubercle bacilli, administered intracutaneously to an animal; the main axis of redness of the skin at the injection site is measured 48 hours after the injection, and the presence of a tubercle bacillus infection can be diagnosed based on the measurement of the main axis. If the main axis of the redness is less than 4 mm, the individual is negative; if the axis lies within the range 4-9 mm, the individual is a false positive; and if the axis is 10 mm or longer, the individual is considered positive.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Forsinkede allergier forbundet med cellulr immunitet omfatter f.eks. hypersensitivitet av Jones-Mote-type, forbigende indusert med en liten mengde protein eller lignende, kontaktallergi overfor medikamenter, slik som pikrylklorid, eller plantetoksiner, slik som japansk lakk, eller allergi forbundet med transplantatrejeksjon (f.eks. allogent transplantat), s vel som den ovenfor nevnte allergi overfor antigen fra infeksise patogene organismer, slik som tuberkulinallergi grunnet tuberkelbasillen beskrevet ovenfor. </span>Delayed allergies associated with cellular immunity include e.g. hypersensitivity of the Jones-Mote type, transiently induced with a small amount of protein or similar, contact allergy to drugs, such as picryl chloride, or plant toxins, such as Japanese lacquer, or allergy associated with graft rejection (eg, allogeneic graft), as well such as the above-mentioned allergy to antigen from infectious pathogenic organisms, such as tuberculin allergy due to the tubercle bacillus described above.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">I denne analysen ble den inhiberende virkning av anti-AILIM-antistoff p hypersensitivitet av forsinket type (forsinket allergi) evaluert ved  benytte den ovenfor nevnte tuberkulinprve. Analysen ble utfrt som flger: Cynomolgus-aper (hanndyr, kroppsvekt: 6,0-8,5 kg, Environmental Biological Life Science Research Center Inc., 3 individer i hver gruppe), som var sensitivisert med BCG ( Bacille de Calmette et Guerin), som er en svekket, levende bakterie av tuberkelbasilltype fra storfe, ble bedvd med ketaminhydroklorid (10 mg/kg, intramuskulr injeksjon), hvoretter en av analyseprvene angitt nedenfor ble tilfrt intrakutant i en mengde p 0,1 ml til hvert injeksjonssete (6 injeksjonsseter/individ) i brystet. Avstanden mellom injeksjonssetene var 3 cm eller mer. (1) l:l-blanding av humant, monoklonalt, antihumant AILIM-antistoff (JMab-136, 0,2 mg, 10 fig i hvert injeksjonssete) og tuberkulin (4 mg/l ml med fysiologisk saltvann); (2) l:l-blanding av humant, monoklonalt, antihumant AILIM-antistoff (JMab-136, 2 mg, 100 fig i hvert injeksjonssete) og tuberkulin (4 fig/l ml med fysiologisk saltvann); (3) fosfatbuffer (PBS (-)) som kontroll; (4) l:l-blanding av kommersielt tilgjengelig antiinflammatorisk steroidmiddel, prednisolon (0,2 mg, 10 fig i hvert injeksjonssete) og tuberkulin (4fig/l ml med fysiologisk saltvann) som positiv kontroll; (5) l:l-blanding av humant, monoklonalt anti-KLH-antistoff (eksempel 2.2, 0,2 mg, 10 fig i hvert injeksjonssete) og tuberkulin (4 mg/l ml med fysiologisk saltvann) som negativ kontroll. 24 timer etter injeksjon av prvene ble hovedaksen og den korteste aksen for det rde omrdet i hvert injeksjonssete mlt for  bestemme arealet av det rde omrdet. </span>In this assay, the inhibitory effect of anti-AILIM antibody on delayed-type hypersensitivity (delayed allergy) was evaluated using the above-mentioned tuberculin test. The analysis was performed as follows: Cynomolgus monkeys (male, body weight: 6.0-8.5 kg, Environmental Biological Life Science Research Center Inc., 3 individuals in each group), which were sensitized with BCG ( Bacille de Calmette et Guerin ), which is an attenuated live bovine tubercle bacillus-type bacterium, was anesthetized with ketamine hydrochloride (10 mg/kg, intramuscular injection), after which one of the assay samples listed below was injected intracutaneously in an amount of 0.1 ml into each injection site (6 injection sites/individual) in the chest. The distance between the injection sites was 3 cm or more. (1) 1:1 mixture of human monoclonal anti-human AILIM antibody (JMab-136, 0.2 mg, 10 g in each injection site) and tuberculin (4 mg/l ml with physiological saline); (2) 1:1 mixture of human monoclonal anti-human AILIM antibody (JMab-136, 2 mg, 100 g in each injection site) and tuberculin (4 g/1 ml with physiological saline); (3) phosphate buffer (PBS (-)) as control; (4) 1:1 mixture of commercially available anti-inflammatory steroid, prednisolone (0.2 mg, 10 g in each injection site) and tuberculin (4 g/l ml with physiological saline) as a positive control; (5) 1:1 mixture of human monoclonal anti-KLH antibody (Example 2.2, 0.2 mg, 10 g in each injection site) and tuberculin (4 mg/1 ml with physiological saline) as a negative control. 24 hours after injection of the samples, the major axis and the shortest axis of the red area in each injection site were measured to determine the area of the red area.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatet er vist i figur 72. </span>The result is shown in figure 72.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatet viste at rdhet grunnet forsinket allergi ble signifikant inhibert i alle grupper behandlet med injeksjon av anti-AILIM antistoff, sammenlignet med kontrollgruppen og den negative kontrollgruppen. Den inhiberende virkning var tilsvarende den til det steroide, antiinflammatoriske medikament som ble anvendt som positiv kontroll. </span>The result showed that redness due to delayed allergy was significantly inhibited in all groups treated with injection of anti-AILIM antibody, compared to the control group and the negative control group. The inhibitory effect was similar to that of the steroid, anti-inflammatory drug used as a positive control.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempel 12 </span>Example 12</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Analyse av ekspresjon av AILIM i forskjellige vev fra pasienter med " graft versus host"- svkdom </span>Analysis of expression of AILIM in different tissues from patients with "graft versus host" disease</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">( GVHD) </span>(GVHD)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ekspresjonen av AILIM i en rekke vev erholdt ved biopsi fra pasienter som var mottakere av allogene transplantater fra donorer, og som klinisk var blitt diagnostisert til  lide av akutt eller kronisk "graft versus host"-sykdom (GVHD) etter transplantasjonen, ble analysert ved en vanlig anvendt fremgangsmte. Vevene ble farget med HE, og humant, monoklonalt, antihumant AILIM-antistoff (JMab-36) fremstilt i eksemplet beskrevet ovenfor. </span>The expression of AILIM in a variety of tissues obtained by biopsy from patients who were recipients of allogeneic donor grafts and who had been clinically diagnosed as suffering from acute or chronic post-transplant graft versus host disease (GVHD) was analyzed by a commonly used method. The tissues were stained with HE, and human monoclonal anti-human AILIM antibody (JMab-36) prepared in the example described above.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Analysen ble utfrt ved anvendelse av 33 prver fra forskjellige vev erholdt fra akutte GVHD-pasienter (28 tilfeller), s vel som 5 prver fra kroniske GVHD-pasienter (5 tilfeller). </span>The analysis was performed using 33 samples from different tissues obtained from acute GVHD patients (28 cases), as well as 5 samples from chronic GVHD patients (5 cases).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatene var som flger: AILIM-positiv reaksjon ble funnet i 15 av 29 prver fra hudvev; i 1 av 3 prver fra magevev; og i 1 av 1 prve fra colonvev; alle erholdt fra akutte GVHD-pasienter. AILIM-positiv reaksjon ble funnet i 1 av 3 prver fra hudvev; og i 2 av 2 prver fra colonvev; alle erholdt fra kroniske GVHD-pasienter. Videre ble AILIM-positiv reaksjon funnet i 10 av 13 prver, i hvilke signifikant lymfocyttinfiltrering var observert. </span>The results were as follows: AILIM-positive reaction was found in 15 of 29 skin tissue samples; in 1 of 3 samples from stomach tissue; and in 1 of 1 samples from colon tissue; all obtained from acute GVHD patients. AILIM-positive reaction was found in 1 of 3 samples from skin tissue; and in 2 of 2 samples from colon tissue; all obtained from chronic GVHD patients. Furthermore, AILIM-positive reaction was found in 10 of 13 samples, in which significant lymphocyte infiltration was observed.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempel 13 </span>Example 13</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Aktivitet av humant, monoklonalt, antihumant AILIM- antistoff p overfringen av det kostimulerende signal i ape- T- celler </span>Activity of human monoclonal anti-human AILIM antibody on the transmission of the costimulatory signal in monkey T cells</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksperimentet utfrt i eksempel 7 har vist at de humane, monoklonale antihumant AILIM-antistoffene iflge foreliggende oppfinnelse kan forsterke proliferasjonen av humane T-celler ved  kontrollere den humane T-cellerespons, nrmere bestemt ved  kontrollere overfringen av det AILIM-formidlede, kostimulerende signal til cellen. I denne analysen ble det analysert hvorvidt de humane, monoklonale antistoffene viser fremmende aktivitet p celleproliferasjonen til ape-T-celler ved samme fremgangsmte som beskrevet i eksempel 7. </span>The experiment carried out in Example 7 has shown that the human monoclonal anti-human AILIM antibodies according to the present invention can enhance the proliferation of human T cells by controlling the human T cell response, more specifically by controlling the transmission of the AILIM-mediated costimulatory signal to the cell. In this analysis, it was analyzed whether the human monoclonal antibodies show promoting activity on the cell proliferation of monkey T cells using the same method as described in example 7.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">13.1 Fortynning av antistoff </span>13.1 Dilution of antibody</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Monoklonalt, antihumant CD3-antistoff SP34 (BD-Pharmingen) ble fortynnet med fosfatbuffer (PBS) til en sluttkonsentrasjon p 1 fig/ml. </span>Monoclonal, anti-human CD3 antibody SP34 (BD-Pharmingen) was diluted with phosphate buffer (PBS) to a final concentration of 1 g/ml.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det ovenfor fremstilte humane, monoklonale antihumant AILIM-antistoff JMAM36 ble fortynnet med PBS til en sluttkonsentrasjon p 40 fig/ml. Antistofflsningene ble fortynnet videre med PBS for fremstilling av forskjellige konsentrasjoner av antistoff (40 (ig/ml-0,064 ng/ml). </span>The human monoclonal anti-human AILIM antibody JMAM36 prepared above was diluted with PBS to a final concentration of 40 g/ml. The antibody solutions were further diluted with PBS to prepare different concentrations of antibody (40 (g/ml-0.064 ng/ml).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">13.2 Belegging av mikroplater med antistoff </span>13.2 Coating of microplates with antibody</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Hver brnn i 96-brnners mikroplater ble belagt med monoklonalt, antihumant CD3-antistoff SP34 (1 ng/ml, 25 ni i hver brnn), og det humane, monoklonale antihumant AILIM-antistoff JMAbl36 (40 ng/ml-0,064 25 ni i hver brnn). Platene ble inkubert ved 37 C i 2 timer. Deretter ble antistofflsningene fjernet, og brnnene ble vasket tre ganger med PBS. Etter vask ble RPMI-1640-medium tilsatt 10 % FCS tilsatt til brnnene (100 nl/brnn), og platene ble inkubert ved 37 C i 1 time. P denne mten ble brnnene i platene belagt med antistoffene nevnt ovenfor. </span>Each well in 96-well microplates was coated with monoclonal anti-human CD3 antibody SP34 (1 ng/ml, 25 ni in each well), and the human monoclonal anti-human AILIM antibody JMAbl36 (40 ng/ml-0.064 25 ni in each well). The plates were incubated at 37C for 2 hours. Then the antibody solutions were removed, and the wells were washed three times with PBS. After washing, RPMI-1640 medium supplemented with 10% FCS was added to the wells (100 nl/well), and the plates were incubated at 37 C for 1 h. In this way, the wells in the plates were coated with the antibodies mentioned above.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Kontrolleksperimenter ble utfrt p samme mte ved anvendelse av plater belagt med humant, monoklonalt anti-KLH-antistoff (JMab23, se eksemplene ovenfor) som kontrollantistoff i stedet for de humane, monoklonale antihumant AILIM-antistoffene. </span>Control experiments were performed similarly using plates coated with human monoclonal anti-KLH antibody (JMab23, see examples above) as control antibody instead of the human monoclonal anti-human AILIM antibodies.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mikroplatene belagt med antistoff ble anvendt i de pflgende analyser. </span>The microplates coated with antibody were used in the subsequent analyses.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">13.3 Fremstilling av en suspensjon av ape- T- celler </span>13.3 Preparation of a suspension of monkey T cells</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Perifert blod ble oppsamlet fra Cynomolgus-aper, og mononuklere celler ble fraksjonert ved tetthetsgradientsentrifugering ved anvendelse av NycoPrep 1.077A (Nycomed). Iflge forsksrettledningen ble ape-T-celler separert fra de mononuklere cellene fra Cynomolgus-ape ved anvendelse av antihumant CD4-antistoff M-T477 (BD-Pharmingen), antihumant CD8-antistoff RPA-T8 (BD-Pharmingen), antimuse-IgG-mikrokuler (Miltenyi) og en magnetisk sorterer. T-celletallet ble bestemt ved anvendelse av et hemacytometer. Ape-T-celler ble suspendert i RPMI-1640-medium tilsatt 10 % FCS. P denne mten ble en suspensjon av ape-T-celler (1 x IO6 celler/ml) fremstilt. </span>Peripheral blood was collected from Cynomolgus monkeys, and mononuclear cells were fractionated by density gradient centrifugation using NycoPrep 1.077A (Nycomed). According to the experimental guidelines, monkey T cells were separated from the mononuclear cells from Cynomolgus monkeys using anti-human CD4 antibody M-T477 (BD-Pharmingen), anti-human CD8 antibody RPA-T8 (BD-Pharmingen), anti-mouse IgG- microspheres (Miltenyi) and a magnetic sorter. The T-cell count was determined using a hemacytometer. Monkey T cells were suspended in RPMI-1640 medium supplemented with 10% FCS. In this way, a suspension of monkey T cells (1 x 106 cells/ml) was prepared.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">13.4 Celledyrking </span>13.4 Cell culture</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(1) Dyrking ved anvendelse av mikroplate belagt med antihumant CD3- antistoff og antihumant AILIM- antistoff </span>(1) Cultivation using microplate coated with anti-human CD3 antibody and anti-human AILIM antibody</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ape-T-cellesuspensjonen ble tilsatt til hver brnn i en mikroplate belagt med antistoffet nevnt ovenfor, og platen ble inkubert ved 37&lt;*&gt;C i 2 dager i en CCVinkubator. </span>The monkey T cell suspension was added to each well of a microplate coated with the antibody mentioned above, and the plate was incubated at 37&lt;*&gt;C for 2 days in a CCVincubator.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Etter avsluttet dyrking ble mikroplatene anvendt i flgende analyser: </span>After completion of cultivation, the microplates were used in the following analyses:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">13.5 Bestemmelse av T- cellenes proliferasjonsaktivitet </span>13.5 Determination of the proliferation activity of the T cells</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Metyl- [3H]tymidin (0,5 (iCi/brnn, Amersham-Pharmacia) ble tilsatt til hver brnn i platene etter inkubering, og platene ble inkubert ved 37&lt;*&gt;C i 6 timer i en C02-inkubator. Etter inkuberingen ble cellene oppfanget p GF/C-filtre (Packard) ved anvendelse av en cellehster. Filtrene ble s trket ved 40&lt;*&gt;C i 3 timer eller mer, og Microscinti 0 (20 jil/brnn, Packard) ble tilsatt til disse.&lt;3&gt;H-radioaktivitet inkorporert i cellene oppfanget p filtrene ble mlt med en teller (TOP COUNT) for analyse av T-celleproliferasjonsgraden etter dyrkingen. </span>Methyl-[ 3 H]thymidine (0.5 (iCi/well, Amersham-Pharmacia) was added to each well of the plates after incubation, and the plates were incubated at 37&lt;*&gt;C for 6 hours in a CO 2 incubator. After the incubation the cells were collected on GF/C filters (Packard) using a cell harvester.The filters were then dried at 40&lt;*&gt;C for 3 hours or more and Microscinti 0 (20 l/well, Packard) was added thereto. &lt;3&gt;H radioactivity incorporated in the cells captured on the filters was measured with a counter (TOP COUNT) for analysis of the T-cell proliferation rate after the cultivation.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatet er vist i figur 73. </span>The result is shown in figure 73.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatet fra denne analysen viste at ape-T-celler hadde signifikant proliferasjon, avhengig av cellekonsentrasjonen dersom mikroplatene var belagt med monoklonalt, antihumant AILIM-antistoff (humant, monoklonalt antistoff eller monoklonalt antistoff fra mus) sammen med antihumant CD3-antistoff. </span>The result from this analysis showed that monkey T cells had significant proliferation, depending on the cell concentration, if the microplates were coated with monoclonal, anti-human AILIM antibody (human, monoclonal antibody or monoclonal antibody from mouse) together with anti-human CD3 antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatet tyder ogs p at de humane, monoklonale antihumant AILIM-antistoffene iflge foreliggende oppfinnelse kan bindes til ape-AILIM og har evnen til  regulere funksjonen av ape-AILIM. </span>The result also suggests that the human, monoclonal anti-human AILIM antibodies according to the present invention can bind to monkey AILIM and have the ability to regulate the function of monkey AILIM.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempel 14 </span>Example 14</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Etablering av en fremgangsmte for identifisering og kvantifisering av forbindelser som kan bindes til AILIM eller AILIM- ligand </span>Establishment of a method for the identification and quantification of compounds that can bind to AILIM or AILIM ligand</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ELISA(enzymkoblet immunadsorpsjonsanalyse)-fremgangsmte ble etablert for identifisering eller kvantifisering av forbindelser som kan bindes til AILIM (ICOS) eller AILIM-ligand (B7h/B7RPl/GL50/LICOS). </span>An ELISA (enzyme-linked immunoadsorption assay) method was established for the identification or quantification of compounds that can bind to AILIM (ICOS) or AILIM ligand (B7h/B7RP1/GL50/LICOS).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Prinsippet for fremgangsmten, beskrevet nedenfor i detalj som et eksempel, er basert p estimering ved ELISA av graden av inhibering p binding mellom lselig humant AILIM (hAILIM-IgFc) og lselig human AILIM-ligand (hB7h-IgFc) som forbindelsen gir. </span>The principle of the method, described below in detail as an example, is based on the estimation by ELISA of the degree of inhibition of binding between soluble human AILIM (hAILIM-IgFc) and soluble human AILIM-ligand (hB7h-IgFc) which the compound provides.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">14.1 Prve </span>14.1 Trial</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Flgende prver ble benyttet: </span>The following samples were used:</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(1) streptavidin-HRP (Southern Biotechnology Associates, Inc.); (2) lselig human AILIM-ligand (fusjonsprotein mellom det ekstracellulre omrdet fra humant B7h og det konstante omrdet fra humant IgGl);
proteinet ble fremstilt ved fremgangsmten beskrevet nedenfor i 14.2; (3) biotinmerket lselig AILIM-IgFc; AILIM-IgFc ble fremstilt ved videre rensing av antigenet erholdt iflge fremgangsmten beskrevet i tidligere patentsknader (JP-A 11-29599 (eksempel 16 (2)) og WO 98/38216 (eksempel 16 (2))) av en av de foreliggende oppfinnere, Tezuka; (4) humant, monoklonalt, antihumant AILIM-antistoff (JMab-136, beskrevet ovenfor); (5) humant, monoklonalt anti-KLH-antistoff (negativt kontrollantistoff, JMab-23, beskrevet ovenfor); (6) fosfatbuffer (PBS (-), Nikken Seibutsu); (7) RPMI-1640-medium (Nikken Seibutsu); (8) ftalt kalveserum (FCS, JRH-Bioscience); (9) 30 % bovint serumalbumin (BSA, Sigma); (10) Tween 20 (BioRad); </span>(1) streptavidin-HRP (Southern Biotechnology Associates, Inc.); (2) soluble human AILIM ligand (fusion protein between the extracellular region from human B7h and the constant region from human IgG1);
the protein was prepared by the method described below in 14.2; (3) biotin-labeled soluble AILIM-IgFc; AILIM-IgFc was prepared by further purification of the antigen obtained according to the method described in previous patent applications (JP-A 11-29599 (Example 16 (2)) and WO 98/38216 (Example 16 (2))) by one of the present inventors , Tezuka; (4) human monoclonal anti-human AILIM antibody (JMab-136, described above); (5) human monoclonal anti-KLH antibody (negative control antibody, JMab-23, described above); (6) phosphate buffer (PBS (-), Nikken Seibutsu); (7) RPMI-1640 medium (Nikken Seibutsu); (8) fetal calf serum (FCS, JRH-Bioscience); (9) 30% bovine serum albumin (BSA, Sigma); (10) Tween 20 (BioRad);</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(11) det kromogene substrat TMB&lt;+&gt;(Dako). </span>(11) the chromogenic substrate TMB&lt;+&gt;(Dako).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">14.2 Fremstilling av lselig human AILIM- ligand ( fusjonsprotein ( hB7h- IgFc) mellom det ekstracellulre omrdet fra humant B7h og det konstante omrdet fra humant IgGli </span>14.2 Preparation of soluble human AILIM ligand (fusion protein (hB7h-IgFc) between the extracellular region from human B7h and the constant region from human IgGli</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Total-RNA ble fremstilt fra mononuklere celler avledet fra humant perifert blod p samme mte som beskrevet i eksemplet ovenfor. cDNA ble syntetisert med det erholdte total-RNA (5 ug) som templat og ved anvendelse av Superscript-preamplifiseringssystem for frstetrds cDNA-syntese (GIBCO-BRL). </span>Total RNA was prepared from mononuclear cells derived from human peripheral blood in the same manner as described in the example above. cDNA was synthesized using the obtained total RNA (5 g) as a template and using the Superscript preamplification system for first-strand cDNA synthesis (GIBCO-BRL).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Deretter ble 5'-primeren (5'-GAGGTCTCCGCCCTCGAGATGCGGCT-GGGCAGTCC-3', SEQ ID NO: 39) med et Xhol-restriksjonssete i enden og 3'-primeren (5'-C AC AGG AC AGCC AGGGG ATCCC ACGTGGCCGCG- 3SEQ ID NO: 40) med et BamHI-restriksjonssete i enden utformet og syntetisert for amplifisering av cDNA som koder for det ekstracellulre omrdet fra human AILIM-ligand (hB7h) ved PCR. Ved anvendelse av cDNA som templat og primerparet ble PCR utfrt for fremstilling av et DNA med Xhol og BamHI i hver sin ende og omfattende cDNA som koder for det ekstracellulre omrdet fra humant B7h. De resulterende PCR-produkter ble kuttet med Xhol og BamHI og fraksjonert ved agarosegelelektroforese for isolering av et bnd tilsvarende et cDNA-fragment p ca. 720-bp, forventet  kode for det ekstracellulre omrdet av interesse. Det isolerte cDNA-fragment ble subklonet i plasmidet pBluescript IISK(+) (Stratagene) som p forhnd var kuttet med Xhol og BamHI. Det ble bekreftet at cDNA-fragmentet inneholdt den del som koder for det ekstracellulre omrdet fra humant B7h ved sekvensanalyse med et automatisert fluorometrisk DNA-sekvenseringsinstrument (Applied Biosystems). </span>Then the 5' primer (5'-GAGGTCTCCGCCCTCGAGATGCGGCT-GGGCAGTCC-3', SEQ ID NO: 39) with an Xhol restriction site at the end and the 3' primer (5'-C AC AGG AC AGCC AGGGG ATCCC ACGTGGCCGCG-3SEQ ID NO: 39) NO: 40) with a BamHI restriction site at the end designed and synthesized for amplification of cDNA encoding the extracellular region from human AILIM ligand (hB7h) by PCR. By using cDNA as template and primer pair, PCR was carried out to produce a DNA with Xhol and BamHI at each end and comprising cDNA encoding the extracellular region from human B7h. The resulting PCR products were cut with XhoI and BamHI and fractionated by agarose gel electrophoresis to isolate a band corresponding to a cDNA fragment of approx. 720-bp, expected to encode the extracellular region of interest. The isolated cDNA fragment was subcloned into the plasmid pBluescript IISK(+) (Stratagene) which had previously been cut with XhoI and BamHI. It was confirmed that the cDNA fragment contained the part coding for the extracellular region from human B7h by sequence analysis with an automated fluorometric DNA sequencing instrument (Applied Biosystems).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">P den annen side ble DNA som koder for Fc fra humant IgGl som fusjonspartner fremstilt som et BamHI-Xbal-DNA-fragment (ca. 1,3 kb) ved  kutte et plasmid (se Cell, vol. 61, s. 1303-1313,1990, fremstilt av dr. Seed et al. ved Massachusetts General Hospital) med BamHI og Xbal. Dette fragment inneholdt exoner som koder for hengselomrdene fra humant IgGl, Cyl2 og Cyl3, XhoI-BamHI-fragmentet som kodet for det ekstracellulre omrdet fra humant B7h (hB7h), og BamHI-Xbal-fragmentet som inneholdt exoner som kodet for Fc (forkortet "IgFc") fra humant IgGl, fremstilt som beskrevet ovenfor, ble subklonet i plasmidet pBluescript IISK(+) (Stratagene) som p forhnd var kuttet med Xhol og Xbal. </span>On the other hand, DNA encoding the Fc of human IgG1 as a fusion partner was prepared as a BamHI-XbaI DNA fragment (about 1.3 kb) by cutting a plasmid (see Cell, vol. 61, pp. 1303- 1313,1990, prepared by Dr. Seed et al at Massachusetts General Hospital) with BamHI and XbaI. This fragment contained exons encoding the hinge regions from human IgGl, Cyl2 and Cyl3, the XhoI-BamHI fragment encoding the extracellular region from human B7h (hB7h), and the BamHI-XbaI fragment containing exons encoding Fc (abbreviated " IgFc") from human IgG1, prepared as described above, was subcloned into the plasmid pBluescript IISK(+) (Stratagene) which had been previously cut with XhoI and XbaI.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Deretter ble plasmidet kuttet med Xhol og Xbal for fremstilling av et DNA-fragment p ca. 1,8 kb som inneholdt fusjons-DNA mellom det ekstracellulre omrdet fra humant B7h og humant IgFc. Ved anvendelse av T4-DNA-ligase ble dette fusjons-DNA-fragment innsatt i ekspresjonsvektoren pME18S (Medical Immunology, vol. 20, nr. 1, s. 27-32, 1990, og "Handbook for Genetic Engineering", Experimental Medicine, supplement, Yodosha, s. 101-107,1992) mellom Xhol-setet og Xbal-setet for konstruksjon av plasmid phB7h-IgFc. </span>The plasmid was then cut with XhoI and XbaI to produce a DNA fragment of approx. 1.8 kb which contained fusion DNA between the extracellular region of human B7h and human IgFc. Using T4 DNA ligase, this fusion DNA fragment was inserted into the expression vector pME18S (Medical Immunology, vol. 20, no. 1, pp. 27-32, 1990, and "Handbook for Genetic Engineering", Experimental Medicine, supplement, Yodosha, pp. 101-107, 1992) between the XhoI site and the XbaI site for construction of plasmid phB7h-IgFc.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Encellelag a COS7-celler (ATCC CRL-1651) dyrket til subkonfluens i DMEM-medium tilsatt 10 % ftalt kalveserum og ampicillin ble transformerte med plasmid phB7h-IgFc ved elektroporering for erholdelse av transformerte celler. </span>Monolayers of COS7 cells (ATCC CRL-1651) grown to subconfluence in DMEM medium supplemented with 10% fetal calf serum and ampicillin were transformed with plasmid phB7h-IgFc by electroporation to obtain transformed cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">De transformerte cellene fikk uttrykke hB7h-IgFc ved dyrking i serumfritt ASF104-medium i 72 timer. </span>The transformed cells were allowed to express hB7h-IgFc by culturing in serum-free ASF104 medium for 72 hours.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">HB7h-IgFc ble renset ved anvendelse av en protein G-Sepharose-affinitetskolonne (Amersham Pharmacia) som flger: Den ovenfor nevnte dyrkingssupernatant ble sentrifugert for erholdelse av en supernatant. Den resulterende supernatant ble psatt en protein G-Sepharose-affinitetskolonne som p forhnd var ekvilibrert med bindingsbuffer. Kolonnen ble s vasket med bindings-bufferen, hvoretter eluering ble utfrt med en elueringsbuffer. Den eluerte lsning ble gjenvunnet og s dialysert mot fosfatbuffer. Den ytre dialysebuffer ble byttet to eller flere ganger. P denne mten ble renset hB7h-IgFc erholdt. </span>HB7h-IgFc was purified using a protein G-Sepharose affinity column (Amersham Pharmacia) as follows: The above culture supernatant was centrifuged to obtain a supernatant. The resulting supernatant was applied to a protein G-Sepharose affinity column pre-equilibrated with binding buffer. The column was then washed with the binding buffer, after which elution was performed with an elution buffer. The eluted solution was recovered and then dialyzed against phosphate buffer. The external dialysis buffer was changed two or more times. In this way, purified hB7h-IgFc was obtained.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">14.3 Fortynning av antistoff og Lselig humant AILIM ( hAILIM- IgFc") og reaksjon mellom disse </span>14.3 Dilution of antibody and Soluble human AILIM (hAILIM-IgFc") and reaction between these</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Utgangslsningene (20fig/ml) av monoklonalt, antihumant AILIM-antistoff (JMab-136) og humant, monoklonalt anti-KLH-antistoff (JMab-23) som negativt kontrollantistoff ble seriefortynnet over 11 niver, og hver prve (200 |4.1) ble tilsatt og blandet godt med 200 \ il RPMI-1640-medium tilsatt 10 % FCS. P denne mten ble antistofflsninger med forskjellige konsentrasjoner fremstilt. Biotinmerket hAILIM-IgFc (2 (4.1/rr, sluttkonsentrasjon 1Hg/ml) ble tilsatt til hver av de fremstilte lsninger med forskjellige konsentrasjoner. De resulterende lsninger ble godt sammenblandet og inkubert ved romtemperatur i 30 minutter. </span>The stock solutions (20g/ml) of monoclonal anti-human AILIM antibody (JMab-136) and human monoclonal anti-KLH antibody (JMab-23) as negative control antibody were serially diluted over 11 levels, and each sample (200 |4.1) was added and mixed well with 200 l RPMI-1640 medium supplemented with 10% FCS. In this way, antibody solutions with different concentrations were prepared. Biotin-labeled hAILIM-IgFc (2 (4.1/tube, final concentration 1Hg/ml) was added to each of the prepared solutions at different concentrations. The resulting solutions were well mixed and incubated at room temperature for 30 minutes.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">14.4 Analyse av den inhiberende aktivitet av monoklonalt anti- AILIM- antistoff p </span>14.4 Analysis of the inhibitory activity of monoclonal anti-AILIM antibody on</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">bindingen mellom hAILIM- IgFc og hB7h- IgFc </span>the binding between hAILIM-IgFc and hB7h-IgFc</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">hB7h-IgFc ble tilsatt til hver brnn i en 96-brnners mikroplate (50fil/brnn (800 ng/brnn)). Platen ble forseglet og inkubert ved 37 C i 1 time. Lsningen ble fjernet fra brnnene, og brnnene ble vasket tre ganger med PBS (120 jxl). Deretter ble PBS tilsatt 0,5 % BSA (100fil/brnn) tilsatt til hver brnn for blokkering av seter som ikke hadde reagert. Platen ble forseglet og inkubert ved 37&lt;*&gt;C i 1 time. Etter inkuberingen ble lsningen fjernet, hvoretter brnnene ble vasket tre ganger med PBS (120 Deretter ble hver prve (50 (il/brnn) fremstilt i 14.3 tilsatt til brnnene. Platen ble forseglet og inkubert ved 37 "C i 1 time. Lsningen ble fjernet fra hver brnn. Brnnene ble vasket tre ganger med RPMI-1640-medium tilsatt 10 % FCS (120 ul), forvarmet til 37 C. Deretter ble PBS tilsatt 3,7 % formalin (100^l/brnn) tilsatt til hver brnn, og platen ble inkubert p is i 5 minutter. Lsningen ble fjernet fra brnnene, og </span>hB7h-IgFc was added to each well of a 96-well microplate (50 l/well (800 ng/well)). The plate was sealed and incubated at 37C for 1 hour. The solution was removed from the wells, and the wells were washed three times with PBS (120 l). Then, PBS supplemented with 0.5% BSA (100 l/well) was added to each well to block unreacted sites. The plate was sealed and incubated at 37&lt;*&gt;C for 1 hour. After the incubation, the solution was removed, after which the wells were washed three times with PBS (120 Then each sample (50 (l/well) prepared in 14.3 was added to the wells. The plate was sealed and incubated at 37 "C for 1 hour. The solution was removed from each well. The wells were washed three times with RPMI-1640 medium supplemented with 10% FCS (120 l), prewarmed to 37 C. Then PBS supplemented with 3.7% formalin (100 l/well) was added to each well , and the plate was incubated on ice for 5 minutes.The solution was removed from the wells, and</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">brnnene ble vasket tre ganger med 0,1 % Tween 20 (120^1). Deretter ble streptavidin-HRP (50 (il/brnn) tilsatt til hver brnn. Platen ble forseglet og inkubert ved romtemperatur i 30 minutter. Lsningen ble fjernet fra brnnene, og platen ble vasket tre ganger med PBS tilsatt 0,1 % Tween 20 (120 ul). Deretter ble det kromogene substrat TMB&lt;+&gt;(50^l/brnn) tilsatt til brnnene, og platen ble inkubert ved romtemperatur i 20 minutter. S ble 2 N svovelsyre (50fil/brnn) tilsatt til brnnene for  stoppe reaksjonen. Absorbansen i hver brnn ble mlt ved en blgelengde p 450 nm med en THERMO max (Molecular Devices). </span>the wells were washed three times with 0.1% Tween 20 (120 l). Then streptavidin-HRP (50 (l/well) was added to each well. The plate was sealed and incubated at room temperature for 30 min. The solution was removed from the wells, and the plate was washed three times with PBS supplemented with 0.1% Tween 20 ( 120 l). Then the chromogenic substrate TMB&lt;+&gt; (50 l/well) was added to the wells, and the plate was incubated at room temperature for 20 minutes. Then 2 N sulfuric acid (50 l/well) was added to the wells to stop The absorbance in each well was measured at a wavelength of 450 nm with a THERMO max (Molecular Devices).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatene er vist i figurene 74-76. </span>The results are shown in figures 74-76.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatene viste at anti-AILIM-antistoff hadde inhiberende aktivitet p bindingen mellom hAILIM-IgFc og hB7h-IgFc p en doseavhengig mte. </span>The results showed that anti-AILIM antibody had inhibitory activity on the binding between hAILIM-IgFc and hB7h-IgFc in a dose-dependent manner.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Flgelig tyder dette eksempel p at et analysesystem illustrert ved den foreliggende fremgangsmte kan benyttes for sk etter og identifisering av forbindelser som kan bindes til AILIM eller AILIM-ligand (f.eks. antistoff eller en syntetisk lavmolekylr forbindelse). </span>Accordingly, this example suggests that an assay system illustrated by the present method can be used to search for and identify compounds that can bind to AILIM or AILIM ligand (eg, antibody or a synthetic low molecular weight compound).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempel 15 </span>Example 15</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Inhiberende aktivitet av humant, monoklonalt, antihumant AILIM- antistoff p proliferasjon av humane T- celler forbundet med overfringen av det AILIM- AILIM- ligand- formidlede, kostimulerende signal </span>Inhibitory activity of human monoclonal anti-human AILIM antibody on human T-cell proliferation associated with the transmission of the AILIM-AILIM ligand-mediated costimulatory signal</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det ble analysert hvorvidt de monoklonale antihumant AILIM-antistoffene iflge foreliggende oppfinnelse hadde regulerende aktivitet p signaloverfringen formidlet av AILIM p overflaten av humane T-celler, basert p mling av den inhiberende virkning av det humane, monoklonale antihumant AILIM-antistoff p celleproliferasjon indusert ved  sette humane T-celler i forbindelse med AILIM-ligand (B7h/B7RPl/GL50/LICOS). </span>It was analyzed whether the monoclonal antihuman AILIM antibodies according to the present invention had regulatory activity on the signal transmission mediated by AILIM on the surface of human T cells, based on measuring the inhibitory effect of the human monoclonal antihuman AILIM antibody on cell proliferation induced by put human T cells in contact with AILIM ligand (B7h/B7RPl/GL50/LICOS).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15.1 Fortynning av antistoff </span>15.1 Dilution of antibody</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Monoklonalt, antihumant CD3-antistoff OKT3 (ATCC CRL-8001) ble fortynnet med fosfatbuffer (PBS) til en sluttkonsentrasjon p 8fig/ml. </span>Monoclonal, anti-human CD3 antibody OKT3 (ATCC CRL-8001) was diluted with phosphate buffer (PBS) to a final concentration of 8g/ml.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den lselige humane AILIM-ligand (hB7h-lgFc) fremstilt ovenfor ble fortynnet med PBS til en sluttkonsentrasjon p 40fig/ml. Antistofflsningene ble fortynnet videre med PBS for fremstilling av forskjellige konsentrasjoner av antistoff (40 ng/ml-0,064 ng/ml). </span>The soluble human AILIM ligand (hB7h-lgFc) prepared above was diluted with PBS to a final concentration of 40 g/ml. The antibody solutions were further diluted with PBS to prepare different concentrations of antibody (40 ng/ml-0.064 ng/ml).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15.2 Belegging av mikroplater med antistoff </span>15.2 Coating of microplates with antibody</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Hver brnn i 96-brnners mikroplater ble belagt med (1) monoklonalt, antihumant CD3-antistoff OKT3 (8 ng/ml, 25 ^1 i hver brnn), og hB7h-lgFc (40 ng/ml-0,064 ^g/rnl, 25^1 til hver brnn). Platene ble inkubert ved 37&lt;*&gt;C i 2 timer. S ble antistofflsningene fjernet, og hver brnn ble vasket tre ganger med PBS. Etter vask ble RPMI-1640-medium tilsatt 10 % FCS tilsatt til brnnene (100fil/brnn), og platene ble inkubert ved 37&lt;*&gt;C i 1 time. P denne mten ble brnnene i platene belagt. </span>Each well of 96-well microplates was coated with (1) monoclonal anti-human CD3 antibody OKT3 (8 ng/ml, 25 l in each well), and hB7h-lgFc (40 ng/ml-0.064 g/rnl, 25^1 to each well). The plates were incubated at 37&lt;*&gt;C for 2 hours. Then the antibody solutions were removed, and each well was washed three times with PBS. After washing, RPMI-1640 medium supplemented with 10% FCS was added to the wells (100 l/well), and the plates were incubated at 37&lt;*&gt;C for 1 hour. In this way, the wells in the plates were coated.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15.3 Fremstilling av en suspensjon av humane T- celler </span>15.3 Preparation of a suspension of human T cells</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Perifert blod ble oppsamlet fra normale, friske personer, og de mononuklere cellene ble fraksjonert ved tetthetsgradientsentrifugering ved anvendelse av "LymphoPrep" </span>Peripheral blood was collected from normal healthy subjects and the mononuclear cells were fractionated by density gradient centrifugation using "LymphoPrep"</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(Nycomed). Iflge den eksperimentelle veiledning ble humane T-celler separert fra humane, mononuklere celler ved anvendelse av et Pan-T-celleisoleringssett (Miltenyi) og en magnetisk sorterer. T-celletallet ble bestemt ved anvendelse av et hemacytometer. Humane T-celler ble suspendert i RPMI-1640-medium med 10 % FCS og tilsatt humant, monoklonalt, antihumant AILIM-antistoff JMabl36 (20fig/ml). Den fremstilte humane T-cellesuspensjon (1 x IO&lt;6&gt;celler/ml) ble inkubert ved romtemperatur i 30 minutter. </span>(Newcomed). According to the experimental guide, human T cells were separated from human mononuclear cells using a Pan-T cell isolation kit (Miltenyi) and a magnetic sorter. The T-cell count was determined using a hemacytometer. Human T cells were suspended in RPMI-1640 medium with 10% FCS and human monoclonal anti-human AILIM antibody JMabl36 (20g/ml) was added. The prepared human T cell suspension (1 x 10 cells/ml) was incubated at room temperature for 30 minutes.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Humant, monoklonalt anti-KLH-antistoff JMAb23 (20fig/ml) ble anvendt som negativt kontrollantistoff. </span>Human monoclonal anti-KLH antibody JMAb23 (20 g/ml) was used as negative control antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15.4 Celledyrking </span>15.4 Cell culture</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">P samme mte som beskrevet ovenfor ble den humane T-cellesuspensjon (100 (4.1/brnn, 1 x 10&lt;5&gt;celler/brnn) tilsatt til hver brnn i en mikroplate belagt med antihumant CD3-antistoff og hB7h-IgFc, og platen ble inkubert ved 37 C i 3 dager i en CCvinkubator. </span>In the same manner as described above, the human T cell suspension (100 (4.1/well, 1 x 10&lt;5&gt; cells/well) was added to each well of a microplate coated with antihuman CD3 antibody and hB7h-IgFc, and the plate was incubated at 37 C for 3 days in a CCvin incubator.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15.5 Bestemmelse av T- celleproliferasjonsaktiviteten </span>15.5 Determination of the T cell proliferation activity</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Metyl- [3H]tymidin (0,5 (iCi/brnn, Amersham-Pharmacia) ble tilsatt til hver brnn i platene etter dyrkingen, og platene ble inkubert ved 37&lt;*&gt;C i 6 timer i en C02-inkubator. Etter inkuberingen ble cellene oppfanget p GF/C-filtre (Packard) ved anvendelse av en cellehster. Filtrene ble s trket ved 40&lt;*&gt;C i 3 timer eller mer, hvoretter Microscinti 0 (20fil/brnn, Packard) ble tilsatt til disse.&lt;3&gt;H-radioaktivitet inkorporert i cellene oppfanget p filtrene ble mlt med en (}-teller (TOP COUNT) for analyse av T-celleproliferasjonsgraden etter dyrkingen. </span>Methyl-[ 3 H]thymidine (0.5 (iCi/well, Amersham-Pharmacia) was added to each well of the plates after cultivation, and the plates were incubated at 37&lt;*&gt;C for 6 hours in a CO 2 incubator. After the incubation the cells were collected on GF/C filters (Packard) using a cell harvester.The filters were then dried at 40&lt;*&gt;C for 3 hours or more, after which Microscinti 0 (20fil/well, Packard) was added to them.&lt; 3&gt;H radioactivity incorporated into the cells captured on the filters was measured with a (-) counter (TOP COUNT) for analysis of the T-cell proliferation rate after the cultivation.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatet er vist i figur 77. </span>The result is shown in figure 77.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatet erholdt i denne analysen viste at humane T-celler hadde signifikant vekst, avhengig av konsentrasjonen av humant B7h-IgFc (i analysen som anvendte det negative kontrollantistoff). I tillegg inhiberte det monoklonale antihumant AILIM-antistoff signifikant proliferasjonen av humane T-celler. </span>The result obtained in this assay showed that human T cells had significant growth, depending on the concentration of human B7h-IgFc (in the assay using the negative control antibody). In addition, the monoclonal anti-human AILIM antibody significantly inhibited the proliferation of human T cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eksempel 16 </span>Example 16</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Inhiberende aktivitet av humant, monoklonalt. antihumant AILIM- antistoff p proliferasjon av ape- T- celler forbundet med overfring av det AILIM- AILIM- ligand- formidlede, kostimulerende signal </span>Inhibitory activity of human, monoclonal. antihuman AILIM antibody on monkey T-cell proliferation associated with transmission of the AILIM-AILIM ligand-mediated costimulatory signal</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Den samme analyse ble utfrt ved anvendelse av ape-T-celler i stedet for de humane T-cellene som ble anvendt i eksempel 15 beskrevet ovenfor. </span>The same analysis was performed using monkey T cells instead of the human T cells used in Example 15 described above.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">16.1 Fortynning av antistoff og andre reagenser </span>16.1 Dilution of antibody and other reagents</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Monoklonalt, antihumant CD3-antistoff SP34 (BD-Pharmingen) ble fortynnet med fosfatbuffer (PBS) til en sluttkonsentrasjon p 1 ng/ml. </span>Monoclonal, anti-human CD3 antibody SP34 (BD-Pharmingen) was diluted with phosphate buffer (PBS) to a final concentration of 1 ng/ml.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det humane B7h-IgFc fremstilt ovenfor ble fortynnet med PBS til en sluttkonsentrasjon p 40 ng/ml. Antistofflsningen ble fortynnet videre med PBS for fremstilling av forskjellige konsentrasjoner av antistoffet (40 ng/ml-0,0064 ng/ml). </span>The human B7h-IgFc prepared above was diluted with PBS to a final concentration of 40 ng/ml. The antibody solution was further diluted with PBS to prepare different concentrations of the antibody (40 ng/ml-0.0064 ng/ml).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">16.2 Belegging av mikroplatet med antistoff </span>16.2 Coating the microplate with antibody</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Hver brnn i 96-brnners mikroplater ble belagt med monoklonalt, antihumant CD3-antistoff SP34 (1 ng/ml, 25 ni i hver brnn) og humant B7h-IgFc (40 ng/ml-0,0064 ng/ml, 25 ni i hver brnn). Platene ble inkubert ved 37 C i 2 timer. Deretter ble antistofflsningen fjernet, og brnnene ble vasket tre ganger med PBS. Etter vask ble RPMI-1640-medium tilsatt 10 % FCS tilsatt til hver brnn (100 nl/brnn), og platene ble inkubert ved 37 C i 1 time. P denne mten ble brnnene i platene belagt med antistoffet. </span>Each well in 96-well microplates was coated with monoclonal anti-human CD3 antibody SP34 (1 ng/ml, 25 ni in each well) and human B7h-IgFc (40 ng/ml-0.0064 ng/ml, 25 ni in each well). The plates were incubated at 37C for 2 hours. Then the antibody solution was removed, and the wells were washed three times with PBS. After washing, RPMI-1640 medium supplemented with 10% FCS was added to each well (100 nl/well), and the plates were incubated at 37 C for 1 h. In this way, the wells in the plates were coated with the antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">16.3 Fremstilling av en suspensjon av ape- T- celler </span>16.3 Preparation of a suspension of monkey T cells</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Perifert blod ble oppsamlet fra Cynomolgus-aper. En fraksjon som inneholdt mononuklere celler ble fremstilt ved tetthetsgradientsentrifugering ved anvendelse av NycoPrep 1.077A (Nycomed). Iflge forsksrettledningen ble ape-T-celler separert fra de mononuklere cellene fra Cynomolgus-ape ved anvendelse av antihumant CD4-antistoff M-T477 (BD-Pharmingen), antihumant CD8-antistoff RPA-T8 (BD-Pharmingen), antimuse-IgG-mikrokuler (Miltenyi) og en magnetisk sorterer. T-celletallet ble bestemt ved anvendelse av et hemacytometer. Ape-T-celler ble suspendert i RPMI-1640-medium tilsatt humant, monoklonalt, antihumant AILIM-antistoff JMab-136 (20 ng/ml) og 10 % FCS for fremstilling av ape T-cellesuspensjon (1 x IO&lt;6&gt;celler/ml). Suspensjonen ble inkubert ved romtemperatur i 30 minutter. </span>Peripheral blood was collected from Cynomolgus monkeys. A fraction containing mononuclear cells was prepared by density gradient centrifugation using NycoPrep 1.077A (Nycomed). According to the experimental guidelines, monkey T cells were separated from the mononuclear cells from Cynomolgus monkeys using anti-human CD4 antibody M-T477 (BD-Pharmingen), anti-human CD8 antibody RPA-T8 (BD-Pharmingen), anti-mouse IgG- microspheres (Miltenyi) and a magnetic sorter. The T-cell count was determined using a hemacytometer. Monkey T cells were suspended in RPMI-1640 medium supplemented with human monoclonal anti-human AILIM antibody JMab-136 (20 ng/ml) and 10% FCS to prepare monkey T cell suspension (1 x 10 cells /ml). The suspension was incubated at room temperature for 30 minutes.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Humant, monoklonalt anti-KLH-antistoff JMab-23 (20 ng/ml) ble anvendt som negativt kontrollantistoff. </span>Human monoclonal anti-KLH antibody JMab-23 (20 ng/ml) was used as negative control antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">16.4 Celledyrking </span>16.4 Cell culture</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">P samme mte som beskrevet ovenfor ble ape-T-cellesuspensjonen (100 nl/brnn, 1 x 10&lt;5&gt;celler/brnn) tilsatt til hver brnn i en mikroplate belagt med antihumant CD3-antistoff og hB7h-IgFc, og platen ble inkubert ved 37 **C i 3 dager i en CO2-inkubator. </span>In the same manner as described above, the monkey T-cell suspension (100 nl/well, 1 x 10&lt;5&gt;cells/well) was added to each well of a microplate coated with antihuman CD3 antibody and hB7h-IgFc, and the plate was incubated at 37 **C for 3 days in a CO2 incubator.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">16.5 Bestemmelse av T- celleproliferasionsaktiviteten </span>16.5 Determination of the T cell proliferation activity</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Metyl- [3H]tymidin (0,5 nCi/brnn, Amersham-Pharmacia) ble tilsatt til hver brnn i platene etter dyrkingen, og platene ble inkubert ved 37 C i 6 timer i en CCvinkubator. Etter inkuberingen ble cellene oppfanget p GF/C-filtre (Packard) ved anvendelse av en cellehster. Filtrene ble s trket ved 40 C i 3 timer eller mer, hvoretter Microscinti 0 (20 nl/brnn, Packard) ble tilsatt til disse.&lt;3&gt;H-radioaktivitet inkorporert i cellene oppfanget p filtrene ble mlt med en (5-teller (TOP COUNT) for analyse av T-celleproliferasjonsgraden etter dyrkingen. </span>Methyl-[ 3 H]thymidine (0.5 nCi/well, Amersham-Pharmacia) was added to each well of the plates after cultivation, and the plates were incubated at 37C for 6 hours in a CCvin incubator. After the incubation, the cells were collected on GF/C filters (Packard) using a cell harvester. The filters were then dried at 40C for 3 hours or more, after which Microscinti 0 (20 nl/well, Packard) was added to them.&lt;3&gt;H radioactivity incorporated into the cells captured on the filters was measured with a (5-count (TOP COUNT) for analysis of the T-cell proliferation rate after the cultivation.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatet er vist i figur 78. </span>The result is shown in figure 78.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultatet erholdt i denne analysen viste at ape-T-celler hadde signifikant vekst, avhengig av konsentrasjonen av humant B7h-IgFc (i analysen som anvendte det negative kontrollantistoff). I tillegg inhiberte det monoklonale antihumant AILIM-antistoff signifikant proliferasjonen av ape-T-cellene. </span>The result obtained in this assay showed that monkey T cells had significant growth, depending on the concentration of human B7h-IgFc (in the assay using the negative control antibody). In addition, the monoclonal anti-human AILIM antibody significantly inhibited the proliferation of the monkey T cells.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Industriell anvendbarhet </span>Industrial applicability</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">De humane, monoklonale antistoffene iflge oppfinnelsen som kan bindes til humant AILIM, er av humant opphav, og disse antistoffene induserer derfor ingen alvorlig immunologisk avvisning grunnet antigenisitet i mennesker, det vil si HAMA (human antimuseantigenisitet) i en vert, noe som har vrt et alvorlig terapeutisk problem (en bivirkning) i farmasytiske antistoffpreparater som omfatter antistoff avledet fra ikke-humane pattedyr, slik som museavledet antistoff. Antistoffet iflge oppfinnelse er sledes av stor verdi som et farmasytisk antistoff. </span>The human monoclonal antibodies according to the invention which can bind to human AILIM are of human origin, and these antibodies therefore do not induce serious immunological rejection due to antigenicity in humans, i.e. HAMA (human antimouse antigenicity) in a host, which has been a serious therapeutic problem (an adverse reaction) in pharmaceutical antibody preparations comprising antibody derived from non-human mammals, such as mouse-derived antibody. The antibody according to the invention is thus of great value as a pharmaceutical antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Det humane, monoklonale antistoff iflge oppfinnelsen mot AILIM (spesielt foretrukket humant AILIM) og farmasytiske preparater som omfatter det humane, monoklonale antistoff, induserer sledes ikke i det hele tatt immunologisk avvisning i verten grunnet HAMA, og kan sledes anvendes som farmasytiske preparater som kan kontrollere en rekke biologiske reaksjoner (f.eks. proliferasjon av celler som uttrykker AILIM, cytokinproduksjon ved AILIM-uttrykkende celler, immuncytolyse eller celledd (apoptose) av celler som uttrykker AILIM og induserende aktivitet p den antistoffavhengige deleggelse av celler som uttrykker AILIM) forbundet med overfring av det AILIM-formidlede, kostimulerende signal (sekundrsignal) til celler som uttrykker AILIM; og/eller kan anvendes for behandling eller forebyggelse av forskjellige sykdommer som er forbundet med overfring av det AILIM-formidlede signal, kontroll og inhibering av sykdommenes start og/eller utvikling. </span>The human monoclonal antibody according to the invention against AILIM (especially preferred human AILIM) and pharmaceutical preparations comprising the human monoclonal antibody thus do not induce immunological rejection in the host due to HAMA at all, and can thus be used as pharmaceutical preparations which can control a variety of biological responses (eg, proliferation of AILIM-expressing cells, cytokine production by AILIM-expressing cells, immunocytolysis or cell death (apoptosis) of AILIM-expressing cells and inducing activity on the antibody-dependent destruction of AILIM-expressing cells) associated with transfer of the AILIM-mediated costimulatory signal (secondary signal) to cells expressing AILIM; and/or can be used for the treatment or prevention of various diseases which are associated with transmission of the AILIM-mediated signal, control and inhibition of the disease's onset and/or development.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ved tilveiebringelse av farmasytiske preparater som inneholder det humane, monoklonale anti-AILIM-antistoff iflge oppfinnelsen eller en del av dette som aktiv bestanddel, er det nrmere bestemt mulig  inhibere eller behandle og forebygge f.eks. en rekke sykdommer (f.eks. reumatoid artritt, multippel sklerose, autoimmun tyreoiditt, allergisk kontaktdermatitt, lichen planus, som er en kronisk inflammatorisk hudsykdom, systemisk lupus erythematosus, insulinavhengig diabetes mellitus, psoriasis osv.) som er klassifisert som autoimmune eller allergiske sykdommer (fortrinnsvis autoimmune sykdommer og forsinkede allergier ved cellulr immunitet), artropatier (f.eks. reumatoid artritt (RA), osteoartritt (OA)), inflammasjon (f.eks. hepatitt), "graft versus host"-reaksjon (GVH-reaksjon), "graft versus host"-sykdom (GVHD), immunologisk avvisning forbundet med transplantasjon (allogent transplantat eller heterogent transplantat) av vev (f.eks. hud, hornhinne og ben) eller organer (lever, hjerte, lunge, nyre, bukspyttkjertel osv.), en immunrespons overfor fremmed antigen eller selvantigener (f.eks. dannelse av antistoff mot antigenet, celleproliferasjon, produksjon av cytokiner osv.), og sykdommer som kan tenkes  skyldes unormaliteter i tarmimmuniteten (nrmere bestemt inflammatorisk tarmsykdom (fortrinnsvis Crohns sykdom og ulcers kolitt) og nringsmiddel-allergier osv. </span>By providing pharmaceutical preparations containing the human, monoclonal anti-AILIM antibody according to the invention or a part thereof as an active ingredient, it is more precisely possible to inhibit or treat and prevent e.g. a number of diseases (eg rheumatoid arthritis, multiple sclerosis, autoimmune thyroiditis, allergic contact dermatitis, lichen planus, which is a chronic inflammatory skin disease, systemic lupus erythematosus, insulin-dependent diabetes mellitus, psoriasis, etc.) that are classified as autoimmune or allergic diseases (preferably autoimmune diseases and delayed allergies in cellular immunity), arthropathies (e.g. rheumatoid arthritis (RA), osteoarthritis (OA)), inflammation (e.g. hepatitis), "graft versus host" reaction (GVH reaction ), "graft versus host" disease (GVHD), immunological rejection associated with transplantation (allogeneic graft or heterogeneous graft) of tissues (eg skin, cornea and bone) or organs (liver, heart, lung, kidney, pancreas) etc.), an immune response to foreign antigen or self-antigens (e.g. formation of antibody against the antigen, cell proliferation, production of cytokines, etc.), and diseases that can be thought to be due to abnormalities in intestinal immunity (specifically inflammatory bowel disease (preferably Crohn's disease and ulcerative colitis) and food allergies, etc.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">De farmasytiske preparatene iflge foreliggende oppfinnelse gjr det mulig  behandle eller forebygge noen inflammasjoner for hvilke forskjellige steroide medikamenter anvendes som antiinflammatoriske medikamenter, f.eks. inflammasjon forbundet med forskjellige artritter (reumatoid artritt, osteoartritt osv.), pneumoni, hepatitt (innbefattet virus-hepatitt), inflammasjon forbundet med infeksise sykdommer, inflammatorisk tarmsykdom, enteritt, nefritt (glomerulusnefritt, inflammasjon forbundet med nyrefibrose, gastritt, vaskulitt, pankreatitt, peritonitt, bronkitt, myokarditt, encefalitt, inflammasjon forbundet med iskemi-reperfusjonsskade (myokaridiskemi-reperfusjonsskade osv.), inflammasjon forbundet med immunologisk avvisning etter transplantasjon av vev eller organer, skoldsr, forskjellige hudinflammasjoner (psoriasis, allergisk kontaktdermatitt, lichen planus som en kronisk inflammatorisk hudsykdom), inflammasjon forbundet med flerorgansvikt, inflammasjon etter operasjon av PTCA eller PTCR, og inflammasjon forbundet med aterosklerose, autoimmun tyreoiditt osv. </span>The pharmaceutical preparations according to the present invention make it possible to treat or prevent some inflammations for which various steroid drugs are used as anti-inflammatory drugs, e.g. inflammation associated with various arthritis (rheumatoid arthritis, osteoarthritis, etc.), pneumonia, hepatitis (including viral hepatitis), inflammation associated with infectious diseases, inflammatory bowel disease, enteritis, nephritis (glomerular nephritis, inflammation associated with renal fibrosis, gastritis, vasculitis, pancreatitis, peritonitis, bronchitis, myocarditis, encephalitis, inflammation associated with ischemia-reperfusion injury (myocardial ischemia-reperfusion injury, etc.), inflammation associated with immunological rejection after transplantation of tissues or organs, scalds, various skin inflammations (psoriasis, allergic contact dermatitis, lichen planus as a chronic inflammatory skin disease), inflammation associated with multiple organ failure, inflammation after PTCA or PTCR surgery, and inflammation associated with atherosclerosis, autoimmune thyroiditis, etc.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nr det gjelder den ovenfor nevnte inhibering og behandling av immunologisk avvisning forbundet med transplantasjon av vev eller organer, som beskrevet ovenfor, kan de farmasytiske preparatene iflge foreliggende oppfinnelse videre anvendes sammen med kjente immunsupprimerende midler som anvendes for inhibering av immunologisk avvisningen ved transplantasjonsbehandling, hvorved den inhiberende virkning av det kjente medikament p transplantat avvisning forsterkes. </span>As regards the above-mentioned inhibition and treatment of immunological rejection associated with the transplantation of tissues or organs, as described above, the pharmaceutical preparations according to the present invention can further be used together with known immunosuppressive agents which are used for the inhibition of immunological rejection in transplantation treatment, whereby the inhibitory effect of the known drug on transplant rejection is enhanced.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ved anvendelse av fremgangsmten for identifisering av forbindelser som kan bindes til AILIM eller AILIM-ligand, som ligger innenfor foreliggende oppfinnelses omrde, er det videre mulig  kontrollere signaloverfringen som er forbundet med interaksjonen mellom AILIM og AILIM-ligand via binding til AILIM eller AILIM-ligand, noe som tillater sk etter og seleksjon av farmasytiske midler (syntetiske, kjemiske forbindelser og antistoff) som har mulig aktivitet for behandling av de ovenfor nevnte sykdommer. </span>By using the method for identifying compounds that can bind to AILIM or AILIM-ligand, which is within the scope of the present invention, it is further possible to control the signal transmission associated with the interaction between AILIM and AILIM-ligand via binding to AILIM or AILIM- ligand, which allows the search for and selection of pharmaceutical agents (synthetic, chemical compounds and antibody) that have possible activity for the treatment of the above-mentioned diseases.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Sekvensliste - fritekst </span>Sequence list - free text</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 1 </span>SEQ ID NO: 1</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert primersekvens, Not/-T. </span>Other information: Description of artificial sequence: Artificially synthesized primer sequence, Not/-T.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 2 </span>SEQ ID NO: 2</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert linkersekvens, 20adp. </span>Other information: Description of artificial sequence: Artificially synthesized linker sequence, 20adp.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 3 </span>SEQ ID NO: 3</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert linkersekvens, 24adp. </span>Other information: Description of artificial sequence: Artificially synthesized linker sequence, 24adp.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 4 </span>SEQ ID NO: 4</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert primersekvens, HIGLC. </span>Other information: Description of artificial sequence: Artificially synthesized primer sequence, HIGLC.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 5 </span>SEQ ID NO: 5</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert primersekvens, NHCc2. </span>Other information: Description of artificial sequence: Artificially synthesized primer sequence, NHCc2.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 6 </span>SEQ ID NO: 6</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert primersekvens, ExcellE. </span>Other information: Description of artificial sequence: Artificially synthesized primer sequence, ExcellE.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 7 </span>SEQ ID NO: 7</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert primersekvens, ckl 17. </span>Other information: Description of artificial sequence: Artificially synthesized primer sequence, ckl 17.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 8 </span>SEQ ID NO: 8</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert primersekvens, M13R. </span>Other information: Description of artificial sequence: Artificially synthesized primer sequence, M13R.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 9 </span>SEQ ID NO: 9</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert primersekvens, 136H. </span>Other information: Description of artificial sequence: Artificially synthesized primer sequence, 136H.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 10 </span>SEQ ID NO: 10</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert primersekvens, 138/9H. </span>Other information: Description of artificial sequence: Artificially synthesized primer sequence, 138/9H.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 11 </span>SEQ ID NO: 11</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert primersekvens, AILIMHC1. </span>Other information: Description of artificial sequence: Artificially synthesized primer sequence, AILIMHC1.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 12 </span>SEQ ID NO: 12</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert primersekvens, HCcl. </span>Other information: Description of artificial sequence: Artificially synthesized primer sequence, HCcl.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 13 </span>SEQ ID NO: 13</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert primersekvens, HCc7. </span>Other information: Description of artificial sequence: Artificially synthesized primer sequence, HCc7.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 14 </span>SEQ ID NO: 14</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert primersekvens, HCc8. </span>Other information: Description of artificial sequence: Artificially synthesized primer sequence, HCc8.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 15 </span>SEQ ID NO: 15</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert primersekvens, HCc3. </span>Other information: Description of artificial sequence: Artificially synthesized primer sequence, HCc3.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 16 </span>SEQ ID NO: 16</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert primersekvens, HCc4. </span>Other information: Description of artificial sequence: Artificially synthesized primer sequence, HCc4.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 17 </span>SEQ ID NO: 17</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert primersekvens, HCc6. </span>Other information: Description of artificial sequence: Artificially synthesized primer sequence, HCc6.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 18 </span>SEQ ID NO: 18</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert primersekvens, HIGHC. </span>Other information: Description of artificial sequence: Artificially synthesized primer sequence, HIGHC.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 19 </span>SEQ ID NO: 19</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert primersekvens, HCc9. </span>Other information: Description of artificial sequence: Artificially synthesized primer sequence, HCc9.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 20 </span>SEQ ID NO: 20</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert primersekvens, HCc5. </span>Other information: Description of artificial sequence: Artificially synthesized primer sequence, HCc5.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 21 </span>SEQ ID NO: 21</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert primersekvens, polyA. </span>Other information: Description of artificial sequence: Artificially synthesized primer sequence, polyA.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 22 </span>SEQ ID NO: 22</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert primersekvens, AILIMLC1. </span>Other information: Description of artificial sequence: Artificially synthesized primer sequence, AILIMLC1.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 23 </span>SEQ ID NO: 23</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert primersekvens, AILIMLC2. </span>Other information: Description of artificial sequence: Artificially synthesized primer sequence, AILIMLC2.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 24 </span>SEQ ID NO: 24</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert primersekvens, LCcl. </span>Other information: Description of artificial sequence: Artificially synthesized primer sequence, LCcl.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 25 </span>SEQ ID NO: 25</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert primersekvens, LCc2. </span>Other information: Description of artificial sequence: Artificially synthesized primer sequence, LCc2.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 26 </span>SEQ ID NO: 26</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert primersekvens, HIK. </span>Other information: Description of artificial sequence: Artificially synthesized primer sequence, HIK.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 39 </span>SEQ ID NO: 39</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert primersekvens. </span>Other information: Description of artificial sequence: Artificially synthesized primer sequence.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 40 </span>SEQ ID NO: 40</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Annen informasjon: Beskrivelse av kunstig sekvens: Kunstig syntetisert primersekvens. </span>Other information: Description of artificial sequence: Artificially synthesized primer sequence.</span>
  </p>
</description>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
            <div class="flex flex-width style-scope patent-result">
              <section id="claims" class="style-scope patent-result">
                <h3 class="style-scope patent-result">
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Claims <span class="style-scope patent-result">(21)</span></div>
                    <div class="collapse style-scope patent-result">
                      Hide Dependent <iron-icon style="height: 15px; width: 15px;" icon="expand-less" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 8l-6 6 1.41 1.41L12 10.83l4.59 4.58L18 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </div>
                  </div>
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result"></div>
                    <div class="righthead style-scope patent-result">translated from Norwegian</div>
                  </div>
                </h3>
                <patent-text name="claims" enable-text-selection="" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><claims mxw-id="PCLM332729358" lang="EN" load-source="google" class="style-scope patent-text">
  <claim num="1" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1. Humant, monoklonalt antistoff som binder til human AILIM,karakterisert vedat det omfatter flgende karakteristika (a) og (b); (a) et variabelt tungkjedeomrde av antistoffet som omfatter enten den ene eller den andre av (I) eller (II); (I) en aminosyresekvens som omfatter aminosyresekvensen fra aminosyrene 20 til 117 iflge SEQ ID NO: 28, eller (II) en aminosyresekvens som omfatter aminosyrene fra posisjon 20 til posisjon 117 i SEQ ID NO: 28 hvorved n til ti aminosyrerester er deletert eller substituert, eller til hvilken n til ti aminosyrerester er innsatt eller tilfyd, og (b) et variabelt lettkjedeomrde av antistoffet som omfatter enten den ene eller den andre av (I) eller (II); (I) en aminosyresekvens som omfatter aminosyresekvensen fra aminosyrene 23 til 116 iflge SEQ ID NO: 30, eller (II) en aminosyresekvens som omfatter aminosyrene fra posisjon 23-116 i SEQ ID NO: 30 i hvilken n til ti aminosyrerester er deletert eller substituert, eller til hvilken n til ti aminosyrerester er innsatt eller tilfyd, betinget av at nr det variable tungkjedeomrde er ovennevnte (II) av (a) eller det variable lettkjedeomrde er ovennevnte (II) av (b) omfatter antistoffet hvilke som helst av karakteristikaene vist i (i) til (iii); (i) en forebyggende aktivitet p en blandet lymfocyttreaksjon, (ii) en aktivitet for  indusere signaloverfring for  indusere interferon-y, og (iii) en aktivitet for  indusere antistoffavhengig cellulr cytotoksisitet overfor AILIM-uttrykkende celler.</span>1. Human, monoclonal antibody that binds to human AILIM, characterized in that it comprises the following characteristics (a) and (b); (a) a heavy chain variable region of the antibody comprising either one or the other of (I) or (II); (I) an amino acid sequence comprising the amino acid sequence from amino acids 20 to 117 according to SEQ ID NO: 28, or (II) an amino acid sequence comprising the amino acids from position 20 to position 117 in SEQ ID NO: 28 whereby one to ten amino acid residues have been deleted or substituted , or to which one to ten amino acid residues have been inserted or added, and (b) a variable light chain region of the antibody comprising either one or the other of (I) or (II); (I) an amino acid sequence comprising the amino acid sequence from amino acids 23 to 116 according to SEQ ID NO: 30, or (II) an amino acid sequence comprising the amino acids from position 23-116 of SEQ ID NO: 30 in which one to ten amino acid residues are deleted or substituted , or to which one to ten amino acid residues have been inserted or added, provided that when the heavy chain variable region is the above (II) of (a) or the light chain variable region is the above (II) of (b), the antibody comprises any of the characteristics shown in (i) to (iii); (i) a preventive activity on a mixed lymphocyte reaction, (ii) an activity to induce signal transduction to induce interferon-, and (iii) an activity to induce antibody-dependent cellular cytotoxicity towards AILIM-expressing cells.</span>
    </claim-text>
  </claim>
  <claim num="2" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2. Humant, monoklonalt antistoff iflge krav 1, hvor det omfatter flgende karakteristika (a) og (b); (a) et tungkjede polypeptid av antistoffet som omfatter enten den ene eller den andre av (I) eller (ii); (I) en aminosyresekvens fra aminosyrene 20-470 iflge SEQ ID NO: 28, eller (II) en aminosyresekvens som omfatter aminosyrene fra posisjon 20 til 470 i SEQ ID NO: 28 hvorved n til ti aminosyrerester er deletert eller substituert, eller til hvilken n til ti aminosyrerester er innsatt eller tilfyd, og (b) et lettkjede polypeptid av antistoffet omfatter enten den ene eller den andre av flgende (I) eller (II); (I) en aminosyresekvens fra aminosyrene 23-236 iflge SEQ ID NO: 30, eller (II) en aminosyresekvens som omfatter aminosyrene fra posisjon 23 til 236 fra SEQ ID NO: 30 hvorved n til ti aminosyrerester er deletert eller substituert, eller til hvilken n til ti aminosyrerester er innsatt eller tilfyd,
betinget av at nr tungkjede polypeptidet er ovennevnte (II) av (a) eller lettkjede polypeptidet er ovennevnte (II) av (b), omfatter antistoffet hvilke som helst av karakteristikaene som angitt i (i) til (iii); (i) en forebyggende aktivitet p en blandet lymfocyttreaksjon, (ii) en aktivitet for  indusere signaloverfring for  indusere interferon-y, og (iii) en aktivitet for  indusere antistoffavhengig cellulr cytotoksisitet overfor AILIM-uttrykkende celler.</span>2. Human monoclonal antibody according to claim 1, where it comprises the following characteristics (a) and (b); (a) a heavy chain polypeptide of the antibody comprising either one or the other of (I) or (ii); (I) an amino acid sequence from amino acids 20-470 according to SEQ ID NO: 28, or (II) an amino acid sequence comprising the amino acids from position 20 to 470 in SEQ ID NO: 28 whereby one to ten amino acid residues have been deleted or substituted, or to which one to ten amino acid residues are inserted or added, and (b) a light chain polypeptide of the antibody comprises either one or the other of the following (I) or (II); (I) an amino acid sequence from amino acids 23-236 according to SEQ ID NO: 30, or (II) an amino acid sequence comprising the amino acids from position 23 to 236 from SEQ ID NO: 30 whereby one to ten amino acid residues have been deleted or substituted, or to which one to ten amino acid residues are inserted or added,
provided that when the heavy chain polypeptide is the above (II) of (a) or the light chain polypeptide is the above (II) of (b), the antibody comprises any of the characteristics set forth in (i) to (iii); (i) a preventive activity on a mixed lymphocyte reaction, (ii) an activity to induce signal transduction to induce interferon-, and (iii) an activity to induce antibody-dependent cellular cytotoxicity towards AILIM-expressing cells.</span>
    </claim-text>
  </claim>
  <claim num="3" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">3. DNA,
karakterisert vedat det er valgt fra (a) eller (b) nedenfor; a) DNA som koder for en tungkjede variabel region av det humane antistoffet iflge krav 1, hvor nevnte tungkjede variabel region omfatter aminosyresekvensen fra aminosyrene 20 til 117 fra SEQ ID NO:28; eller b) DNA som koder for en lettkjede variabel region av antistoffet iflge krav 1, hvor nevnte lettkjede variabel region omfatter aminosyresekvensen fra aminosyrene 23 til 116 fra SEQ ID NO: 30.</span>3. DNA,
characterized in that it is selected from (a) or (b) below; a) DNA encoding a heavy chain variable region of the human antibody according to claim 1, wherein said heavy chain variable region comprises the amino acid sequence from amino acids 20 to 117 from SEQ ID NO:28; or b) DNA which codes for a light chain variable region of the antibody according to claim 1, where said light chain variable region comprises the amino acid sequence from amino acids 23 to 116 from SEQ ID NO: 30.</span>
    </claim-text>
  </claim>
  <claim num="4" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">4. DNA iflge krav 3, hvor nevnte tungkjede variabel region omfatter aminosyre sekvensen fra aminosyrene 20 til 470 iflge SEQ ID NO: 28.</span>4. DNA according to claim 3, where said heavy chain variable region comprises the amino acid sequence from amino acids 20 to 470 according to SEQ ID NO: 28.</span>
    </claim-text>
  </claim>
  <claim num="5" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5. DNA iflge krav 4, hvor nevnte lettkjede variabel region omfatter aminosyresekvensen fra aminosyrene 23 til 236 iflge SEQ ID NO: 30.</span>5. DNA according to claim 4, where said light chain variable region comprises the amino acid sequence from amino acids 23 to 236 according to SEQ ID NO: 30.</span>
    </claim-text>
  </claim>
  <claim num="6" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">6. DNA iflge krav 3, hvor DNA (a) er et DNA som omfatter nukleotidsekvensen fra nukleotidene 126 til 419 iflge SEQ ID NO:27, og hvor DNA (b) er et DNA som omfatter nukleotidsekvensen fra nukleotidene 105 til 386 iflge SEQ ID NO:29.</span>6. DNA according to claim 3, where DNA (a) is a DNA comprising the nucleotide sequence from nucleotides 126 to 419 according to SEQ ID NO:27, and where DNA (b) is a DNA comprising the nucleotide sequence from nucleotides 105 to 386 according to SEQ ID NO:29.</span>
    </claim-text>
  </claim>
  <claim num="7" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">7. DNA iflge krav 3, hvor DNA (a) er et DNA som omfatter nukleotidsekvensen fra nukleotidene 69 til 1481 iflge SEQ ID NO: 27, og hvor DNA (b) er et DNA som omfatter nukleotidsekvensen fra nukleotidene 39 til 749 iflge SEQ ID NO: 29.</span>7. DNA according to claim 3, where DNA (a) is a DNA comprising the nucleotide sequence from nucleotides 69 to 1481 according to SEQ ID NO: 27, and where DNA (b) is a DNA comprising the nucleotide sequence from nucleotides 39 to 749 according to SEQ ID NO: 29.</span>
    </claim-text>
  </claim>
  <claim num="8" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">8. Vektor,
karakterisert vedat den omfatter DNA iflge hvilke som helst av kravene 3-7.</span>8. Vector,
characterized in that it comprises DNA according to any of claims 3-7.</span>
    </claim-text>
  </claim>
  <claim num="9" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">9. Vektor iflge krav 8, hvor den omfatter et DNA som omfatter nukleotidsekvensen fra nukleotidene 126 til 419 iflge SEQ ID NO: 27.</span>9. Vector according to claim 8, where it comprises a DNA comprising the nucleotide sequence from nucleotides 126 to 419 according to SEQ ID NO: 27.</span>
    </claim-text>
  </claim>
  <claim num="10" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10. Vektor iflge krav 8, hvor den omfatter et DNA som omfatter nukleotidsekvensen fra nukleotidene 69 til 1481 iflge SEQ ID NO: 27.</span>10. Vector according to claim 8, where it comprises a DNA comprising the nucleotide sequence from nucleotides 69 to 1481 according to SEQ ID NO: 27.</span>
    </claim-text>
  </claim>
  <claim num="11" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">11. Vektor iflge krav 8, hvor den omfatter et DNA som omfatter nukleotidsekvensen fra nukleotidene 105 til 386 iflge SEQ ID NO: 29.</span>11. Vector according to claim 8, where it comprises a DNA comprising the nucleotide sequence from nucleotides 105 to 386 according to SEQ ID NO: 29.</span>
    </claim-text>
  </claim>
  <claim num="12" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">12. Vektor iflge krav 8, hvor den omfatter et DNA som omfatter nukleotidsekvensen fra nukleotidene 39 til 749 iflge SEQ ID NO: 29.</span>12. Vector according to claim 8, where it comprises a DNA comprising the nucleotide sequence from nucleotides 39 to 749 according to SEQ ID NO: 29.</span>
    </claim-text>
  </claim>
  <claim num="13" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">13. Vektor iflge krav 8, hvor den omfatter et DNA iflge (a) og (b) som flger; a) DNA som omfatter nukleotidsekvensen fra nukleotidene 126 til 419 iflge SEQ ID NO: 27, og b) DNA som omfatter nukleotidsekvensen fra nukleotidene 105 til 386 iflge SEQ ID NO: 29.</span>13. Vector according to claim 8, where it comprises a DNA according to (a) and (b) as follows; a) DNA comprising the nucleotide sequence from nucleotides 126 to 419 according to SEQ ID NO: 27, and b) DNA comprising the nucleotide sequence from nucleotides 105 to 386 according to SEQ ID NO: 29.</span>
    </claim-text>
  </claim>
  <claim num="14" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">14. Vektor iflge krav 8, hvor den omfatter et DNA iflge (a) og (b) som flger; a) DNA som omfatter nukleotidsekvensen fra nukleotidene 69 til 1481 iflge SEQ ID NO: 27, og b) DNA som omfatter nukleotidsekvensen fra nukleotidene 39 til 749 iflge SEQ ID NO: 29.</span>14. Vector according to claim 8, where it comprises a DNA according to (a) and (b) as follows; a) DNA comprising the nucleotide sequence from nucleotides 69 to 1481 according to SEQ ID NO: 27, and b) DNA comprising the nucleotide sequence from nucleotides 39 to 749 according to SEQ ID NO: 29.</span>
    </claim-text>
  </claim>
  <claim num="15" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15. Celle,
karakterisert vedat den produserer det humane monoklonale antistoffet iflge kravene 1 eller 2, hvori cellen ikke er en human embryonisk celle.</span>15. Cell,
characterized in that it produces the human monoclonal antibody according to claims 1 or 2, wherein the cell is not a human embryonic cell.</span>
    </claim-text>
  </claim>
  <claim num="16" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">16. Celle iflge krav 15, hvor den er en fusjonscelle erholdt ved  fusjonere en B-celle avledet fra et pattedyr som kan danne det humane, monoklonale antistoff og en myelomcelle avledet fra et pattedyr.</span>16. Cell according to claim 15, where it is a fusion cell obtained by fusing a B cell derived from a mammal capable of forming the human monoclonal antibody and a myeloma cell derived from a mammal.</span>
    </claim-text>
  </claim>
  <claim num="17" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">17. Genetisk rekombinant ikke-human vert,
karakterisert vedat den er transformert med en vektor iflge ethvert av kravene 8-14, hvori nevnte vert er avledet fra et pattedyr valgt fra gruppen bestende av kveg, geit, kanin, mus, rotte, hamster og marsvin.</span>17. Genetically recombinant non-human host,
characterized in that it is transformed with a vector according to any one of claims 8-14, wherein said host is derived from a mammal selected from the group consisting of cattle, goat, rabbit, mouse, rat, hamster and guinea pig.</span>
    </claim-text>
  </claim>
  <claim num="18" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">18. Genetisk rekombinant vert iflge krav 17, hvor den er en ikke-human pattedyrcelle.</span>18. Genetic recombinant host according to claim 17, wherein it is a non-human mammalian cell.</span>
    </claim-text>
  </claim>
  <claim num="19" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">19. Genetisk rekombinant vert iflge krav 17, hvor den er et befruktet egg fra et ikke-humant pattedyr.</span>19. Genetic recombinant host according to claim 17, wherein it is a fertilized egg from a non-human mammal.</span>
    </claim-text>
  </claim>
  <claim num="20" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20. Farmasytisk preparat,
karakterisert vedat det omfatter det humane antistoffet iflge kravene 1 eller 2 og en farmasytisk akseptabel brer.</span>20. Pharmaceutical preparation,
characterized in that it comprises the human antibody according to claims 1 or 2 and a pharmaceutically acceptable carrier.</span>
    </claim-text>
  </claim>
  <claim num="21" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">21. Anvendelse av antistoffet iflge kravene 1 eller 2, for fremstilling av et farma-sytisk preparat for forebyggelse, behandling eller profylakse av allergi av forsinket type, reumatoid artritt, systemisk lupus erythematosus, psoriasis, insulinavhegig diabetes mellitus, graft-versus-host sykdom, immun-awisning forbundet med transplantasjon eller nefritt.</span>21. Use of the antibody according to claims 1 or 2, for the production of a pharmaceutical preparation for the prevention, treatment or prophylaxis of delayed-type allergy, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, insulin-dependent diabetes mellitus, graft-versus-host disease , immunodeficiency associated with transplantation or nephritis.</span>
    </claim-text>
  </claim>
</claims>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
          </div>

          <div class="footer style-scope patent-result">

            
            <h3 id="patentCitations" class="scroll-target style-scope patent-result">
              Patent Citations (50)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CH642458A5/en"><a id="link" href="#" class="style-scope state-modifier">CH642458A5</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1980-04-25</span>
                    <span class="td style-scope patent-result">1984-04-13</span>
                    <span class="td style-scope patent-result">Hoffmann La Roche</span>
                    <span class="td style-scope patent-result">Immunological method 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4873191A/en"><a id="link" href="#" class="style-scope state-modifier">US4873191A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1981-06-12</span>
                    <span class="td style-scope patent-result">1989-10-10</span>
                    <span class="td style-scope patent-result">Ohio University</span>
                    <span class="td style-scope patent-result">Genetic transformation of zygotes 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2615456B2/en"><a id="link" href="#" class="style-scope state-modifier">JP2615456B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1987-11-13</span>
                    <span class="td style-scope patent-result">1997-05-28</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Speaker system
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP0617127A1/en"><a id="link" href="#" class="style-scope state-modifier">EP0617127A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1987-12-31</span>
                    <span class="td style-scope patent-result">1994-09-28</span>
                    <span class="td style-scope patent-result">Tanox Biosystems, Inc.</span>
                    <span class="td style-scope patent-result">Antigenic epitopes on B cell-bound IgE Immunoglobulins 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5506126A/en"><a id="link" href="#" class="style-scope state-modifier">US5506126A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1988-02-25</span>
                    <span class="td style-scope patent-result">1996-04-09</span>
                    <span class="td style-scope patent-result">The General Hospital Corporation</span>
                    <span class="td style-scope patent-result">Rapid immunoselection cloning method 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6075181A/en"><a id="link" href="#" class="style-scope state-modifier">US6075181A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1990-01-12</span>
                    <span class="td style-scope patent-result">2000-06-13</span>
                    <span class="td style-scope patent-result">Abgenix, Inc.</span>
                    <span class="td style-scope patent-result">Human antibodies derived from immunized xenomice 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP1690935A3/en"><a id="link" href="#" class="style-scope state-modifier">EP1690935A3</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1990-01-12</span>
                    <span class="td style-scope patent-result">2008-07-30</span>
                    <span class="td style-scope patent-result">Abgenix, Inc.</span>
                    <span class="td style-scope patent-result">Generation of xenogeneic antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6641809B1/en"><a id="link" href="#" class="style-scope state-modifier">US6641809B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1990-03-26</span>
                    <span class="td style-scope patent-result">2003-11-04</span>
                    <span class="td style-scope patent-result">Bristol-Myers Squibb Company</span>
                    <span class="td style-scope patent-result">Method of regulating cellular processes mediated by B7 and CD28 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/DK0546073T3/en"><a id="link" href="#" class="style-scope state-modifier">DK0546073T3</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1990-08-29</span>
                    <span class="td style-scope patent-result">1998-02-02</span>
                    <span class="td style-scope patent-result">Genpharm Int</span>
                    <span class="td style-scope patent-result">
  Production and use of transgenic, non-human animals capable of forming heterologous antibodies
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5770197A/en"><a id="link" href="#" class="style-scope state-modifier">US5770197A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1991-06-27</span>
                    <span class="td style-scope patent-result">1998-06-23</span>
                    <span class="td style-scope patent-result">Bristol-Myers Squibb Company</span>
                    <span class="td style-scope patent-result">Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP3162438B2/en"><a id="link" href="#" class="style-scope state-modifier">JP3162438B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1991-09-12</span>
                    <span class="td style-scope patent-result">2001-04-25</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Highly sensitive specific antibody assay
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1994002602A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1994002602A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-07-24</span>
                    <span class="td style-scope patent-result">1994-02-03</span>
                    <span class="td style-scope patent-result">Cell Genesys, Inc.</span>
                    <span class="td style-scope patent-result">Generation of xenogeneic antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN1173991C/en"><a id="link" href="#" class="style-scope state-modifier">CN1173991C</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-11-13</span>
                    <span class="td style-scope patent-result">2004-11-03</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Fik-1 as receiptor of growth factor of blood vessel inner-skin 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU6819494A/en"><a id="link" href="#" class="style-scope state-modifier">AU6819494A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1993-04-26</span>
                    <span class="td style-scope patent-result">1994-11-21</span>
                    <span class="td style-scope patent-result">Genpharm International, Inc.</span>
                    <span class="td style-scope patent-result">Transgenic non-human animals capable of producing heterologous antibodies 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5484892A/en"><a id="link" href="#" class="style-scope state-modifier">US5484892A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1993-05-21</span>
                    <span class="td style-scope patent-result">1996-01-16</span>
                    <span class="td style-scope patent-result">Dana-Farber Cancer Institute, Inc.</span>
                    <span class="td style-scope patent-result">Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP0749323B1/en"><a id="link" href="#" class="style-scope state-modifier">EP0749323B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1994-03-08</span>
                    <span class="td style-scope patent-result">2000-11-29</span>
                    <span class="td style-scope patent-result">Dana-Farber Cancer Institute</span>
                    <span class="td style-scope patent-result">Methods for modulating t cell anergy 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6719972B1/en"><a id="link" href="#" class="style-scope state-modifier">US6719972B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1994-06-03</span>
                    <span class="td style-scope patent-result">2004-04-13</span>
                    <span class="td style-scope patent-result">Repligen Corporation</span>
                    <span class="td style-scope patent-result">Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5747461A/en"><a id="link" href="#" class="style-scope state-modifier">US5747461A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1994-07-26</span>
                    <span class="td style-scope patent-result">1998-05-05</span>
                    <span class="td style-scope patent-result">Markov; Angel K.</span>
                    <span class="td style-scope patent-result">Synergistic administration of cyclosporine and fructose diphosphate 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP3580948B2/en"><a id="link" href="#" class="style-scope state-modifier">JP3580948B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1995-05-02</span>
                    <span class="td style-scope patent-result">2004-10-27</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Monoclonal antibody reactive with human-derived CETP and method for quantifying human-derived CETP
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5914112A/en"><a id="link" href="#" class="style-scope state-modifier">US5914112A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-01-23</span>
                    <span class="td style-scope patent-result">1999-06-22</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Anti-CD18 antibodies in stroke 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/DK0877626T3/en"><a id="link" href="#" class="style-scope state-modifier">DK0877626T3</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-01-23</span>
                    <span class="td style-scope patent-result">2002-12-30</span>
                    <span class="td style-scope patent-result">Univ Vermont</span>
                    <span class="td style-scope patent-result">
  Anti-CD18 antibodies for use against stroke
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU723669B2/en"><a id="link" href="#" class="style-scope state-modifier">AU723669B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-09-18</span>
                    <span class="td style-scope patent-result">2000-08-31</span>
                    <span class="td style-scope patent-result">Zetesis S.P.A</span>
                    <span class="td style-scope patent-result">Use of proteins as agents against autoimmune diseases 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/BR9713498A/en"><a id="link" href="#" class="style-scope state-modifier">BR9713498A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-11-08</span>
                    <span class="td style-scope patent-result">2000-02-29</span>
                    <span class="td style-scope patent-result">Idec Pharma Corp</span>
                    <span class="td style-scope patent-result">
  Identification of unique binding interactions between some antibodies and human co-stimulatory antigens b7.1 and b7.2
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1998037415A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1998037415A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-02-20</span>
                    <span class="td style-scope patent-result">1998-08-27</span>
                    <span class="td style-scope patent-result">The Regents Of The University Of California</span>
                    <span class="td style-scope patent-result">ULCERATIVE COLITIS pANCA SECRETORY VESICLE ANTIGEN AND METHODS OF USING SAME 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP3521382B2/en"><a id="link" href="#" class="style-scope state-modifier">JP3521382B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-02-27</span>
                    <span class="td style-scope patent-result">2004-04-19</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Cell surface molecules that mediate cell-cell adhesion and signal transduction
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7112655B1/en"><a id="link" href="#" class="style-scope state-modifier">US7112655B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-02-27</span>
                    <span class="td style-scope patent-result">2006-09-26</span>
                    <span class="td style-scope patent-result">Japan Tobacco, Inc.</span>
                    <span class="td style-scope patent-result">JTT-1 protein and methods of inhibiting lymphocyte activation 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB9704174D0/en"><a id="link" href="#" class="style-scope state-modifier">GB9704174D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-02-28</span>
                    <span class="td style-scope patent-result">1997-04-16</span>
                    <span class="td style-scope patent-result">Univ Birmingham</span>
                    <span class="td style-scope patent-result">Agent for medical treatment 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001018022A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2001018022A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-09-03</span>
                    <span class="td style-scope patent-result">2001-03-15</span>
                    <span class="td style-scope patent-result">Human Genome Sciences, Inc.</span>
                    <span class="td style-scope patent-result">52 human secreted proteins 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU743758B2/en"><a id="link" href="#" class="style-scope state-modifier">AU743758B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-04-07</span>
                    <span class="td style-scope patent-result">2002-02-07</span>
                    <span class="td style-scope patent-result">Genentech Inc.</span>
                    <span class="td style-scope patent-result">Anti-VEGF antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2293666A1/en"><a id="link" href="#" class="style-scope state-modifier">CA2293666A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-06-12</span>
                    <span class="td style-scope patent-result">1998-12-17</span>
                    <span class="td style-scope patent-result">Applied Research Systems Ars Holding N.V.</span>
                    <span class="td style-scope patent-result">Cd28/ctla-4 inhibiting peptidomimetics, pharmaceutical compositions thereof, and method of using same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU752433B2/en"><a id="link" href="#" class="style-scope state-modifier">AU752433B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-09-23</span>
                    <span class="td style-scope patent-result">2002-09-19</span>
                    <span class="td style-scope patent-result">Bundesrepublik Deutschland letzvertreten durch Den Direktor des Robert-Koch-Instituts</span>
                    <span class="td style-scope patent-result">Costimulating T-cell polypeptide, monoclonal antibodies, their preparation and use 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/DE19821060A1/en"><a id="link" href="#" class="style-scope state-modifier">DE19821060A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-09-23</span>
                    <span class="td style-scope patent-result">1999-04-15</span>
                    <span class="td style-scope patent-result">Bundesrepublik Deutschland Let</span>
                    <span class="td style-scope patent-result">
  T cell co-stimulating polypeptide, monoclonal antibodies, and the production and use thereof
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6297022B1/en"><a id="link" href="#" class="style-scope state-modifier">US6297022B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-10-08</span>
                    <span class="td style-scope patent-result">2001-10-02</span>
                    <span class="td style-scope patent-result">Smithkline Beecham Corporation</span>
                    <span class="td style-scope patent-result">Method of identifying agonists and antagonists for tumor necrosis related receptor TR1 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JPH11228442A/en"><a id="link" href="#" class="style-scope state-modifier">JPH11228442A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-02-09</span>
                    <span class="td style-scope patent-result">1999-08-24</span>
                    <span class="td style-scope patent-result">Cypros Pharmaceut Corp</span>
                    <span class="td style-scope patent-result">Use of fructose diphosphate for reducing cyclosporin dose after organ transplantation 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2000154151A/en"><a id="link" href="#" class="style-scope state-modifier">JP2000154151A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-09-14</span>
                    <span class="td style-scope patent-result">2000-06-06</span>
                    <span class="td style-scope patent-result">Kyo Jo</span>
                    <span class="td style-scope patent-result">Immunosuppressant 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU767241B2/en"><a id="link" href="#" class="style-scope state-modifier">AU767241B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-09-14</span>
                    <span class="td style-scope patent-result">2003-11-06</span>
                    <span class="td style-scope patent-result">Qiang Xu</span>
                    <span class="td style-scope patent-result">Immunosuppressive agents 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU1102000A/en"><a id="link" href="#" class="style-scope state-modifier">AU1102000A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-10-07</span>
                    <span class="td style-scope patent-result">2000-04-26</span>
                    <span class="td style-scope patent-result">Millennium Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Novel th2-specific molecules and uses thereof 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20010101987A/en"><a id="link" href="#" class="style-scope state-modifier">KR20010101987A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-02-03</span>
                    <span class="td style-scope patent-result">2001-11-15</span>
                    <span class="td style-scope patent-result"> . </span>
                    <span class="td style-scope patent-result">Novel polypeptides involved in immune response 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN1377279A/en"><a id="link" href="#" class="style-scope state-modifier">CN1377279A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-05-06</span>
                    <span class="td style-scope patent-result">2002-10-30</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Use of soluble cosmetimulatory molecules to enhance immune responses 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6613327B1/en"><a id="link" href="#" class="style-scope state-modifier">US6613327B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-07-28</span>
                    <span class="td style-scope patent-result">2003-09-02</span>
                    <span class="td style-scope patent-result">Genetics Institute, Inc.</span>
                    <span class="td style-scope patent-result">Methods of preventing immune-mediated abortion by inhibiting a CD28-mediated costimulatory signal 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU6458400A/en"><a id="link" href="#" class="style-scope state-modifier">AU6458400A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-08-11</span>
                    <span class="td style-scope patent-result">2001-03-13</span>
                    <span class="td style-scope patent-result">Isis Innovation Limited</span>
                    <span class="td style-scope patent-result">Nucleic acid, polypeptides, assays, therapeutic methods and means 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP3871503B2/en"><a id="link" href="#" class="style-scope state-modifier">JP3871503B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-08-30</span>
                    <span class="td style-scope patent-result">2007-01-24</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Immune disease treatment
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP4210454B2/en"><a id="link" href="#" class="style-scope state-modifier">JP4210454B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-03-27</span>
                    <span class="td style-scope patent-result">2009-01-21</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Inflammatory bowel disease treatment
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP4737905B2/en"><a id="link" href="#" class="style-scope state-modifier">JP4737905B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-09-21</span>
                    <span class="td style-scope patent-result">2011-08-03</span>
                    <span class="td style-scope patent-result">  </span>
                    <span class="td style-scope patent-result">
  GL50 molecules and uses thereof
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU1342501A/en"><a id="link" href="#" class="style-scope state-modifier">AU1342501A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-10-29</span>
                    <span class="td style-scope patent-result">2001-05-14</span>
                    <span class="td style-scope patent-result">Human Genome Sciences, Inc.</span>
                    <span class="td style-scope patent-result">32 human secreted proteins 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2001245396A1/en"><a id="link" href="#" class="style-scope state-modifier">AU2001245396A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-03-02</span>
                    <span class="td style-scope patent-result">2001-09-12</span>
                    <span class="td style-scope patent-result">Mayo Foundation For Medical Education And Research</span>
                    <span class="td style-scope patent-result">Hb7-h2, a novel co-stimulatory molecule 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN101498731A/en"><a id="link" href="#" class="style-scope state-modifier">CN101498731A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-05-18</span>
                    <span class="td style-scope patent-result">2009-08-05</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Human monoclonal antibody against a costimulatory signal transduction molecule ATLIM and pharmaceutical use thereof 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP3597140B2/en"><a id="link" href="#" class="style-scope state-modifier">JP3597140B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-05-18</span>
                    <span class="td style-scope patent-result">2004-12-02</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Human monoclonal antibody against costimulatory molecule AILIM and pharmaceutical use thereof
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2002217969B2/en"><a id="link" href="#" class="style-scope state-modifier">AU2002217969B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-11-28</span>
                    <span class="td style-scope patent-result">2007-12-20</span>
                    <span class="td style-scope patent-result">Amgen Canada Inc.</span>
                    <span class="td style-scope patent-result">Polypeptides involved in immune response 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP4212278B2/en"><a id="link" href="#" class="style-scope state-modifier">JP4212278B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-03-01</span>
                    <span class="td style-scope patent-result">2009-01-21</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Graft rejection inhibitor
 
     </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                </div>
              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner,  Cited by third party</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="citedBy" class="scroll-target style-scope patent-result">
              Cited By (87)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP3521382B2/en"><a id="link" href="#" class="style-scope state-modifier">JP3521382B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-02-27</span>
                    <span class="td style-scope patent-result">2004-04-19</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Cell surface molecules that mediate cell-cell adhesion and signal transduction
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7112655B1/en"><a id="link" href="#" class="style-scope state-modifier">US7112655B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-02-27</span>
                    <span class="td style-scope patent-result">2006-09-26</span>
                    <span class="td style-scope patent-result">Japan Tobacco, Inc.</span>
                    <span class="td style-scope patent-result">JTT-1 protein and methods of inhibiting lymphocyte activation 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/DE19821060A1/en"><a id="link" href="#" class="style-scope state-modifier">DE19821060A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-09-23</span>
                    <span class="td style-scope patent-result">1999-04-15</span>
                    <span class="td style-scope patent-result">Bundesrepublik Deutschland Let</span>
                    <span class="td style-scope patent-result">
  T cell co-stimulating polypeptide, monoclonal antibodies, and the production and use thereof
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP4210454B2/en"><a id="link" href="#" class="style-scope state-modifier">JP4210454B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-03-27</span>
                    <span class="td style-scope patent-result">2009-01-21</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Inflammatory bowel disease treatment
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP3871503B2/en"><a id="link" href="#" class="style-scope state-modifier">JP3871503B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-08-30</span>
                    <span class="td style-scope patent-result">2007-01-24</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Immune disease treatment
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7393652B2/en"><a id="link" href="#" class="style-scope state-modifier">US7393652B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-05-10</span>
                    <span class="td style-scope patent-result">2008-07-01</span>
                    <span class="td style-scope patent-result">The Trustees Of Columbia University In The City Of New York</span>
                    <span class="td style-scope patent-result">Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8022058B2/en"><a id="link" href="#" class="style-scope state-modifier">US8022058B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-05-10</span>
                    <span class="td style-scope patent-result">2011-09-20</span>
                    <span class="td style-scope patent-result">The Trustees Of Columbia University In The City Of New York</span>
                    <span class="td style-scope patent-result">Agents for preventing and treating disorders involving modulation of the RyR receptors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7879840B2/en"><a id="link" href="#" class="style-scope state-modifier">US7879840B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-08-25</span>
                    <span class="td style-scope patent-result">2011-02-01</span>
                    <span class="td style-scope patent-result">The Trustees Of Columbia University In The City Of New York</span>
                    <span class="td style-scope patent-result">Agents for preventing and treating disorders involving modulation of the RyR receptors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7718644B2/en"><a id="link" href="#" class="style-scope state-modifier">US7718644B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-01-22</span>
                    <span class="td style-scope patent-result">2010-05-18</span>
                    <span class="td style-scope patent-result">The Trustees Of Columbia University In The City Of New York</span>
                    <span class="td style-scope patent-result">Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP3597140B2/en"><a id="link" href="#" class="style-scope state-modifier">JP3597140B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-05-18</span>
                    <span class="td style-scope patent-result">2004-12-02</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Human monoclonal antibody against costimulatory molecule AILIM and pharmaceutical use thereof
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP4212278B2/en"><a id="link" href="#" class="style-scope state-modifier">JP4212278B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-03-01</span>
                    <span class="td style-scope patent-result">2009-01-21</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Graft rejection inhibitor
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2004003544A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2004003544A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-06-26</span>
                    <span class="td style-scope patent-result">2004-01-08</span>
                    <span class="td style-scope patent-result">Millennium Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Methods and compositions for the diagnosis and treatment of demyelinating inflammatory disorders 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2007525165A/en"><a id="link" href="#" class="style-scope state-modifier">JP2007525165A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-03-07</span>
                    <span class="td style-scope patent-result">2007-09-06</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Type 1 ryanodine receptor based method
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN103880955A/en"><a id="link" href="#" class="style-scope state-modifier">CN103880955A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-07-18</span>
                    <span class="td style-scope patent-result">2014-06-25</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Specific binding agents to hepatocyte growth factor 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/HN2004000285A/en"><a id="link" href="#" class="style-scope state-modifier">HN2004000285A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-08-04</span>
                    <span class="td style-scope patent-result">2006-04-27</span>
                    <span class="td style-scope patent-result">Pfizer Prod Inc</span>
                    <span class="td style-scope patent-result">
  ANTIBODIES DIRECTED TO c-MET
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7435799B2/en"><a id="link" href="#" class="style-scope state-modifier">US7435799B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-01-08</span>
                    <span class="td style-scope patent-result">2008-10-14</span>
                    <span class="td style-scope patent-result">Applied Molecular Evolution</span>
                    <span class="td style-scope patent-result">TNF- binding molecules 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8710045B2/en"><a id="link" href="#" class="style-scope state-modifier">US8710045B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-01-22</span>
                    <span class="td style-scope patent-result">2014-04-29</span>
                    <span class="td style-scope patent-result">The Trustees Of Columbia University In The City Of New York</span>
                    <span class="td style-scope patent-result">Agents for preventing and treating disorders involving modulation of the ryanodine receptors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2442386T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2442386T3</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-04-23</span>
                    <span class="td style-scope patent-result">2014-02-11</span>
                    <span class="td style-scope patent-result">Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr</span>
                    <span class="td style-scope patent-result">
  Method for the treatment of conditions mediated by T cells by the decrease of positive ICOS cells in vivo.
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7397250B2/en"><a id="link" href="#" class="style-scope state-modifier">US7397250B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-11-12</span>
                    <span class="td style-scope patent-result">2008-07-08</span>
                    <span class="td style-scope patent-result">Baker Hughes Incorporated</span>
                    <span class="td style-scope patent-result">High resolution resistivity earth imager 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7385401B2/en"><a id="link" href="#" class="style-scope state-modifier">US7385401B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-07-08</span>
                    <span class="td style-scope patent-result">2008-06-10</span>
                    <span class="td style-scope patent-result">Baker Hughes Incorporated</span>
                    <span class="td style-scope patent-result">High resolution resistivity earth imager 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7704990B2/en"><a id="link" href="#" class="style-scope state-modifier">US7704990B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-08-25</span>
                    <span class="td style-scope patent-result">2010-04-27</span>
                    <span class="td style-scope patent-result">The Trustees Of Columbia University In The City Of New York</span>
                    <span class="td style-scope patent-result">Agents for preventing and treating disorders involving modulation of the RyR receptors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7365545B2/en"><a id="link" href="#" class="style-scope state-modifier">US7365545B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-12-29</span>
                    <span class="td style-scope patent-result">2008-04-29</span>
                    <span class="td style-scope patent-result">Baker Hughes Incorporated</span>
                    <span class="td style-scope patent-result">Two-axial pad formation resistivity imager 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2009530391A/en"><a id="link" href="#" class="style-scope state-modifier">JP2009530391A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-03-22</span>
                    <span class="td style-scope patent-result">2009-08-27</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Compositions and methods relating to modulation of immune system factors
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/TWI395754B/en"><a id="link" href="#" class="style-scope state-modifier">TWI395754B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-04-24</span>
                    <span class="td style-scope patent-result">2013-05-11</span>
                    <span class="td style-scope patent-result">Amgen Inc</span>
                    <span class="td style-scope patent-result">Humanized c-kit antibody 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9244059B2/en"><a id="link" href="#" class="style-scope state-modifier">US9244059B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-04-30</span>
                    <span class="td style-scope patent-result">2016-01-26</span>
                    <span class="td style-scope patent-result">Immutep Parc Club Orsay</span>
                    <span class="td style-scope patent-result">Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2008137915A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2008137915A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-05-07</span>
                    <span class="td style-scope patent-result">2008-11-13</span>
                    <span class="td style-scope patent-result">Medimmune, Llc</span>
                    <span class="td style-scope patent-result">Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2009009114A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2009009114A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2007-07-12</span>
                    <span class="td style-scope patent-result">2009-01-15</span>
                    <span class="td style-scope patent-result">Oncomed Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Compositions and methods for treating and diagnosing cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8753690B2/en"><a id="link" href="#" class="style-scope state-modifier">US8753690B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-02-27</span>
                    <span class="td style-scope patent-result">2014-06-17</span>
                    <span class="td style-scope patent-result">Biomet Biologics, Llc</span>
                    <span class="td style-scope patent-result">Methods and compositions for delivering interleukin-1 receptor antagonist 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2259774B1/en"><a id="link" href="#" class="style-scope state-modifier">EP2259774B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-02-27</span>
                    <span class="td style-scope patent-result">2012-12-12</span>
                    <span class="td style-scope patent-result">Biomet Biologics, LLC</span>
                    <span class="td style-scope patent-result">Methods and compositions for delivering interleukin-1 receptor antagonist 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8390294B2/en"><a id="link" href="#" class="style-scope state-modifier">US8390294B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-07-23</span>
                    <span class="td style-scope patent-result">2013-03-05</span>
                    <span class="td style-scope patent-result">Baker Hughes Incorporated</span>
                    <span class="td style-scope patent-result">Multi-resolution borehole resistivity imaging 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8174266B2/en"><a id="link" href="#" class="style-scope state-modifier">US8174266B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-07-23</span>
                    <span class="td style-scope patent-result">2012-05-08</span>
                    <span class="td style-scope patent-result">Baker Hughes Incorporated</span>
                    <span class="td style-scope patent-result">Multi-resolution borehole resistivity imaging 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2358392B1/en"><a id="link" href="#" class="style-scope state-modifier">EP2358392B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-11-12</span>
                    <span class="td style-scope patent-result">2019-01-09</span>
                    <span class="td style-scope patent-result">MedImmune, LLC</span>
                    <span class="td style-scope patent-result">Antibody formulation 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2010138184A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2010138184A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-05-27</span>
                    <span class="td style-scope patent-result">2010-12-02</span>
                    <span class="td style-scope patent-result">Synageva Biopharma Corp.</span>
                    <span class="td style-scope patent-result">Avian derived antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP3381937A3/en"><a id="link" href="#" class="style-scope state-modifier">EP3381937A3</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-08-13</span>
                    <span class="td style-scope patent-result">2018-10-31</span>
                    <span class="td style-scope patent-result">The Johns Hopkins University</span>
                    <span class="td style-scope patent-result">Methods of modulating immune function 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9763875B2/en"><a id="link" href="#" class="style-scope state-modifier">US9763875B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-08-27</span>
                    <span class="td style-scope patent-result">2017-09-19</span>
                    <span class="td style-scope patent-result">Biomet Biologics, Llc</span>
                    <span class="td style-scope patent-result">Implantable device for production of interleukin-1 receptor antagonist 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2011097477A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2011097477A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-02-04</span>
                    <span class="td style-scope patent-result">2011-08-11</span>
                    <span class="td style-scope patent-result">The Trustees Of The University Of Pennsylvania</span>
                    <span class="td style-scope patent-result">Icos critically regulates the expansion and function of inflammatory human th17 cells 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP3147297B1/en"><a id="link" href="#" class="style-scope state-modifier">EP3147297B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-03-31</span>
                    <span class="td style-scope patent-result">2018-12-12</span>
                    <span class="td style-scope patent-result">INSERM (Institut National de la Sant et de la Recherche Mdicale)</span>
                    <span class="td style-scope patent-result">Antibodies directed against icos and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2013059885A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2013059885A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-10-28</span>
                    <span class="td style-scope patent-result">2013-05-02</span>
                    <span class="td style-scope patent-result">Cephalon Australia Pty Ltd</span>
                    <span class="td style-scope patent-result">Polypeptide constructs and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN104968364A/en"><a id="link" href="#" class="style-scope state-modifier">CN104968364A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-12-03</span>
                    <span class="td style-scope patent-result">2015-10-07</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Enhancing anti-cancer activity of immunomodulatory Fc fusion proteins 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9758806B2/en"><a id="link" href="#" class="style-scope state-modifier">US9758806B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-03-15</span>
                    <span class="td style-scope patent-result">2017-09-12</span>
                    <span class="td style-scope patent-result">Biomet Biologics, Llc</span>
                    <span class="td style-scope patent-result">Acellular compositions for treating inflammatory disorders 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10208095B2/en"><a id="link" href="#" class="style-scope state-modifier">US10208095B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-03-15</span>
                    <span class="td style-scope patent-result">2019-02-19</span>
                    <span class="td style-scope patent-result">Biomet Manufacturing, Llc</span>
                    <span class="td style-scope patent-result">Methods for making cytokine compositions from tissues using non-centrifugal methods 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20140271589A1/en"><a id="link" href="#" class="style-scope state-modifier">US20140271589A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-03-15</span>
                    <span class="td style-scope patent-result">2014-09-18</span>
                    <span class="td style-scope patent-result">Biomet Biologics, Llc</span>
                    <span class="td style-scope patent-result">Treatment of collagen defects using protein solutions 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9878011B2/en"><a id="link" href="#" class="style-scope state-modifier">US9878011B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-03-15</span>
                    <span class="td style-scope patent-result">2018-01-30</span>
                    <span class="td style-scope patent-result">Biomet Biologics, Llc</span>
                    <span class="td style-scope patent-result">Treatment of inflammatory respiratory disease using biological solutions 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10143725B2/en"><a id="link" href="#" class="style-scope state-modifier">US10143725B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-03-15</span>
                    <span class="td style-scope patent-result">2018-12-04</span>
                    <span class="td style-scope patent-result">Biomet Biologics, Llc</span>
                    <span class="td style-scope patent-result">Treatment of pain using protein solutions 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9950035B2/en"><a id="link" href="#" class="style-scope state-modifier">US9950035B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-03-15</span>
                    <span class="td style-scope patent-result">2018-04-24</span>
                    <span class="td style-scope patent-result">Biomet Biologics, Llc</span>
                    <span class="td style-scope patent-result">Methods and non-immunogenic compositions for treating inflammatory disorders 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9895418B2/en"><a id="link" href="#" class="style-scope state-modifier">US9895418B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-03-15</span>
                    <span class="td style-scope patent-result">2018-02-20</span>
                    <span class="td style-scope patent-result">Biomet Biologics, Llc</span>
                    <span class="td style-scope patent-result">Treatment of peripheral vascular disease using protein solutions 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2902831C/en"><a id="link" href="#" class="style-scope state-modifier">CA2902831C</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-03-15</span>
                    <span class="td style-scope patent-result">2023-04-25</span>
                    <span class="td style-scope patent-result">Glaxosmithkline Intellectual Property Development Limited</span>
                    <span class="td style-scope patent-result">Anti-lag-3 binding proteins 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP3074507B1/en"><a id="link" href="#" class="style-scope state-modifier">EP3074507B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-11-26</span>
                    <span class="td style-scope patent-result">2022-01-05</span>
                    <span class="td style-scope patent-result">Biomet Biologics, LLC</span>
                    <span class="td style-scope patent-result">Methods of mediating macrophage phenotypes 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201403775D0/en"><a id="link" href="#" class="style-scope state-modifier">GB201403775D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-03-04</span>
                    <span class="td style-scope patent-result">2014-04-16</span>
                    <span class="td style-scope patent-result">Kymab Ltd</span>
                    <span class="td style-scope patent-result">Antibodies, uses &amp; methods 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20160145344A1/en"><a id="link" href="#" class="style-scope state-modifier">US20160145344A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-10-20</span>
                    <span class="td style-scope patent-result">2016-05-26</span>
                    <span class="td style-scope patent-result">University Of Southern California</span>
                    <span class="td style-scope patent-result">Murine and human innate lymphoid cells and lung inflammation 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10441635B2/en"><a id="link" href="#" class="style-scope state-modifier">US10441635B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-11-10</span>
                    <span class="td style-scope patent-result">2019-10-15</span>
                    <span class="td style-scope patent-result">Biomet Biologics, Llc</span>
                    <span class="td style-scope patent-result">Methods of treating pain using protein solutions 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/MA41414A/en"><a id="link" href="#" class="style-scope state-modifier">MA41414A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-01-28</span>
                    <span class="td style-scope patent-result">2017-12-05</span>
                    <span class="td style-scope patent-result">Centre Nat Rech Scient</span>
                    <span class="td style-scope patent-result">
  ICOS AGONIST BINDING PROTEINS
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9763800B2/en"><a id="link" href="#" class="style-scope state-modifier">US9763800B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-03-18</span>
                    <span class="td style-scope patent-result">2017-09-19</span>
                    <span class="td style-scope patent-result">Biomet C. V.</span>
                    <span class="td style-scope patent-result">Implant configured for hammertoe and small bone fixation 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/BR112017020054A2/en"><a id="link" href="#" class="style-scope state-modifier">BR112017020054A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-03-23</span>
                    <span class="td style-scope patent-result">2018-06-05</span>
                    <span class="td style-scope patent-result">Jounce Therapeutics Inc</span>
                    <span class="td style-scope patent-result">
  antibodies to icos
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20210089270A/en"><a id="link" href="#" class="style-scope state-modifier">KR20210089270A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-07-16</span>
                    <span class="td style-scope patent-result">2021-07-15</span>
                    <span class="td style-scope patent-result">  </span>
                    <span class="td style-scope patent-result">Compositions and methods for treating cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/IL257260B/en"><a id="link" href="#" class="style-scope state-modifier">IL257260B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-07-31</span>
                    <span class="td style-scope patent-result">2022-09-01</span>
                    <span class="td style-scope patent-result">Vascular Biogenics Ltd</span>
                    <span class="td style-scope patent-result">Motile sperm domain containing protein 2 and cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2836684T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2836684T3</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-07-31</span>
                    <span class="td style-scope patent-result">2021-06-28</span>
                    <span class="td style-scope patent-result">Vascular Biogenics Ltd</span>
                    <span class="td style-scope patent-result">
  Protein 2 containing motile sperm domain and inflammation
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/PT3344654T/en"><a id="link" href="#" class="style-scope state-modifier">PT3344654T</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-09-02</span>
                    <span class="td style-scope patent-result">2021-01-26</span>
                    <span class="td style-scope patent-result">Immutep Sas</span>
                    <span class="td style-scope patent-result">Anti-lag-3 antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/RU2756236C2/en"><a id="link" href="#" class="style-scope state-modifier">RU2756236C2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-06-20</span>
                    <span class="td style-scope patent-result">2021-09-28</span>
                    <span class="td style-scope patent-result"> </span>
                    <span class="td style-scope patent-result">Pd-l1 specific antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9567399B1/en"><a id="link" href="#" class="style-scope state-modifier">US9567399B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-06-20</span>
                    <span class="td style-scope patent-result">2017-02-14</span>
                    <span class="td style-scope patent-result">Kymab Limited</span>
                    <span class="td style-scope patent-result">Antibodies and immunocytokines 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2018029474A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2018029474A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-08-09</span>
                    <span class="td style-scope patent-result">2018-02-15</span>
                    <span class="td style-scope patent-result">Kymab Limited</span>
                    <span class="td style-scope patent-result">Anti-icos antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/BR112019002529A2/en"><a id="link" href="#" class="style-scope state-modifier">BR112019002529A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-08-09</span>
                    <span class="td style-scope patent-result">2019-05-28</span>
                    <span class="td style-scope patent-result">Kymab Ltd</span>
                    <span class="td style-scope patent-result">
  isolated antibody, composition, method for modulating t-cell balance, method for treating a therapy-treatable disease or condition, method for treating cancer, igg1 antibody combination, anti-ics antibody, transgenic non-human mammal, and method for producing a antibody
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10793632B2/en"><a id="link" href="#" class="style-scope state-modifier">US10793632B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-08-30</span>
                    <span class="td style-scope patent-result">2020-10-06</span>
                    <span class="td style-scope patent-result">Xencor, Inc.</span>
                    <span class="td style-scope patent-result">Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US11779604B2/en"><a id="link" href="#" class="style-scope state-modifier">US11779604B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-11-03</span>
                    <span class="td style-scope patent-result">2023-10-10</span>
                    <span class="td style-scope patent-result">Kymab Limited</span>
                    <span class="td style-scope patent-result">Antibodies, combinations comprising antibodies, biomarkers, uses and methods 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/TWI788340B/en"><a id="link" href="#" class="style-scope state-modifier">TWI788340B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-04-07</span>
                    <span class="td style-scope patent-result">2023-01-01</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Anti-icos agonist antibodies and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP6886854B2/en"><a id="link" href="#" class="style-scope state-modifier">JP6886854B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-04-13</span>
                    <span class="td style-scope patent-result">2021-06-16</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Information acquisition method for test substances
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201709808D0/en"><a id="link" href="#" class="style-scope state-modifier">GB201709808D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-06-20</span>
                    <span class="td style-scope patent-result">2017-08-02</span>
                    <span class="td style-scope patent-result">Kymab Ltd</span>
                    <span class="td style-scope patent-result">Antibodies 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10981992B2/en"><a id="link" href="#" class="style-scope state-modifier">US10981992B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-11-08</span>
                    <span class="td style-scope patent-result">2021-04-20</span>
                    <span class="td style-scope patent-result">Xencor, Inc.</span>
                    <span class="td style-scope patent-result">Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US11629189B2/en"><a id="link" href="#" class="style-scope state-modifier">US11629189B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-12-19</span>
                    <span class="td style-scope patent-result">2023-04-18</span>
                    <span class="td style-scope patent-result">Kymab Limited</span>
                    <span class="td style-scope patent-result">Bispecific antibody for ICOS and PD-L1 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201721338D0/en"><a id="link" href="#" class="style-scope state-modifier">GB201721338D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-12-19</span>
                    <span class="td style-scope patent-result">2018-01-31</span>
                    <span class="td style-scope patent-result">Kymab Ltd</span>
                    <span class="td style-scope patent-result">Anti-icos Antibodies 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP3502140A1/en"><a id="link" href="#" class="style-scope state-modifier">EP3502140A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-12-21</span>
                    <span class="td style-scope patent-result">2019-06-26</span>
                    <span class="td style-scope patent-result">F. Hoffmann-La Roche AG</span>
                    <span class="td style-scope patent-result">Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA3093850A1/en"><a id="link" href="#" class="style-scope state-modifier">CA3093850A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-03-26</span>
                    <span class="td style-scope patent-result">2019-10-03</span>
                    <span class="td style-scope patent-result">Regeneron Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Humanized rodents for testing therapeutic agents 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA3103629A1/en"><a id="link" href="#" class="style-scope state-modifier">CA3103629A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-06-15</span>
                    <span class="td style-scope patent-result">2019-12-19</span>
                    <span class="td style-scope patent-result">Flagship Pioneering Innovations V, Inc.</span>
                    <span class="td style-scope patent-result">Increasing immune activity through modulation of postcellular signaling factors 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP3962493A2/en"><a id="link" href="#" class="style-scope state-modifier">EP3962493A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-05-03</span>
                    <span class="td style-scope patent-result">2022-03-09</span>
                    <span class="td style-scope patent-result">Flagship Pioneering Innovations V, Inc.</span>
                    <span class="td style-scope patent-result">Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN114531878A/en"><a id="link" href="#" class="style-scope state-modifier">CN114531878A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-06-27</span>
                    <span class="td style-scope patent-result">2022-05-24</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Novel ICOS antibodies and tumor-targeted antigen-binding molecules comprising same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2023509359A/en"><a id="link" href="#" class="style-scope state-modifier">JP2023509359A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-12-17</span>
                    <span class="td style-scope patent-result">2023-03-08</span>
                    <span class="td style-scope patent-result">   </span>
                    <span class="td style-scope patent-result">
  Combination anticancer therapy with inducers of iron-dependent cell degradation
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20230181753A1/en"><a id="link" href="#" class="style-scope state-modifier">US20230181753A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-05-12</span>
                    <span class="td style-scope patent-result">2023-06-15</span>
                    <span class="td style-scope patent-result">Inserm (Institut National De La Sante Et De La Recherche Medicale)</span>
                    <span class="td style-scope patent-result">New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB202007099D0/en"><a id="link" href="#" class="style-scope state-modifier">GB202007099D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-05-14</span>
                    <span class="td style-scope patent-result">2020-07-01</span>
                    <span class="td style-scope patent-result">Kymab Ltd</span>
                    <span class="td style-scope patent-result">Tumour biomarkers for immunotherapy 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA3184366A1/en"><a id="link" href="#" class="style-scope state-modifier">CA3184366A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-06-29</span>
                    <span class="td style-scope patent-result">2022-01-06</span>
                    <span class="td style-scope patent-result">Darby Rye Schmidt</span>
                    <span class="td style-scope patent-result">Viruses engineered to promote thanotransmission and their use in treating cancer 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2023547026A/en"><a id="link" href="#" class="style-scope state-modifier">JP2023547026A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-09-10</span>
                    <span class="td style-scope patent-result">2023-11-09</span>
                    <span class="td style-scope patent-result">  </span>
                    <span class="td style-scope patent-result">
  Motile sperm domain-containing protein 2 antibody and its use
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP4313109A1/en"><a id="link" href="#" class="style-scope state-modifier">EP4313109A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-03-31</span>
                    <span class="td style-scope patent-result">2024-02-07</span>
                    <span class="td style-scope patent-result">Flagship Pioneering Innovations V, Inc.</span>
                    <span class="td style-scope patent-result">Thanotransmission polypeptides and their use in treating cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2022243378A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2022243378A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-05-18</span>
                    <span class="td style-scope patent-result">2022-11-24</span>
                    <span class="td style-scope patent-result">Kymab Limited</span>
                    <span class="td style-scope patent-result">Uses of anti-icos antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB202107994D0/en"><a id="link" href="#" class="style-scope state-modifier">GB202107994D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-06-04</span>
                    <span class="td style-scope patent-result">2021-07-21</span>
                    <span class="td style-scope patent-result">Kymab Ltd</span>
                    <span class="td style-scope patent-result">Treatment of cancer 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2022303363A1/en"><a id="link" href="#" class="style-scope state-modifier">AU2022303363A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-06-29</span>
                    <span class="td style-scope patent-result">2024-01-18</span>
                    <span class="td style-scope patent-result">Flagship Pioneering Innovations V, Inc.</span>
                    <span class="td style-scope patent-result">Immune cells engineered to promote thanotransmission and uses thereof 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2023222854A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2023222854A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-05-18</span>
                    <span class="td style-scope patent-result">2023-11-23</span>
                    <span class="td style-scope patent-result">Kymab Limited</span>
                    <span class="td style-scope patent-result">Uses of anti-icos antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2024040194A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2024040194A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-08-17</span>
                    <span class="td style-scope patent-result">2024-02-22</span>
                    <span class="td style-scope patent-result">Capstan Therapeutics, Inc.</span>
                    <span class="td style-scope patent-result">Conditioning for in vivo immune cell engineering 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2024077191A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2024077191A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-10-05</span>
                    <span class="td style-scope patent-result">2024-04-11</span>
                    <span class="td style-scope patent-result">Flagship Pioneering Innovations V, Inc.</span>
                    <span class="td style-scope patent-result">Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>

              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner,  Cited by third party,  Family to family citation</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="similarDocuments" class="scroll-target style-scope patent-result">
              Similar Documents
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication</span>
                    <span class="th style-scope patent-result">Publication Date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/NO333921B1/en"><a id="link" href="#" class="style-scope state-modifier">NO333921B1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-10-21</span>
                    <span class="td style-scope patent-result">
  Human monoclonal antibody to a costimulatory signal transfer molecule, AILIM, DNA encoding all or part of the antibody, vector comprising the DNA, cell producing the antibody, genetically recombined non-human host transformed with the vector and pharmaceutical preparation comprising the antibody, and use thereof
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/RU2262511C2/en"><a id="link" href="#" class="style-scope state-modifier">RU2262511C2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-10-20</span>
                    <span class="td style-scope patent-result">Humanized monoclonal antibody raised against ailim, co-stimulating molecule for signal transfer and its pharmaceutical applying 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/NO327500B1/en"><a id="link" href="#" class="style-scope state-modifier">NO327500B1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-07-20</span>
                    <span class="td style-scope patent-result">
  Polypeptide constituting a cell surface molecule, polypeptide fragment, gene, vector, transformant, fusion polypeptide, homodimeric molecule, pharmaceutical preparation, antibody, or part thereof, hybridoma, transgenic mouse and knockout mouse.
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2008131944A/en"><a id="link" href="#" class="style-scope state-modifier">JP2008131944A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2008-06-12</span>
                    <span class="td style-scope patent-result">Family of immunomodulators designated leukocyte immunoglobulin-like receptors (lir) 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP4386776B2/en"><a id="link" href="#" class="style-scope state-modifier">JP4386776B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-12-16</span>
                    <span class="td style-scope patent-result">
  Human monoclonal antibody against costimulatory molecule AILIM and pharmaceutical use thereof
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP4234992B2/en"><a id="link" href="#" class="style-scope state-modifier">JP4234992B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-03-04</span>
                    <span class="td style-scope patent-result">
  Human monoclonal antibody against costimulatory molecule AILIM and pharmaceutical use thereof
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP3543966B2/en"><a id="link" href="#" class="style-scope state-modifier">JP3543966B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-07-21</span>
                    <span class="td style-scope patent-result">
  Human monoclonal antibody against costimulatory transfer molecule AILIM and its pharmaceutical use
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2477192A1/en"><a id="link" href="#" class="style-scope state-modifier">CA2477192A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-11-18</span>
                    <span class="td style-scope patent-result">Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof 
     </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="relatedApplications" class="scroll-target style-scope patent-result">Priority And Related Applications</h3>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="appsClaimingPriority" class="scroll-target style-scope patent-result">
              Applications Claiming Priority (3)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        JP2000147116<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2000-05-18</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP3597140B2/en"><a id="link" href="#" class="style-scope state-modifier">JP2001099508A</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2001-03-30</span>
                    <span class="td style-scope patent-result">
  Human monoclonal antibody against costimulatory molecule AILIM and pharmaceutical use thereof
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2001087981A2/en"><a id="link" href="#" class="style-scope state-modifier">PCT/JP2001/004035</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2001-05-15</span>
                    <span class="td style-scope patent-result">Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="legalEvents" class="scroll-target style-scope patent-result">
              Legal Events
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Date</span>
                    <span class="th style-scope patent-result">Code</span>
                    <span class="th style-scope patent-result">Title</span>
                    <span class="th style-scope patent-result">Description</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">2021-01-04</span>
                    <span class="td nowrap style-scope patent-result">MM1K</span>
                    <span class="td nowrap style-scope patent-result">Lapsed by not paying the annual fees</span>
                    <span class="td style-scope patent-result">
                      <template is="dom-repeat" as="attr" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
              <h3 id="concepts" class="scroll-target layout horizontal style-scope patent-result">
                <div class="flex style-scope patent-result">Concepts</div>
                <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
              </h3>
              <div class="layout horizontal style-scope patent-result">
                <div class="flex style-scope patent-result">
                  <span id="conceptsWarning" class="righthead tooltip-hint style-scope patent-result">machine-extracted</span>
                  <overlay-tooltip positioning-target="#conceptsWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The concepts are extracted by a computer and may be incomplete or incorrect.
    </div>
  </overlay-tooltip>
                </div>
                <span class="headerButton style-scope patent-result"><a href="#" target="_blank" style="display: inline-block;" class="style-scope patent-result"><iron-icon icon="icons:file-download" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M19 9h-4V3H9v6H5l7 7 7-7zM5 18v2h14v-2H5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download</a></span>
                <span class="style-scope patent-result">
                  <dropdown-menu multi="true" label="Filter table" show-label="true" change-action="RESULT_CONCEPT_MENU" class="style-scope patent-result">
    
    <span class="label style-scope dropdown-menu">
      <span class="style-scope dropdown-menu">Filter table</span>
      <span id="selected" class="style-scope dropdown-menu" hidden="">
        <span style="margin: 0 4px 0 2px" class="style-scope dropdown-menu"></span>
        <span class="style-scope dropdown-menu"></span>
      </span>
      <iron-icon icon="icons:arrow-drop-down" class="style-scope dropdown-menu x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 10l5 5 5-5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><iron-icon icon="icons:arrow-drop-up" class="style-scope dropdown-menu x-scope iron-icon-0" hidden=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
    </span>
    <iron-dropdown allow-outside-scroll="" horizontal-align="left" vertical-align="top" class="style-scope dropdown-menu" aria-disabled="false" aria-hidden="true" style="outline: none; display: none;">
    

    <div id="contentWrapper" class="style-scope iron-dropdown">
      <div class="dropdown-content style-scope dropdown-menu" slot="dropdown-content" id="menu" multi="">
        <div class="style-scope dropdown-menu">
          
            <div class="item style-scope dropdown-menu">Anatomy</div>
          
            <div class="item style-scope dropdown-menu">Chemical class</div>
          
            <div class="item style-scope dropdown-menu">Chemical compound</div>
          
            <div class="item style-scope dropdown-menu">Chemical group</div>
          
            <div class="item style-scope dropdown-menu">Diseases</div>
          
            <div class="item style-scope dropdown-menu">Drugs</div>
          
            <div class="item style-scope dropdown-menu">Effects</div>
          
            <div class="item style-scope dropdown-menu">Human genes</div>
          
            <div class="item style-scope dropdown-menu">Inorganic materials</div>
          
            <div class="item style-scope dropdown-menu">Methods</div>
          
            <div class="item style-scope dropdown-menu">Natural products</div>
          
            <div class="item style-scope dropdown-menu">Nutrition</div>
          
            <div class="item style-scope dropdown-menu">Polymers</div>
          
            <div class="item style-scope dropdown-menu">Proteins</div>
          
            <div class="item style-scope dropdown-menu">Species</div>
          
            <div class="item style-scope dropdown-menu">Substances</div>
          
            <div class="item style-scope dropdown-menu">Toxicity</div>
          <template is="dom-repeat" class="style-scope dropdown-menu"></template>
        </div>
      </div>
    </div>
  </iron-dropdown>
  </dropdown-menu>
                </span>
              </div>
              <div class="responsive-table style-scope patent-result">
                <div class="table style-scope patent-result">
                  <div class="thead style-scope patent-result">
                    <div class="tr style-scope patent-result">
                      <span class="th style-scope patent-result">Name</span>
                      <span class="th style-scope patent-result">Image</span>
                      <span class="th style-scope patent-result">Sections</span>
                      <span class="th style-scope patent-result">Count</span>
                      <span class="th style-scope patent-result">Query match</span>
                    </div>
                  </div>
                  <div class="tbody style-scope patent-result">
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Species style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Homo sapiens</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,description</span>
                        <span class="td nowrap style-scope patent-result">648</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">vector</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,description</span>
                        <span class="td nowrap style-scope patent-result">40</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">pharmaceutical preparation</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,description</span>
                        <span class="td nowrap style-scope patent-result">26</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Homo sapiens Inducible T-cell costimulator</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Human genes style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Inducible T-cell costimulator</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">costimulatory effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,description</span>
                        <span class="td nowrap style-scope patent-result">57</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">transfer</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,description</span>
                        <span class="td nowrap style-scope patent-result">7</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Anatomy style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">cell</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">315</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Species style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Mus &lt;mouse, genus&gt;</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">116</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Homo sapiens ICOS gene</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">99</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">nucleotide</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">87</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical group style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">nucleotide group</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">87</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical class style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">amino acids</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">85</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">mixed lymphocyte reaction assay</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">79</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">processed proteins &amp; peptides</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">76</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Polymers style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">polypeptide</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">72</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Human genes style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">processed proteins &amp; peptides</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">72</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">effects</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">56</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Hypersensitivity</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">36</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">allergic disease</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">35</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">manufacturing process</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">34</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">allergy</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">32</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Species style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Rattus</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">30</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Interferon-gamma</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">29</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical group style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">amino acid group</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">28</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">treatment</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">28</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">fusion</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">25</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">signal transduction</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">24</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">antibody-dependent cellular cytotoxicity</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">19</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">genetic effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">19</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Species style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Mammalia</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">18</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Plasma cell myeloma</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">15</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">myeloid neoplasm</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">15</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Anatomy style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">b-lymphocyte</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">12</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Species style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Capra</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">11</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Species style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Cricetinae</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">11</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">transplantation</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">11</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">rheumatoid arthritis</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">10</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Species style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Bos taurus</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">9</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Anatomy style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">mammalian cell</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">8</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">prevention</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">8</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Species style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Oryctolagus cuniculus</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">6</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Psoriasis</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">6</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Human genes style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Interferon-gamma</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">drug carrier</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">graft versus host disease</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">interferon gamma</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Species style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Cavia porcellus</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Type 1 diabetes mellitus</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">nephritis</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">preventive effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">systemic lupus erythematosus</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">type 1 diabetes mellitus 1</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Graft vs Host Disease</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Immunodeficiency</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">2</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Immunodeficiency disease</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">2</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Anatomy style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">embryonic cell</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">2</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">immunodeficiency</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">2</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">prophylaxis</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">2</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical group style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">alpha amino acid group</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims</span>
                        <span class="td nowrap style-scope patent-result">14</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    <template is="dom-repeat" initial-count="25" class="style-scope patent-result"></template>
                    
                      <div class$="tr layout horizontal conceptDomain" class="style-scope patent-result">
                        <a href="#" class="td flex style-scope patent-result">
                          Show all concepts from the description section
                        </a>
                      </div>
                    <template is="dom-if" class="style-scope patent-result"></template>
                  </div>
                </div>
              </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <div id="notices" class="vertical layout center style-scope patent-result">
              
                <span class="style-scope patent-result">Data provided by IFI CLAIMS Patent Services</span>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
          </div>
          <div class="bottombar style-scope patent-result">
            <bottom-bar class="style-scope patent-result"><template is="dom-if" class="style-scope bottom-bar"></template>
</bottom-bar>
          </div>
        </div>
      </div>
      <template is="dom-if" class="style-scope patent-result"></template>
    </div>
  </patent-result>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
  </result-container>
        </div>
      </div>
    
        </div>
      </div>
      <search-footer class="style-scope search-ui">
    
    

    <div id="footer" class="vertical layout center style-scope search-footer">
        <span class="links style-scope search-footer">
          <overlay-tooltip positioning-target="#footerAbout" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Learn more about data coverage, search syntax and other features.
    </div>
  </overlay-tooltip>
          <a id="footerAbout" data-proto="ABOUT" href="https://support.google.com/faqs/answer/6390996" target="_blank" class="style-scope search-footer">About</a>
          <overlay-tooltip positioning-target="#footerFeedback" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Send feedback about technical issues or feature requests for Google Patents.
    </div>
  </overlay-tooltip>
          <a id="footerFeedback" data-proto="SEND_FEEDBACK" href="#" onclick="sendFeedback();" class="style-scope search-footer">Send Feedback</a>
          <a data-proto="PUBLIC_DATASETS" href="https://console.cloud.google.com/marketplace/product/google_patents_public_datasets/google-patents-public-data" target="_blank" class="style-scope search-footer">Public Datasets</a>
          <a data-proto="TERMS" href="https://www.google.com/policies/terms/" target="_blank" class="style-scope search-footer">Terms</a>
          <a data-proto="PRIVACY_POLICY" href="https://www.google.com/privacy/privacy-policy.html" target="blank" class="style-scope search-footer">Privacy Policy</a>
          <a data-proto="SEARCH_HELP" href="https://support.google.com/websearch/" target="_blank" class="style-scope search-footer">Help</a>
        </span>
    </div>
  </search-footer>
    </div>

  </search-ui>
  </search-result>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <paper-toast id="toast" duration="3000" class="style-scope search-app x-scope paper-toast-0" aria-hidden="true" style="outline: none; display: none;">
    

    <span id="label" class="style-scope paper-toast"></span>
    
      <div id="noticeContent" class="style-scope search-app"></div>
    
  </paper-toast>
  </search-app>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  

<iframe id="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.2576500506" name="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.2576500506" style="width: 1px; height: 1px; position: absolute; top: -100px; display: none;" src="https://scone-pa.clients6.google.com/static/proxy.html?usegapi=1&amp;jsh=m%3B%2F_%2Fscs%2Fabc-static%2F_%2Fjs%2Fk%3Dgapi.lb.en.IKZeRvoAYNY.O%2Fam%3DAAAQ%2Fd%3D1%2Frs%3DAHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw%2Fm%3D__features__#parent=https%3A%2F%2Fpatents.google.com&amp;rpctoken=615615449" tabindex="-1" aria-hidden="true"></iframe><iron-a11y-announcer>
    
    <div class="style-scope iron-a11y-announcer" aria-live="polite"></div>
  </iron-a11y-announcer></body></html>